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Congenital Heart Disease (CHD) is the most common congenital defect, but the 
genetic aetiology of a large proportion of CHD is unexplained. This project aimed to 
delineate novel genetic causes of CHD using Whole Exome Sequencing (WES) in a 
family-based approach. 
 
Sixteen families were recruited to the study. WES data analysis followed a 
standardized pipeline and candidate variants were prioritized on the basis of in silico 
pathogenicity prediction tools and review of the current literature.  
 
Known and candidate genes in CHD were successfully identified using WES. In one 
family, a mutation in PIGV was identified, providing a diagnosis of Hyperphosphatasia 
and Mental Retardation syndrome and expanding the known phenotype of this 
condition. In a family with early-onset cardiomyopathy, a mutation in PPA2 was 
identified, encoding a mitochondria-specific pyrophosphatase enzyme. Through 
collaboration this gene was identified to be causative in three further families and 
mutation pathogenicity was investigated by functional studies. 
 
In a further family, a missense mutation in DNAAF1 was associated with heterotaxy, in 
the absence of clinical features of Primary Ciliary Dyskinesia, the phenotype usually 
associated with this gene. Zebrafish studies supported the pathogenicity of this variant 
and functional experiments identified novel interactants of DNAAF1 to include Pontin, 
Reptin and IFT88. Pontin was found to be expressed on the left side of the embryonic 
node in mice and zebrafish, a pattern which was abolished in dnaaf1-/- mutant fish, 
suggesting DNAAF1 and Pontin to be involved in the development of early laterality. In 
two families with athelia, choanal atresia and CHD a candidate variant in KMT2D was 
identified. The phenotype was distinct from Kabuki syndrome and is likely to represent 
a novel KMT2D-related disorder. 
 
WES was a successful tool in gene identification in CHD and, coupled with functional 
studies, has provided novel insights into the pathogenesis of CHD.  
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 1 
1 Introduction 
1.1 General Introduction 
Congenital Heart Disease (CHD) is the most common congenital defect and affects 
0.5-0.8% of all live births (Reller et al., 2008). CHD is a complex group of conditions 
that encompass disorders of structural cardiac development, including septal, valvular 
and outflow tract lesions. These disorders demonstrate a wide spectrum of severity, 
from the complex forms of CHD, to milder lesions, such as bicuspid aortic valve (BAV), 
that may not cause symptoms apparent from birth. 
 
The complex forms of CHD carry a high burden of morbidity and mortality (Moller and 
Anderson, 2013), with approximately 25% of patients requiring intervention before the 
age of 1 year (Ahrens-Nicklas et al., 2016). Advances in the surgical and medical 
management of CHD have led to improved survival for patients, who are now more 
likely to survive into adulthood and reproduce (Pierpont et al., 2007), meaning that 
understanding the underlying genetic aetiologies of CHD are of increasing importance. 
 
The majority of instances of CHD are sporadic occurrences and the cause of these 
events remains largely unknown (Zaidi and Brueckner, 2017). It has been traditionally 
suspected that many of these sporadic cases are heterogenic or the result of a genetic-
environmental interaction. There is now strong evidence to support the genetic basis of 
CHD, including the increased risk of familial occurrence. The prevalence of CHD has 
been shown to be higher in first-degree relatives of an affected individual than second-
degree relatives, and higher between monozygotic twins than siblings (Wang et al., 
2013). The recurrence risk for CHD is estimated to be between 4-6% for unaffected 
parents (Fesslova et al., 2011) and as high as 10% when two previous siblings are 
affected (Chaix et al., 2016). The recurrence risk from affected parents to offspring is 8-
10%, with the highest risks associated with affected mothers, rather than fathers, and 
with left-sided lesions rather than other types of CHD (Chaix et al., 2016, van der Bom 
et al., 2011). The heritability of some types of CHD has been shown to be as high as 
70-90%, indicating a strong genetic contribution (Cripe et al., 2004, McBride et al., 
2005, Hinton et al., 2007). However, it is not yet clear whether this genetic contribution 
is attributable to single loci, to the additive interactions of multiple loci, or to various 
combinations of these (Zaidi and Brueckner, 2017). Other non-genetic aetiologies of 
CHD include maternal drug exposures, for example smoking and alcohol use (Jenkins 
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et al., 2007), maternal diabetes (Wren et al., 2003) and congenital infections, such as 
the rubella virus (Zhu et al., 2009).  
 
Advancements in cytogenetic analysis, such as the availability of Array Comparative 
Genome Hybridization (aCGH) and molecular techniques such as Whole Exome 
Sequencing (WES) have led to a number of exciting recent advances in the genetic 
aetiology of CHD and have improved our understanding of the complex developmental 
networks involved in human cardiac development (LaHaye et al., 2016, Al Turki et al., 
2014). The number of genes known to be associated with CHD has grown rapidly in 
recent years, but the genetic aetiology of a large proportion of CHD remains unknown 
(Andersen et al., 2013). In total, the known genetic causes of CHD, including 
syndromic causes, account for less than one third of all cases (Pediatric Cardiac 
Genomics Consortium et al., 2013, Zaidi and Brueckner, 2017).  
 
Improved understanding of the genetic aetiology of CHD is important to allow insight 
into the biological mechanisms, interactions and pathways involved in these disorders, 
and to allow disease stratification and categorization of risk. This is crucial in defining 
prognosis for affected patients and in counseling family members. Furthermore, this 
may lead to the development of more accurate prognostic testing, new management 
strategies and treatments (Pierpont et al., 2007). This project aims to identify new 
genetic causes of CHD through the use of Whole Exome Sequencing in a family-based 
approach. 
1.2 Formation of the Foetal Heart 
The formation of the foetal heart commences at 15-16 days gestation in humans. 
Precursors of the majority of cardiac cells are the splanchnic mesodermal cells, the 
exception being the cushions of the outflow tract, which are formed, in part, from 
ectodermal-derivatives of the cardiac neural crest (Sylva et al., 2014). During 
gastrulation, these cells migrate to the midline myocardial plate and form the cardiac 
crescent, also known as the first heart field. The cardiac crescent then folds and 
eventually fuses in the midline to create the heart tube. The heart tube has two venous 
inlets and one arterial outlet.  
 
Addition of cells from the secondary heart field causes the heart tube to elongate at the 
either pole. The heart tube then undergoes ventral bending and right heart looping, at 
gestational day 28. Formation of the cardiac loop is closely related to the establishment 
of laterality at the embryonic node (see section 1.5.2.3) (Lin et al., 2012). Differential 
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gene expression in the looped heart causes dilatation of the atrial and ventricular 
chambers, and the heart tube becomes segmented into the primitive atria, 
atrioventricular canal (AVC), primitive ventricles, and outflow tract (Lin et al., 2012). 
This dilatation requires multiple regulators and transcription factors expressed in 
overlapping gradients, including important cardiac transcription factors, such as Nkx2.5 
and Gata4 (Boogerd et al., 2009). Cushions form in the inner vessel walls of the AVC 
and outflow tract, through a process of epithelial-mesenchymal cell transformation 
(EMT). EMT is regulated by Bone Morphogenetic Proteins (BMPs), TGF-beta and 
Notch signaling (Sylva et al., 2014). 
 
Following this, during days 50-90 of gestation in humans, the atrial and ventricular 
chambers septate to form the four-chambered heart. The atrioventricular (AV) cushions 
fuse at the AVC and the outflow tract is septated by the septal and parietal outflow tract 
ridges to form the ventricular outlets (Sylva et al., 2014). The AV cushions, having 
undergone EMT, are remodeled to become the AV valves and the outflow tract 
cushions give rise to the semilunar valves (Lin et al., 2012). The valves undergo a final 
remodeling stage to create three distinct valvular layers (Sylva et al., 2014). Figure 1-1 
shows a representation of the formation of the embryonic heart in both human and 
mouse.  
 
Figure 1-1: The process of cardiac embryology in human and mouse.  
Image adapted from Zaidi et al., 2017. Scale shows gestational days 15-55 in humans, and 7-




1.3 Classification of Congenital Heart Disease 
Congenital Heart Disease can be defined as a defect in the normal structure of the 
heart that is present from birth. CHD includes septal defects such as Ventricular Septal 
Defects (VSD), Atrial Septal Defects (ASD) and Atrio-Ventricular Septal Defects 
(AVSD), describing an abnormal connection between the right and left sides of the 
heart. Valvular abnormalities include atresia, describing an absence of the valve orifice, 
and stenosis, describing narrowing, due to an abnormality in the structure or function of 
the valve. CHD also encompasses more complex defects such as Tetralogy of Fallot 
(TOF), a combination of VSD, pulmonary stenosis, right ventricular hypertrophy and an 
overriding aorta, and hypoplastic left heart syndrome, an abnormality in the formation 
of the left ventricle, often associated with valvular defects. Congenital 
cardiomyopathies are not strictly CHDs, but describe diseases of the heart muscle 
present from birth (van der Bom et al., 2011). Table 1-1 shows a classification of 
different types of CHD according to the major structural abnormality present.  
 
Table 1-1: Classification of CHD.  
Table adapted from (Miyague et al., 2003). Prevalence of different types of CHD is given per 
million live births, based on data from the CONCOR (Dutch Congenital Corvitia) Database (van 
der Bom et al., 2012). 
Structure affected Type of CHD Prevalence per million 
live births 
 (van der Bom et al., 
2012) 









Outflow tract Transposition of the Great Arteries  
Double outlet right or left ventricle 
(DORV/ DOLV) 
Truncus Arteriosus (TA) 
Pulmonary Stenosis (PS) 
Pulmonary Atresia 
Aortic Stenosis 
Tetralogy of Fallot (TOF) 










Septum Atrioventricular Septal Defect 
Atrial Septal Defect (ASD) 
















1.4 Management of CHD 
CHDs can now be detected using prenatal echocardiography at 17-18 weeks gestation 
and many CHDs are well-tolerated during foetal life, due to the support of the maternal 
circulation. However, following birth, many will manifest clinically. Before the advent of 
cardiac surgery, CHD was one of the leading causes of death in neonates and infants. 
Since the introduction of surgery and intensive care in the 1950s, there has been a 
huge change in the life expectancy of these patients, with >90% now surviving to 
adulthood (Triedman and Newburger, 2016).  
 
Paediatric cardiac surgery is now commonly performed at a number of specialist 
cardiac centers throughout he UK, providing a range of medical and surgical services, 
allowing for specialist commissioning (https://www.engage.england.nhs.uk/) and 
combined multidisciplinary expertise. Furthermore, many lesions can now be managed 
by cardiac catheter, for example ASD and pulmonary valve stenosis, without the need 
for open cardiac surgery (Abu-Tair et al., 2016, Singh et al., 2015, Moustafa et al., 
2016).  
 
The required surgery for CHD will depend on the nature of the lesion present. In the 
case of VSD, an abnormal connection between the two ventricles, the patient may 
require surgery to close the hole in the septum if the lesion is large and unlikely to 
close spontaneously. This involves the insertion of a synthetic patch to close the 
connection, either by cardiac catheter or open-heart surgery (Holzer et al., 2016). In 
transposition of the great arteries (TGA), where the aorta is abnormally attached to the 
right side of the heart and the pulmonary artery is on the left, an arterial switch repair is 
required shortly after birth that transposes the orientation of these vessels (Villafane et 
al., 2014). As well as corrective procedures, some patients require a cardiac shunt - 
the insertion of a short synthetic tube - to relocate the flow of blood in the cardiac 
circulation. This is performed either as a palliative procedure or prior to later planned 
palliative or corrective surgery. A Blalock-Taussig (BT) shunt is used in cyanotic heart 
defects, such as pulmonary atresia. In this procedure, one branch of the subclavian or 
carotid artery is separated and connected to the pulmonary artery to relieve the 
symptoms of cyanosis. A bidirectional cavopulmonary anastomosis (Glenn shunt) 
involves disconnecting the superior vena cava from the right atrium and connecting it 
the right pulmonary artery. This allows deoxygenated blood to return directly to the 
lungs without going through the heart, reducing the workload on the heart. A Glenn 
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shunt is often one of a series of operations in the treatment of uni-ventricular disease 
(Mainwaring et al., 1994).  
 
The increase in life expectancy for CHD patients has brought new challenges, with 
adult CHD patients being at risk of long-term complications, for example arrhythmia, 
heart failure, endocarditis and aneurysm (Postma et al., 2016). The main causes of 
death in this population are heart failure and sudden cardiac death. Current 
management guidelines focusing on adults with CHD recommend surveillance, advise 
on the risk of complications and offer advice for pregnancy (Warnes et al., 2008, 
Baumgartner et al., 2010).  
1.5 The Known Genetic Aetiology of Congenital Heart 
Disease 
The known causes of CHD are varied and include cytogenetic abnormalities, single 
gene disorders, epigenetic alteration or multifactorial causes. CHD can occur as an 
isolated feature, or part of a known or undiagnosed syndrome of congenital anomalies 
(Landis and Ware, 2016). Approximately 25% of children with CHD are thought to have 
a syndromic cause, due to the presence of other congenital anomalies or 
neurodevelopmental delay (Landis and Ware, 2016). However, this definition is not 
always clear-cut, and sometimes the gene responsible for a syndromic form of CHD 
can cause non-syndromic disease. For example, JAG1 mutations can cause Alagille 
syndrome, but are also seen in non-syndromic TOF (Eldadah et al., 2001). This section 
describes some of the known genetic causes of congenital heart disease.  
1.5.1 Copy Number Variation 
Copy Number Variation is classed as a structural variation within the genome, 
specifically a duplication or deletion event (McCarroll and Altshuler, 2007). This type of 
variation can affect whole chromosomes (aneuploidy, for example Trisomy 21), down 
to the level of a single base-pair deletion or duplication. Different technologies are able 
to identify CNVs of differing size; a karyotype will identify deletions or duplications 
down to the resolution of approximately 5Mb (Geiersbach et al., 2014), an array CGH 
those down to approximately 50-100kb (although this is dependent upon the array 
platform and differs across the genome) (Coe et al., 2007) and whole genome Single 
Nucleotide Polymorphism (SNP) array those of sub-100kb (dependent upon the 
platform and markers used) (Peiffer et al., 2006). 
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Chromosomal aberrations and aneuploidies are known to be a common cause of 
syndromic CHD, with 22q11 deletion being a common cause, occurring in 1 in 4000 
live births and accounting for around 15% of TOF cases (Agergaard et al., 2012). 
22q11 deletion encompasses the TBX1 gene, haploinsufficiency of which is reported to 
underlie the cardiac phenotype (Jerome and Papaioannou, 2001). TBX1 has recently 
been shown to regulate monomethylation of H3K4me1 (Histone H3 monomethylated at 
lysine 4) through the recruitment of histone methyltransferases (Fulcoli et al., 2016) 
and H3K4 methylation is known to be important in cardiac development (see section 
1.5.3).  
 
Since the introduction of array CGH technology, new microdeletion and duplication 
syndromes associated with syndromic CHD have been identified, such as the 16p11.2 
deletion syndrome (Ghebranious et al., 2007) and 8p23 deletion, which includes the 
GATA4 gene (Pehlivan et al., 1999). 
 
Rare copy number variants (CNVs) (<1% population frequency) have increasingly 
become a focus for investigation in many complex diseases, including CHD (Soemedi 
et al., 2012). Patients with non-syndromic CHD have been found to have a higher than 
expected number of submicroscopic rare CNVs (Erdogan et al., 2008). There are a 
number of recent studies of whole-genome CNV screening in CHD cohorts, many of 
which have identified an increase in rare CNVs in CHD patients when compared to 
controls (Silversides et al., 2012, Soemedi et al., 2012, Hitz et al., 2012, Fakhro et al., 
2011, Iascone et al., 2012). CNVs identified by this methodology provide a method for 
identifying potential candidate genes. However, there is little consistency between 
these studies, perhaps due to variations in study size and cardiac phenotype 
investigated (Andersen et al., 2013).  
 
In a recent paper, Glessner et al., 2014, used high-density SNP arrays and WES to 
detect small de novo CNVs in a trio study of 538 cases of conotruncal defects, 
heterotaxy and left ventricular outflow tract defects. The results were compared to 
those of 1301 healthy controls. There was a significant increase in de novo CNVs in 
cases compared to controls. A number of the CNVs identified encompassed genes that 
interact with NKX2-5 and GATA4, known to play important roles in cardiac 
development (Glessner et al., 2014).  
 
Overall the incidence of pathogenic CNVs, identified by array CGH or SNP array, in 
isolated CHD is reported to be between 4-14%, although the genomic architecture of 
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these CNVs is often unknown; some appear to be single causative alleles, but others 
are additive at two or more different loci (Soemedi et al., 2012, Breckpot et al., 2011). 
This is lower than in syndromic CHD where the incidence may be as high as 15-20% 
(Breckpot et al., 2011, Tomita-Mitchell et al., 2012). CNVs identified in non-syndromic 
CHD more often have a moderate effect size and reduced penetrance, as compared to 
those causative of syndromic CHD (Breckpot et al., 2011). 
1.5.2 Single Gene Variants 
1.5.2.1 Transcription Factors 
The importance of key transcription factors in cardiac development has been 
highlighted by the discovery of mutations in genes such as NKX2-5 (Schott et al., 
1998), GATA4 (Tomita-Mitchell et al., 2007), GATA5, GATA6 (Zheng et al., 2012) and 
TBX5 (Reamon-Buettner and Borlak, 2004) in human CHD. These core transcription 
factors interact in a complex pathway, along with other key transcription factors in the 
developing heart. Some of these interactions are illustrated in Figure 1-2.  
 
GATA4, 5 and 6 are zinc-finger transcription factors expressed in overlapping regions 
in the developing heart (Durocher and Nemer, 1998). Mouse models have shown that 
Gata4 works together with Smad4 to regulate EMT, and therefore plays a key role in 
cardiac septation and valve formation (Moskowitz et al., 2011). Gata4 also interacts 
with other crucial transcription factors, including Hand2, Nkx2.5 and Tbx5 (Garg et al., 
2003). Mice lacking endocardial Gata4 have halted EMT at the AV cushions and 
develop hypoplastic ventricles, whereas mice with heterozygous Gata4 mutations 
develop AVSD and DORV (Rivera-Feliciano et al., 2006). GATA4 mutations are found 
to be the cause of non-syndromic septal, valvular and outflow tract defects in humans, 
including Pulmonary Stenosis (PS) and TOF, as well as dextrocardia (Moskowitz et al., 
2011). Similarly, mutations in both GATA5 and GATA6 have been found to cause 
disorders of the aortic valve and outflow tract in humans (Kodo et al., 2009, Wei et al., 
2013). 
 
In mice, Nkx2-5 is expressed in both the first and second heart field and is involved in 
the specification of cardiac precursors and in the development of the outflow tract 
(McCulley and Black, 2012). Nkx2-5 is regulated by Smad proteins and interacts with 
both Gata4 and Tbx5 to regulate septation in the atria and ventricles (Lien et al., 1999, 
Hiroi et al., 2001). Nkx2.5 null mice do develop a primary heart tube, but do not 
undergo the processes of cardiac looping or septation. Mutations in NKX2-5 in humans 
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are responsible for a broad range of CHDs including DORV, TOF, VSD and ASD 
(Schott et al., 1998). Furthermore, NKX2-5 mutations are also associated with cardiac 
conduction defects (Benson et al., 1999). 
 
The T-box transcription factors play important roles in the developing heart and 
regulate cardiomyocyte identity. TBX5, a member of the T-box transcription factors, is 
expressed in a gradient from the venous pole to the right ventricle and activates 
chamber-specific gene expression, as well as playing a role in cardiac looping and 
septation (Sylva et al., 2014). Tbx5 null mice suffer early lethality and do not undergo 
cardiac looping or form cardiac chambers. Heterozygous mutations of Tbx5 in mice 
cause ASD and VSD (Bruneau et al., 2001). Mutations in the TBX5 gene in humans 
cause Holt-Oram syndrome, a condition associated with a spectrum of congenital heart 
defects and limb abnormalities (Gall et al., 1966). Somatic TBX5 mutations have also 
been associated with CHD in patients without Holt-Oram Syndrome (Reamon-Buettner 
and Borlak, 2004). Furthermore, gain-of-function mutations in TBX5 have recently been 
reported in TOF patients (Baban et al., 2014). Mutations in other T-box genes have 
also been associated with CHD, for example TBX20 mutations are associated with 
septal defects and DCM and TBX1 with DiGeorge syndrome (Yagi et al., 2003). Tbx5 
and NKX2-5 synergistically bind the promoter of the Nppa gene (cardiac specific 
natriuretic peptide precursor A) and cause activation during cardiac development (Hiroi 




Figure 1-2: Transcription factors involved in region-specific cardiac development.  
Schematic that is a representation of the major transcription factors involved in cardiac 
development and their interactions. Arrowheads indicate positive regulatory effects, whereas 
bars represent negative effects. Red lines indicate known protein-protein interactions. Adapted 
from (Srivastava, 2006) and (Mitchell et al., 2007). 
1.5.2.2 Signaling Pathways 
The NOTCH signaling pathway is an excellent example of the importance of signaling 
pathways in human cardiac development. This pathway regulates cell-fate decisions in 
heart morphogenesis, and is involved in myocardial development and left-right 
partitioning. The Notch pathway also regulates EMT in development of the cardiac 
valves (Niessen and Karsan, 2008). Alagille syndrome is caused by mutations in genes 
in this pathway (JAG1 and NOTCH2) and is associated with pulmonary stenosis. 
Mutations in Notch1 in mice cause hypoplastic endocardial cushions, reported to be 
due to impaired EMT (Timmerman et al., 2004). Mutations in genes encoding proteins 
involved in the Notch signaling pathway have been associated with human aortic valve 
disease and BAV with thoracic aortic aneurysm (McKellar et al., 2007), as well as left 
ventricular outflow tract obstruction (McBride et al., 2008). In a recent study using 
custom NGS panels, Blue et al., 2014, identified five variants in four genes in 16 
families with CHD, including NOTCH1, which were associated with disease (Blue et al., 
2014). Variants in NOTCH1 have also been associated with non-syndromic LVOTO in 
the study by Jia et al., 2015, however the pathogenicity of these variants was not 
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certain, as the variants did not consistently segregate with disease in the identified 
families and the causality of these variants was not further investigated by functional 
studies (Jia et al., 2015). In a further study, mutations in genes of the NOTCH pathway 
(NOTCH1, MAML1 and JAG1) were enriched in 51 families affected by CHD affecting 
the left ventricular outflow tract (McBride et al., 2008). NOTCH1 haploinsufficiency was 
recently identified to cause Adams-Oliver Syndrome, characterized by limb defects, 
cutis aplasia and, in around half of cases, CHD (Southgate et al., 2015). 
1.5.2.3 Laterality in the Early Embryo 
Left-right patterning in the developing embryo is principally determined by nodal cilia in 
the embryonic node of the primitive streak (see section 1.6), although some earlier 
influences on left-right patterning may occur by processes such as planar cell polarity 
(Vandenberg and Levin, 2013). The clockwise rotational movement of the nodal cilia 
produces a leftward fluid flow. This nodal flow is reported to be either detected by 
mechanosensory (primary) cilia surrounding the node, or to initiate the movement of 
small vesicles containing morphogens such as Sonic Hedgehog or retinoic acid which 
move towards the left side of the node (Shinohara et al., 2012). This morphogenic 
signal may cause an influx of intracellular calcium in the cells to the left of the node, 
which activates a left-sided signalling pathway, involving genes such as NODAL, 
LEFTY2, ACVR2B, CFC1, CITED2, PITX2, FOXH1 and ZIC3 (Ramsdell, 2005, 
Sutherland and Ware, 2009). Creation of an artificial rightward flow at the node in 
mouse embryos causes inverted cardiac looping and contralateral expression of Pitx2 
and Nodal (Nonaka et al., 2002). Human mutations in genes involved in the 
establishment of embryonic laterality, such as ZIC3, ACVR2B, CFC1 and LEFTYA 
cause a broad range of CHD, often associated with laterality defects (Sutherland and 
Ware, 2009). Mutations in these genes can also cause CHD without a laterality defect, 
for example a cohort of patients with TGA, but no other laterality defect, were found to 
have mutations in CFC1 (Goldmuntz et al., 2002). 
1.5.2.4 Variants in Structural Genes 
Mutations in genes encoding components of the cardiac sarcomere have been linked 
to CHD. Mutations in myosin heavy chain 6 (MYH6) have been linked to ASD (Ching et 
al., 2005). Furthermore, mutations in MYH7 have been identified to cause Ebstein’s 
anomaly (Postma et al., 2011, Bettinelli et al., 2013). Mice with homozygous mutations 
in Myh11 showed delayed closure of the arterial duct, and mutations in the human 
orthologue of this gene can cause Patent Ductus Arteriosus (PDA) associated with 
thoracic aortic aneurysm (Zhu et al., 2006). In two large families with autosomal 
dominant ASD, linkage analysis and candidate gene sequencing revealed the 
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causative mutation to lie in alpha-cardiac actin (ACTC1), a major component of the 
sarcomeric thin filaments, essential for heart muscle contraction (Matsson et al., 2008). 
1.5.3 Epigenetics 
Epigenetic modulation of the cardiovascular system plays a key role in cardiac 
embryology and defective regulation has recently been identified as an important 
cause of CHD. Knockdown experiments in animal models of chromatin factors, such as 
Brg1 and Chd7, and histone modifiers, such as Jumonji and Ptdsr, have demonstrated 
a variety of CHDs (Chang and Bruneau, 2012, Zhang and Liu, 2015).  
 
Brg1 is a chromatin remodeling protein that has been identified to play an important 
role in cardiovascular development. Brg1 plays a dose-dependent role in the activation 
of cardiac specific target genes to control tissue growth and differentiation. Cardiac 
transcription factors Nkx2.5, Tbx4 and Gata4 have all been shown to physically interact 
with Brg1, via Baf60c. Brg1 has also been shown to genetically interact with Tbx5 
(Bevilacqua et al., 2013). These interactions are known to be complex and there are 
sets of genes that appear to rely on the balance between Brg1 and Nkx2.5 or Tbx5 for 
their regulation (Hang et al., 2010). Deletion of Brg1 in the early embryo causes 
lethality with cardiac underdevelopment, and deletion at a later stage produces mice 
with thin ventricular walls and an absent ventricular septum (Hang et al., 2010). 
Heterozygous Brg1 mutations in mice cause multiple heart defects including VSD, PFO 
and dilated cardiomyopathy (Lickert et al., 2004). Morpholino oligonucleotide 
knockdown of Brg1 in zebrafish embryos causes abnormal cardiac looping with a 
hypoplastic myocardium (Chang and Bruneau, 2012). BRG1 is re-activated in some 
human patients with hypertrophic cardiomyopathy and its level seems to correlate with 
disease severity (Hang et al., 2010).  
 
H3K4 methylation is associated with transcriptionally active genes in the developing 
embryo. H3K4 methylation is maintained by methyltransferases, for example the 
MLL/KMT family of proteins. Mutations in a number of these methyltransferases cause 
human disease associated with CHD (Zhang and Liu, 2015). Mutations in CHD7, 
encoding a chromatin remodeling helicase protein, cause CHARGE syndrome 
(Coloboma, Heart defects, Atresia choanae, Retarded growth and development, 
Genital hypoplasia and Ear abnormalities/deafness) (Vissers et al., 2004). The 
associated cardiac defects are usually outflow tract malformations. Mice with 
heterozygous Chd7 mutations have a similar combination of defects to human patients 
with CHARGE syndrome. This is replicated by chd7 knockdown in frog embryos, which 
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also demonstrate similar features (Randall et al., 2009, Bajpai et al., 2010). Chd7 was 
shown to interact with Brg1 and Pbaf to control neural crest activation by 
immunoprecipitation experiments in human neural crest cells and this may be the 
reason for the propensity to defects in outflow tract development in this condition, as 
the neural crest cells contribute to the formation of the outflow tract (Bajpai et al., 
2010). Mutations in an additional H3K4 methyltransferase, KMT2D, cause Kabuki 
syndrome, which is also associated with a number of CHDs such as septal defects (Ng 
et al., 2010). Furthermore, heart-specific knockout of Kmt2d results in outflow tract 
septation defects in mice (Ang et al., 2016).  
 
The Jumonji (Jarid2) gene codes for a histone demethylase. Homozygous mutations in 
Jarid2 in mice cause lethal cardiac defects, including VSD, non-compaction 
cardiomyopathy, DORV and aortic dilatation. There is a reduction in atrial and 
ventricular chamber-specific gene regulation in these mice (Lee et al., 2000). Jarid2 is 
known to inhibit expression of cardiac transcription factors such as Nkx2.5 and Gata4, 
affecting the regulation of early cardiac differentiation (Kim et al., 2004). 
 
The importance of histone modifying genes in human CHD was highlighted in an 
influential paper by Zaidi et al., in 2013. This group studied 362 parent-offspring trios 
consisting of a child affected with CHD and their unaffected parents. Exome 
sequencing techniques were used to identify de novo variants in the affected children. 
Control subjects were 264 trios consisting of unaffected siblings of autism cases and 
their parents. On initial review there was not a significant difference in the number of de 
novo variants identified between cases and controls. However, RNA sequencing was 
used to identify genes expressed at embryonic day E14.5 in the mouse heart and the 
group identified an increase in deleterious de novo mutations in these genes in cases 
compared to controls (Odds Ratio = 7.5). When the genes mutated in the case group 
were examined, eight were found to be involved in H3K4 methylation production, 
removal or reading. SMAD2 was found to be mutated in two cases, both with 
dextrocardia. Interestingly, SMAD2 is known to be involved in demethylation of H3K27 
at the left-right organizer of the embryonic node. The group concluded that genes 
within the H3K4 methylation and H3K27 methylation pathway must be important in 
cardiac development (Zaidi et al., 2013). This would be consistent with prior evidence 
that genes in the H3K4me-H3K27me pathway are important in regulating genes 
involved in embryonic development, including those involved in cardiac development 
(Paige et al., 2012). 
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1.5.4 MicroRNAs 
The importance of the non-coding parts of the genome is becoming apparent in many 
disease processes, including cardiovascular diseases. MicroRNAs (miRNAs) are 
usually around 22 nucleotides in length and bind to complementary sequences on 
target mRNA, often resulting in gene silencing or repression. They act either by 
reducing mRNA stability or inhibiting translation (Li et al., 2013). It is thought that there 
are perhaps as many as 1000 miRNA genes in the human genome. These are highly 
conserved across species and have been implicated in numerous disease processes 
including cardiac disease and cancers (Salmena et al., 2011). There is evidence that 
other non-coding components of the genome, such as long non-coding RNAs 
(lncRNAs) and small nucleolar RNAs (snoRNAs) are also crucial in organismal 
development and may also be implicated in CHD (O'Brien et al., 2012). 
 
Research into miRNAs in cardiovascular pathologies such as heart failure and 
cardiomyopathies has recently rapidly expanded. This is, in part, due to the 
identification of the importance of miRNAs in cardiac development in animal models. 
This importance has been demonstrated by disruption of the miRNA processing 
enzyme Dicer, an RNAse III endonuclease, required in the maturation of most miRNAs. 
In both mice and zebrafish, cardiac specific disruption of Dicer causes 
underdevelopment of the ventricular myocardium, dilated cardiomyopathy and cardiac 
failure (Ono et al., 2011).  
 
miR-1 and miR-133 are involved in cardiomyocyte cell differentiation and cardiac 
muscle cell differentiation respectively. These families of miRNAs are generated as 
pairs and their expression is specific to cardiac and skeletal muscle (Chen and Wang, 
2012). Overexpression of miR-1 in mice leads to thinning of the ventricular wall and 
early lethality (Zhao et al., 2005). Conversely, miR-1 knockout mice were found to have 
hyperplastic ventricles (O'Brien et al., 2012). One of the targets of miR-1 in the heart is 
Hand2, a transcription factor that plays a key role in cardiac myocyte development. 
Hand2 mutant mice have similar cardiac defects to miR-1 mutants (Zhao et al., 2005).  
 
Compound deletion of miR-133a-1 and miR-133a-2 causes early embryonic lethality, 
VSDs, dilated cardiomyopathy and cardiac failure in mice (Liu et al., 2008). 
Overexpression of miR-133a causes thinning of the ventricular wall and septal defects 
resulting in lethality (Liu et al., 2008). 
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miR-138 is expressed in very specific domains in the zebrafish heart and is reported to 
be involved in cardiac patterning. Morpholino antisense oligonucleotide knockdown of 
miR-138 expression in zebrafish caused a lack of cardiac maturation (Morton et al., 
2008), although the effect of off-target effects in these experiments cannot be 
discounted. There are several miRNAs known to be linked to septal defects, including 
miRNA126 (Lin et al., 2012) and miRNA-1-1 and miRNA-181c (Li et al., 2013).  
 
O’Brien et al., 2012, studied expression of miRNA and snoRNA in cardiac tissue of 16 
non-syndromic patients with Tetralogy of Fallot, 3 fetal samples and 8 control samples. 
They carried out microarrays for 847 human miRNAs and 922 snoRNAs. They found 
61 miRNAs and 135 snoRNAs to have significantly different expression between the 
cases and control samples. Of those miRNAs with differential expression, there was an 
increased incidence of those known to regulate genes with direct links to cardiac 
development. The difference in expression of miRNAs and snoRNAs between the 
control and case samples suggests the importance of these non-coding RNAs in 
cardiac development and CHD due to their role in the regulation of key cardiac genes 
(O'Brien et al., 2012).  
 
Long non-coding RNAs are >200 nucleotides in length and are transcribed throughout 
the genome. In general they have low evolutionary conservation. lncRNAs can interact 
with proteins, such as transcription factors and chromatin modifying complexes, or 
other RNAs such as miRNAs, to affect gene regulation and expression (Scheuermann 
and Boyer, 2013). It is known that lncRNAs play a role in important cell processes such 
as imprinting and cell cycle regulation. Recently it has been identified that lncRNAs 
play a role in cardiac development. One example of this is Braveheart, a lncRNA that is 
expressed in the mouse heart. Using multiple embryonic stem cells, Klattenhoff et al., 
2013, demonstrated that removal of Braveheart impaired formation of cardiomyocytes 
and was important in embryonic cardiac cell fate (Klattenhoff et al., 2013). Braveheart 
is required for the activation of MesP1, an upstream regulator of core cardiac 
transcription factors such as Gata4, Gata6, Tbx2 and Nkx2.5. lncRNAs have also been 
implicated in adult-onset cardiac diseases such as myocardial infarction and dilated 
cardiomyopathy. These non-coding RNAs are likely to be associated with congenital 
heart diseases due to their role in cardiac development and interaction with cardiac 
transcription factors, although this has not, as of yet, been demonstrated 
(Scheuermann and Boyer, 2013). 
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1.6 Cilia and CHD 
1.6.1 Cilia 
Cilia are small microtubule-based organelles, formed from a mother centriole, that play 
a sensory role in response to chemical, light, morphogenic and mechanical stimuli. The 
majority of mammalian cell types express an immotile primary cilium. The structure of 
this organelle is complex and it contains an axoneme structure with nine microtubule 
doublets in a 9+0 arrangement (see Fig. 1-3). At the base of the axoneme is the basal 
body and between the basal body and the cilium is a specialised area called the ‘ciliary 
gate’, a barrier between the cilium and the cytoplasm. This ciliary gate consists of two 
regions; the distal appendages of the centriole and the transition zone. Cargo 
molecules are transported along the axoneme by intraflagellar transport (IFT) 
molecules, which consist of subcomplexes A and B (Malicki and Johnson, 2017). The 
importance of the primary cilium has been highlighted by a group of diseases called 
ciliopathies, which cause neurodevelopmental, skeletal, renal and retinal disease, and 
are linked to CHD (Hildebrandt et al., 2011).  
 
 
Figure 1-3: The major known structures of the primary cilium. 
(A) Diagram of the primary cilium showing the major known structures, (B) Electron-microscopy 
to show the nine microtubular doublets in a 9+0 arrangement in the primary cilium. Arrows 
indicate the Y-shaped links of the transition zone. Figure adapted from Malicki et al., 2017. 
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Specialized motile cilia are present on a smaller number of cells types that, in humans, 
include those of the respiratory tract, Fallopian tubes and inner ear. Motile cilia differ 
from primary cilia in that they have an outer ring of nine microtubular doublets around a 
central microtubule pair (9+2 arrangement). In motile cilia, inner and outer dynein arms 
(IDA and ODA) connect the microtubules and act as molecular motors to provide the 
force required for ciliary motility (Nicastro et al., 2006). A further type of specialized 
motile cilia are present at the embryonic node, with a 9+0 microtubule structure. These 
nodal cilia are involved in the creation of the leftward fluid flow at the embryonic node, 
a crucial function in the development of left-right asymmetry in the early embryo (see 
section 1.5.2.3). 
1.6.2 Defects in Primary Cilia are Associated with CHD 
Mutations in genes affecting the structure and function of primary cilia have been 
identified as an important cause of CHD. A number of ciliopathies have CHD as 
associated clinical features, for example those disorders associated with mutations in 
NPHP4, KIF7 and MKS1 (Braun and Hildebrandt, 2017). In E9.5-12.5 Kif3a-mutant 
mouse hearts, which totally lack cilia, there was thinning of the myocardium and 
abnormal development of the endocardiac cushions, whereas mouse mutants for the 
left-right dynein gene (lrd-/-), which have static cilia, had relatively normal hearts 
(Slough et al., 2008). This suggests a sensory role for primary cilia in cardiac 
development. Furthermore, in a forward genetic screen in mice, where severe CHD 
was detected by fetal ultrasound scan, 61 genes were identified related to recessively-
inherited CHD. Notably, of these, 34 were cilia-related genes. These cilia-related genes 
contributed not only to laterality-related CHD, but also non-laterality related disease. 
This demonstrates the important role of primary cilia in cardiac development, separate 
from the role in breaking laterality in the developing embryo (Li et al., 2015).  
1.6.3 Defects in Motile Cilia are Associated with CHD 
Defects in genes associated with motile cilia cause a condition called ‘Primary Ciliary 
Dyskinesia’ (PCD). PCD is characterized by neonatal respiratory distress, chronic 
respiratory tract infections, bronchiectasis and sinusitis (Horani et al., 2014). Situs 
solitus is the term used to describe a normal arrangement of body anatomy, where 
situs inversus is the mirror image of this arrangement. A failure of asymmetry of the 
unpaired organs is called situs ambiguus or heterotaxy, and is associated with major 
CHD. Around 50% of PCD patients have situs inversus due to defects in the nodal cilia 
and therefore dysfunction in development of asymmetry in the early embryo. Both 
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heterotaxy and complex CHD are more common in PCD than in the general 
population, with an incidence of around 6.3% (Kennedy et al., 2007).  
1.7 Gene Identification in Congenital Heart Disease 
In the past 10 years more than 60 genes associated with human CHD have been 
identified. CHD gene identification has characteristically been difficult, with the majority 
of cases being sporadic occurrences and the rarer familial cases being often 
complicated with variable expression, differences in age of presentation and variable 
penetrance (Blue et al., 2017). Mutations may also involve non-exonic DNA, such as 
regulatory regions, which can be missed by modern technologies and confirmation of 
their pathogenicity is more problematic. CHD gene discovery is further limited as many 
identified mutations are family-specific or private mutations, making genotype-
phenotype correlation difficult (Chaix et al., 2016). 
 
Original techniques for gene discovery focused either on positional cloning or 
candidate gene analysis. Positional cloning using linkage analysis was used 
successfully in CHD to identify mutations in genes such as NKX2-5 (Schott et al., 
1998) and ACTC1 (Matsson et al., 2008). Similarly, the candidate gene approach uses 
information from animal models, known protein function, expression patterns or 
developmental pathways to identify likely functional candidates as the focus of analysis 
in affected individuals or families. In some cases, CNVs, such as microdeletions or 
translocations, were used to identify functional candidates. This was the case in the 
identification of the role of GATA4 in human CHD (Pehlivan et al., 1999). 
 
These approaches were often undertaken in families where there was an apparent 
Mendelian pattern of inheritance. However, large families segregating CHD are rare, 
limiting the possibilities for gene discovery with these techniques.  
1.7.1 Next Generation Sequencing Technologies 
The development of massively-parallel sequencing (or Next-Generation Sequencing, 
NGS) has significantly reduced the cost and increased the speed of DNA sequencing. 
The original sequencing of the complete human genome took around 10 years and 
cost nearly $3 billion (Lander et al., 2001). NGS technologies have reduced the cost of 
Whole Genome Sequencing (WGS) to around $1000-$1500 per genome and the 
process takes a matter of days. NGS describes new technologies that, instead of 
undertaking sequencing using the classic Sanger chain-termination method, allow for 
large-scale multiplex sequencing-by-synthesis. The Leeds Sequencing Facility use 
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Illumina technologies (https://www.illumina.com/technology/next-generation-
sequencing.html) on an Illumina Hiseq2500 or Hiseq3000 machine to undertake NGS, 
which uses a proprietary reversible ‘Sequencing-by-Synthesis’ technology (see chapter 
2, section 2.2.14). NGS technologies can be used to undertake sequencing of custom 
gene panels, Whole Exome Sequencing and Whole Genome Sequencing.  
1.7.2 Whole Exome Sequencing 
The advent of NGS has altered the landscape of genetic research. Now genes can be 
sequenced at a faster speed, at reduced cost and a hypothesis-free approach to gene 
discovery can be undertaken. WES is the use of NGS technologies to sequence the 
entire coding sequence of DNA (around 1.6% of the whole genome), following 
enrichment with a capture approach. This has been used successfully in gene 
discovery for many Mendelian conditions, including familial CHD (Greenway et al., 
2014). This technique often involves variant comparison between affected and 
unaffected family members or affected and unaffected cohorts to identify putative 
pathogenic variants.  
 
Autosomal recessive disorders, particularly in consanguineous families, have 
traditionally been a focus in some WES studies, as the analysis of variants is more 
directed when searching for shared homozygous or biallelic variants in affected 
individuals. In CHD, examples of successful identification of causative mutations in 
recessive disease using WES include SHROOM3 (Tariq et al., 2011), and WDR16 (Ta-
Shma et al., 2015). However, the investigation of recessive causes of CHD has, to 
date, been relatively understudied (Zaidi and Brueckner, 2017). 
 
WES in the setting of autosomal dominant inheritance commonly uses linkage analysis 
of a large pedigree to indicate a likely disease locus (Boycott et al., 2013).  LaHaye et 
al., 2016, performed WES in six families with autosomal dominant inheritance of CHD, 
four with ASD and two with PDA. They identified likely pathogenic mutations in GATA4, 
TLL1 and MYH11, demonstrating the clinical utility of WES in this setting (LaHaye et 
al., 2016). Some difficulties arise in the presence of non-penetrance, which has been 
observed in CHD families, for example in well-characterized genes such as NOTCH1 
(Kerstjens-Frederikse et al., 2016). This may indicate unidentified modifier alleles are 
present that affect disease penetrance in these families, and suggests that epistasis 
between alleles is an important determinant of phenotypic variability. 
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WES has been used successfully in the setting of de novo dominant mutations, 
particularly with the use of parent-child trios (Gibson et al., 2012). Due the large 
number of sporadic cases of non-syndromic CHD, it is supposed that de novo 
mutations may play a major contribution (Zaidi and Brueckner, 2017). In a large cohort 
of 1213 trios, which included CHD with extra-cardiac malformations and 
neurodevelopmental abnormalities, de novo mutations were found to be present in a 
high number of CHD cases associated with syndromes and other abnormalities (20% 
of syndromic cases, but only 2% of isolated CHD cases) (Homsy et al., 2015). 
 
In a further example, Sifrim et al., 2016 undertook a large exome sequencing study of 
patients with both syndromic and non-syndromic CHD, examining 1891 probands. In 
the syndromic cases there was an increase in de novo protein truncating variants, 
however, in non-syndromic CHD there was an enrichment of truncating variants 
inherited from unaffected parents, compared to controls. This finding suggests a level 
of non-penetrance in non-syndromic CHD and implies the effect of modifier alleles, for 
example intronic SNVs that affect splicing. This large exome study was able to identify 
new disease genes including CDK13 and PRKD1 (Sifrim et al., 2016).  
 
It is likely that NGS technology will continue to become increasingly less costly and 
quicker and easier to perform, meaning that small families and those with more 
complex inheritance patterns may be examined.  
1.7.2.1 Whole Exome Sequencing in Consanguineous Unions 
In the ethnically-diverse region of Bradford in Yorkshire, there is a large community of 
residents of Pakistani origin. Around 40% of births in this community are to first cousin 
unions (Sheridan et al., 2013). For medical purposes, consanguinity is defined as a 
union between second degree cousins or closer relatives. Populations where 
consanguineous marriage is common have high rates of autosomal recessive disease, 
due to the increased likelihood of homozygosity. In the Bradford community, it has 
been shown that consanguineous union doubles the risk of congenital anomaly 
(multivariate risk ratio [RR] 2.19, 95% CI 1.67–2.85), including CHD (Sheridan et al., 
2013). There are now 200 distinct recessive disorders recorded in the Bradford 
population. In other communities, consanguinity, particularly first cousin unions, has 
been shown to be associated with an increased incidence of CHD (Becker and Al 
Halees, 1999, Sadiq et al., 1995, Hoffman and Kaplan, 2002, Yunis et al., 2006). 
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The increased prevalence of autosomal recessive disorders in the Bradford community 
offers a unique research opportunity. Previously, gene identification in this community 
used the application of autozygosity mapping in larger consanguineous families to 
identify shared homozygous regions between affected individuals. However, more 
recent work has allowed the identification of novel disease genes without the need for 
prior autozygosity mapping, even in trios and sporadic cases (Parry et al., 2013). It is 
therefore now feasible to study smaller families, even in the presence of genetic 
heterogeneity.  
1.7.3 Whole Genome Sequencing 
Whole Genome Sequencing is the sequencing of an entire organism’s DNA sequence. 
In variant discovery, WGS still has some limitations over WES, although it has been 
used successfully to identify candidate disease genes (C. Yuen et al., 2017). Current 
difficulties include a lack of comprehensive databases of normal variation, standardized 
pipelines for data analysis and availability of storage for large data files. These factors 
are likely to be overcome in the near future, with decreasing costs and increasing 
understanding of the non-coding regions. This will lead to an improved understanding 
of the effect of mutations in enhancers and promoter regions on disease. This may be 
very relevant in CHD disease-gene research, for example a homozygous variant in a 
TBX5 enhancer was recently shown to be the cause of disease in a patient with septal 
defects (Smemo et al., 2012). WGS, as it is lacking a capture step, can also provide 
more complete coverage of the exomic regions than WES (Belkadi et al., 2015) and it 
can lead to detection of intronic Single Nucleotide Variants (SNVs), CNVs and 
translocations, which is not possible with WES. 
1.7.4 GWAS  
The complex nature of non-syndromic CHD suggests it may often be a multifactorial 
disorder and behave like a complex trait. Genome Wide Association Studies (GWAS) 
have become increasingly utilised in many common disorders to identify the 
association between the disorder and common low-penetrance variants. This 
methodology has only recently been applied in the setting of CHD.  
 
Goodship et al., 2012, studied 207 Single Nucleotide Polymorphisms (SNPs) in 22 
candidate genes in their cohort of 362 non-syndromic patients with TOF, 717 
unaffected parents and 183 unrelated controls. Candidate genes were selected on 
evidence of involvement in outflow tract development from transcriptional studies or 
mouse models. They found a significant association between a SNP in the PTPN11 
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gene (rs11066320) and non-syndromic TOF and this was replicated in a further large 
cohort. Gain of function mutations in PTPN11 are responsible for Noonan Syndrome 
and the authors hypothesised that this common SNP may up-regulate the RAS-MAPK 
pathway to a lesser extent to that seen in Noonan syndrome, leading to a raised 
susceptibility to TOF (Goodship et al., 2012).  
 
In 2013, Cordell et al. undertook a large international GWAS study involving over 5000 
patients, divided into three major categories of CHD comprising septal, obstructive and 
cyanotic defects. Analysis of over 500,000 SNPs was undertaken in these cases and 
over a thousand controls. In the initial analysis, no SNP was found to show reliably 
significant association. However, when patients were divided into diagnostic groups, 
three SNPs on chromosome 4p16 were found to be significantly associated with ASD. 
The most significant of these, rs870142, conferred an Odds Ratio of 1.46 (p = 9.5x10-
7). This SNP lies in the region between the STX18 and MSX1 genes. Large deletions of 
this region cause Wolf-Hirschhorn syndrome, known to be associated with cardiac 
defects. MSX1 is expressed in the atrial septum in the mouse and is known to interact 
with TBX5 (Cordell et al., 2013).  
 
In another recent paper, Hu et al., 2013, carried out a GWAS study looking at septal 
defects, including ASD, VSD and AVSD in the Han Chinese population. They assessed 
over 700,000 SNPs in 957 cases and 1,246 controls. Two SNPs (rs2474937 at 1p12 
and rs1531070 at 4q31.1) were found to have significant association in this group and 
in a validation sample. rs2474937 is located near to the TBX15 gene and rs1531070 is 
within the MAML3 gene, which are both expressed in high levels in human cardiac 
tissue. MAML3 plays an important role in the Notch signalling pathway (see section 
1.5.2.2) (Hu et al., 2013).  
1.8 Clinical Utility of Gene Identification 
The identification of new genetic aetiologies in CHD are likely to assist in patient 
management, both in the fields of preventative care and in therapeutics. Identification 
of monogenic causes of CHD allows for genetic investigation and testing, providing 
knowledge for patients on inheritance patterns, risk assessment, screening for 
relatives, and allows clinical teams to counsel families on recurrence, prenatal 
diagnosis and prenatal intervention. Furthermore, gene identification allows for 
pathophysiological insights into the familial cases of CHD, which may help to delineate 
causes in sporadic cases (Chaix et al., 2016).  
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Genetic testing in the context of CHD in a clinical setting may give information on 
potential other non-cardiac organ involvement, or other associated cardiac 
complications. For example, in NKX2-5-related ASD, atrioventricular block and 
progressive ventricular dysfunction are a further risk (Pashmforoush et al., 2004). Also, 
mutations in MYH6 can cause structural heart disease as well as cardiomyopathy 
(Granados-Riveron et al., 2010). Genetic testing may also be used to identify CHD 
patients who are more at risk of poor neurodevelopmental outcomes, allowing for 
earlier supportive intervention (Zaidi and Brueckner, 2017).   
 
A genetic basis for disease may allow for prognostic information for affected patients, 
as disease stratification according to genetic aetiology becomes more available, and 
factors such as post-operative survival or long-term outcome may be assessed 
according to underlying cause. As an example of this, endothelin-1 c.5665G>T 
(p.K198N, rs5370) has been associated with improved transplant-free survival in 
patients with Hyperplastic Left Heart Syndrome (HLHS) (Kirshbom et al., 2008).  
 
Ultimately, the goal of genetic diagnosis in CHD is therapeutic potential, and targeted 
curative therapy. This is currently beyond our reach, but will theoretically be possible in 
the future. An encouraging example of this type of work is the knockout Wnt2 mouse 
model, where AVSD could be rescued on activation of Wnt signaling (Tian et al., 2010).  
1.9 Aims  
The overall objective of this research project was the identification of novel CHD genes 
by Whole Exome Sequencing. The methods of this study were to identify families 
where there was a likely monogenic cause of CHD, so where the family structure was 
consistent with a Mendelian pattern of inheritance, and/or there was parental 
consanguinity. Both syndromic and non-syndromic forms of CHD were included and 
‘CHD’ was broadly defined to include both structural defects and congenital or early 
onset myopathies. As well as the formation of partnerships with local clinicians in the 
Leeds-Bradford area, collaborations were formed with other genetics and cardiac 
centers nationally for the recruitment of patients. The full inclusion criteria are given in 
appendix A.  
 
The following were specific objectives of the project: 
1) To identify families with a likely Mendelian inheritance of CHD, according to 
inclusion criteria, obtain informed consent for research and to gain appropriate DNA 
samples from consented family members. 
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2) To perform WES for selected individuals from recruited families and to use a 
bioinformatic workflow of filtering sequence variant data to identify novel CHD genes. 
4) To confirm the pathogenicity of putative mutations by comparison with exome 
sequencing data, both within local cohorts and/or by screening genes in other cohorts 
available by collaboration. 
5) To perform functional characterization of new disease proteins using 
established biochemical and cell biology techniques. The pathogenic potential of 
putative missense mutations could then be investigated using in vitro cell and zebrafish 
morphant models.  
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2 Materials and Methods 
2.1 Materials 
Room Temperature (RT) is defined as 20-22oC. 
2.1.1 General Reagents 
Water       Milipore 
Ethanol     Sigma-Aldrich 
Methanol     Sigma-Aldrich 
Phosphate Buffered Saline (PBS) 1x  Sigma-Aldrich  
2.1.2 Solutions 
2.1.2.1 PBST 
1x  PBS 
0.1% [v/v]   Tween20 (Sigma-Aldrich) 
2.1.2.2 Tris-EDTA (TE) Buffer 1x  
10mM  Tris HCl (pH 8.0) (Sigma-Aldrich) 
1mM EDTA (pH 8.0) (Ambion®, Thermo Fisher Scientific, Waltham, MA, 
USA) 
2.1.2.3 Tris-Acetate-EDTA (TAE) Buffer 50x 
2M  Tris HCl 
50mM  EDTA (pH 8.0) 
0.97M  Glacial acetic acid (Sigma-Aldrich) 
2.1.2.4 Tris-Borate-EDTA (TBE) Buffer 10x 
890mM  Tris HCl 
890mM Boric Acid (Sigma-Aldrich) 
20mM  EDTA  
2.1.2.5 Gel Loading Dye 2x 
50%[v/v] Glycerol (Sigma-Aldrich) 
10%  TBE 10x 
0.1%[w/v]  Orange G (Sigma-Aldrich) 
0.1%[w/v] Xylene Cyanol (Sigma-Aldrich) 
 26 
2.1.2.6 NP40 Lysis Buffer 
1%[v/v] NP40 (IPEGAL CA-630) (Sigma-Aldrich) 
50mM   Tris-HCl (pH 8.0) 
150mM NaCl (Sigma-Aldrich) 
1x  Protease Inhibitor Cocktail (Thermo Fisher Scientific) 
2.1.2.7 IP Wash Buffer 
150mM NaCl 
50mM  Tris-HCl (pH 8.0) 
0.5mM  EDTA  
0.1% [v/v] NP40 
2.1.2.8 IP Incubation Buffer 
150mM NaCl 
50mM  Tris-HCl (pH 8.0) 
1x  Protease Inhibitor Cocktail 
2.1.2.9 SDS Loading Buffer 
100 mM  Tris – HCl pH 6.8 
4%[w/v]  SDS (BDH, Poole, UK) 
20%[v/v]  Glycerol 
20 mM  β – mercaptoethanol (BDH, Poole, UK) 
0.004% [v/v] Bromophenol Blue (Sigma-Aldrich) 
2.1.2.10 Lysis Buffer for Cellular DNA Extraction 
10mM   Tris pH 8.0 
100mM  EDTA 
20µg/µl  RNAse (Sigma-Aldrich) 
0.25%[w/v] SDS  
2.1.2.11 TAP Wash Buffer 
1x  TBS 
1x  Protease/Phosphatase Inhibitor Cocktail 
0.1% [v/v] NP40 
2.1.2.12 D-desthiobiotin Elution Buffer 
100mM  Tris HCl pH8.0 
150mM  NaCl 
1mM   EDTA 
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5mM   D-desthiobiotin. 
 
2.1.3 Cell Lines 
hTERT- RPE1 cells   Source ATCC (Manassas, Virginia, USA) 
HEK293 cells    Souce ATCC (Manassas, Virginia, USA) 
IMCD3 cells    Souce ATCC (Manassas, Virginia, USA) 
 
2.1.4 Primary Antibodies 
Primary antibodies were used as detailed in table 2-1. 
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Table 2-1: List of primary antibodies.  
Table includes the species the antibody was raised in, dilutions of antibodies used in IF, whole mount in situ hybridization and western blot, as well as the 
antibody supplier. 
Antigen Species raised 
in 
Polyclonal/ monoclonal; 
Clone name; Isotype 





DNAAF1 Rabbit Polyclonal 1/50 1/50  Santa-Cruz 
DNAAF1 Rabbit Polyclonal 1/100   Abcam 
RPGRIP1L Guinea Pig Polyclonal 1/500   Proteintech 
γ-tubulin Mouse Monoclonal; GTU-88; IgG1 1/1000   Sigma-Aldrich 
Centrin 3 Mouse Polyclonal 1/100   Merck 
Acetylated 
alpha-tubulin 
Mouse Monoclonal; 6-11B-1; 
IgG2b 




Mouse Monoclonal; GT335; IgG1κ 1/100   AdipoGen, San 
Diego, CA, USA 
Pontin Mouse Monoclonal; 5G3-11; IgG 1/200 1/200 1/1000 Sigma-Aldrich 
Gamma-tubulin Goat Polyclonal 1/50 1/100  Santa Cruz 
Reptin Mouse Monoclonal; 2E9-5; IgG 1/200 1/200 1/1000 Sigma-Aldrich 
FLAG Mouse Monoclonal; M2; IgG1 1/500  1/1000 Sigma-Aldrich 
ARL13B Rabbit Polyclonal 1/500 1/1000  Proteintech 
ARL13B Mouse Monoclonal; N295B/66 
IgG2a 
1/500   Antibodies Inc, 
Davis, CA, USA 
IFT88 Rabbit Polyclonal 1/200   Proteintech 
 “Living 
Colours” 
Mouse A mixture of monoclonal 
antibodies against native 
fluorescent proteins, that 
recognizes GFP, YFP and 
CFP 
  1/1000 Clontech 
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2.2 Methods 
2.2.1 Patient Identification 
Families were identified through collaborators in Departments of Clinical Genetics and 
Departments of Paediatric & Adult Cardiology across the UK, including Yorkshire, 
Newcastle-Upon-Tyne and North West Thames (Kennedy-Galton Centre). To raise 
awareness of the research study, a presentation was given at the Yorkshire Regional 
Cardiac Network meeting (June 2013), at the Leeds Teaching Hospitals Paediatric 
Cardiac Surgery meeting (August 2013) and at the Yorkshire Regional Genetics 
weekly multidisciplinary meeting (August 2013). Verbal and written information was 
distributed to Clinical Geneticists, Genetic Counselors, Consultant Cardiologists, 
Cardiac Nurses and Cardiac Radiologists within Leeds Teaching Hospitals Trust, 
containing contact details for the research team and patient inclusion criteria. 
 
Patients were ascertained according to inclusion criteria as detailed in Appendix A. 
Families identified in the clinical setting were provided with verbal and written 
information regarding the research project (see Appendix B). The lead consultant then 
referred to the family to the research team. On referral an appointment was made for 
the research team to meet the family, undertake a full clinical examination and obtain 
informed consent and DNA sampling as detailed below.  
 
Furthermore, a systematic search of medical records was undertaken in the 
Department of Clinical Genetics, Chapel Allerton Hospital, Leeds. Medical records for 
patients coded under ‘Congenital Heart Disease’ were identified and assessed. Once 
families meeting the inclusion criteria were identified, a letter was sent from their lead 
consultant. Patients were only further contacted if they expressed interest and returned 
the consent form.  
2.2.2 Consent 
Interested families were contacted by telephone and a home visit or clinical 
appointment was arranged with Dr Hartill and Mrs Shabana Khan, a clinical research 
nurse. At the time of home visit, families were given verbal information about the study 
and were presented with the written information sheet. They were then asked to give 
written informed consent using the approved consent form (see Appendix C).  
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2.2.3 Ethical Approval 
The study title associated with this project is 'Molecular genetic investigations of 
autosomal recessive conditions', granted ethical approval for 5 years by South 
Yorkshire LREC on 18th Feb 2011, ref. number 11/H1310/1. There is also local Leeds 
Teaching Hospitals Trust R&D approval (see Appendix D). 
2.2.4 Clinical Assessment 
A full detailed family pedigree, medical history and clinical examination, including 
cardiac examination and assessment of dysmorphic features was performed for all 
patients. The medical and clinical genetics notes, plus any previously performed 
radiological imaging was reviewed for all consented patients. Previously performed 
genetic testing, for example Array CGH, was assessed for all consented patients. 
2.2.5 Clinical Investigation for PCD 
Clinical investigations for PCD were performed in one family. These investigations 
were performed by a representative of a specialist PCD center (UCL, Institute for Child 
Health, London, UK). Nasal Nitric Oxide (NO) levels were assayed using a 
chemiluminescence analyser. Three NO measurements were taken per nostril, with the 
mean of these being taken as the NO level. Ambient NO level was recorded before 
each test. Respiratory epithelial cells were obtained by nasal brush biopsy and 
suspended in cell culture medium, before transfer to the London laboratory. Light, 
electron, and immunofluorescence microscopy were used to analyse ciliary motility and 
structure. Human Transmission Electron Microscopy (TEM) and high-speed video 
microscopy were carried out as previously reported (Shoemark et al., 2012).  
2.2.6 DNA Sampling 
Blood or saliva samples were obtained from affected individuals, parents and, where 
possible, unaffected siblings. These were collected by standard methods. Oragene 
saliva collection kits (DNA Genotek, Orasure Technologies Inc., Ottawa, Canada) were 
used for saliva collection.  
2.2.7 DNA Extraction 
2.2.7.1 Peripheral Blood Samples 
DNA extraction from blood samples was performed by the Yorkshire Molecular 
Genetics Laboratory (St James’ University Hospital, Leeds, UK). DNA was extracted 
from peripheral blood leukocytes and stored in Tris-EDTA buffer (pH 8.0) using a 
standard salt precipitation protocol. 
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2.2.7.2 Saliva Samples 
DNA extraction from saliva samples was performed using prepIT L2P DNA extraction 
kits (DNA Genotek, Orasure Technologies Inc.), according to the manufacturer’s 
protocol. DNA pellets were dissolved in 1x TE buffer for long-term storage.  
2.2.7.3 Cell Culture 
DNA extraction from cell cultures was performed using a standard phenol/chlorophorm 
extraction. In brief, cells were resuspended in a total volume of 200µl of lysis buffer 
(see 2.1.2.10) following one 1xPBS wash. They were incubated at 37oC for one hour. 
Proteinase K (Sigma-Aldrich) was added to a final concentration of 100µg/µl and 
incubated at 55oC for one hour. An equal volume of phenol and chloroform was added, 
vortexed and then centrifuged at 16,000xg for 5 minutes. DNA was precipitated from 
the aqueous phase in 100% ethanol with 0.2M NaCl. The extracted DNA was washed 
in 75% ethanol twice and dissolved in 1X TE buffer. The DNA concentration was 
determined using a Qubit BR dsDNA assay (Life Technologies, Thermo Fisher 
Scientific), see 2.2.14. 
2.2.7.4 Paraffin-Embedded Slides 
In one case, paraffin-embedded slides of renal tissue were available for DNA 
extraction. DNA extraction was performed twice from these slides, initially by Dr 
Gemma Hemmings, Leeds Institute of Cancer & Pathology (LICAP), University of 
Leeds, and the second extraction was performed by Dr Hartill, using identical methods. 
Initially samples were dewed in a xylene/ ethanol series. This involved immersing 
slides in xylene (Sigma-Aldrich) for 4 x 5 mins, 100% ethanol for 3 x 4 mins and then in 
decreasing ethanol concentrations for four minutes each. Microdissection was used to 
collect the tissue of interest from the slides. DNA extraction used the Formalin-Fixed 
Paraffin-Embedded (FFPE) kit from Qiagen (Germantown, MD, USA) and extraction 
was performed according to the kit protocol. 
2.2.8 Whole Genome Amplification 
Where a very low quantity of DNA was available, for example in the case of DNA 
extracted from FFPE slides, Whole Genome Amplification (WGA) was used to increase 
DNA quantity for Polymerase Chain Reaction (PCR). This was performed using the 
Illustra GenomiPhi V2 DNA amplification kit (GE Healthcare). 1µl (10ng) of template 
DNA was combined with 9µl of sample buffer. The DNA was denatured at 95oC for 
three minutes and then cooled to 4oC on ice. The amplification master mix was created 
from 9µl reaction buffer and 1µl enzyme mix (Phi29 DNA polymerase). This was 
transferred to the cooled sample. DNA amplification was carried out at 30oC for 18 
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hours (longer than suggested in the protocol) and then the enzymes were inactivated 
at 65oC for 10 minutes.  The sample was cooled to 4oC and stored at -20oC. It was then 
used as usual in downstream applications.  
2.2.9 RNA extraction 
RNA was extracted from cells in culture. All solutions were prepared with RNase-free 
water. Growth media was removed from the culture dish. An appropriate volume of 1x 
Phosphate Buffered Saline (PBS) was added and cells were scraped off into the PBS 
and centrifuged for 5 minutes at 200xg at RT. The cell pellet then underwent a further 
1xPBS wash and was spun down. Trizol® reagent (Life Technologies) was added to 
the cell pellet at a volume of 1ml of Trizol per 10cm2 culture dish surface area. The 
cells were pipetted up and down several times to lyse. The homogenized sample was 
incubated for 5 minutes at RT. 0.2ml of chloroform was added per 1ml Trizol reagent, 
shaken and incubated for 2-3 minutes at RT. The sample was centrifuged at 12,000xg 
for 15 minutes at 4oC. The aqueous phase of the sample was removed. 0.5ml of 100% 
isopropanol per 1ml Trizol was added to the aqueous phase and the sample was 
incubated at RT for 10 minutes. The sample was then centrifuged at 12,000xg for 10 
minutes at 4oC. The RNA pellet was washed in 75% ethanol and left to air dry. The 
RNA pellet was resuspended in RNAse free water. 
2.2.10  Polymerase Chain Reaction 
2.2.10.1 Primer Design 
Primers were designed using the Primer 3 program (http://bioinfo.ut.ee/primer3/) or 
Auto Primer 3 (https://github.com/gantzgraf/autoprimer3), which retrieves gene 
information from UCSC (the University of California Santa Cruz Genome Browser) and 
uses Primer 3 to design primers. Primers were designed to avoid common SNPs and 
parameters were set to produce primers with an optimum annealing temperature of 
around 60oC and with products of between 250-600bps. Primer sequences were 
checked using a BLAST tool (http://blast.ncbi.nlm.nih.gov/Blast) to ensure specific 
binding and avoidance of SNPs. Primers for genomic sequencing were designed to 
cover all exons and at least 15bp of flanking intronic regions. Overlapping primers were 
used in cases where exons were too large for the product to be amplified in a single 
experiment. Primer sequences used in this project are listed in appendix E.  
2.2.10.2 PCR Reaction 
PCR reactions were set up in a total volume of 10µl. 20ng of genomic DNA was 
combined with 2µM of forward and reverse primers (Sigma-Aldrich), 1 unit of Taq DNA 
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polymerase (ABgene), 0.25µM dNTPs (Thermo Fisher Scientific) and PCR buffer 
(75mM Tris-HCl buffer pH8.8, 20 mM (NH4)2SO4, 0.01% Tween 20 and 1.5 mM MgCl2). 
Alternatively 20ng of genomic DNA was combined with 2µM forward and reverse 
primers and 1 x HotShot Diamond PCR Master Mix (Clent Life Science, Stourbridge, 
UK).  
 
Reactions were performed in a Veriti Thermal Cycler (Thermo Fisher Scientific). 
Denaturation was at 95oC for 5min, followed by 45 cycles of 94oC for 15 seconds, the 
appropriate annealing temperature for 15 seconds, 72oC for 30secs and then finally 
extension at 94oC for 30secs. PCR products were visualized by agarose gel 
electrophoresis (see section 2.2.10.3).  
 
Where necessary, for GC rich regions, reactions were supplemented with 5 x 
Combinational Enhancer Solution (5 x CES); 2.7 M betaine, 6.7 mM DTT, 6.7% DMSO 
and 55 µg/ml BSA.  
2.2.10.3 Agarose Gel Electrophoresis 
Samples were mixed in a 1:1 [v/v] ratio with 2x loading buffer. The gel was composed 
of molecular biology grade agarose powder (Bioline, London, UK) dissolved in 1 x TAE 
to a concentration of 2% [w/v]. Ethidium bromide (Sigma-Aldrich) was added to a final 
concentration of 0.5µg/ml or Midori Green (Geneflow, Staffordshire, UK) at 5µl per 
100ml gel. A DNA size standard ladder was used (Easy Ladder I, Bioline). An electric 
field was applied at 120V for 40min. The gel was visualized on a UV transilluminator 
and displayed using Image Lab (v. 4.0) analysis software (Bio-Rad, Hemel Hempstead, 
UK).  
2.2.11 Purification with ExoSAP 
Prior to sequencing, samples were purified with ExoSAP-IT® (Affymetrix, Thermo 
Fisher Scientific) to remove unused primer and dNTPs. For 2.5µl of PCR product, 1µl 
of ExoSAP-IT was added. Samples were incubated for 45min at 37oC and then 
inactivated for 15min at 80oC. 
2.2.12 Sanger Sequencing 
ExoSAP-IT purified PCR products were sequencing using the BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific). 1µl of product was combined 
with 1µl of BigDye®, 1µl of forward or reverse primer at a final concentration of 0.2µM, 
1.5µl of BigDye® buffer and 5.5µl of dH20.  
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Reactions were performed in a Veriti Thermal Cycler (Thermo Fisher Scientific). 
Denaturation was at 96oC for 1min, followed by 45 cycles of 96oC for 10 seconds, 50oC 
for 15 seconds, and 60oC for 4 minutes. Temperatures were ramped at 1oC/second.  
 
Precipitation was performed by adding 1µl of 0.25M EDTA to the sample, followed by 
31µl of 100% ethanol. This was centrifuged at 3900xg for 30 minutes at 4oC. The plate 
was then inverted onto tissue and spun upside down at 200xg for 5 seconds. Next, 
60µl of 70% [v/v] ethanol was added and the sample was centrifuged at 3900xg for 15 
minutes. Then the plate was inverted and spun at 200xg for 5 seconds. The sample 
was then left to air dry for 15min at RT under foil or on a hot block at 37oC for a few 
minutes. To resuspend the samples, 10ul HiDi Formamide (water-free and deionized, 
Applied Biosystems, Thermo Fisher Scientific) was added. The plate was sequenced 
on an ABI3130xl Genetic Analyzer (Applied Biosystems) using polymer POP7 (Applied 
Biosystems). Resulting data was analysed using Seqscape v2.5 (Applied Biosystems) 
or 4Peaks (Mek&Tosj.com). 
2.2.13 Genotyping with SNP array 
DNA for Affymetrix Genome-Wide Human SNP Array 6.0 was sent from selected family 
members to AROS Applied Biotechnology, Denmark, for commercial processing. 
Received data was analyzed using SnpViewer 
(https://sourceforge.net/projects/snpviewer/files/). This program allows homozygous 
regions of the genome to be identified using colour-coded bars for homozygous and 
heterozygous SNP calls. Affected and unaffected family members can then be 
assessed together by eye or by using the program’s ‘find regions’ tool. 
2.2.14 Whole Exome Sequencing 
DNA samples for WES were quantified using Quant-iT dsDNA assay (Lifetechnologies, 
Waltham, MA, USA), to ensure an appropriate amount of DNA was used for shearing. 
The Quant-iT Reagent was diluted to 1:200 in Quant-IT buffer. 1µl of sample DNA or 
10µl of control standard were added to the assay tube and vortexed for 2-3 seconds. 
The tubes were incubated for 2 minutes at room temperature and read in the Qubit 
fluorometer. The concentration was calculated by multiplication with the dilution factor.  
 
Two methods for WES were undertaken, the SureSelect XT method (Agilent, Santa 
Clara, CA, USA), which uses 1-3µg of DNA, and the SureSelect QXT method (Agilent, 
Santa Clara, CA, USA), which uses 25ng DNA.  
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2.2.14.1 Sure Select XT method 
The Sure Select XT method was performed using either the SureSelect XT Human All 
Exon V4 or V5 kits (Agilent Technologies). DNA shearing was carried out for 1-3µg of 
DNA using a Covaris S2 Adaptive Focused Acoustics Sonicator (Covaris, Woburn, MA, 
USA). This method uses focused bursts of ultrasonic acoustic energy to create 200-
300bp fragments of DNA. Standard settings of 10% Duty Factor, Peak Incident Power 
175, 200 Cycles Per Burst, treatment time of 360s and bath temperature 4-8oC were 
used. Following shearing, the quality and quantity of the prepared library was assessed 
using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), as 
per the manufacturer’s protocol. Quantification was performed using the 2100 
Bioanalyser software (Agilent) by interrogating the area under the curve. The 
SureSelect XT library preparation was carried out according to the kit instructions and 
involves the following steps: repairing the ends of sheared DNA, adding ‘A’ bases to 
the 3’ end of the DNA fragments, ligating index-specific paired-end adaptors and 
amplification of the adaptor-ligated library using a 6-cycle enrichment PCR. Before 
each step, the sample is purified using Agencourt AMPure XP beads. Figure 2-1 shows 
a summary of the Agilent SureSelect workflow for paired-end sequencing.  
 
Following amplification, the quality and quantity of the prepared library was further 
assessed using the Agilent 2100 Bioanalyzer. A Savant SpeedVac 110 vacuum 
concentrator (ThermoFisher Scientific, Waltham, MA, USA) was used where necessary 
to achieve a prepared library concentration of 221ng/µl in 3.4µl (750ng) before 
hybridisation. The prepared genomic sample was hybridized to SureSelect biotinylated 
RNA library baits and hybrid capture was carried out using streptavidin coated 
magnetic beads. For hybridization, 5.6µl of SureSelect Block mix was added to 3.4µl of 
221ng/µl prepared library. This was heated to 95oC for 5 minutes and then held at 
65oC. This stops adapted-ligated DNA hybridising end-to-end. 13µl of Hybridisation 
buffer was added to 7µl of the SureSelect capture library mix and 13µl of the resulting 
reagent was added to the prepared library. This was maintained at 65oC for 16 hours. 
 
Capture of the resulting hybridisation was performed using Dynabeads® MyOneTM 
Streptavidin T1 (Life Technologies) following incubation at room temperature for 30 
minutes. SureSelect index tags were added to each sample by post-hybridization 
amplification, with a total of 12 cycles, and the quality was finally assessed, using a 
high-sensitivity protocol, on an Agilent 2100 Bioanalyzer. Equal molar quantities of 
each captured sample were pooled and diluted to 10nM in nuclease-free water. Six 
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samples were pooled per lane for multiplex sequencing on an Illumina HiSeq 2500 
DNA sequencing system (Illumnia, San Diego, CA) in 100bp paired end mode.  
 
Cluster amplification and generation, as well as subsequent sequencing was 
performed by the Leeds Next Generation Sequencing Facility (Leeds, UK, 
http://dna.leeds.ac.uk/genomics/) (see Fig. 2-2). The  
Next Generation sequencing facility uses an Illumina HiSeq 2500 (and more recently a 
HiSeq 3000), which use ‘clonal bridge amplification’ and a ‘sequencing by synthesis’ 
reversible dye-termination method (Bentley et al., 2008) (Figure 2-2). This process 
involves washing the prepared DNA fragments onto a flow cell where oligonucleotides 
complementary to the adaptors are situated. Each DNA fragment forms a bridge 
between two adaptors and is then PCR amplified, the so-called ‘bridging amplification’, 
which forms clusters of identical DNA sequences on the flow-cell. Fluorescently labeled 
reversible terminators are washed across the flow cell and a single terminator is added 
to each strand. As each terminator is incorporated and is laser-excited, all of the stands 
in a cluster fluoresce with the same colour, which is detected by the sequencer. 
Following this, the terminator is chemically inactivated so that the next cycle can 
commence. This process is termed ‘sequencing by synthesis’ The resulting recorded 
sequence is called a ‘read’. In paired-end sequencing, once the first strand reaction is 





















Figure 2-1: Agilent SureSelect XT workflow for Paired-end Sequencing, DNA shearing to exome capture with addition of biotinylated RNA library 
baits.  
In this protocol, DNA is sheared using sonication, the ends of sheared DNA are repaired, ‘A’ bases are added to the 3’ end of the DNA fragments, index-
specific paired-end adaptors are ligated and the adaptor-ligated library is amplified using a 6-cycle enrichment PCR. Library capture involves the addition of 























































Figure 2-2: Illumina sequencing protocol, showing cluster amplification on a flow cell.  
Prepared DNA fragments are washed onto the flow cell where complementary oligonucleotides 
are situated. Each DNA fragment forms a bridge between two adaptors and is then PCR 
amplified (‘bridging amplification’). This forms clusters of identical DNA strands on the flow-cell. 
Fluorescently labeled reversible terminators are washed across the flow cell and a single 
terminator is added to each strand (‘base-by-base addition’). Each base is laser-excited, 
causing all of the strands in a cluster to fluoresce with the same colour, detected by the 
sequencer. Following this, the terminator is chemically inactivated so that the next cycle can 
commence. 
2.2.14.2 Sure Select QXT Method 
The Sure Select QXT method was performed using either the Sure Select QXT Human 
All Exon V5 or V6 kits (Agilent Technologies). The kit protocol was followed exactly. 
Each DNA sample was prepared to a dilution of 25ng/µl using the Qubit ds BR assay. 
Fragmentation of DNA samples and addition of adaptors was performed in a single 
enzymatic step, using SureSelect QXT Enzyme Mix ILM, with an incubation time of 10 
min at 45oC. Purification following each step was carried out using AMPure XP beads. 
The adaptor-tagged library was amplified using Herculase II fusion DNA polymerase in 
an 8 cycle PCR reaction. DNA library quantity and quality was assessed on the Agilent 



























For hybridization of the DNA samples to the capture library, 1500ng of the prepared 
DNA library was made up to 12µl in nuclease-free water. 5µl of SureSelect QXT Fast 
Blocker Mix was added and the samples were held at 65oC for 10 mins. 25% RNase 
block and the capture library, along with a buffer, were added and a thermal cycler was 
used to perform 60 cycles of 65oC for 1 min and 37oC for 3s. Dynabeads® MyOneTM 
Streptavidin T1 (Life Technologies) magnetic beads were used for DNA hybrid capture 
following a 30min incubation at 65oC. A magnetic separator was used for bead capture. 
Index tags were added using Herculase II Fusion DNA polymerase in a 10 cycle PCR. 
A further assessment of DNA quality and quantity was performed on an Agilent 2100 
Bioanalyzer, using a high sensitivity chip, following purification with AMPure XP beads. 
Equal molar quantities of each captured sample were pooled and diluted to 10nM in 
nuclease-free water. Nine or ten samples were pooled per lane and sequencing was 
performed on an Illumina HiSeq 3000 DNA sequencing system by the Leeds Next 
Generation Sequencing Facility (Leeds, UK, http://dna.leeds.ac.uk/genomics/). 
2.2.14.3 WES Data Analysis 
For each sample, a standardized data analysis workflow was followed. Data was 
initially collected from the Hiseq2500 or Hiseq3000 in .fastq format. Reads were 
aligned to the reference sequence (GRCh37, Genome Reference Consortium human 
reference assembly build 37) using Novoalign (Novocraft Technologies, Selangor, 
Malaysia) or BWA (Burrows-Wheeler Aligner (Li and Durbin, 2009)) to create a .sam 
(sequence alignment map) file. Each .sam file was sorted into chromosome order with 
Picard v1.85 (http://picard.sourceforge.net) and converted to .bam (binary alignment 
map) format. Picard tools were used to mark and remove duplicate reads. The Indel 
Realigner function of the Genome Analysis Toolkit (GATK, Broad Institute, USA) was 
used to perform realignment around indels (insertions and deletions). The 
BaseRecalibrator (GATK) was used to create a recalibration model, which was 
assessed by creating recalibration plots. Base quality score recalibration was then 
applied. This recalibrates quality scores for all bases in a read, taking into account the 
reported quality score, position of the base within a read, and the preceding and 
concurrent nucleotide.  
 
Variants were called using HaplotypeCaller (GATK). This was predominantly used over 
the Unified Genotyper (GATK) due to the reported superior calling of indels (Dr David 
Parry, personal communication). This program can be multithreaded for multiple 
samples. This created a .vcf (variant call format) file containing variants from all family 
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members in a single file. Familial samples were called together to increase confidence 
in the calls.  
 
Variants were hard filtered using the VariantFiltration programme (GATK). Indels and 
SNPs were separated before hard filtering. This program labels variants falling below 
certain specified parameters. Parameters used for indels and SNP/MNPs are shown in 
Table 2-2. 
 
Table 2-2: Parameters used for hard filtering of variants. 
Variation Abbreviation Character Parameter to be 
marked 
Indel QD Quality by Depth <2.0 reads 
 FS Fisher Strand PHRED 
scaled p-value to detect 
strand bias 
>200.00 
 Readposranksum Mann-Whitney Test for 
distance from end of 
read for alternate allele 
in het call 
<-20 
SNP/MNP QD Quality by Depth <2.0 reads 
 FS Fisher Strand >60.00 
 ReadPosRankSum Distance from end of 
read for alternate allele 
<-8 
 mappingqualityranksum Mann-Whitney Rank 
Sum Test for Mapping 




Variants were then further filtered to remove those with a mean allele frequency (MAF) 
of above a user specified cut-off in The National Center for Biotechnology Information’s 
(NCBI’s) database of single nucleotide polymorphisms (dbSNP) version 129 and 
previous (Sherry et al., 2001), the NHLBI Exome Sequencing Project (ESP) 
(http://evs.gs.washington.edu/EVS/), the Broad Institute’s Exome Aggregation 
Consortium (ExAC) version 0.3 database (http://exac.broadinstitute.org) and 3000 
ethnically-matched in-house control exomes. Cut-off values for MAF were ≥1% for 
suspected rare recessive disease and ≥2% for suspected rare dominant disease. 
Variants were then annotated using the Variant Effect Predictor (Ensembl, (McLaren et 
al., 2010)) and likely ‘functional’ variants were identified (indels within coding regions, 
non-synonymous SNPs or alterations of splice consensus sequences). Samples were 
filtered on family structure using bespoke perl scripts ‘vcf hacks’ (Dr. David Parry, 
https://github.com/gantzgraf/vcfhacks) and annotated to give gene information in 
Microsoft Excel format. These scripts allow for a family pedigree to be utilized in .ped 
format or for certain characteristics, for example to filter for biallelic variants present in 
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affected individuals and absent in unaffected family members, to be identified. The 
pathogenicity of putative mutations was assessed using PolyPhen2 
(http://genetics.bwh.harvard.edu/pph2/) (Adzhubei et al., 2010), SIFT (Sorting 
Intolerant From Tolerant, http://sift.jcvi.org) (Ng and Henikoff, 2003) and Condel 
(http://bg.upf.edu/fannsdb/). Variants were ranked according to Combined Annotation 
Dependent Depletion (CADD) score version 1.3  (http://cadd.gs.washington.edu). 
Remaining variants were annotated to give a summary of known gene function and 
mouse model information. For all remaining candidate variants a literature review was 
undertaken including assessment of interacting partners, expression pattern and 
animal models. Further to filtering in this manner, variants falling within known disease-
causing genes were checked using in silico pathogenicity prediction tools (PolyPhen2, 
SIFT, Condel and CADD score) and segregation in affected family members, even if 
they were not present following filtering steps.  
 
The workflow for WES data analysis is summarized in Figure 2-3. Before using this 
pipeline on the study samples, it was trialed on data from a patient with a known 
mutation to demonstrate that this as an appropriate variant filtering strategy.  
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Figure 2-3: Data analysis pipeline used for WES data. 
2.2.14.4 Assessment of Mutation Pathogenicity 
Variants identified following WES filtering methods were further assessed for likely 
pathogenicity by the following methods: 
(a) Selection of potential pathogenic variants in candidate genes on the basis of 
putative function in cardiac development and/or members of known 
developmental pathways from literature review and known protein interaction 
data (String Database; http://string-db.org). 
(b) Collaborators from The Netherlands provided the group with a list of genes 
obtained from co-expression modeling with known ciliary proteins. These were 
used to screen potential candidate variants (unpublished communication; Dr 
Dorus Mans, UMC Utrecht, The Netherlands). 
(c) Comparison to a list of candidate ciliary genes from an Austrian collaborator. 
These were identified in Drosophila by tissue-specific RNAi-mediated depletion 


























motile cilia that form in the canonical, IFT-dependent manner), muscle (non-
ciliated) and throughout the animal. Mutants were then examined in C. elegans 
where possible. This gave a list of 72 novel genes, which presented clear cilia 
phenotypes in the fly and/or worm. This list was used to screen against 
potential candidates (unpublished communication; Prof. Alex Dammermann, 
University of Vienna, Austria). 
(d) Comparison to RNA expression data. RNA expression data from fetal heart 
tissue was downloaded from publically available resources (NCBI, Sequence 
Read Archive data) (http://www.ncbi.nlm.nih.gov/sra). This was analysed using 
Cufflinks (Trapnell et al., 2009) after alignment with the “splice aware” aligner 
TopHat2 (Trapnell et al., 2009). This list of highly expressed genes was 
compared to candidates from WES.  
(e) Structural modeling of the position of candidate variants within a protein or 
specific protein domain. This was performed using tools such as Cn3D 
(http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml) and Swiss Pdb-
viewer (http://www.expasy.org/spdbv/). 
(f) Where possible, screening further cohorts of patients with the same phenotype 
for mutations in a candidate gene. This was often through collaboration.  
2.2.14.5 WES Assessment of Quality of Data 
To assess the quality of data obtained from WES, a number of methods were used. 
Firstly, GATK’s Depth Of Coverage tool was used to assess average read depth 
across the exome (specified using a .bed file) and percentage of positions with 
coverage >5 reads. This tool can also give depth across a certain gene. Secondly, 
Picard tools CollectMultipleMetrics command was used 
(https://broadinstitute.github.io/picard/command-line-
overview.html#CollectMultipleMetrics). This runs a number of alignment and quality 
metrics including quality score distribution, insert size metrics and sequencing artifact 
metrics. Output is in a graphical form that can be compared across samples/runs. 
Percentage of duplicate reads was also assessed using Picard’s Mark Duplicates tool 
(https://broadinstitute.github.io/picard/command-line-overview.html#MarkDuplicates).  
2.2.14.6 Autozygosity Mapping from WES Data 
Where SNP microarray analysis was not available and the family history suggested 
consanguinity, autozygosity mapping was performed from WES data. This was 
performed using VCF Hacks script ‘VCFtoSnpViewer’ which selects common SNPs 
from the data, identifies them as homozygous or heterozygous calls and converts them 
into files compatible with SnpViewer v0.9.2 
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(https://sourceforge.net/projects/snpviewer/). Samples could then be viewed as 
described previously, in order to identify large regions of homozygosity (see section 
2.2.13). 
2.2.14.7 Copy Number Variation from WES Data 
In the majority of families, Array CGH was performed as part of Clinical Genetics input 
prior to referral to the study. The result of this test was assessed for all consented 
patients. For families with and without an array CGH result, further analysis for CNVs 
was performed using WES data. 
 
The ‘Exome Depth’ program was utilized to perform this function (Plagnol et al., 2012). 
This program compares read depth between the test sample and 5-10 control samples. 
Control samples were selected to be as close as possible to the test sample, for 
example those run on the same sequencing run as the test sample, with libraries 
prepared using identical WES methodology. Only samples from unrelated individuals 
were used as controls. The output from the ExomeDepth program was in the form of a 
.csv file. This was annotated to indicate common CNVs from control populations 
(Conrad et al., 2010). CNV calls were then ranked by the Bayes Factor, defined as the 
log10 likelihood ratio of data for the CNV call divided by normal copy number. CNV 
calls were manually inspected to assess read ratio and involved genes. These genes 
were crossed-reference against the cardiac literature, cilia-related gene lists and 
exome call data for each sample. For example, if a putative heterozygous deletion of a 
certain gene was identified in an affected individual, this gene was checked for the 
presence of a pathogenic SNP in WES data. A graphical representation of the results 
was created using Broad Institute’s Integrative Genomics Viewer (IGV) (Robinson et 
al., 2011).  
2.2.15 Whole Genome Sequencing at Low Read Depth 
WGS at low read depth was utilized in some cases in order to identify potential 
pathogenic CNVs.  
 
DNA samples were quantified by Qubit BR dsDNA assay (see section 2.2.14) and 
were sent to the Leeds Next Generation Sequencing Facility who prepared the libraries 
for sequencing using the NEBNext® UltraTM DNA Library Prep Kit for Illumina (New 
England Biolabs, Ipswich, MA, USA). Library preparation was carried out according to 
the manufacturer’s directions. DNA shearing was performed using a Covaris S2 
Adaptive Focused Acoustics sonicator to create fragments of a peak size of 185bp. 
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PCR amplification was carried out in a 12 cycle PCR. Ten libraries were pooled per 
lane and sequencing performed on the Illumina HiSeq2500 platform (Illumina) in 50bp 
single end read rapid mode. 
 
Data analysis was performed with support from Dr David Parry (Post Doctoral 
Research Fellow, Leeds Institute of Molecular Medicine). Alignment to the GRCh37 
reference sequence was performed using the Burrow-Wheeler Aligner (BWA) (Li and 
Durbin, 2009). Duplicate reads were removed using Picard (Broad Institute; 
http://picard.sourceforge.net). 
 
Three different analysis programs were used: CNVnator (http://sv.gersteinlab.org/), 
readdepth (http://code.google.com/p/readdepth/) and 
CNV-seq (http://tiger.dbs.nus.edu.sg/cnv-seq/). Each was utilized according to the 
product protocol. CNVnator and readdepth infer CNVs from average read depth across 
a single sample, while CNV-seq compares read depths from a test sample against a 
selected reference sample. For CNV-seq, CNV calls were calculated for all possible 
pairwise combinations of samples available. Plots were created for each chromosome 
with a CNV call. The output files from each of the three programs were compared. All 
called CNVs were analyzed in detail and particular attention was paid to those called 
by more than one program. These calls were also compared to databases of known 
population CNVs, as well as CNV calls from exome data.  
2.2.16 Whole Genome Sequencing and Breakpoint Analysis 
WGS was used in one instance to correctly map a deletion identified in WES data. This 
analysis was performed by Dr Chris Watson, Leeds Sequencing Facility, Leeds 
Teaching Hospitals NHS Trust, including the described Sanger sequencing. WGS in 
this instance was performed with 1µg of DNA, which was sheared using a Covaris S2 
machine (Covaris Inc , Woburn, MA, USA). A WGS library was created using the 
NEBNext® UltraTM reagents, following the manufacturer’s protocols (New England 
Biolabs, Ipswich, MA, USA). The library insert size was 300-400bp and 6 cycles of 
enrichment PCR were used. The Agilent Bioanalyser was used to check the quality of 
the library, as previously described. Sequencing was performed on an Illumina 
HiSeq3000 DNA sequencer (Illumina, San Diego, CA, USA), which generated paired-
end 151bp reads. From .fastq files, adapter sequences and low quality bases (QC<10) 
were trimmed using Cutadapt v.1.9.1 (https://github.com/marcelm/cutadapt). Alignment 
to the reference sequence was with BWA MEM v.0.7.13 (http://bio-
bwa.sourceforge.net). Picard v.2.1.1 was used to mark duplicates and aligned 
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sequence reads were visualized with IGV Integrative Genome Viewer v.2.3.80 
(http://software.broadinstitute.org/software/igv/). Reads aligning to the locus of interest 
were interrogated using samtools v.0.1.18 (Li et al., 2009) to identify potential 
breakpoint spanning reads and a BLAT search (http:// genome.ucsc.edu) was used to 
interrogate the sequence of these.  
 
Sanger sequencing was used to identify the exact breakpoint (see section 2.2.12). A 
PCR amplicon was optimized to cover the identified breakpoint using a forward and 
reverse primer (for primer sequences see appendix E) to generate a 377bp product. A 
further reverse primer was used to give a larger (551bp) product, specific to the normal 
allele.  
2.2.17 Microbiology 
Microbiology methods were performed in a dedicated microbiology lab. Luria Bertani 
(LB) broth was made up with 20g LB powder (Sigma-Aldrich) in 1 litre of dH2O and 
autoclaved in a bench top autoclave (Prestige Medical, Coventry UK). Agar was made 
up from 10g of agar powder (Merck) plus 10g LB powder (Sigma-Aldrich) in 500ml 
dH2O. This was autoclaved in a bench top autoclave (Prestige Medical, Coventry UK) 
and cooled to around 50oC. An appropriate concentration of antibiotic was added (see 
Table 2-3) and 25ml of agar was plated per 100 x 15mm plate, left to cool and stored at 
4oC. SOC medium (Super Optimal broth with Catabolite repression) was a commercial 
product obtained from New England Biolabs. For bacterial colony growth, plates were 
incubated at 37oC in a dedicated incubator. 
 
Table 2-3: Antibiotics used in microbiology methods, concentration used and supplier. 
Antibiotic Concentration Supplier     
Ampicillin 100mg/ml Melforth labs (Suffolk, UK) 
Kanamycin 100mg/ml Sigma-Aldrich 
2.2.17.1 Gateway Cloning 
Gateway technology is a method of cloning which takes advantage of the specific 
recombination properties of bacteriophage lambda I. It is fast and highly efficient. The 






Figure 2-4: Gateway cloning methods.  
Gateway cloning is a method of transfer of DNA fragments between plasmids, making use of 
the site-specific recombination system used by Phage I, and using recombination sites labeled 
‘att’ and specific recombination enzymes. The ‘LR’ reaction allows the gene of interest within an 
entry clone to be combined with the destination vector to create the desired expression clone. 
This process is reversible, using the ‘BP’ reaction to convert an expression clone of interest plus 
donor vector into an entry clone.  
 
BP Clonase II reaction (Thermo Fisher Scientific) was performed as per manufacturer’s 
protocol. 150ng of expression clone was combined with 150ng of entry clone vector. 
This was made up to 9µl with dH2O. The BP Clonase II Enzyme Mix was thawed on ice 
for 2 minutes and vortexed before addition of 1µl to the reaction. Following a further 
two vortexes, the reaction was incubated at 25oC for one hour in a water bath. 1µl of 
Proteinase K was added to terminate the reaction. Following a brief vortex, samples 
were incubated at 37oC for 10mins. Samples were then transformed in E. coli DH5-
alpha competent cells (New England Biolabs) (see section 2.2.17.2) and DNA 
extracted from bacterial cultures by mini and maxi preps (see section 2.2.17.4 and 
2.2.17.5). 
 
The LR Clonase gateway reaction (Thermo Fisher Scientific) was performed to 
subclone cDNA into destination vectors pCS2+ and GW331 (N-terminal SF-TAP). 
150ng of entry clone was combined with 150ng of destination vector, 2µl 5xLR Clonase 
Reaction Buffer and 4µl TE buffer. LR Clonase enzyme mix was thawed on ice for 2 
minutes and vortexed briefly twice. 1µl of enzyme mix was added to each reaction and 
vortexed briefly twice. The reaction was incubated at 25oC for 60mins. 2µg of 
















The resulting plasmid was transformed into competent cells as described above (see 
section 2.2.17.2 for details). 
 
All cDNA clone sequences were confirmed by Sanger sequencing. For primer 
sequences see appendix E.  
2.2.17.2 Bacterial Transformation 
Bacterial transformation was performed in a dedicated microbiology room. 1µl of the 
desired plasmid was added to an aliquot of E. coli DH5-alpha competent cells (New 
England Biolabs), freshly thawed at 4oC and maintained at this temperature. This 
mixture was flicked briefly to combine and left on ice for 20mins. A heat shock at 45oC 
in a water bath for 45s was performed. The reaction was then immediately transferred 
into ice for 5 min. 500µl of SOC medium (New England Biolabs), which was 
prewarmed to RT, was added to the tube. This was left in the orbital shaker (Excella 
E25, Eppendorf, Hamburg, Germany) at 300 rpm at 37oC for at least 1 hour. 150µl of 
the bacterial sample was then spread on an LB agar plate with the appropriate 
antibiotic (Table 2-3). The plate was incubated for no more than 16hr (usually 
overnight) at 37oC, to reduce the likelihood of satellite colonies growing.  
 
The following morning, individual colonies were selected from the plate, using a loop, 
for growth in a 5ml culture. The 5ml culture was made up in a universal container, with 
5ml of LB and the appropriate antibiotic (Table 2-3). Each 5 ml culture was grown in an 
orbital shaker (Excella E25, Eppendorf, Hamburg, Germany) at 300 rpm at 37oC 
overnight, to ensure sufficient aeration of the culture. DNA was extracted from these 
samples by mini-prep (Qiagen) (see 2.2.19) and Sanger sequencing was performed. 
For samples with the desired sequence, bacterial colonies were further grown in a 
200ml LB culture, in microbiology flasks with baffles to ensure adequate aeration of the 
culture. Maxi-prep (Qiagen) for DNA extraction was then performed (see 2.2.20). 
2.2.17.3 Site-Directed Mutagenesis 
Site-directed mutagenesis (SDM) was performed using the Q5 site-directed 
mutagenesis kit protocol (New England Biolabs), following the manufacturer’s 
directions. Primers were designed on the NEBaseChanger website 
(http://nebasechanger.neb.com). A reaction consisted of 6.25µl Hot Start High-Fidelity 
Master mix (2x), 1.25µl Forward and Reverse primer (10µM), 0.5µl plasmid DNA 
(25ng/µl), and 4.5µl dH20. The reaction was vortexed and transferred to a thermocycler 
to perform a PCR with the following conditions: 98oC for 30s, 25x cycles of 98oC for 
10s, ‘X’oC for 30s and 72oC for ‘Y’s, then 72oC for 2mins and hold at 4oC. Here ‘X’ is 
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the appropriate temperature for primer annealing, calculated using NEBaseChanger, 
and ‘Y’ is 30s/kb of plasmid DNA.  
 
Following the PCR the ‘KLD’ step was performed, which stands for Kinase, Ligase and 
Dpnl. For this reaction, 0.5µl of PCR product was combined with 2.5µl 2 x KLD reaction 
buffer, 0.5µl 10x KLD enzyme mix and 1.5µl dH2O. This was pipette-mixed and 
incubated at RT for 5mins. Finally, a transformation was performed (see section 
2.2.17.2).   
2.2.17.4 Mini Preps of Plasmid DNA 
Bacterial colonies were grown in a 5ml LB culture at 37oC overnight in an orbital 
shaker. Samples were pelleted by centrifugation at 10,000xg for 3 mins. Mini-prep 
(Qiagen) was performed according to the manufacturer’s protocol. Pelleted bacterial 
cells were resuspended in 250µl buffer P1. 250µl of buffer P2 was added and the 
reaction was mixed thoroughly by inverting the tube 4-6 times. Then, 350µl of Buffer 
N3 was added and mixed by inverting the tube 4-6 times. The sample was centrifuged 
for 10 mins at 17,900xg. The supernatants were added to a QIA prep spin column and 
centrifuged for 60s. The spin column was washed with 0.5ml buffer PB and centrifuged 
for 60s, then further washed with 0.75ml buffer PE and centrifuged for 60s. To elute the 
DNA, 50µl buffer EB was added to the spin column, left to stand for 1 min and 
centrifuged for 1 min. DNA concentration was measured on a Nanodrop instrument 
(Thermo Fisher Scientific) prior to Sanger sequencing.  
2.2.17.5 Maxi Preps of Plasmid DNA 
For large-scale plasmid growth and DNA extraction, Maxi-preps (Qiagen) were utilized. 
These were performed following a 200ml LB broth growth at 37oC for 12-16 hours. The 
kit protocol was followed. The bacterial culture was harvested by centrifuging at 
4000xg for 25 mins at 4oC. The pellet was completely resuspended in buffer P1. 10mls 
of buffer P2 was added and the tube was mixed by inverting 4-6 times. The reaction 
was incubated at RT for 5min. Following this, 10ml of buffer P3 was added and mixed 
by inverting 4-6 times. The lysate was poured into a QIAfilter Cartridge and incubated 
at RT for 10min. 10ml of Buffer QBT was used to equilibrate the Qiagen-tip and 
allowed to drip through by gravity flow. The cell lysate was discharged through the 
QIAfilter Cartridge into the Qiagen-tip and allowed to enter the resin by gravity flow. 
The tip was washed with two washes of 30ml of buffer QC. DNA was eluted with 15ml 
of buffer QF. DNA was precipitated with 10.5ml RT isopropanol and centrifuged at 
15,000xg for 30 mins at 4oC. The supernatant was decanted and 5ml RT 70% ethanol 
was added and centrifuged at 15,000xg for 10 min. The supernatant was removed and 
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the DNA pellet was air-dried for 10 min under foil. The DNA pellet was redissolved in 
500µl of sterile TE buffer. DNA concentration was measured on a Nanodrop instrument 
(Thermo Fisher Scientific). 
2.2.18 Restriction Enzyme Digest 
Restriction enzyme mapping was performed to confirm the correct organization of the 
plasmid before Sanger sequencing. A restriction enzyme was selected with appropriate 
sites within the construct using the SNAP gene viewer (http://www.snapgene.com). 
Digestion was performed using an appropriate concentration of enzyme and buffer and 
was incubated on a thermocycler as per manufacturer’s directions. The resulting 
fragments were run on 2% agarose gel stained with ethidium bromide (see 2.2.9.3).  
2.2.19 Cell Culture 
hTERT-RPE1, mIMCD3 and HEK293 cells were grown in culture according to standard 
aseptic techniques. All cell culture was performed in a dedicated Tissue Culture room. 
Media was DMEM/F12 + GlutaMAXTM (Life Technologies, Thermo Fisher Scientific) 
supplemented with 10% Fetal Calf Serum (FCS) (Life Technologies) with cells grown at 
37°C/5% CO2 in a humidified tissue culture incubator. Patient fibroblasts were grown in 
DMEM/F12 + GlutaMAXTM + 10% FCS in an incubator dedicated for primary cell 
culture.  
2.2.20 Cell Passage and Harvesting 
Cell-lines were grown in T75 flasks. When cultures reached near confluency they were 
passaged. Initially, growth media was removed and cells were washed in 5mls 1xPBS. 
2ml 1x trypsin/EDTA was then added and the cells left for five minutes to lift into 
suspension. 8ml of growth media was then added and the cells were spun down at 
200xg for 5mins in a 15ml Falcon tube. The cell pellet was resuspended in 10ml media. 
An appropriate volume of cells was then transferred to a new flask with warmed media. 
All cell-lines were split according to the supplier’s recommendations: RPE1 cells 1:10 
twice weekly, HEK293 cells 1:10 weekly, IMCD3 1:8 twice a week. When plating for 
further experiments, the cell number was determined using a Trypan Blue stain 
(Invitrogen) and Countess® cell counter (Invitrogen) and an appropriate number of 
cells were plated per well. All cell lines were passaged to a maximum number of 35 




Cell cultures were grown in 6 well plates to 70-80% confluency. If immunofluorescence 
was to be performed, glass cover slips treated with ethanol and acetone were used to 
line the base of the plate. For hTERT-RPE1 and HEK293 cells, 80% confluency was 
achieved by plating 1x105 cells per well, 48 hours prior to transfection. 1µg of plasmid 
DNA was added to Opti-MEMTM (Thermo Fisher Scientific) to a total volume of 250µl. If 
two different plasmids were to be transfected, 0.5µg of each was used. 6µl of 
Lipofectamine®2000 (Life Technologies) was separately combined with 246µl of Opti-
MEMTM. This was incubated for 5 minutes. The Lipofectamine®2000/Opti-MEMTM mix 
was added to the DNA/Opti-MEMTM and incubated for 20 minutes. Cell growing media 
was exchanged for Opti-MEMTM and the transfection complexes were added. These 
were left for 4-6 hours at 37oC. Finally, Opti-MEMTM was exchanged for normal growing 
media (DMEM F12 plus 10% FCS) or starvation media (DMEM F12 plus 0.2% FCS) if 
required, to stimulate cilia formation. Assays were performed after 48-72 hours.  
 
If required, for example in the case of co-immunoprecipitation, experiments were 
scaled-up and performed in a T75 flask. Volumes were scaled accordingly; so 1.5ml of 
Opti-MEMTM was combined with 5µg DNA and then 1.5ml Opti-MEMTM and 45µl 
Lipofectamine®2000 were combined and incubated for 5 min. These two pools were 
combined for 20 minutes. This gave a total of 3ml of complexes to transfect one T75 
flask of cells, where normal growing media was exchanged for 9mls of Opti-MEMTM 
and complexes were added. Otherwise the protocol was followed as for a 6-well plate.  
2.2.21.2 siRNA Knockdown 
siRNA knockdown was performed alongside construct transfection and over-
expression studies, so Lipofectamine®2000 (Life Technologies) was used for both 
simultaneously. Commercial siRNAs were On-TargetPlus siRNA Smartpool oligos 
(Dharmacon) used at a final concentration of 50nM. 
 
hTERT-RPE1 cells were grown in 6 well plates to 70-80% confluency. 1µg of plasmid 
DNA for overexpression and 50nM siRNA was added to Opti-MEMTM (Thermo Fisher 
Scientific) to a total volume of 250µl. 6µl of Lipofectamine®2000 (Life Technologies) 
was separately combined with 246µl of Opti-MEMTM. This was incubated for 5 minutes. 
The Lipofectamine®2000/Opti-MEMTM mix was added to the siRNA/Opti-MEMTM pool 
and incubated for 20 minutes. Cell growing media was exchanged for Opti-MEMTM and 
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the complexes were added. These were left for 4-6 hours at 37oC. Finally, Opti-MEMTM 
was exchanged for normal growing media (DMEM F12 plus 10% FCS) or starvation 
media (DMEM F12 plus 0.2% FCS) if required to stimulate cilia formation. The assays 
were performed after 48 hours. Scrambled siRNA (Dharmacon) was used as a control. 
 
The efficiency of siRNA knockdown was assessed using Western blotting, using 
methods as described in section 2.2.23. Statistical tests to compare results were 
performed using SPSS version 22 (IBM) (see section 2.2.29). 
2.2.22 Immunofluorescence and Confocal Microscopy 
At 48-72 hours following transfection or at 80% confluency for non-transfected cells, 
fixation to coverslips was performed. Fixation was either with ice-cold methanol for 
5min at -20°C or with 2% [w/v] para-formaldehyde (PFA), where 2% PFA was added 
for 20 minutes at RT, then permeabilised with 0.01% [v/v] Triton X-100 (Sigma-Aldrich) 
for 5 min. Coverslips were blocked in 1% [w/v] Marvel milk solution for at least 5 
minutes (occasionally overnight at 4oC). Marvel milk solution was clarified by 
centrifugation immediately before use to remove any particulates. Primary antibodies 
(see Table 2-1) were made up in 1% Marvel milk solution and incubated with coverslips 
in a humid chamber for a time period dependent on the primary antibody, usually 1 
hour. Coverslips were then washed three times in 1x PBS. Incubation with the 
appropriate AlexaFluor® conjugated secondary antibodies (Life Technologies), plus 
DAPI for nuclear staining, was in 1% Marvel milk solution was carried out for 1 hour. 
Five 1x PBS washes were then performed, followed by 1x dH2O wash. Coverslips were 
set to slides in 30µl Mowiol® (Sigma-Aldrich).  
 
Confocal imaging was carried out using a Nikon A1R confocal microscope, processed 
by NIS-Elements Confocal 4.5 (Nikon) software. Image J (https://imagej.nih.gov/ij/) or 
Fiji (https://fiji.sc) was used for post-capture image processing. Co-localisation was 
assessed using Fiji’s Coloc2 tool, following best practice guidelines, or was assessed 
manually by eye by a scientist blinded to the experimental conditions of each slide. 
Corrected Total Cell Fluroescence (CTCF) was calculated by designating a region of 
interest and using the following formula: CTCF = Integrated Density – (Area of selected 
cell  X Mean fluorescence of background readings). 
2.2.23 Western Blotting 
At 48-72hr post-transfection, cells were collected for preparation of Whole Cell Extract 
(WCE). All procedures were done at 4oC. Cells were washed once with ice-cold 
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1xPBS. A further wash of 1xPBS was added and cells were scraped into the PBS 
using a cell scraper. Cells were centrifuged at 200xg for 15mins at 4oC to create a cell 
pellet.  
 
Cell lysis was performed by addition of NP40 cell lysis buffer (see 2.1.2.5), at a volume 
of 100µl for a 6-well plate or 500µl for a T75 flask.  The samples were incubated on ice 
for 30 minutes. The lysate was centrifuged at 14000xg for 15 minutes. Each sample 
was sonicated using a Sanyo Soniprep 150 Sonicator for 10 secs. Protein 
concentration was determined using a Bradford Assay (Bio-rad, Life Science, Berkley, 
California, USA), following the manufacturer’s guidelines. Absorbance was measured 
on a spectrophotometer at 690 nm and compared to a range of BSA standards 
(Sigma).  
 
20µg of protein was used per sample. Samples were mixed with 2xSDS loading buffer 
and 2.5% of 2-mercaptoethanol was added to each sample. Samples were then heated 
to 95oC for 5 minutes on a hot block. Lysates were electrophoresed in NuPAGE 4%–
12% Bis-Tris gel (Life Technologies), alongside All Blue Standards Precision Plus 
Protein Ladder (Bio-rad) for 1.5hours at 120V. NuPAGE® MES-SDS Running Buffer 
(Thermo Fisher Scientific) was used. Transfer to PVDF membranes (Life Technologies) 
was performed at 30V for 1.5 hours. NuPAGE® Transfer Buffer (Thermo Fisher 
Scientific) was used in the transfer. Membranes were blocked in 5% Marvel milk in 
1xPBST (see section 2.1.2.1) for 2 hours. Membranes were washed four times in 
1xPBST (10 minute incubations) and incubation in the primary antibody, made up in 
5%[w/v] Marvel milk, clarified by centrifugation, was performed for 30 minutes (anti-
FLAG antibody) or 1 hour (all other antibodies) at 4oC in a Falcon tube on an electric 
roller. Membranes were washed four times with 1xPBST (10 minute incubations) and 
incubation with the appropriate HRP-tagged secondary antibody (Dako, Agilent 
Technologies) at a concentration of 1:10000 in 5% Marvel milk was performed for 1 
hour at 4oC. Membranes were developed using SuperSignal West Femto kit (Thermo 
Fisher Scientific), following a final four 1xPBST washes. Images were acquired using a 
Bio-Rad molecular image ChemiDoc™ MP Imaging System with a UV transilluminator 
and displayed and analyzed using Image Lab (v. 4.0) analysis software (Bio-Rad, 
Hemel Hempstead, UK). Band intensity was calculated using the Image Lab software 
and compared to a beta-actin loading control for quantification. 
 
For membrane stripping, the membrane was washed in 1xPBST and then 5ml of 
stripping buffer (Restore™ Plus, Thermo Fisher Scientific) was used to wash the 
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membrane for 10min. A further two 1xPBST washes were performed prior to further 
staining. 
2.2.24 Co-Immunoprecipitation 
Whole Cell Extract (WCE) was prepared by following the protocol for western blotting 
(see section 2.2.23). Protein A agarose beads (Sigma) were prepared with a total of 3 
washes. For each wash a 50% solution [v/v] with incubation buffer (see 2.1.2.7) was 
created and then spun at 1000xg at 4oC for 1 minute. The beads were finally made up 
to a 50% [v/v] solution in incubation buffer. 
 
500-1000µg of soluble protein was made up to 1000µl in incubation buffer. The 
samples were pre-cleared with end-to-end mixing with 30µl of washed Protein A 
agarose beads for 30min at 4oC on a rotating wheel. The beads were extracted by 
centrifugation at 1000xg at 4oC for 1min. The supernatant was incubated with 1µg of 
the appropriate antibody overnight at 4oC on an orbital shaker. The capture of 
immunocomplexes was performed by adding 70µl of washed Protein A beads to each 
sample and incubating for 3 hours at 4oC. The beads were centrifuged at 1000xg for 1 
minute to collect and then washed 3 times with 500µl ice-cold IP wash buffer (see 
2.1.2.8) with a spin at 1000xg for 1 minute between each wash. Protein elution was 
performed by the addition of 20µl 2%SDS and incubation for 30 minutes at room 
temperature. The sample was then centrifuged at 14,000xg for 2 min and the 
supernatant collected in a new tube.  
2.2.25 Tandem Affinity Purification 
This experiment was performed by Dr Kasia Szymanska, Post Doctoral Research 
Fellow, Leeds Institute of Molecular Medicine. In brief, at 48 hours following 
transfection, cells were collected in 1×PBS and lysed in NP40 lysis buffer (see section 
2.1.2.6), supplemented with protease inhibitors (Thermo Fisher Scientific). The cell 
lysates were collected by centrifugation for 5min at 200xg, at a temperature of 4oC. 
Approximately 2mg of lysate was incubated with 100µl of washed streptactin 
“Superflow” beads (IBA,	   Goettingen, Germany). End-to-end mixing was performed for 
1.5 hours at 4oC. The sample was centrifuged at 5000xg to pellet the beads and the 
beads were transferred to a new microspin column. Three washes with 500µl of TAP 
wash buffer (see section 2.1.2.11) were performed with centrifugation for 10s at 
1000xg following each wash. 200µl ice-cold D-desthiobiotin elution buffer (see section 
2.1.2.12) was used to elute bound proteins with a 15 min incubation at 4oC. The 
reaction was transferred to a new microspin column and centrifuged at 1000xg for 10s. 
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The elute was incubated with 50µl of washed anti-FLAG M2 affinity gel beads (Sigma 
Aldrich) for 1.5 hours on a rotating wheel. A 1000xg spin was used to separate the 
beads. The beads were washed three times with 500µl of ice-cold wash buffer and 
once with 500µl 1xPBS. Proteins were eluted with 200µl of ice-cold FLAG peptide 
elution buffer (200 µg/ml FLAG peptide (Sigma Aldrich) in 1xPBS) for 15 minutes at 
4oC. The samples were centrifuged at 1000xg and the elute transferred to a fresh tube.  
 
Precipitated proteins were sent for mass spectrometry at a collaborating centre (Centre 
for Ophthalmic Research, Tubingen, Germany).  Analysis of mass spectrometry data 
was performed using DAVID software (https://david.ncifcrf.gov) and displayed in an 
Excel spreadsheet. Results of the three biological replicates were pooled together. The 
pulled down peptides were matched to corresponding proteins. Those hits that were 
observed in only one replicate, as well as those that were an effect of contamination 
(present in BSA washes) were removed. The results were ordered to show the number 
of pulled down peptides per protein.   
2.2.26 Mouse Embryo Dissection 
Mouse embryo dissection and staining was performed in close collaboration with Dina 
Abdelmottaleb, Visting Researcher, Leeds Institute of Molecular Medicine, Leeds, UK. 
Black six mouse embryos at embryonic stages E7.0-E8.5 were euthanized and a small 
midline lateral incision was made with surgical scissors. The two uterine horns were 
identified and dissected into 1xPBS + 1% BSA (Sigma-Aldrich). Under a dissecting 
microscope, each embryonic sack was isolated by cutting between the implantation 
sites along the uterine horn. The surrounding tissues were removed from the 
embryonic sack and it was dissected longitudinally. As it was opened the embryo was 
identified and collected. Intact embryos were transferred to a 12-well plate containing 
1xPBS + 1% BSA. Further careful dissection was performed to remove the Reichart's 
membrane from each embryo and intact embryos were taken forward for fixation and 
staining. 
2.2.27 Mouse Embryo Whole Mount Immunofluorescence 
Fixation of dissected mouse embryos was performed in 4% para-formaldehyde for 1 
hour at RT. Embryos were then rehydrated in a series of methanol dilutions in PBS for 
15 minutes at each decreasing concentration; 100% for 15 mins, 75% for 15 mins, 50% 
for 15 mins, 25% for 15 mins. Embryos were washed 3 times in PBS for 5 mins each. 
Embryos were blocked in 1% BSA for 1 hour on the rocker. The primary antibody was 
diluted in 1% BSA and incubated with the sample overnight at 4oC. Three 1xPBS 
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washes were then performed. Incubation with secondary antibody and DAPI, at 1:1000 
concentration, was in 1% BSA for one hour. Finally, samples underwent three 1xPBS 
washes. Samples were imaged using either light-sheet microscopy (see section 2.2.29) 
or confocal microscopy, where the sample was mounted in Mowiol (Sigma-Aldrich) and 
imaged using a Nikon A1R confocal microscope, processed by NIS-Elements Confocal 
4.5 (Nikon) software. 
2.2.28 Light Sheet Microscopy 
A Zeiss Z1 light sheet fluorescence microscope, based at the University of Sheffield, 
was used for imaging mouse embryo specimens. This technology illuminates a thin 
section of tissue at a time, detected by a perpendicular digital camera and so 
generates an optical section of the sample. This is a good method for imaging within an 
organism and photobleaching is reduced compared to confocal microscopy (Keller et 
al., 2010). It also allows imaging to be performed from multiple viewpoints, allowing the 
anatomy to be visualised during imaging and a 360o image to be created. Each embryo 
was suspended in 1% low melting point agarose gel in a 1.5ml glass capillary before 
loading into the microscope for imaging. Imaging was performed as per best practice 
guidelines (http://applications.zeiss.com). Post-image processing was performed using 
Image J software. 
2.2.29 Statistical Tests 
Statistical tests were performed using SPSS version 22 (IBM). Normal distribution was 
tested using the Shapiro-Wilk test and by plotting a normal Q-Q Plot. Levene’s test was 
used to test equality of covariance. Results are depicted in the form of box plots or bar 
charts, and error bars show the Standard Error of the Mean. Statistically significant 
differences between the means were calculated using the Independent Samples T test 
(two groups, parametric), Mann-Whitney-U test (two groups, non-parametric) or one-
way ANOVA (three or more groups). Significance is described as P=<0.05. 
 
In this study ‘biological replicates’ describe a repeat of the entire experiment, using 
different cell samples, tissues and plates. ‘Technical replicates’ would describe 
different fields of view from the same sample well or plate (Blainey et al., 2014). 
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3 Whole Exome Sequencing can Identify Known 
and Candidate Genes in Families with 
Congenital Heart Disease 
3.1 Introduction 
In this chapter, the overall results of the library preparation for Whole Exome 
Sequencing (WES) are presented. Further to this, the results of WES data analysis 
from 11 families recruited to the study are described. Five further recruited families are 
discussed in detail in chapters 4, 5 and 6.  
 
The results of clinical phenotyping and variant filtering are presented according to the 
following categories: families with mutations in known genes; families affected with 
Congenital Heart Disease phenotypes; and finally patients with laterality disorders 
recruited to the Deciphering Developmental Delay (DDD) project. The methods of 
variant filtering and a discussion of the candidate variants for these patient groups are 
summarized at the end of each sub-section. 
 
The results show that the achieved sequencing depth and coverage were consistent 
across the sequenced samples, and that the different preparation methods gave 
results consistent with the published literature. WES is shown to be a successful 
method for identification of mutations in known disease genes and potential novel 
candidates in CHD. In the sub-section of families described with independent CHD 
phenotypes, in which 10 families are assessed, no clear functional candidates were 
identified, but a number of possible disease-causing variants were discovered and their 
potential pathogenicity is discussed.  
3.2 Overall Results 
3.2.1 Patient Recruitment and Phenotyping 
In total, 16 families were recruited to the CHD study. Family members gave informed 
consent for research studies and had detailed phenotyping undertaken, followed by 
DNA extraction from blood or saliva samples. In total, 57 DNA samples were collected. 
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3.2.2 Whole Exome Sequencing 
53 DNA samples from 16 families were prepared for WES. For three samples (JT583, 
JT785 and JT619), WES library preparation was attempted but was unsuccessful. All 
of these samples had low concentration and quality of DNA. Following initial shearing, 
Agilent Bioanalyzer traces were poor with either severe under-fragmentation or low 
DNA concentration and so the analyses were discontinued (see Figure 3-1). One 
sample (JT475) was not taken forward for WES library preparation, as this sample was 
from an unaffected sibling and was not deemed necessary for the analysis. 
3.2.2.1 Assessment of WES Library Preparation 
WES library preparation was undertaken with either the Illumina XT or QXT methods 
(see Chapter 2, section 2.2.14). For XT preparation, library quality was checked at 
three stages during the preparation, comprising the post-shearing, post-amplification 
and post-hybridization steps. Figure 3-1:B-D shows an example of Bioanalyzer traces 
at the three stages of analysis from one sample (JT380), as an example, which was 
prepared using the XT method. DNA concentration was calculated from these traces 
by measuring the area under the curve.  
 
For QXT library preparation, Bioanalyzer traces were recorded at two stages: post-
shearing and post-hybridization. Figure 3-2 shows an example of results from sample 
JT584, which was prepared using the QXT kit. Occasionally, when using the QXT kit, 
under-shearing of fragments occurred. If the DNA quantity at the appropriate fragment 
length (around 200bp) was acceptable, then samples were still taken forward to 
hybridization and post-hybridization traces always normalized (see example fig. 3-3, 











Figure 3-1: Bioanalyzer results for samples JT785 and JT380. 
A: Bioanalyzer results from sample JT785 following post-shearing, discontinued due to poor 
shearing. B-D: Bioanalyzer results from sample JT380 prepared using the XT method showing 
B:post-shearing, C:post-amplification and D:post-hybridization analysis. Library concentrations 










Figure 3-2: Bioanalyzer results from sample JT584 prepared using the QXT method.  
A:post-shearing and B:post-hybridization analysis. Library concentrations are given by 










Figure 3-3: Bioanalyzer results from sample JT624 prepared using the QXT method. 
A: post-shearing, showing under-fragmentation and B: post-hybridization, showing a correction 





















3.2.2.2 WES Data Quality Scores 
3.2.2.2.1 Depth	  of	  Coverage	  
Data from WES was assessed for depth of coverage from all analyzed samples, using 
GATK, as described in Chapter 2, section 2.2.14.5. The full results of this analysis are 
given in appendix F. These results show the mean coverage (number of reads aligned) 
across the exome, the percentage of bases covered by > 5 reads, the total number of 
reads, mapped reads and percentage of reads mapped. The data shows a consistently 
high level of coverage across the exome, with a minimum mean read depth of 57 
reads, and with greater than 95% of bases covered by at least 5 reads, in all samples 
processed. The mean read depth was further assessed to identify whether library 
preparation method or sequencing method affected the coverage. Figure 3-4 shows 
that the mean depth of coverage was not affected by the library preparation method 
(XT or QXT) or the input DNA method (blood, saliva or fibroblasts). However, the type 
of sequencing instrument did affect the depth of coverage, with an lllumina HiSeq 3000 
giving a higher mean depth of coverage than an Illumina Hiseq 2500. The version of 
the capture library also appeared to affect depth of coverage, with version 6 giving a 
higher coverage than version 4 or 5. However, this increase in coverage is probably 
due to the fact that version 6 of the library was only sequenced on the HiSeq3000. 
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Figure 3-4: Mean depth of coverage across the exome comparing different library 
preparation, input and sequencing methods. 
A: Mean depth of coverage across the exome comparing library preparation method, XT or QXT 
method. Statistical test is Mann-Whitney-U test. B: Mean depth of coverage across the exome 
comparing DNA source. Statistical test is one-way ANOVA. C: Mean depth of coverage across 
the exome comparing sequencing machine, Illumina HiSeq 2500 or 3000, statistical test is 
Mann-Whitney U test, P= 0.000005. D: Mean depth of coverage across the exome comparing 
the version of capture library used. Statistical test is one-way ANOVA, P=0.000000002. Error 
bars are standard error of the mean. 
 
The percentage of duplicate reads per sample was assessed using PICARD’s “Mark 
Duplicates” tool. Duplicates are often remnants from the PCR processes inherent to 
library preparation, but can also represent optical duplicates (sequences from one 
cluster which are identified by the software as from multiple adjacent clusters). Figure 
3-5:A shows the percentage of duplicates recognized by the software (number of 
duplicates/ total number of reads *100) for each sample. As is clear from the data, 
there is a difference in percentage duplication from sample JT538 onwards. This is 
when library preparation was changed from the XT method to the QXT method. Figure 
3-5:B shows a comparison of the mean percentage duplication for XT versus QXT 
method. As can be seen from Figure 3-5:B, the QXT method gives a significantly 
higher percentage duplication (p=<0.05, Student’s t-test) than the XT method. 





























































QXT method, at consistently less than 35% (Shigemizu et al., 2015) and the 
percentage duplication did not affect the mean coverage or downstream processing.  
 
Figure 3-5: Percentage duplication according to sample number and WES method. 
A: Percentage duplication per sample number. A higher percentage duplication is identified from 
sample JT538 and above, consistent with a move to the QXT method. B: Mean percentage 
duplication comparing library preparation method, XT or QXT method. Statistical test is Mann-
Whitney-U test. 
3.2.2.2.2 PICARD’s	  Collect	  Multiple	  Metrics	  
Figure 3-6 shows an example of the summary of quality scores from sample JT380 
using PICARD’s “Collect Multiple Metrics” tool. The output includes ‘base distribution 
by cycle’. In this context a ‘cycle’ is a single sequenced base, as the sequence runs 
through one procedure (cycle) per base. As can be seen from figure 3-6:A, the 
percentage of bases of each type, A, T, C and G, is consistent across the read, with 
the relative proportions representing the AT:GC content of the exome. Figure 3-6:B is a 
histogram showing insert size distribution, demonstrating a mean insert size of around 
200 bases, as expected. Figure 3-6:C shows the mean PHRED-scaled quality score by 
cycle, demonstrating a consistently high quality score across the read. The distribution 
of PHRED-scaled quality scores by observation, showing that the majority of quality 
scores fall between 30 and 45, is shown in Figure 3-6:D. Graphical representations of 
quality scores were produced for all samples prior to analysis as a quality measure. 


































Figure 3-6: A & B: Quality scores for sample JT380 from Picard’s Collect Multiple Metrics Tool.  
A: Base distribution per cycle; the percentage of base of each type, A (red), T (purple), C (yellow) and G (blue), is shown across the read, with a cycle 
representing one base. Percentage of each base is consistent across the read and the anomaly at base 101 represents the change-over for paired-end 






















Figure 3-7: C & D: Quality scores for sample JT380 from Picard’s Collect Multiple Metrics Tool.  
C: Mean PHRED-scaled quality score by cycle, with each cycle representing the addition of a base, demonstrating a consistently high quality score across the 
read, the anomaly at base 101 represents the change-over for paired-end reads. D: The distribution of PHRED-scaled quality scores by observation count, 





















3.3 Family with a Mutation in a Known Gene  
3.3.1 Family CHD14 
3.3.1.1 Clinical Phenotype 
Family CHD14 is a consanguineous family of Pakistani origin who have two children 
affected with a similar phenotype. Their first affected child had coarctation of the aorta, 
hydronephrosis and a congenital diaphragmatic hernia. This individual died in the 
newborn period.  The second affected child had ASD, episodes of Supraventricular 
Tachycardia (SVT), renal dilatation, absent bladder, neonatal encephalopathy, absent 
nails on the 3rd, 4th and 5th toes bilaterally and small 5th nails on the hands. She died at 
the age of 3 months. The family was referred with a possible diagnosis of Fryns 
syndrome. DNA was available from the second affected child (JT724), two unaffected 
siblings (JT722, JT723) and both parents (JT720 and JT721). 
 
 
Figure 3-8: Pedigree of family CHD14.  
Shading indicates an affected individual. 
3.3.1.1.1 Autozygosity	  Mapping	  
Autozygosity mapping was performed on WES data from the available family 
members. Large regions of homozygosity present in the affected individual, JT724, but 
absent in her unaffected siblings and parents, are shown in Table 3-1. For brevity only 
the 10 largest homozygous regions are shown in this table, but all regions of >1000000 









Table 3-1: The ten largest regions of homozygosity identified in family CHD14.  
Regions shown are present in the affected individual and absent in her unaffected siblings and 
parents. 












3.3.1.1.2 Whole	  Exome	  Sequencing	  
WES libraries were set up using the Illumina QXT method and sequencing was 
performed on the Illumina Hiseq 3000 with nine samples pooled per lane. DNA from 
the affected individual, the two unaffected siblings and both parents were sequenced. 
 
Data analysis assumed a recessive disease model. Table 3-2 shows the number of 
variants remaining following each stage of filtering. Table 3-3 shows the candidate 
homozygous variants remaining following filtering in this family. 
 
Table 3-2: Number of variants remaining following each filtering step in family CHD14 
Stage in Analysis Number of variants 
Called with GATK 688027 
<1% dbSNP 125310 
<1% EVS 124240 
<1% ExAC 120234 




Pass hard filters 41 
CADD >15 21 
Homozygous 5 
 67 
Table 3-3: Homozygous variants remaining following filtering, assuming a recessive disease model, in family CHD14. 
 






OMIM disease In region of 
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31 19/248784 Tyrosine kinase 
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protein 2 
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24.3 23/252324 WD repeat 
containing 
protein 
? Van der Woude 
syndrome 
yes 















3.3.1.2 Sanger Sequencing 
Sanger sequencing confirmed that the variant in PIGV segregated with disease in the 
family and was performed on a diagnostic basis by the Yorkshire Molecular Laboratory. 
These results were reported back to the consenting clinician. 
3.3.1.3 Discussion of Candidate Variants 
The variant in PIGV was the most notable of the variants that remained after filtering. 
Although it did not carry the highest CADD score, the variant occurred in a gene 
associated with a known disease phenotype. The other variants with higher CADD 
scores were in genes that were less convincing as functional candidates, and the 
variant in RIMBP2 did not fall within a large (>1,000,000 bp) region of homozygosity.  
 
PIGV is known to cause Hyperphosphatasia and Mental Retardation Syndrome 
(HPMRS) or Mabry syndrome (MIM: 239300). This is an autosomal recessive condition 
with the features of dysmorphism (hypertelorism, downturned mouth, long palpebral 
fissures and thin upper lip), mental retardation, seizures, and raised levels of alkaline 
phosphatase, which can be up to 20 times the normal range (Krawitz et al., 2010). 
Other associated features include hypoplastic nails of the terminal phalanges, 
anorectal abnormalties, Hirschsprung’s disease, cleft lip and palate, vesicoureteric 
abnormalities, CHDs such as VSD and PFO, and deafness (Horn et al., 2011, Horn et 
al., 2014).  
 
PIGV encodes GPI mannosyltransferase 2, an enzyme that acts in the 
Glycosylphosphatidylinositol (GPI) anchor biosynthesis pathway. Many different 
proteins require GPI anchors to function, and the steps involved in synthesizing the 
GPI anchor involve at least 18 different proteins. GPI-anchored proteins fall into many 
functional classes, for example receptors and adhesion molecules (Krawitz et al., 
2010). It is thought that the phenotype observed in HPMRS is due to the dysfunction of 
proteins that require a GPI anchor. The reason that alkaline phosphatase is raised in 
these patients is that alkaline phosphatase is a GPI-anchored protein that is normally 
expressed on the cell surface. In normal cells, secretion of alkaline phosphatase 
requires GPI transamidase, which cleaves the GPI attachment signal, and attaches a 
mature GPI anchor, so that the protein is expressed on the cell surface and a small 
amount only is secreted in the serum. In PIGV mutant cells, GPI transamidase cleaves 
the attachment signal, but GPI anchoring cannot be completed correctly and so a 
larger amount of alkaline phosphatase is secreted (Murakami et al., 2012). HPMRS 
can also be caused by mutations in other genes of the same pathway, including 
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PGAP2 (Krawitz et al., 2013), PIGO (Krawitz et al., 2012), PIGL (Fujiwara et al., 2015), 
PGAP3 (Howard et al., 2014), PIGW (Chiyonobu et al., 2014) and PIGY (Ilkovski et al., 
2015). 
 
The phenotype of HPMRS fits well with that of family CHD14, and the identified variant 
has previously been reported as a pathogenic mutation in the literature (Horn et al., 
2014). The bladder absence noted in the second affected child has not previously been 
reported in this syndrome and neither has congenital diaphragmatic hernia, making this 
an interesting observation. On referral, this family was initially suspected to have Fryns 
syndrome (MIM: 229850), a condition consisting of congenital diaphragmatic hernia, 
dysmorphic facial features, pulmonary hypoplasia and distil limb hypoplasia (Slavotinek 
et al., 2005). Interestingly, the only gene known to cause Fryns syndrome is PIGN, a 
further member of the GPI anchor biosynthesis pathway (McInerney-Leo et al., 2016). 
Our findings suggest that there may be molecular overlap between Fryns syndrome 
and HPMRS, and screening other genes in the GPI anchoring pathway in cases of 
Fryns syndrome may help to further understand the genetic aetiology of this condition. 
Following the finding of this mutation, previous biochemical testing in both affected 
children was assessed. No results were available from the first child in this family, but 
the second child was found to have had an alkaline phosphatase level of 2573 IU/L 
(normal range 44 to 147 IU/L). This clinical finding was strongly supportive of the 
molecular diagnosis in this family. This finding and the subsequent analysis have been 
reported back to the referring clinician.  
3.4 Families Affected with CHD  
3.4.1 Clinical Phenotypes 
The results from a total of 10 families are summarized in this section. All were recruited 
under the CHD project. Table 3-4 shows a summary of the clinical features of the 
patients in these families. The pedigrees for these recruited families are shown in 
Figures 3-8 to 3-12. Patients identified by ‘JT’ numbers (e.g. JT384) are those 
individuals for whom DNA samples were available. 
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Table 3-4: Clinical features of families recruited to the project with CHD phenotypes, but without mutations identified in known disease genes.  
M= male, F= female, NC= non-consanguineous, C= consanguineous, AR= autosomal recessive, DN= de novo. Age of affected individual is at last clinical 
assessment, *=deceased at this age. TAAD= Thoracic aortic aneurysm and dissection, SIT= Situs inversus totalis, DCM= Dilated Cardiomyopathy, TOF= 
Tetralogy of Fallot, PH= Pulmonary Hypertension, HLHS= Hypoplastic left heart syndrome, TA= Truncus Arteriosus. 
Family 
no. 









no. (JT no.) 










Pakistani C AR 1 (JT385) F 49yrs  TAAD  None  










3 F 43yrs*  TAAD  None  
4 M 36yrs*  TAAD  None  
5 (JT384) F 46yrs TAAD  None  















































Pakistani C AR  1 M  Stillbirth 
28/40 
  None  
2 M 18wks* DCM  None  









 None  
5 (JT445) M 2 
months 





NC AR 1 (JT543) F 10yrs TOF  Tall 
stature 
 










Pakistani C AR 1  F 2 days*  TA and 
critical AS 
   





























































NC AR 1 (JT624) F 23yrs Secundum 
ASD 
 None  
2 (JT625) F 20 yrs Secundum 
ASD 












































































































Figure 3-9: Pedigrees of families A: CHD3 and B: CHD4.  
JT385 
Aortic dilatation and/or dissection = 
JT381 JT384 JT386 











Figure 3-10: Pedigree of family CHD5 
 
 












Figure 3-11: Pedigree of family CHD6. 


























































3.4.2 Whole Exome Sequencing 
 
Variants were filtered as previously described (Chapter 2, section 2.2.14.3). Those that 
remained after filtering were rare (<1%) in control populations, predicted to have an 
effect on protein function, passed hard filters and their segregation was compatible with 
the assumed inheritance pattern in the family. Where more than one inheritance 
pattern was possible in the family, variants consistent with all possible inheritance 
patterns were assessed. Known disease-causing genes, appropriate to each 
phenotype, were assessed independently of this filtering. For a list of known genes 
assessed in each family see appendix G. Table 3-5 shows the variants remaining in 
each family following filtering. Only variants with a CADD score >15 and compatible 
with the assumed inheritance patterns are shown. For heterozygous variants remaining 
following filtering in family CHD3 see appendix H. 
 
In family CHD5, there were no variants that remained after filtering, based on a 
recessive disease model if both JT443 and JT445 are considered as affected 
individuals. Variants were therefore assessed separately for either individual JT443 or 
JT445. Initially, this was performed assuming a recessive model of inheritance. These 
variants are shown in Table 3-5. De novo variants present in each individual were also 
assessed, but no candidates remained after filtering.  
 
In family CHD13, analysis was performed to look for de novo variants in the affected 
individual, but none remained after filtering, variants reported are those identified under 
a recessive disease model.  In families CHD15 and CHD16 only homozygous variants, 
identified under a recessive disease model are shown in Table 3-5 due to the large 
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3.4.3 CNV analysis 
CNV analysis was carried out using whole exome data in all samples where WES was 
performed in this study. WGS at low read depth provides a cost-effective method of 
CNV assessment (Dong et al., 2016). WGS gives coverage not only of the exonic 
regions, but also of the non-coding regions, meaning that CNVs are less likely to be 
missed, particularly if they are present in or overlap with non-coding regions. 
Resources were not available to perform WGS at low read depth in all samples and so 
two samples from two families were selected for this analysis. These samples were 
selected on the basis of a strongly suggestive recessive inheritance pattern, but no 
clear causative homozygous variant identified on WES data analysis. 
3.4.3.1 Whole Genome Sequencing at Low Read Depth 
WGS at low read depth was performed for samples JT381 (family CHD3) and JT443 
(family CHD5). The results were analyzed for CNV calls, as described in Chapter 2, 
section 2.2.15, using the CNV-seq, CNVnator and ReadDepth programs. Tables 3-6 
and 3-7 show a summary of CNV calls that were called by all three programs. 
Appendix I contains a summary of CNV calls from all programs. As can be seen in 
these tables, the majority of calls were present in the Database of Genomic Variants 
(DGV) (http://dgv.tcag.ca/dgv/app/home), making them unlikely to be pathogenic. 
Variants were also assessed for CHD phenotypes present in patients with overlapping 




Table 3-6: A summary of CNV calls from patient JT381 which were called by all three CNV 
analysis programs; CNV-seq, CNVnator and ReadDepth. 


































Del CD49 Homo sapiens 
cancer/testis antigen 49 
(non-protein coding) 








Associated with Joubert 
syndrome 











































Table 3-7: A summary of CNV calls from patient JT443 which were called by all three CNV 
analysis programs; CNV-seq, CNVnator and ReadDepth. 






















Del PARK2 Proteasomal 
degradation. 
Mutations in this 






Yes PFO, ASD, VSD 
7:8815943-
8872405 








Defensin, beta 4B 















family member 7 
yes ASD, Pulmonary 
stenosis, 
coarctation of 
the aorta, TOF. 
8:39225268-
39396877 






Del none  yes No patients with 
cardiac defects 
3.4.3.2 CNV Analysis Using Exome Depth 
CNV analysis using the Exome Depth program was performed on one affected sample 
from each family. A full list of identified copy number variants can be found in appendix 
J. No putative pathogenic CNV containing a candidate gene could be linked to the 
phenotypes of any of the families in the study. Where heterozygous CNVs occurred, 
exome data was analyzed to look for any candidate SNPs in the hemizygous state (ie 
appearing in the homozygous state because a CNV was on one allele and a disease-
causing mutation was on the other). In this manner, all candidate CNVs were ruled out 
as a cause for disease. 
3.4.4 Comparison of Variants to Ciliopathy Databases 
All identified candidate variants were compared to databases of cilia-related genes. 
None of the identified variants showed an overlap with these databases. 
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3.4.5 Fetal RNA Data Analysis 
One publically available dataset of RNA expression data from a fetal heart sample 
(sample number SRR643779, gestation not given; downloaded from 
http://www.ncbi.nlm.nih.gov/sra) was analyzed and compared to results from WES 
analysis. The expression levels of candidate genes for families CHD1 to 16 are listed in 
Table 3-8, as a strategy to increase the evidence that any genes were good functional 
candidates. Where genes were expressed, an FPKM value is given (Fragments Per 
Kilobase of transcript per Million mapped reads). Candidate genes with the highest 
expression in fetal heart were EIF4H and TBCA. 
 
Table 3-8: Candidate genes from CHD patients and their expression in fetal heart sample 
SRR643779. 
Gene CHD pedigree Transcript FPKM in fetal heart sample 
SRR643779 
DNAAF1 1  Not detected 
CCDC158 3  Not detected 
HIP1 3 NM_005338 6.868 
PKHD1L1 3 NM_177531 0.388 
PLCB3 3 NM_000932 1.184 
PSMB7 3  Not detected 
RCE1 3  Not detected 
SLIT2 3 NM_004787 1.326 
TRBV5-4 3  Not detected 
BCR 4 NM_004327 2.422 
GPM6B 4  Not detected 
DYM 5  Not detected 
EIF4H 5 NM_03199 113.646 
KLHL29 5 NM_052920 0.441 
MFSD2B 5 NM_001080473 0.137 
MLX1PL 5  Not detected 
ZFPM1 5  Not detected 
INPP5D 6 NM_005541 0.975 
SOX30 6 NM_007017 0 
C2ORF88 7 NM_032321 2.163 
RREB1 7  Not detected 
SULT4A1 7 NM_014351 0.0792 
TMEM260 7  Not detected 
SYDE2 8  Not detected 
KMT2D 9  Not detected 
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Gene CHD pedigree Transcript FPKM in fetal heart sample 
SRR643779 
PTPRM 9 NM_001105244 2.241 
RBM25 9  Not detected 
SOGA1 9  Not detected 
PTCH1 10  Not detected 
FAM136A 12 NM_032822 23.634 
PLEC 13  Not detected 
RASGRF1 13 NM_153815 0.0129 
ZNF302 13  Not detected 
PIGV 14  Not detected 
RIMBP2 14 NM_015347 0.00326 
SORT1 14  Not detected 
TIE1 14 NM_005424 4.411 
WDR65 14  Not detected 
CDH19 15  Not detected 
CLOCK 15  Not detected 
MDM4 15  Not detected 
PIGR 15 NM_002644 0.556 
SERPINB11 15 NM_080475 0 
STAB2 15 NM_017564 0.583 
TBCA 15 NM_004607 101.979 
ZBTB46 15  Not detected 
ZMYM6 15 NM_001195156 4.0264 
ACADSB 16 NM_001609 10.75 
CYP34A 16  Not detected 
KLRD1 16 NM_001114396 1.896 
NPAS4 16 NM_178864 0.096 
PRLHR 16 NM_004248 0 
RBM48 16  Not detected 
ZNF441 16 NM_152355 3.0404 
3.4.6 Sanger sequencing 
Sanger sequencing was performed in family CHD7 to confirm and segregate the 
variants identified in C2ORF88 and RREB1, as both were candidates of interest. Both 
variants were confirmed to segregate with disease status in the family. Figure 3-13 
shows the results of C2ORF88 sequencing. The frameshift variant, c.133_134delAA, is 
shown to be heterozygous in the unaffected mother, father and sibling and 
homozygous in the affected child. Figure 3-14 shows the results of RREB1 
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sequencing. The c.3682G>A variant is heterozygous in the three unaffected family 




Figure 3-14: Sanger sequencing electropherograms to demonstrate a frameshift variant, 
c.133_134delAA, in C2ORF88 in family CHD7. 
The reverse complementary sequence is shown. The frameshift mutation is shown to be 
heterozygous in the unaffected mother (A), unaffected father (B) and unaffected sibling (D) and 
homozygous in the affected child (C). The asterisk indicates the position of the mutation, grey 
shading indicates PHRED-score. The black arrow indicates the direction of sequencing, with 




















Figure 3-15: Sanger sequencing electropherograms to demonstrate the c.3682G>A 
variant in RREB1 in family CHD7.  
The variant is shown to be heterozygous in the unaffected mother (A), unaffected father (B) and 
unaffected sibling (D) and homozygous in the affected child (C). The asterisk indicates the 
position of the mutation. 
 
Variants identified in TMEM260 identified in this family were proven to segregate with 
disease and were confirmed on a diagnostic basis by Sanger sequencing by the Leeds 
Molecular Genetics Laboratory. Results were reported back to the referring clinician. 
3.4.7 Discussion of Families with CHD 
3.4.7.1 Discussion of Recruited Families 
In this section we consider families that were recruited to the study but did not result in 
the identification of a mutation in a known CHD gene. The majority of families had an 
assumed autosomal recessive pattern of inheritance, comprising of unaffected parents 
with affected offspring or being consanguineous unions, for whom recessive disease is 
more likely to occur. Other inheritance patterns were possible in a number of the 
families, and so variant filtering was not strictly limited to a recessive disease model.  
 
The phenotypes of the CHD families consisted of structural defects, such as ASD and 



















disorders. Both families with syndromic and non-syndromic disease were included. 
One family (family CHD3) was affected with aortic dilation and dissection. Although this 
is not strictly a CHD, this family was included due to the consanguineous nature of the 
family history, and early onset of disease without further risk factors, making a genetic 
cause more likely.  
 
Overlap of CHD phenotype was seen in a number of families assessed, for example 
families CHD6, CHD7, CHD8, CHD12, CHD13 and CHD15 were affected with septal 
defects. Furthermore, Tetralogy of Fallot was seen in families CHD6 and CHD16.  
 
Families with syndromic forms of CHD included families CHD13, CHD15 and CHD16. 
The phenotype in family CHD13 consisted of dysmorphic features, ASD, VSD, retinal 
colobomas, horseshoe kidney, cerebellar vermis hypoplasia, hypoplasia of the corpus 
callosum and slight elongation of the superior cerebellar peduncles. This would be 
consistent with 3C or Ritscher-Schinzel syndrome, a condition characterized by 
cerebellar, cardiac and craniofacial abnormalities. Cerebellar abnormalities are 
typically cerebellar vermis hypoplasia, Dandy-Walker malformation and enlargement of 
the cisterna magna. Craniofacial abnormalities include dysmorphic features, such as 
down-slanted palpebral fissures, low set ears and micrognathia, cleft palate and ocular 
colobomas. VSD and ASD are cardiac malformations seen in this syndrome (Leonardi 
et al., 2001). Horseshoe kidneys are not a typical feature of this condition, but have 
previously been reported (Seidahmed et al., 2011). Leonardi et al., 2001, have cited 
minimum diagnostic criteria for this condition, which the affected individual in family 
CHD13 would fulfill (Leonardi et al., 2001). This affected individual did have a 
depigmentation abnormality on one arm and leg, which is not known to be a 
characteristic of this condition, and can sometimes be an indication of chromosomal 
mosaicism, as well as a number of other syndromes.  
 
The only gene previously identified to be associated with autosomal recessive 3C 
syndrome is KIAA0196, which was identified in a Canadian family who had 
homozygous splice site mutations in the gene. The c.3335+2T>A variant identified in 
these patients was shown to affect splicing (Elliott et al., 2013). Missense mutations in 
this gene were previously associated with a dominant spastic paraplegia (Valdmanis et 
al., 2007). This gene, and specifically this splice site mutation, was assessed in our 
affected patient and mutations were not present, indicating that there may be genetic 
heterogeneity in this condition. The described features in our family do have overlap 
with other genetic diagnoses. For example, optic colobomas and heart defects are 
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seen in CHARGE syndrome, Meckel-Gruber syndrome, CHIME syndrome (Coloboma-
congenital heart disease-ichthyosiform dermatosis-intellectual disability-ear anomalies 
syndrome), and Kabuki syndromes. However, none of these other diagnoses fits with 
all of the features identified in this family. 
 
Ventriculomegaly and AVSD were identified in the affected member of family CHD15. 
There are a large number of genetic conditions that could manifest with these features. 
A search on the London Dysmorphology Database (Guest et al., 1999) reveals 37 
genetic diagnoses that could encompass this presentation, including a number of 
microdeletion syndromes, Smith-Lemli-Opitz syndrome and Kleefstra syndrome. With 
only one affected pregnancy, this makes forming a differential diagnosis difficult. 
Genes associated with conditions that were identified as possible differential diagnoses 
were specifically assessed when analyzing the results from this family.  
 
The phenotype of the affected individual in family CHD16 was of Tetralogy of Fallot, 
renal agenesis, deafness, talipes, hypospadias and developmental delay, with some 
mild dysmorphic features. Chromosomal diagnoses such as 22q11 deletion and 
Williams syndrome were ruled out by a normal result following array CGH analysis. 
Fanconi’s anaemia was a possible differential diagnosis, but this is commonly 
associated with radial ray abnormalities, abnormal skin pigmentation, short stature and 
microcephaly, and a predisposition to bone marrow failure, which were not present in 
this child. However, an absence of these features does not rule out the diagnosis 
(Glanz and Fraser, 1982). McKuisick-Kauffman syndrome was a further differential 
diagnosis for this presentation, but this is characterized by the presence of polydactyly, 
which was not present in this case (Schaefer et al., 2011). Genes known to cause 
these syndromic presentations were taken into consideration during the data analysis. 
3.4.7.2 Discussion of Identified Candidate Variants in CHD Families 
The candidate variants that remained after filtering of WES data for each family are 
described in this section, to highlight the strongest putative candidate gene in each 
family.  
3.4.7.3 Family CHD3 
In family CHD3, where a number of family members have been affected with aortic 
dilatation and dissection, only compound heterozygous variants in two genes remained 
following filtering.  TRBV5-4 encodes T-cell receptor beta variable 5-4 (Slightom et al., 
1994), a T-cell receptor. This gene is unlikely to be related to aortic dilatation. The 
other gene was PKHD1L1. This gene is polycystic kidney and hepatic disease 
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autosomal recessive-like 1, a homolog of the autosomal recessive polycystic kidney 
disease gene (PKHD1). It is a large gene with 78 exons. It has been screened in a 
large number of patients with Autosomal Recessive Polycystic Kidney Disease 
(ARPKD), but no causative mutations have been identified (Hogan et al., 2003). It is 
predicted to encode a large receptor protein (fibrocystin-L) with a signal peptide, 
transmembrane domain and short cytoplasmic tail, similar to the PKHD1 protein. It is 
ubiquitously expressed at low levels. It was found to be up-regulated in T lymphocytes, 
so was suspected to play a role in cellular immunity (Hogan et al., 2003). ARPKD is an 
inherited childhood nephropathy. It is rare, affecting 1:20,000 live births, and is 
characterized by fusiform dilatation of the collecting ducts, alongside hepatic fibrosis. 
This is a severe condition: 30% of affected children die as neonates and progression to 
end stage renal disease is likely within 15 years (Harris and Rossetti, 2004). PKHD1L1 
initially seemed unlikely to be the cause of the phenotype in this family, as none of the 
family members are affected with renal disease. Furthermore, only one of the two 
variants was predicted to be pathogenic by in silico tools. However, the dominant form 
of polycystic kidney disease, caused by mutations in PKD1 and PKD2, has been 
associated with vascular disease, including aortic aneurysms and dissections (Bichet 
et al., 2006), vascular endothelial dysfunction (Peterson et al., 2013) and a 10% risk of 
intracranial aneurysm (Chapman et al., 1992). Vascular disease is less common in 
ARPKD, but sub-arachnoid haemorrhage has been reported in three published cases 
(Chalhoub et al., 2013). ARPKD rat models also have impaired aortic vascular function, 
with a reduction in vasoreaction to vasodilators (Peterson et al., 2013). It is possible, 
therefore, that mutations in a gene with similar functions to PKHD1 are related to the 
aortic disease seen in this family, and this remains the most likely candidate in this 
family. However, further functional work would be required to assess the effect of these 
mutations on the protein, and the possible association between this and renal disease. 
This is beyond the remit of the current research project.  
 
Family CHD3 were also assessed for heterozygous variants, due to the number of 
family members who were affected with disease and the uncertain status of the father 
of the five affected siblings, who died suddenly of a myocardial infarction in Pakistan, 
and did not undergo post mortem examination. It is possible that he also suffered an 
aortic dilatation. Of the heterozygous variants that remained after filtering, the variant in 
SLIT2 has the strongest link to vascular disease. SLIT2 is a secreted glycoprotein that 
is a ligand for the ROBO family of immunoglobulin receptors, specifically Robo1. The 
main role of this protein is in neuronal migration and axon guidance. However, there is 
literature that suggests a role in cardiac development (Mommersteeg et al., 2013). For 
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example, murine embryos lacking Robo1 have absence of parts of the pericardium and 
Robo1/2 double mutants have reduced sinus horn myocardium and abnormalities of 
the caval veins (Mommersteeg et al., 2013). Although no abnormalities of the aorta 
were identified in these mice, Slit2 is expressed in mouse aortic smooth muscle cells 
(Ni et al., 2016). An additional role for SLIT2 is in angiogenesis and endothelial cell 
permeability, where it has been shown to inhibit VEGF-induced migration, tube 
formation and permeability through the activation of Robo4 (Jones et al., 2008). There 
is, however, no strong link between mutations in SLIT2 and aortic dilatation and 
dissection, as seen in this family.  
 
CNV analysis was performed in family CHD3 by a number of methods. CNVs on 
chromosome 12 were consistently identified by the programs used and were not in a 
region of known variation. This region was called as a concurrent deletion and simple 
duplication (copy number 1.5), both predicted to affect the CEP290 gene. This region 
included the gene CEP290, mutations in which cause Joubert syndrome, a very 
different phenotype to that seen in this family and not known to be associated with 
aortic dilatation, although other CHDs have been reported in this condition (Karp et al., 
2012). 
3.4.7.4 Family CHD4 
The only compound heterozygous variants that remained after filtering in family CHD4 
were in BCR. In this family two children are affected with Situs Inversus Totalis (SIT). 
This gene is disrupted as part of a Philadelphia chromosome translocation. In this 
translocation, a fusion protein is created which contains some sequence from BCR and 
some from ABL. This condition is found in most cases of Chronic Myelogenous 
Leukaemia (CML) and some cases of Acute Lymphoblastic Leukaemia (ALL) and 
Acute Myelogenous Leukaemia (AML) (Kurzrock et al., 2003). However, the other roles 
of BCR, apart from this, are largely unknown. The protein it encodes has 
serine/threonine kinase activity and it is a GTPase-activating protein for RAC1. There 
is no evidence to link this gene to situs inversus.  
 
Two variants were identified on the X chromosome that would segregate with disease 
in this family. One, in GPM6B was present in a hemizygous form in the control 
datasets, making it unlikely to be the cause in this family. The other was in GPRASP1, 
a G protein-coupled receptor associated sorting protein, which may be involved in 




Deletion of GPRASP1 is identified in Xq22.1 del syndrome, along with a number of 
other genes. This syndrome causes epilepsy, mental retardation, cleft palate and 
dysmorphic features in females, with failure to thrive and respiratory failure in affected 
males (Cao and Aypar, 2016). GPRASP1 is one of four critical genes for this 
phenotype. A mouse model of the deletion has growth delay, respiratory failure, 
epilepsy and cleft palate (Zhou et al., 2014). There is no known association with situs 
inversus and so this variant seems an unlikely candidate in this family.  
3.4.7.5 Family CHD5 
Family CHD5 consists of two sib-ships affected with dilated cardiomyopathy (DCM) in 
infancy. No homozygous variants were present in both affected individuals that passed 
the filtering criteria for family CHD5. There could be a number of reasons for this. It 
may be that the mutation is in an area poorly covered by the exome data, perhaps in a 
non-coding or promoter region. The assumed inheritance pattern in this family could be 
incorrect, perhaps with the two separate occurrences of DCM being coincidental, or 
due to environmental factors. For this reason, the two individuals were also assessed 
independently.  
 
In patient JTT443, biallelic variants in ZFPM1 were identified, one a frameshift variant 
and the other a missense variant. However, the missense variant was not predicted as 
deleterious by in silico tools. ZFPM1, also known as FOG1, encodes a zinc finger 
protein that binds GATA1, an essential transcription factor for the development of 
erythroid and megakaryocytic cells (Tsang et al., 1997). Mutations in GATA1 are 
associated with X-linked macrothrombocytopenia with dyserythropoietic anemia 
(Freson et al., 2003).  
 
The other identified variants were in MFSD2B and KLHL29. The variant in KLHL29 did 
not have strong in silico support for pathogenicity. This is a member of the Kelch-like 
gene family and very little is known about its function (Dhanoa et al., 2013). The variant 
in MFSD2B had a higher pathogenicity prediction on in silico tools. It is part of the 
major facilitator superfamily of transport proteins. There is little research into its 
function, but a previous paper suggested a likely role of MFSD2A in adaptive 
thermogenesis and the two proteins share many sequence and structural 
characteristics (Angers et al., 2008).  
 
In patient JT445, the three variants that remained after filtering were in DYM, MLXIPL 
and EIF4H. They were missense variants present in the homozygous form, but none 
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had a deleterious call from in silico tools. Mutations in DYM have previously been 
associated with Dyggve-Melchior-Clausen syndrome (MIM. 223800), a recessive 
skeletal dysplasia (El Ghouzzi et al., 2003). The pathogenic mutations described 
previously include nonsense, splice site, or frameshift mutations. This gene encodes 
dymeclin, which is expressed in the brain and co-localises with the Golgi apparatus, 
perhaps playing a role in trafficking to and from the cytoplasm (Dimitrov et al., 2009). 
This condition is not known to be associated with cardiomyopathy. 
 
MLXIPL encodes a helix-loop-helix transcription factor of the Myc/Max/Mad family. It is 
also known as carbohydrate-responsive-element-binding protein (ChREBP). It is 
known to form a heterodimeric complex with the MAX-like protein and activate 
lipogenic and glycolytic enzymes (Merla et al., 2004).  In adipose tissue, MLXIPL is 
regulated by GLUT4, and therefore plays a role in insulin sensitivity (Herman et al., 
2012). MLXIPL is present in the region of the genome that is deleted in William-Beuren 
Syndrome (WBS) (7q11.23 deletion syndrome). WBS has previously been associated 
with cardiomyopathy (Mauser and Bonnemeier, 2012), but it is proposed that the 
reduction in levels of elastin, rather than other deleted genes is responsible (Mauser 
and Bonnemeier, 2012). EIF4H is located near to MLXIPL and is also a gene deleted in 
William-Beuren Syndrome. It is a eukaryotic translation initiation factor and contains an 
RNA binding domain sequence (Richter-Cook et al., 1998). There is no strong 
evidence to suspect either MLXIPL or EIF4H as a candidate gene for DCM. 
3.4.7.6 Family CHD6 
In family CHD6 two children were affected with Tetralogy of Fallot and Pulmonary 
Stenosis with VSD. Filtering on a recessive disease model gave only two remaining 
variants. One variant in SOX30 was found to be homozygous in the GnomAD 
database, therefore ruling it out as a candidate. This leaves the compound 
heterozygous variants in INPP5D. These variants did not have strong in silico support 
for pathogenicity. This gene encodes an inositol polyphosphate-5-phosphatase. This 
hydrolyses inositol 1,4,5-triphosphate (Ins(1,4,5)P3), which mobilizes intracellular 
calcium. The mouse orthologue of this gene is expressed in early development, 
specifically during hematopoiesis and spermatogenesis (Liu et al., 1998) and is 
suspected to play a role in differentiation and maintenance of hematopoietic cell 
lineages (Liu et al., 1998). Homozygous knockout mice have failure to thrive and 
reduced survival. They have a myeloproliferative-like syndrome with lung infiltration 
with macrophages (Helgason et al., 1998). Congenital heart disease was not a 
described feature in these mice, making this an unlikely candidate gene. 
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3.4.7.7 Family CHD7  
Family CHD7, a consanguineous union, have two children affected with Truncus 
Arteriosus. The variant that remained after filtering with the highest CADD score fell in 
TMEM260, a transmembrane protein. Until very recently little was known about the 
function of this protein, also called C14ORF101, although a polymorphism in this gene 
had been associated with survival in non-Hodgkins lymphoma (Yang et al., 2014) and 
risk of gastric cancer development (Wang et al., 2016a).  
 
In April 2017, a paper was published identifying TMEM260 to be the cause of disease 
in two families with a ‘neurodevelopmental, cardiac and renal syndrome’ (Ta-Shma et 
al., 2017). The authors present two families from consanguineous pedigrees, one of 
Ashkenazi Jewish heritage and the other of Arabic heritage. There were three affected 
children in the first family and two in the second. The key described features included 
cardiac defects (VSD in four, two had truncus arteriosus, one had TOF, and one just 
stated as CHD), Central Nervous System (CNS) defects (agenesis of the corpus 
callosum in two, microcephaly in one and no defect in one), and renal defects. The 
renal defects were variable and consisted of elevated creatinine, which was 
accompanied with oliguria in one case and anuria in another, and one patient had renal 
cysts. One individual also had polydatcyly, but this was not a feature in the other 
patients. Some mild dysmorphic features, such as low-set ears, skin tags and webbed 
neck were noted. Death occurred in four of the patients before the age of one year, but 
one was surviving at two years of age. These families were both found to have 
homozygous mutations in TMEM260; c.1393C>T (p.Gln465*)  and c.1698_1701del9 
(p.Try567Thrfs*27) on WES. 
 
On functional investigation, the authors found that both mutations map to regions of 
TMEM260 that are present solely in the long isoform of TMEM260 (another short 
isoform is also predicted). They assessed quantitative PCR of the long and short 
isoforms in patient and control lymphoblastoid cell lines and found the long isoform to 
be reduced in the patient samples compared to controls, whereas the short isoform 
was unaffected. They went on to assess translation-blocking morpholino 
oligonucleotides (MO) of tmem260 in zebrafish embryos and noted that the MO-
injected zebrafish had a smaller optic size and fewer intertectal neurons than 
uninjected controls. Rescue of the CNS abnormalities was shown with TMEM260 long 
isoform mRNA and partial rescue was seen with the short isoform. c.1698_1701del 
TMEM260 mRNA did not rescue the phenotype, supporting its pathogenicity. They also 
developed a CRISPR-cas9 zebrafish model, targeting deletions to the long isoform, 
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which demonstrated a reduction in the number of intertectal neurons and optic tecta 
size. However, the mutant zebrafish did not appear to have consistency with the 
cardiac defects identified; pericardial oedema was noted, but was not rescued, and 
may therefore have been a non-specific finding. A noted kidney filtration defect was 
also not rescued. These findings could also be due to cross-species differences.  
 
Our patients displayed features consistent with the previously described phenotypes; 
they had Truncus Arteriosus, and low-set ears were also described. The first child of 
our family also died in the early neonatal period, at day 2, however the second is alive 
at the age of 3 and a half years. Our patients did not have the same renal or CNS 
abnormalities that were present in these described families. A review of the medical 
records of the second affected child in our family showed a creatinine level within the 
normal range at 29µM/L (normal range 15-31µM/L), although there was mention in the 
notes of a deterioration in renal function at 2 weeks of age. A renal ultrasound scan did 
show a degree of nephrocalcinosis bilaterally. This patient was born preterm, at 31 
weeks gestation, which may have contributed to early renal deterioration. Our patients 
did not suffer from any known CNS abnormalities and cranial ultrasound scan in the 
second sibling at one month of age was normal. The variant we describe in TMEM260 
is a missense variant, where the other described variants are predicted to be protein 
truncating. Our variant does fall within exon 11, which is predicted to fall only within the 
long isoform of the protein, consistent with the previously described cases. This variant 
is predicted to be pathogenic by in silico pathogenicity predictors and is very rare in 
control populations (2 of 250452 alleles in the GnomAD database). Overall, we assess 
that this variant is likely to be the cause of disease in this family, but we cannot be 
certain without further functional assessment. This variant has been confirmed by 
Sanger sequencing, and reported back to the referring clinician. We have given the 
variant a class III, uncertain significance (Best Practice Guidance on Reporting of 
Unclassified Variants, http://www.acgs.uk.com). 
 
There were other variants present in this family that could be linked to the phenotype. 
C2ORF88 contained a homozygous frameshift mutation that was remaining following 
filtering in this family. This gene is also known as smAKAP. This is a ubiquitously 
expressed AKAP (protein kinase A anchoring protein). It is named small membrane 
AKAP as it localises to the plasma membrane. This molecule provides specificity for 
cAMP-dependent protein kinase (protein kinase A). smAKAP mRNA was detected at 
relatively high levels in human and murine heart samples (Burgers et al., 2012). The 
cAMP-PKA pathway plays an important role in cardiac development. smAKAP interacts 
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with PRKAR1A, a regulatory subunit of PKA (Rual et al., 2005) and has specificity for 
the R1 regulatory subunit of PKA over the RII subunit (Burgers et al., 2012). A mouse 
knockout of the RIα regulatory subunit has disrupted development of mesoderm-
derived structures and homozygous mutant embryos fail to develop a functional heart 
tube (Amieux et al., 2002).  Furthermore, in the hearts of Prkar1a knock-out mice, there 
is a downregulation of cardiac transcription factors, such as Gata4 and Nkx2-5 (Yin 
and Kirschner, 2009). Patients with Carney complex, caused by mutations in 
PRKAR1A, have been reported to suffer from CHD (Stratakis et al., 2001). There is 
therefore some evidence that smAKAP may be a conceivable candidate gene for 
Truncus Arteriosus in this family. 
 
In this family, there was also a variant in the gene RREB1 remaining following filtering. 
This was a missense variant and, although in silico pathogenicity predictors did not 
support pathogenicity, there was a moderately high CADD score of 20.5. This gene 
encodes Ras-responsive element binding protein 1, a zinc finger transcription factor 
involved in histone modification. It appears to bind the distal Ras-responsive element in 
the calcitonin gene (Thiagalingam et al., 1996) and acts as a transcription modulator of 
several tumour suppressor genes. The Drosophila orthologue, HNT, is known to play 
important developmental roles including embryonic germ band retraction and retinal 
cell regulation (Ming et al., 2013). A recent study identified variants in RREB1 in a 
whole exome sequencing study in individuals with 22q11.2 deletion syndrome. This 
study compared those patients with CHD (the majority of whom had conotruncal 
defects, such as Tetralogy of Fallot) to those without cardiac defects, in an attempt to 
identify genetic modifiers. This identified rare, deleterious SNPs in RREB1 in 8 affected 
cases, but no control subjects. These variants were spread throughout the gene, but 
one was at an adjacent amino acid position to that identified in our study 
(p.Asp1229Gly). Other histone modifiers were also identified as important in CHD 
pathogenesis by this study, including JMJD1C and KDM7A. The authors propose that 
dysregulation of transcription via modification of histones plays an important role in 
CHD pathogenesis in 22q11.2 deletion syndrome (Guo et al., 2015). It is therefore 
possible that the variants identified in RREB1 in our family are playing a role in the 
pathogenesis of Truncus Arteriosus. 
 
Sanger sequencing confirmed the variants in both smAKAP and RREB1 to segregate 
with disease in this family. It is difficult to assess the effect of these variants on the 
phenotype observed in this family. Due to the publication of other patients with similar 
phenotypes affected with mutations in TMEM260, this is the most likely disease 
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candidate. However, it may be that the variants in smAKAP and RREB1 are playing a 
modifier role in the phenotype observed.  
3.4.7.8 Family CHD8 
Family CHD8 have a complex phenotype, with a number of children affected with CHD, 
but with a mix of abnormalities including VSD, dextrocardia and hypoplastic left heart 
syndrome. Due to the number of siblings affected it was assumed that a recessive 
genetic model was appropriate, however all of the variants that remained following 
filtering were present in a homozygous state in control databases, effectively ruling 
them out as the cause. In a case such as this, with differing phenotypes in the affected 
children, it may be that more complex genetics or even environmental factors are 
playing a role. It is also possible that WES is not identifying the causative genes due to 
non-penetrance in one of the parents or the presence of a mutation in a non-coding 
region. 
3.4.7.9 Family CHD12 
Family CHD12 consists of two siblings affected with secundum AVSD. The only 
variants remaining following filtering in family CHD12 were compound heterozygous 
variants in FAM136A. This protein is expressed in the inner ear where it has been 
shown to co-localize with COX4, a mitochondrial marker (Requena et al., 2015). 
Variants in this gene have previously been associated with Meniere’s disease, a 
chronic disease that causes vertigo, hearing loss and tinnitus (Sajjadi and Paparella, 
2008). There is no known link between this gene and cardiac disease.  
3.4.7.10 Family CHD13 
In family CHD13 there is one affected individual with a complex phenotype 
encompassing ASD/VSD, kidney abnormalities, retinal colobomas, and cerebellar 
vermis hypoplasia. The variants remaining following filtering in this family fell within 
three genes: ZNF302, PLEC and RASGRF1. ZNF302 is a zinc finger protein of largely 
unknown function, it is known to be deleted in the heterozygous form in 19q13.11 
deletion syndrome. This condition manifests as failure to thrive, microcephaly, 
developmental delay, feeding difficulties, ectodermal dysplasia and dysmorphic 
features including hypertelorism, low set ears and high-arched palate. Deafness, hand 
and foot abnormalities and Genito-Urinary (GU) abnormalities (such as hypospadias) 
have also been reported. ZNF302 appears to belong to the minimal region of overlap 
for this syndrome (Gana et al., 2012), along with four other genes (ZNF181, ZNF599, 
ZNF30 and LOC400685). There is a single report of ASD occurring in this syndrome 
(Chowdhury et al., 2014). However, this condition does not have significant overlap 
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with the phenotype seen in our family. Our family has horseshoe kidney and retinal 
colobomas, which are not described in 19q13.11 deletion syndrome. Furthermore, our 
family does not have ectodermal dysplasia, which is one of the key features of 
19q13.11 deletion syndrome. It is also important to note that the described deletions at 
this locus are in the heterozygous state and so may not be informative in this case. 
 
PLEC encodes plectin-1, a large filament-binding protein. It acts a cross-linking 
element in the cytoskeleton (Pytela and Wiche, 1980). Mutations in this gene have 
previously been associated with various forms of inherited Epidermolysis Bullosa 
Simplex (EBS), including EBS with muscular dystrophy (Smith et al., 1996) and EBS 
with Pyloric Atresia (Pfendner and Uitto, 2005), due to truncating or nonsense 
mutations in the gene causing a loss of protein (Pulkkinen et al., 1996).  
 
RASGRF1 encodes Ras protein-specific guanine nucleotide releasing factor. RAS 
proteins regulate many signaling pathways in cell growth and differentiation. RAS 
activation requires the release of GDP. The product of the RASGRF1 gene is known to 
augment this GDP release (Schweighoffer et al., 1993). Its expression is mainly at 
neuronal synapses and decreased expression has been identified in the brains of 
patients with intractable temporal lobe epilepsy (Zhu et al., 2013), although expression 
at the pancreatic islet cells has also been shown (Font de Mora et al., 2003). 
RASGRF1 knockout mice exhibit reduced postnatal growth, low insulin and IGF I 
levels, glucose intolerance, impaired synaptic plasticity, and impaired hippocampal-
dependent learning (Font de Mora et al., 2003, Giese et al., 2001, Brambilla et al., 
1997). There is no known cardiac disease in these mice. Polymorphisms in this gene 
have previously been associated with myopia (Chen et al., 2015). 
3.4.7.11 Family CHD15 
In family CHD15, where a single pregnancy was affected with AVSD and 
ventriculomegaly, the variant with the highest CADD score was in TBCA. This was a 
rare variant, present in a large region of homozygosity. This gene encodes Tubulin-
Specific Chaperone A. This is a molecular chaperone of beta-tubulin (TUBB), a key 
component of microtubules (Nolasco et al., 2005). TBCA knockdown with siRNA in two 
cell lines decreased soluble tubulin, created microtubule disruption and caused cell 
cycle arrest (Nolasco et al., 2005). Mutations in TUBB and other tubulins including 
TUBBA1A, TUBB2A, TUBB2B, TUBB3 and TUBG1 are associated with structural brain 
malformations, for example cortical dysplasia (Breuss et al., 2012), usually as a de 
novo occurrence, termed ‘tubulinopathies’. It is possible that a mutation in a tubulin 
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gene could manifest as ventriculomegaly on USS (Fallet-Bianco et al., 2014), however 
there is no previous report of cardiac defects in the tubulinopathies. It is notable that 
TBCA was highly expressed in foetal heart tissue, making this the most likely candidate 
variant in this family.  
3.4.7.12  Family CHD16 
Family CHD16 have a child affected with Tetralogy of Fallot, renal agenesis, deafness, 
talipes, hypospadias and developmental delay. They have a further pregnancy affected 
with Tetralogy of Fallot. A variant in RBM48 was the variant with the highest CADD 
score remaining following filtering. This is an RNA binding motif protein, containing one 
RNA recognition motif. There is very little previous research on the function of this 
protein. A missense variant in this gene was previously associated with disease in a 
patient with nephronophthisis, a renal ciliopathy, and Jeune asphyxiating thoracic 
dystrophy, a skeletal dysplasia (Braun et al., 2016). These diagnoses are not 
consistent with the phenotype seen in our patient. None of the other variants that 
remained following filtering in this family were considered as likely candidates for the 
phenotype. 
3.4.7.13 Overlapping Findings in CHD Patients 
As was suspected from the range of phenotypes of families recruited, there was very 
little overlap of candidate genes in this cohort. However, variants in genes in the same 
functional or developmental pathways were seen repeatedly in the cohort. The most 
prominently represented group was that of zinc finger proteins, including ZFPM1, 
RREB1, ZNF302, ZMYM6, ZBTB46 and ZNF441. These proteins contain motifs that 
involve zinc ions for stabilization. They have diverse functions which include 
transcriptional regulation, RNA binding, protein folding and assembly and regulation of 
apoptosis (Laity et al., 2001). Zinc finger proteins are one of the most abundant forms 
of protein in the eukaryotic cell, which may account for their high representation in this 
dataset (Laity et al., 2001). However, zinc finger transcription factors are known to play 
key roles in cardiac development, for example GATA 4, 5 and 6 (McCulley and Black, 
2012), mutations in which are associated with CHD. All three are expressed at high 
levels in the developing heart and are known to regulate expression of cardiac-specific 
genes (Pikkarainen et al., 2004). It may be, therefore, that the high incidence of zinc 
finger proteins and other transcription factors in our dataset is due to the role of these 
proteins in cardiac development. The candidate variants identified in these CHD 
families have been uploaded to the Matchmaker Exchange website 
(http://www.matchmakerexchange.org), via Decipher (https://decipher.sanger.ac.uk) in 
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an attempt to identify other families with similar phenotypes and variants in the same 
genes.  
3.5 Patients with Laterality Disorders from the DDD 
Project 
3.5.1 Introduction 
The Deciphering Developmental Disorders (DDD) project is a research study based at 
the Sanger Institute (Cambridge, UK) investigating the cause of developmental 
disorders in children and adults using array CGH analysis and WES in a trio-based 
approach. Access was granted through a DDD-Complimentary Analysis Project (DDD-
CAP) to access data from patients recruited to the project. These patients were those 
with ‘laterality disorders’ as classified by the following Human Phenotype Ontology 
(HPO) terms: abnormal anatomic location of the heart, abnormal special orientation of 
the cardiac segments, abnormality of abdominal situs and abnormality of pulmonary 
situs, plus all derivative terms. 
 
The data was received in the form of annotated .vcf files for the affected patient and 
both parents. .vcf files from each family were initially merged and then data analysis 
carried out using the standardized pipeline, commencing at the filtering of variants by 
comparison with databases of known population variants. 
3.5.2 Results 
3.5.2.1 Clinical Summary 
In total, data from 11 patients coded as ‘laterality disorder’ was received from the DDD 
project, as well as their parents. Phenotypic information was available, as provided to 
the study, from the patient’s clinician. This included information such as classification of 
anomalies present, birth history, growth parameters, dysmorphic features and family 
history. Table 3-9 shows a summary of clinical information for all 11 patients. 
3.5.2.2 Identification of Known Disease-Causing Genes 
In four patients from the project, mutations in known disease-causing genes, 
associated with laterality, were identified. Where appropriate these findings have been 




Table 3-9: Clinical features of patients from the DDD project coded as ‘laterality disorder’.  













DDD1  + Pigmentary 
retinopathy 




    
DDD2 +    Absent radius. 
Short thumb. 
    







DDD4 + +       Synophrys, high 
arched palate 
DDD5 + +   Radial 
hypoplasia.  
  ASD, PS, DORV.  
DDD6 +    Absent thumb    Hypertelorism. 
Upslanted pfs 
DDD7 +       +  
DDD8 Mesocardia.        Bilateral ptosis. 
DDD9 + +       Preauricular skin 
tag.  
DDD10 +       PS Bilateral ptosis 
DDD11 + +      Right aortic arch. 
Interrupted aortic arch, 








Gene Variant Protein change Polyphen2 SIFT CADD MAF 
GnomAD 
Known disease 








35 5/281560 NEK8- associated ciliopathy 








24 -  










24.8 - Primary Ciliary Dyskinesia 
DDD10 MMP21 10:127456129TTC>T p.K461VfsTer14;  
NP_671724 
- - - 2/ 252118 Published as a new laterality 
gene in 2016 (Akawi et al., 2015) 





Deleterious(0)  17/282466  
DDD11 MMP21 10:127460819C>T W316X;  
NP_671724 
- - 37 2/252418  





Deleterious(0) 28.4 -  
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3.5.2.3 Candidate Laterality Variants 
As well as filtering on each sample individually, data was compared across all samples 
to identify variants falling within the same gene, in an attempt to identify novel disease 
candidates. This was done using filtered biallelic and de novo candidate gene lists, 
comparing only variants which passed hard filters and had a CADD score >15. None of 
these variants reoccurred in the remaining seven samples.  
3.5.3 Discussion of Findings from the DDD Project 
In 4 of the 11 patients analyzed, putative mutations were identified in known disease 
causing genes. Patient DDD3 was affected with situs inversus with polysplenia, but 
also had renal dysplasia, liver failure, complex CHD and hypertrophic cardiomyopathy. 
Compound heterozygous variants in NEK8 were identified, which were in trans. These 
variants had high CADD scores and were predicted as deleterious by in silico tools. 
They were also rare in control datasets. NEK8 (never in mitosis A related kinase 8) 
causes a ciliopathy that is associated with liver disease (congenital hepatic fibrosis, bile 
duct hypoplasia or ductal plate malformation), enlarged cystic dysplastic kidneys, and 
congenital heart malformations (Rajagopalan et al., 2016). Hypertrophic 
cardiomyopathy, situs inversus (Frank et al., 2013) and renal dysplasia (Rajagopalan 
et al., 2016) have also been reported. Skeletal defects and brain malformations can 
also be associated with this condition (Grampa et al., 2016). This diagnosis would be 
consistent with the features identified in this patient. The NEK8 gene is a protein 
kinase, found to be critical for ciliary function and important in cell cycle control (Moniz 
et al., 2011). It is located in the ‘inversin compartment’ of the cilium, a proximal part of 
the axoneme (Grampa et al., 2016). A mouse knock-out model has cystic kidneys and 
heart-looping defects and a similar phenotype is seen in zebrafish (Liu et al., 2002). 
The mutations identified here have not previously been reported, but V337G falls in the 
Regulation of Chromatin Condensation 1 (RCC1) domain of the protein, where 
previous disease-causing missense mutations have been identified. This domain is 
critical for NEK8 localization to cilia and is thought to be involved in centrosome 
recruitment (Zalli et al., 2012). R246Q falls in the serine/threonine catalytic domain, 
which we would predict to affect the protein kinase function (Zalli et al., 2012). 
Missense mutations have previously been identified as disease-causing in this 
condition and some are reported to have a gain-of-function effect, typically causing 
renal dysplasia, rather than enlarged cystic kidneys (Grampa et al., 2016). This would 




Patient DDD4 was affected with a clinical diagnosis of Primary Ciliary Dyskinesia 
(PCD), but also had the unexplained findings of learning disability and dysmorphic 
features. A homozygous missense mutation in DNAH5 was identified. This variant 
scored highly on pathogenicity prediction tools. It is not a previously published 
mutation, but falls in a region of the protein that is commonly mutated in PCD. This 
finding does not explain the additional features of learning difficulties and dysmorphic 
features identified in this patient and so its pathogenicity is not certain. 
 
Patients DDD10 and DDD11 were identified to have mutations in MMP21. Following 
identification of the mutations in these patients, we recognised that these exact families 
have already been published in the literature (Akawi et al., 2015). MMP21 encodes a 
matrix metalloproteinase that is reported to modulate cell migration through effects on 
the extra cellular matrix (Ahokas et al., 2002). The authors modeled these identified 
variants in the structure of MMP21 and showed them to be close to a conserved zinc-
binding site and they were predicted to have a strong impact on enzymatic function 
(Akawi et al., 2015). Two mouse models with missense mutations close to the zinc-
binding domain have heterotaxy and complex CHD. These mice had normal ciliary 
motility at the embryonic node, suggesting MMP21 acts downstream of the ciliary beat 
in the formation of laterality (Akawi et al., 2015). Mutations in MMP21 are suspected to 
be a relatively common cause of heterotaxy in humans (Guimier et al., 2015).  
 
In this study we did not identify further overlapping causes of heterotaxy in the 
remaining samples from the DDD project without a mutation in a known gene. It may 
be that the genetic causes in these families are different, as there is phenotypic 
variability between the families in the cohort. It may also be that some cases of 
heterotaxy are caused by mutations in the non-coding parts of the genome, or that 
environmental factors play a role, as is already known for congenital heart disease.  
3.6 Conclusions 
We have shown that in families with a recurrence of CHD, WES can identify putative 
pathogenic mutations. We have described one family with mutations in PIGV causing 
Hyperphosphatasia and Mental Retardation Syndrome (HPMRS), with the novel 
features of absence of the bladder and congenital diaphragmatic hernia. We have 
described 10 families with no mutation in a known disease-causing gene, but with 
putative candidate variants identified by this approach. In 11 patients from the DDD 
project with ‘laterality disorders’ we have recognized four with mutations in known 
disease-causing genes, but no further overlapping candidates.  
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4 PPA2 Mutations Cause Early Onset 
Cardiomyopathy and Sudden Infant Death 
4.1 Introduction 
This chapter describes the investigation of a family, CHD2, affected with sudden 
unexpected death in childhood associated with cardiomyopathy on post mortem 
examination. Using WES we were able to identify a likely causative mutation in a novel 
gene, PPA2. Collaboration allowed for the identification of three other families affected 
with mutations in the same gene and allowed us to delineate the disease phenotype. 
Functional analysis was undertaken to support the pathogenicity of these mutations 
and to give insight into the function of this important protein.  
 
Of the work described in this chapter, Dr Hartill was directly involved in the recruitment 
of family CHD2 to the study, including taking informed consent, clinical phenotyping 
and DNA extraction from patient samples, as well as preparation of whole exome 
libraries, analysis of WES data and bioinformatic analysis of variants identified in family 
CHD2, identifying PPA2 as the likely cause of disease. Dr Hartill made initial contact 
and formed an ongoing collaboration with an international research team, including 
colleagues in Newcastle-Upon-Tyne (Prof. Robert Taylor) who identified further 
families affected by mutations in PPA2. The functional work described in this chapter 
including pyrophosphatase activity assays described in the results section and western 
blot and oxygen consumption assays described in the discussion section were 
performed in full by international collaborators in Austria (Ms Lavinija Mataković and Dr 
Johannes Mayr and colleagues, Department of Pediatrics, Paracelsus Medical 
University Salzburg, Salzburg, Austria). 
4.2 Results 
4.2.1 Clinical Phenotype 
Family CHD2 is a multiply consanguineous family of Pakistani origin, living in Leeds, 





Figure 4-1: Pedigree of family CHD2. 
The first child in this family (JT609) was well with normal growth and development until 
the age of 5 ½ months. She became unwell following a 24 hour history of a vomiting 
and diarrheal illness and suffered a seizure at home. She had further seizures on 
arrival at hospital and was intubated and ventilated. A Computerised Tomography (CT) 
head scan was normal. Echocardiogram showed poor contractility and a small amount 
of tricuspid regurgitation. She was transferred to a teaching hospital, although on 
transfer she unfortunately suffered multiple cardiac arrests, and she eventually died 
during the course of these.  
 
On post mortem examination, the brain showed mild hypoxic injury. Skeletal survey, 
metabolic and toxicology screens were all normal. Fatty acid oxidation levels were 
performed on skin fibroblasts and were normal. Rotavirus was identified from stool 
samples taken on admission. Tests for myocarditis were normal. Cerebrospinal fluid 
(CSF) glucose was low, but this was undertaken on a post mortem sample. The heart 
appeared normal in size, shape and macroscopic structure. Cardiac histology showed 
areas of recent necrosis, and there was also evidence of long-standing myocyte loss 
with increased interstitial collagen and focal myocyte fibre disarray in the left ventricle 
and interventricular septum. This was described as a cardiomyopathy and the cause of 
death was described as sudden infant death due to a cardiomyopathy of unknown 
cause. 
 
Their second child (JT578) is fit and well at 4 years of age. A recent echocardiogram 
was normal, and tests for lactate, acylcarnitine and Creatinine Kinase (CK) were all 
within the normal range. 












The third child in this family (JT579) became acutely unwell at the age of 8 months. 
She had suffered symptoms of a viral illness and a week’s history of increasing 
hypotonia and weakness. At this time, her CK was raised at 15,000 IU/L (normal range 
<250IU/L) and her plasma lactate was raised at 5mmol/L (normal range 0.5-2.2 
mmol/L). Free carnitine was within the normal range at 43.6µmol/L (normal range 30-
60µmol/L), but propionylcarnitine was raised at 2.38µmol/L (normal range <1.5 µmol/L). 
Her urine organic acids and renal function were normal. Her weakness and hypotonia 
improved over the next two weeks and her CK level reduced. Echocardiogram at this 
time was normal. 
 
She presented again at the age of 11 months with a further viral illness causing 
diarrhoea and vomiting. She became increasingly drowsy. An initial blood gas 
demonstrated a lactic acidosis. Following admission to her local hospital she suffered 
focal seizures, followed by a generalized seizure. CT head scan at this time was 
normal. She then suffered a cardiac arrest and was intubated and ventilated. Maximal 
cardiopulmonary resuscitation was continued for 20 minutes, but was not successful.  
 
Post mortem examination showed extensive fibrosis of the heart muscle, in a similar 
distribution to that seen in her sister. There were no other macroscopic observations at 
post mortem. Norovirus infection was confirmed on stool samples from admission. 
 
Mitochondrial disease was suspected and investigations were perfomed at Newcastle 
Mitochondrial Disease Service. These included DGUOK and ACAD9 gene sequencing, 
which did not demonstrate a pathogenic mutation. Respiratory chain analysis on 
peripheral muscle tissue was normal, and histological and histochemical assessment 
of muscle biopsy did not reveal any major mitochondrial abnormalities. At the time of 
recruitment to the study, the mother was pregnant with the family’s fourth child.  
4.2.2 Whole Exome Sequencing 
WES was undertaken in five family members from this family: JT576, JT577, JT578, 
JT579 and JT609 (see Fig. 4-1). The samples were prepared using the Illumina QXT 
methodology and Agilent v5 library kit. Samples were pooled with 18 other patient 
samples and run across 4 lanes on an Illumina HiSeq 2500 instrument.  
 
Data analysis was performed as described previously (see Chapter 2, section 
2.2.14.3). For this family, variants present at >1% minor allele frequency were removed 
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after comparison with the following databases: dbSNP 138 and previous, NHLBI 
Exome Sequencing Project (ESP) Exome Variant Server, the Exome Aggregation 
Consortium (ExAC), 300 local ethnically-matched exomes and over 3000 ethnically-
matched control samples from the Born in Bradford project (mothers of babies 
recruited to the project) (http://www.borninbradford.nhs.uk). Variants were retained that 
were predicted to have a functional effect on the protein using Ensembl’s Variant Effect 
Predictor (VEP), and these included missense, splice site variants and indels. Variants 
were retained which followed the predicted autosomal recessive inheritance pattern in 
the family i.e. were biallelic or homozygous in the affected siblings, but not in the 
unaffected sibling and heterozygous in the parents. Table 4-1 shows the number of 
variants remaining following each filtering step in the pipeline. Variants were manually 
inspected and retained if predicted ‘pathogenic’ by any one of Polyphen2, SIFT or 
Condel. Finally, variants were ordered by CADD score and those with CADD score >15 
were retained. Data quality statistics were performed on WES data from this family and 
are shown in appendix F. 
 
Table 4-1: Number of variants remaining at each stage of variant filtration in the analysis 











Following filtering, three variants remained (see Table 4-2). The variant in PPA2 had 
the highest CADD score of 32. Figure 4-2 shows an IGV read out showing alignment of 
the sequencing reads in the 5 family members and the presence of the PPA2 variant.  
Stage in Analysis Number of variants 
Called with GATK 459205 
Filter on dbsnp <1% 
MAF 
123881 
EVS <1% MAF 120698 
BIB <1% MAF 108087 
Exac <1% MAF 103935 
Local exomes <1% 88749 
Functional variants 1035 
Biallelic shared by 
affected sibs 
14 
Pathogenic on in silico 
tools 
6 (all homozygous) 





Table 4-2: Variants remaining following filtering WES data using the data analysis pipeline in family CHD2. 
Gene 
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Figure 4-2: IGV read-out showing sequencing reads aligned to the reference genome 
(GRCh37) in family CHD2.  
The variant in PPA2, c.500C>T, is highlighted by the green arrow, shown as G>A as present on 
the reverse strand. The variant is shown to be heterozygous in the parents and unaffected 
sibling (a: JT576, b: JT577 & c: JT578) and homozygous in affected patients (d: JT579, e: 
JT609).  
4.2.3 Autozygosity Mapping  
Autozygosity mapping was performed on WES data. Regions of more than 100000bp 
and containing at least 25 SNPs were identified which were shared by the affected 
family members, but not shared with the unaffected individuals. Table 4-3 shows the 
large homozygous regions that fit these criteria. The variant in PPA2 falls within the 













Table 4-3: Output of SNP Viewer program showing large regions of homozygosity shared 
between affected individuals and not with unaffected individuals in family CHD2. 
Chromosome position 
 













4.2.4 CNV analysis 
CNV analysis was performed using the Exome Depth software on WES data from 
individual JT579. A number of potential candidate CNVs were identified by the 
program, but a number were present in control datasets and none overlapped a likely 
candidate gene for cardiomyopathy. A full list of CNV variants identified is provided in 
appendix J. 
4.2.5 Bioinformatic Analysis of the PPA2 variant 
The PPA2 gene codes for an inorganic pyrophosphatase, an enzyme that catalyses 
the hydrolysis of pyrophosphate to inorganic phosphate. In humans, there are two 
forms of pyrophosphatase: PPA1 is cytosolic and present in the majority of cell types 
and PPA2 is specific to mitochondria. Following review of the literature, and due to the 
suspicion of mitochondrial disease in this family, this gene appeared a good candidate 
for the phenotype observed. Further bioinformatics analysis was performed to reinforce 
this hypothesis. The variant was assessed using in silico pathogenicity prediction tools. 
It was rated as ‘probably damaging’ by Polyphen2 (1), ‘deleterious’ by SIFT (0) and 
‘deleterious’ by Condel (0.945) (see Table 4-2).  
 
Investigation of this variant, c.500C>T, in publically available control databases showed 
it to be extremely rare. It was not present in 3000 ethnically-matched in-house control 
samples and was present as four heterozygous calls in 240938 alleles in the GnomAD 
database (all of South Asian origin), giving a MAF of 0.0000166. It was present in 
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dbSNP142 with a MAF of 0.0002. The variant falls in exon 6 of the gene. This affects 
the canonical transcript of the protein (ENST00000341695) at a highly conserved 
position conserved in mammalian species through to Xenopus (see Fig. 4-3).  
 
Figure 4-3: Evolutionary conservation of p.P167L in vertebrates.  
Output adapted from HomoloGene (https://www.ncbi.nlm.nih.gov/homologene). 
 
There was no recorded knockout mouse model of PPA2 at the time of investigation. 
Interrogation of the String database (http://string-db.org) showed interaction of PPA2 
with a number of ATPases and ATP synthases, for example ATP5A1 (Fig. 4-4).  
 
 
Figure 4-4: Output from the String database to summarize a query of interacting partners 
of PPA2.  
Known interactions are demonstrated by light blue lines (curated databases) and pink lines 
(experimentally determined). Blue lines indicate predicted interactions due to gene co-
occurrence, green due to similar gene neighbourhood and red due to gene fusions. Yellow 
associations are from text-mining, black associations from co-expression experiments and 
purple associations from protein homology.  
P167L&
Homo sapiens 
Pan troglodytes  
Macaca mulatta 
Canis lupus familiaris 
Bos taurus 
Mus musculus 
 Rattus norvegicus 
Gallus gallus 
Danio rerio 
Xenopus tropicalis  
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4.2.6 Sanger Sequencing 
Sanger sequencing was performed by the Yorkshire Molecular Genetics Diagnostic 
Laboratory and confirmed the presence of the mutation in PPA2 in the family, being 
homozygous in the affected individuals and heterozygous in the parents and 
unaffected sibling. Results were reported back to the referring clinician.  
4.2.7 Identification of Further Families with Mutations in PPA2 
Having identified a likely candidate gene in family CHD2, we wished to identify further 
families with a similar phenotype who may have mutations in the same gene. For this, 
we formed a collaboration with Prof. Robert Taylor, head of the Rare Mitochondrial 
Disease Service for Adults and Children, Newcastle-upon-Tyne. Through this 
collaboration we were able to identify three further families with homozygous or 
compound heterozygous mutations in PPA2 (here referenced as families 2b, 2c and 
2d). WES was performed at a number of other international centers to identify these 
mutations in PPA2. Pedigrees of families 2b, 2c & 2d are shown in Figure 4-5.  
 
We were also able to obtain, with consent, a skeletal muscle biopsy sample and skin 
fibroblast sample from patient JT579 (here also labeled P9), which had both been 
stored following post-mortem examination. The skeletal muscle sample was sent 
immediately to collaborators for functional assays as described below. The fibroblast 
sample was cultured in the Leeds laboratory, RNA was extracted and cells were frozen 





Figure 4-5: Pedigrees of families with PPA2 mutations.  
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Family 2b is of Caucasian origin, living in New Zealand. The parents are unrelated. All 
four of their children exhibit extreme sensitivity to alcohol. This manifests as pallor and 
severe arm and chest pain following consumption of very small amounts of alcohol, for 
example having consumed less than 0.1g of alcohol in a cough medicine. Two of the 
siblings died in their teenage years following the consumption of small amounts (<1 
unit) of alcohol. Sibling 1 died suddenly at the age of 15 years. Post mortem showed 
dilatation of both cardiac ventricles, with histology showing focal inflammation of 
neutrophils, lymphocytes and eosinophils. Skeletal muscle histology was normal. A 
diagnosis of myocarditis and sudden arrhythmic cardiac death was made. 
 
Sibling 3 also died following consumption of <10g alcohol at the age of 20 years. Post 
mortem examination revealed a dilated left ventricle, with a distinctive circumferential 
scarring in the midmyocardium with focal sub-endocardial scarring. Microscopic 
examination of cardiac tissue revealed widespread, mature scarring of mid-
myocardium (see appendix K). 
 
Due to the family history, siblings 2 and 4 were assessed by cardiac MRI examination 
and both were found to have mid-myocardial fibrosis. On medical alcohol challenge, 
both suffered severe chest pain. Both siblings have now been fitted with an Implantable 
cardioverter defibrillator (ICD) device, although neither has had an event to date. 
 
Family 2c is a family of Sri Lankan origin, living in Switzerland. The parents are first 
cousins. Family 2d are a non-consanguineous family of Northern Irish origin. Both 
families 2c and 2d are affected with a similar phenotype to that seen in family CHD2. 
They have had children affected with sudden, unexpected death between the ages of 
11 days and 2 years. In the majority of cases a viral illness preceded deterioration and 
death. In both of these additional families, a metabolic cause was suspected with a 
history of lactic acidosis, seizures, hypotonia, and cardiac arrhythmia. Post mortem 
consistently demonstrated cardiac fibrosis and myocyte loss or disarray. In the majority 
of assessed cases, respiratory chain analysis was normal in fibroblasts and skeletal 
muscle. In P10, there was a slight reduction in complex I and IV in cardiac muscle.  
4.2.8 Mutation Analysis 
In total, four separate mutations in PPA2 were identified across the four affected 




Table 4-4: Mutations in PPA2 identified in families 2b-d alongside in silico pathogenicity 









Polyphen2 SIFT GnomAD, 
heterozygotes 


































































The identified mutations in PPA2 were all scored as ‘pathogenic’ by in silico tools (see 
Table 4-4) and occurred at highly conserved positions of the protein. These variants 
were further assessed as to their frequency in control populations, for example the 
EXaC (http://exac.broadinstitute.org) and GnomAD databases 
(http://gnomad.broadinstitute.org). All were present at low levels, with no homozygotes 
present in control datasets. Table 4-4 shows the frequency of these variants in the 
GnomAD database. 
 
Structural modeling of these variants was possible due to the similarities between 
PPA2 and the yeast homologue IPP1. Three of the mutations were found to be located 
at the predicted enzyme active site (514G>A, 500C>T and 380G>T), so were predicted 
to disrupt the enzymatic function. The 683C>T variant was located on the outer surface 
of the molecule, and was predicted to disrupt dimerization due to its position at the 







Figure 4-6: Structural modeling of PPA2 variants.  
(a) p.Pro228Leu is shown to be located at the surface of the dimerization boundary. Image created using CN3D with reference PDB: 1M38. (b) p.Glu172Lys, 
p.Arg127Leu and p.Pro167Leu are found at the enzyme active site, modeled by the purple sphere. Image created using Swiss-PdbViewer with reference 




4.2.9 Pyrophosphatase Activity 
Pyrophosphatase activity experiments were undertaken by the collaborating center in 
Austria, including wet laboratory work, quantification, statistical analysis, interpretation 
and confirmation. Pyrophosphatase activity was measured by determining formation of 
inorganic phosphate using a malachite green colorimetric assay (Van Veldhoven and 
Mannaerts, 1987). This was performed using fibroblast-extracted mitochondria from 
three patient samples and 15 control samples. Activity was significantly reduced in 
patients P5, P7 and P9 (see Fig. 4-5) when compared to controls, at various different 
MgCl2 and PPi concentrations (see Figure 4-7). Inactivation with CaCl2 was similar in 
affected and control individuals (Fig. 4-7).  
 
Wildtype PPA2 c.DNA was cloned into expression vector pRSET B by the collaborating 
center. The cloned construct omitted the first 96 nucleotides of the protein, which 
corresponds to the N-terminal mitochondrial targeting sequence. The pathogenic 
variants identified in families CHD2 and 2b, c and d (c.500C>T (p.Pro167Leu), 
c.514G>A (p.Glu172Lys), and c.683C>T (p.Pro228Leu)) were introduced using site 
directed mutagenesis. These recombinant proteins were expressed in E. coli. Equal 
amounts of wildtype and mutant proteins, measured using Western Blot, were used in 
a Pyrophosphatase assay. Both the c.500C>T (p.Pro167Leu) and c.514G>A 
(p.Glu172Lys) variants had a 5-10% activity compared to the wildtype enzyme at PPi 
concentrations 18–500 µmol/L. The c.683C>T (p.Pro228Leu) variant showed a 24-28% 






Figure 4-7: Pyrophosphatase activity in control and patient fibroblasts and recombinant 
proteins at different PPi concentrations.  
A & B: Pyrophosphatase activity in patient (P) and control (C) fibroblast mitochondria isolations 
at 0.0001-0.1mM PPi concentrations at either (A) 0.5 mmol/L MgCl2 or (B) 3.0 mmol/L MgCl2. C: 
Pyrophosphatase activity in three control subjects (black line) compared to patient P5 (red line) 
at different CaCl2 concentrations and 0.5 mmol/L MgCl2. The larger graph shows a PPi 
concentration of 0.1mmol/l, with the small insert showing a PPi concentration of 0.01mmol/l. D: 
PPA activity of equal amounts of recombinant proteins at different PPi concentrations. E: 
Western blot to show addition amounts of recombinant proteins. Statistics shown are a 
Student’s unpaired T-test. The error bars indicate the standard error of the mean * = P<0.01, 
**=P<0.0001. Adapted from Kennedy et al., 2016. This work was performed by the collaborating 




4.3.1 Candidate Variants in Sudden Unexpected Death with 
Cardiomyopathy 
We have identified mutations in PPA2 in four families affected with sudden unexpected 
death associated with cardiomyopathy. Cardiomyopathy is an inherited or acquired 
non-inflammatory disease of the myocardium (Chung and Kang, 2015). Clinically, 
cardiomyopathy is divided into hypertrophic, dilated and restrictive types, dependent 
upon echocardiographic assessment or the observation of the myocardium at post-
mortem (Cecchi et al., 2012). In family CHD2, the disease was said to appear similar to 
hypertrophic cardiomyopathy, but did not fulfill the criteria for diagnosis, consisting 
mainly of fibrosis, cell disarray and scarring.  
 
Families CHD2, 2c & 2d have a similar phenotype. In these families, children are 
affected with the condition in infancy, all children having suffered death before the age 
of 2 years. There was a consistent cardiac phenotype in these affected individuals with 
myocardial fibrosis and disarray identified on post mortem. In a number of these cases, 
there was a history of viral infection prior to the acute episode, and diagnosis of a viral 
illness was documented in P8 and P9. In family CHD2, one of the siblings had an 
episode of muscle weakness and hypotonia, prior to the onset of cardiomyopathy, but 
muscular disease was not a consistent phenotype in all of the four families. In family 
2b, the phenotype was of later onset. The trigger for illness in this family appears to 
have been alcohol ingestion, to which the patients had an exquisite sensitivity. The 
mid-myocardial fibrosis seen in this family appears to be a pre-existing condition, 
having been identified as present in both living siblings.  
 
The variant in PPA2 in the Leeds family was identified from WES data. Following 
filtering, three variants remained. The PPA2 variant was specifically prioritized as it 
was a good functional candidate and had the highest CADD score. However, the other 
two variants could not initially be ruled out as pathogenic. Both had high pathogenicity 
scores. The variant in EPHA5 falls within a smaller homozygous region on 
chromosome 4. EPHA5 codes for an ephrin receptor of the protein-tyrosine kinase 
family. It is involved in mediating developmental events, particularly in the nervous 
system (Das et al., 2016). This gene was a less convincing functional candidate than 
PPA2, as homozygous mutant mice have abnormal retinal mapping, but are otherwise 
phenotypically normal (Feldheim et al., 2004). The homozygous variant in RALGAPA1 
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(TULIP1) falls outside of the largest homozygous regions. This gene encodes a major 
subunit of the RAL-GTPase activating protein and is a candidate for developmental 
delay, as zebrafish knockdown results in delayed brain development (Shimojima et al., 
2009). There is no published literature to support a link between TULIP1 and 
cardiomyopathy.  
 
The variant in PPA2 was therefore prioritized as the likely causative gene in this family 
based its segregation with disease in the family, high pathogenicity scores and 
previously published functional data.  
4.3.2 Mitochondrial Function 
A large proportion of the body’s energy derived from fat and carbohydrate breakdown 
is created by oxidative phosphorylation (OXPHOS), which takes place in mitochondria. 
NADH and FADH2 are created from the breakdown of glucose. During OXPHOS, 
electrons derived from NADH and FADH2 combine with molecular oxygen and the 
energy released is used to drive the conversion of Adenosine Diphosphate (ADP) to 
Adenosine Triphosphate (ATP). Prior to energy release, these electrons are passed 
through a series of carriers, four complexes (I-IV) located on the inner mitochondrial 
membrane forming the Electron Transport Chain (ETC), and a final fifth complex, ATP 
synthase, that couples electron transport to ATP synthesis (Cooper and Hausman, 
2016) (Fig. 4-8). 
 
Figure 4-7: Diagram showing the complexes of the electron transport chain located at the 
inner mitochondrial membrane.  
ATP synthase is shown converting ADP to ATP with the addition of Pi. Adapted from (Ow et al., 
2008).  
 
The phenotype identified in these families of cardiomyopathy, intermittent muscle 
weakness, hypotonia, raised CK and lactate was suggestive of a mitochondrial 
disease. Mitochondrial diseases often involve multiple organ systems and commonly 
present with neurological and myopathic features (Chinnery, 1993). Mitochondrial 
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diseases can also be specific to certain organ-systems, for example Leber Hereditary 
Optic Neuropathy (LHON), which affects only the eye. There is a known link between 
mitochondrial disease and cardiomyopathy. Cardiomyopathy is commonly seen in 
mitochondrial disorders, such as MELAS syndrome (Myopathy, Mitochondrial 
Encephalopathy, Lactic Acidosis, Stroke) (Jose et al., 2011) and the heart is known to 
be sensitive to the affects of mitochondrial disease as a high energy-expending organ. 
Cardiomyopathy has also been linked to mitochondrial disease in a number of animal 
models. For example, OPA1 encodes a mitochondrial fusion protein and a mouse 
model carrying a nonsense mutation in Opa1 develops late-onset cardiomyopathy 
(Chen et al., 2012). Furthermore, mitochondria are now being investigated as a 
potential drug target in the treatment of cardiomyopathy (Walters et al., 2012).  
4.3.3 The Function of PPA2 
Inorganic pyrophosphatases (PPAs) are enzymes that catalyze the conversion of 
inorganic pyrophosphate (PPi) into inorganic phosphate (Pi) (see Fig. 4-9). PPi is 
formed during many important cellular processes, for example DNA, RNA, protein and 
lipid synthesis. Pi formation is critical in the cell, as it is required for the formation of 
ATP (see Fig. 4-9). PPAs are therefore key cellular enzymes and are present in all 
forms of life. Eukaryotes have two forms of PPA: PPA1 is present in the cytoplasm and 
PPA2 is the mitochondrial form of the enzyme. PPA2 has a 60% homology to PPA1 
and contains an N-terminal mitochondrial import sequence. PPA2 is ubiquitously 
expressed with the highest expression levels in liver, muscle, heart and kidney (Curbo 
et al., 2006). PPA2 has previously been shown to be located at the mitochondrial 
matrix (Curbo et al., 2006) and it has been suggested that the soluble catalytic part of 
the protein binds to an uncharacterized inner mitochondrial protein (Volk et al., 1983).  
 
 
Figure 4-8: The formation of Inorganic Phosphate from Inorganic Pyrophosphate by 
PPA2. 
Prior to this investigation, the key studies of PPA2 function involved the yeast 
Saccharomyces cerevisiae. Lundin et al., 1991, first cloned the PPA2 gene in yeast. To 
























viable yeast strain, but it could no longer grow on respiratory carbon sources, for 
example acetate or ethanol. The yeast strain lacking ppa2 was found to have a lack of 
mitochondrial DNA and the authors therefore concluded that PPA2 was essential for 
the maintenance of the mitochondrial genome (Lundin et al., 1991). Based on this 
finding Curbo et al. sequenced PPA2 in 13 patients with mitochondrial depletion 
syndromes, but were not able to identify a pathogenic mutation (Curbo et al., 2006). 
  
From our findings, it seemed reasonable to suggest that mutations in PPA2 were 
causing a mitochondrial dysfunction in our families, possibly due to a deficiency in 
mitochondrial Pi, causing a defect in mitochondrial ATP synthesis. This defect in 
mitochondrial function was presenting as a cardiomyopathy, a phenotype consistent 
with mitochondrial dysfunction. 
4.3.4 Discussion of Functional Studies Performed in PPA2 
A number of functional studies to investigate PPA2 function in the patients identified in 
this study were undertaken by our collaborators in Austria. The results of these 
experiments are described in detail in the associated publication (Kennedy et al., 
2016). In summary, Western blot analysis confirmed a normal level of PPA2 protein in 
the majority of tissue samples tested from affected patients. Western blot was 
performed for all individuals where fibroblast, skeletal muscle or cardiac tissue samples 
were available. The only reduction in PPA2 levels were in fibroblast mitochondria and 
skeletal muscle samples from patient P9, although these were normal in P6, who 
carried the same mutation, perhaps implying experimental or tissue-specific differences 
in expression, rather than a functional defect. In heart autopsy samples, patient P10 
appeared to have a reduction in PPA2 protein levels compatible with a complex I 
deficiency, showing a reduction of NDUFS4, a subunit of the complex I respiratory 
chain. P10 was the only patient identified to have a defect in respiratory chain analysis 
on cardiac tissue samples, affecting complexes I and IV, which would be in keeping 
with this finding. In cardiac tissue samples, patient P7 appeared to have a reduction in 
total mitochondrial number, demonstrated by a reduction in levels of PPA2, NDUFS4, 
CS and porin, but this was not mirrored in the fibroblast sample from P7 or the other 
patient samples available, and so may be due to changes in tissue composition post 
mortem. Overall, it did not appear that the identified mutations were consistently 





Oxygen Consumption Rate (OCR) was undertaken by our collaborators and was 
measured by micro scale respirometry by Seahorse Assay (XF96 Seahorse 
Biosciences, Agilent Technologies) in three patient and three control fibroblast 
samples. This analysis showed similar results for patient and control samples, except 
for following the addition of the mitochondrial uncoupler FCCP (Carboyl-cyanide-4-
(trifluoromethoxy)-phenylhydrazone), where patient samples showed almost double the 
rate of controls (Kennedy et al., 2016). An uncoupling protein dissipates the 
mitochondrial proton gradient inhibiting ATP synthesis without affecting the respiratory 
chain (Terada, 1990). Addition of FCCP is a measure of the reserve respiratory 
capacity (RRC), an estimate of the difference between basal and maximal 
mitochondrial activity, or how well mitochondria respond to stress (Sansbury et al., 
2011). Although an effect on RRC is a relatively non-specific finding, it could be 
hypothesized that the observed difference is due to the limitation of ATP synthesis in 
patient cells due to a lack of Pi. To support this hypothesis, cells from patients with a 
specific ATP synthase deficiency, due to mutations in TMEM70 or ATP5E, 
demonstrate an almost identical change in OCR (Cizkova et al., 2008, Mayr et al., 
2010).  
 
Due to the non-specific nature of the OCR results, further functional studies were used 
to measure pyrophosphatase activity in mitochondria extracted from patient fibroblasts 
and recombinant proteins were expressed to model the identified missense mutations. 
The results of both of these experiments supported the pathogenicity of the mutations 
identified in this gene. The c.500C>T (p.Pro167Leu) and c.514G>A (p.Glu172Lys) 
variants had a 5-10% activity compared to the wildtype enzyme, but the c.683C>T 
(p.Pro228Leu) variant showed a 24-28% activity when compared to wildtype (Kennedy 
et al., 2016). c.683C>T (p.Pro228Leu) is the variant identified in family 2b, who had a 
later onset of disease than the other families studied, which may be explained by the 
higher residual enzyme activity. None of the missense mutations appeared to have any 
effect on the stability of the protein. 
4.3.5 Identified Mutations in PPA2 are Hypomorphic 
All of the PPA2 mutations identified in this study are missense mutations. It is 
reasonable to hypothesise that biallelic loss-of-function mutations in this gene would be 
incompatible with life, and that the identified mutations are hypomorphic. To support 
this, in the large exome/genome project GnomAD, only 25 loss-of-function alleles are 
present in PPA2 and none of these are present in a homozygous state. In the EXaC 
database, only 71 potentially pathogenic missense variants are listed in PPA2 (those 
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with a SIFT score <0.05), which would result in an incidence for PPA2-related disease 
at 1 in 170,000. This suggests the PPA2 mutations identified are hypomorphic, leaving 
some residual enzyme function that would be compatible with viability.  
4.3.6 How is PPA2 Dysfunction Linked to the Clinical 
Phenotype? 
Some of the individuals identified in this study were shown to have a pre-existing 
cardiac fibrosis, proven by magnetic resonance imaging (MRI) investigation in the 
siblings of family 2b. Sudden demise or death in the described families was apparently 
triggered by an acute event. The pathophysiology of these trigger events is not clear 
and we are not able to readily explain the difference in phenotypic presentation 
observed between these families. In family 2b, the trigger appeared to be alcohol. In 
families CHD2, 2c and 2d, a viral illness was suspected to be the trigger. At the same 
time as the publication of our findings, a French group published a paper in the same 
journal describing three families with a very similar phenotype, where children had died 
of sudden cardiac arrest between the ages of 4 and 20 months and had biallelic 
mutations in PPA2. Similar cardiac findings were observed at post mortem, ranging 
from focal myocarditis to hypertrophic cardiomyopathy and cardiac fibrosis. One case 
was diagnosed with a myopathy prior to cardiac arrest. The same association with a 
‘trigger’ was not recorded in these cases (Guimier et al., 2016).  
 
Further work will be required to fully understand the pathophysiology of the clinical 
presentation associated with PPA2 mutations. The observed pre-existing 
cardiomyopathy could be due to a chronic ATP deficiency, affecting the cardiac 
muscle. Cardiomyocytes are particularly sensitive to defects in ATP-generating 
processes and impairments in ATP synthesis can rapidly affect their contractile 
function (Doenst et al., 2013). Conversely, ATP depletion is seen in disease processes 
such as heart failure (Doenst et al., 2013). High levels of PPi could also be associated 
with the cardiac cell dysfunction seen, which beyond a certain threshold has resulted in 
sudden cardiac arrest. It is known that abnormally high levels of PPi can result in 
competitive inhibition of mitochondrial ADP/ATP translocase (Griffiths and Halestrap, 
1993), which enables the exchange of ADP and ATP across the inner mitochondrial 
membrane, and this may be associated with a reduction in the ability of the cell to 
produce energy for contraction. Furthermore, the accumulation of PPi is known to 
inhibit a number of other important cellular processes, such as the biosynthesis of 
NAD+, the sequestration of Mg2+ ions and the polymerization of macromolecules 
(Heinonen, 2013). An excessive accumulation of PPi in respiring yeast cells leads to 
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cell cycle arrest, which is reversed with the removal of accumulated pyrophosphate. 
Fermenting yeast cells suffer not only cell cycle arrest, but also eventual cell death by 
autophagy (Serrano-Bueno et al., 2013). The phenotype observed in these families 
may therefore be a manifestation of chronic ATP deficiency, high PPi concentrations, 
or a combination of both of these factors.  
 
Further to this, there is a known link between alcohol ingestion and PPA function. 
Ethanol is oxidized to acetaldehyde and further to acetic acid. Acetic acid is activated 
to acetyl co-enzyme A, which is accompanied by formation of stoichiometric amounts 
of PPi (Yamashita et al., 2001, Yamada et al., 1988). If PPA function is deficient, an 
excess accumulation of PPi in the body’s tissues and, specifically cardiac tissues, may 
therefore be playing a role in the suspected fibrosis and sudden arrhythmia and death 
observed in family 2b. We can hypothesize that an excess of cellular PPi following 
alcohol consumption could lead to cardiac cell dysfunction and apoptosis, exacerbating 
the underlying cardiomyopathy, and acting as an acute trigger for disease. 
4.3.7 The Importance of the Identification of Mutations in PPA2 
Mutations in PPA2 were identified in four families with a very severe phenotype, 
leading to cardiomyopathy and early death in affected family members. The phenotype 
investigated in these families is an extremely important one, as, although rare, it is a 
differential for Sudden Unexpected Death in Infants and Children (SUDIC). SUDIC is 
the most common cause of post-neonatal mortality in developing countries (Fleming et 
al., 2015). The cause of SUDIC is often unidentified, but potentially pathogenic variants 
in genes associated with cardiomyopathy, cardiac arrhythmia or cardiac ion channel 
dysfunction may be associated in a proportion of cases (Klaver et al., 2011) and 
metabolic diseases related to fatty acid oxidation and ketone body metabolism also 
require exclusion (Oshima et al., 2017). The families investigated in this report have 
not only lost one or more children to this condition, but have often been through a 
lengthy process in attempting to reach a diagnosis for their children, and in attempting 
to understand the likely risks to the surviving siblings and extended family members. 
The identification of a genetic cause for disease has provided information and 
knowledge for the families and clinicians involved in these cases and has directly 
affected clinical management. 
 
The identification of mutations in this gene has provided key information for the families 
described. These families can now access information regarding future recurrence risk 
and prenatal testing could be offered if so desired. In family CHD2, the surviving sibling 
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has undergone genetic testing to ascertain their risk of disease and carrier testing is 
now available to further extended family members. This has been of great importance 
to the family who were very concerned regarding the risks to their surviving child and 
current pregnancy.  
 
This case has provided an excellent example of a condition where reaching a genetic 
diagnosis has made a clear difference to patient management and has allowed life-
saving measures to be employed. For example, in family 2b, the surviving siblings 
have been fitted with ICD devices, are having regular MRI surveillance, and have been 
educated on the avoidance of alcohol, with the aim of avoiding arrhythmia and sudden 
death.  
 
Diagnostic testing in this condition can be performed by PPA2 mutation analysis, but 
could also be aided by MRI investigation to assess for signs of cardiomyopathy and 
conceivably PPA activity levels could be used in diagnosis, although this type of testing 
is currently only available on a research basis. It may be that, as more families with this 
condition are identified, further genotype-phenotype correlation can be delineated and 
standardized strategies for the management of affected patients can be created.  
 
It is not known whether heterozygous carriers of PPA2-related disease are at risk of 
cardiac anomaly, none of the known heterozygous carriers in the families described 
are affected with a clinical phenotype, but analysis of PPA activity could be used to 
further assess carriers for mild features of the disease. PPi is known to be an inhibitor 
of calcium phosphate deposition, where high serum Pi promotes ectopic calcification in 
a number of tissues, including blood vessels (Villa-Bellosta et al., 2017). Vascular 
calcification is associated with cardiovascular disease, for example coronary 
atherosclerosis (Otsuka et al., 2014). It is therefore reasonable to hypothesize that the 
PPA2 gene could be a susceptibility gene for later-onset cardiovascular disease, with 
variants affecting PPA2 levels to a lesser degree than observed in our families with 
severe, young-onset disease. It would be extremely interesting to screen large cohorts 
of patients with later-onset cardiovascular disease for variants in this gene. 
4.4 Conclusions 
We have shown that mutations in PPA2, coding for an inorganic pyrophosphatase, are 
a rare cause of sudden unexpected death in infancy and childhood. This is an 
important clinical phenotype, as PPA2-related disease is a differential for sudden 
unexpected death in childhood. We also describe a family with an unusual phenotype 
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of extreme sensitivity to alcohol with mutations in this gene. PPA2-related disease 
encompasses these two very distinctive phenotypes, for which a molecular diagnosis 
should be sought if suspected. A molecular diagnosis of PPA2-related disease is of 
great importance as screening of family members, using cardiac MRI, mutation 
analysis or analysis of PPA activity could identify those individuals at risk. For family 
members at risk, interventions such as education on the avoidance of possible triggers 
and implantation of an ICD device may prevent the lethal consequence of disease.  
 
The finding of mutations in PPA2 in human disease highlights the critical role that 
PPA2 plays in mitochondrial function and gives further insight into the pathophysiology 




5 Mutations in DNAAF1 are Associated with 
Congenital Heart Disease in the Absence of 
Primary Ciliary Dyskinesia 
5.1 Introduction 
DNAAF1 is a dynein arm assembly factor and a known cause of PCD in humans 
(Loges et al., 2009). The link between PCD, laterality disorders and complex CHD has 
been long-established. Here we describe the identification of a missense mutation in 
DNAAF1 (a known PCD disease gene and dynein arm assembly factor, MIM number 
613193) in a family with heterotaxy and complex CHD, but without a clinical diagnosis 
of PCD. We have sought to identify typical clinical features of PCD in this family, but 
clinical investigations did not support this diagnosis. 
 
We have collaborated to ascertain a small cohort of patients with mutations in 
DNAAF1. Those with frameshift mutations or deletions in the gene have a typical 
phenotype of PCD, often associated with cardiac defects. We hypothesize that the 
missense mutation identified in our family is hypomorphic, affecting the nodal cilia in 
embryonic development and leading to cardiovascular defects, but having no apparent 
effect on respiratory ciliary function. We have demonstrated the pathogenicity of this 
missense mutation by modeling in a dnaaf1-/- null mutant zebrafish model. 
 
We have also investigated the function of DNAAF1 by assessment of protein-protein 
interactions and protein co-localisation in ciliated cells. The results of these 
experiments have identified novel interactions of DNAAF1 and have provided new 
insights into the possible functions of DNAAF1 during dynein arm assembly in motile 
cilia. Specifically, we have investigated the expression of DNAAF1 and a novel 
interacting partner, RUVBL1/Pontin at the murine and zebrafish embryonic node and 
developing heart. Our data suggests that the DNAAF1-RUVBL1 interaction is required 
for symmetry breaking during the development of laterality in early embryogenesis.  
 
The work described in this chapter was part of a multi-center collaboration, led by the 
researchers at the University of Leeds. Where the described work was performed by 




5.2.1 Clinical Phenotype 
Family CHD1 are a consanguineous family of Pakistani origin who have two children 
affected with complex CHD (Figure 5-1). Affected individual JT66 has right atrial 
isomerism (RAI) with complete AVSD, AV valve regurgitation, double outlet right 
ventricle, pulmonary atresia, and right pulmonary artery stenosis. Blalock-Taussig (BT) 
shunt and subsequent bidirectional cavopulmonary (Glenn) shunt have been 
performed. The affected sibling, JT67, has heterotaxy; dextrocardia, right atrial 
isomerism, left-sided liver, right-sided stomach and polysplenia. In terms of cardiac 
anatomy, he has double outlet right ventricle with the pulmonary artery to the right and 
the aorta to the left side. Both ventricles are described as small on MRI imaging and 
there is a large inlet VSD and severe sub-pulmonary stenosis. This child has had a 
previous Glenn shunt performed. Neither child complains of recurrent chest infections 
or chronic cough. They are non-dysmorphic and have normal learning, with average 
performance at school. Karyotype analysis has previously been performed and was 
normal.  
 
Figure 5-1: Pedigree of Family CHD1.  
Shaded individuals are affected with complex CHD. DNA samples were available from 




5.2.2 SNP microarray 
Affymetrix 6.0 SNP microarray analysis was performed on samples from both affected 
individuals in this family (JT66 and JT67). Large regions of homozygosity (>1,000,000 
bp) shared between the affected individuals are shown in Table 5-1. 
 
Table 5-1: Large regions of homozygosity, identified on SNP array, shared between the 
affected siblings in family CHD1. 
Chromosome 
 
Start position End position Size (bp) 
chr13 30744080 43111120 12367040 
chr1 49589806 51029387 1439581 
chr2 228056368 234938781 6882413 
chr2 237132461 243102476 5970015 
chr5 45417643 50062543 4644900 
chr12 130320647 133779461 3458814 
chr16 1119946 3640274 2520328 
chr11 2544340 4867962 2323622 
chr14 21511789 23329446 1817657 
chr1 147635483 149396403 1760920 
chr5 129573666 130769785 1196119 
chr20 25040884 26129447 1088563 
chr5 41629963 42714692 1084729 
chr14 66824734 67897700 1072966 
chr16 83207071 84258711 1051640 
chr1 155086148 156135241 1049093 
chr8 50367785 51371466 1003681 
5.2.3 Whole Exome Sequencing 
WES was performed for both affected individuals. For patient JT66, this was performed 
on an Illumina MiSeq prior to the start of this research project. For JT67 this was 
performed using the Illumina XT kit, as previously described, on an Illumina Hiseq 2500 
with 6 samples pooled per lane.  
 
Data analysis followed the standardized pipeline. In this instance, variants were filtered 
out which were present at a Minor Allele Frequency (MAF) >1% in dbSNP 138, the 
NHLBI Exome Sequencing Project (ESP) Exome Variant Server, the Exome 
Aggregation Consortium (ExAC) database, and 200 locally-sequenced ethnically-
matched control samples. Variants were also retained if they followed the predicted 
autosomal recessive inheritance pattern in the family (i.e. were homozygous in both 
affected siblings). Table 5-2 shows the number of variants remaining after each stage 
of data filtering and analysis.   
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Table 5-2: Number of variants remaining following each step in WES data analysis for 
family CHD1. 
Stage in Analysis 
 
Number of variants 
Called with GATK 424054 
Filter on dbSNP/EVS (<1%) 116753 
<1% local exomes 92525 
<1% ExAC 92062 
Functional variants 732 
Filter on family structure (homozygous 
shared between affecteds) 
Predicted ‘pathogenic’ by in silico tools 










Table 5-3: Variants remaining following filtering in family CHD1. 
Gene Variant Protein 
change 
















Dynein assembly factor 













The variant in DNAAF1 appeared to be the most likely candidate in this family. It fell 
within a large homozygous region, identified from the SNP data, on chromosome 16. 
An IGV readout showing this variant in homozygous form in both affected individuals is 
shown in Figure 5-2. WES quality scores and depth of coverage were assessed and 
showed high quality sequencing (see appendix F). 
 
 
Figure 5-2: IGV readout showing the variant in DNAAF1, c.571C>T, which is homozygous 
in both affected individuals in family CHD1. 
The variant is shown in affected individuals a) JT66 and b) JT67. The C>T variant is marked by 
the red arrow. Aligned reads are shown in grey. 
5.2.4 CNV analysis 
CNV analysis was performed using the Exome Depth software on WES data in 
individual JT67. A number of potential candidate CNVs were identified by the program, 
but none overlapped a likely candidate gene for complex CHD and heterotaxy. A full 
list of CNV variants identified is provided in appendix J. 
5.2.5 Analysis of the Missense Variant in DNAAF1 
The variant in DNAAF1 was prioritized over the other filtered variants. Using in silico 
tools, it scored ‘probably damaging’ on PolyPhen2, ‘deleterious’ on SIFT and 
‘deleterious’ on Condel. The CADD score was 25.6. This variant was very rare: it was 
absent from the ExAC and the GnomAD databases. In a local control dataset there 






homozygous. The position of the variant is highly conserved in other vertebrate 
species, specifically mammals and amphibians, as shown in Figure 5-3.  
 
Figure 5-3: Conservation of variant p.L191F in DNAAF1 orthologues. 
Conservation is shown within the region of LRR (leucine-rich repeats) in the proteins. The 
indicated protein sequences were aligned by HomoloGene. The arrow indicates the 
conservation of the Leu191 residue in all species down to Xenopus tropicalis.  
 
This variant causes an amino acid substitution, leucine to phenylalanine, in exon 5 of 
DNAAF1. It lies within one of the LRR (leucine-rich repeat) domains of the protein. This 
domain contains a motif of repeats with a highly-conserved leucine present at specific 
points along the sequence. LRR domains are often involved in protein-protein 
interactions (Loges et al., 2009). The putative mutation would be predicted to substitute 
a phenylalanine for a conserved leucine (Figure 5-3 above) and is therefore likely to 
disrupt protein function by perturbing protein-protein interactions. The domains of the 




Figure 5-4: Position of c.571C>T in the DNAAF1 gene and position of the missense 
substitution, L191F, in the DNAAF1 protein.  








 Rattus norvegicus 











5.2.6 Sanger Sequencing Confirmation of Variant in DNAAF1 
Confirmation of the variant in DNAAF1 by Sanger sequencing was performed for both 
affected individuals and their unaffected mother. DNA from the father was not available 
for testing. Figure 5-5 shows the variant in DNAAF1 present in the homozygous state 
in both of the affected individuals and in the heterozygous state for their mother. Primer 




Figure 5-5: Sanger sequencing electropherograms to show the c.571C>T variant in 
DNAAF1 in family CHD1. 
Electropherograms showing (A) the mother of JT66 and JT67, showing the variant in 
heterozygous state, (B) individual JT66 (affected male) and (C) individual JT67 (affected male), 
showing the variant in the homozygous state. The variant in DNAAF1 is highlighted with blue 
shading. 
5.2.7 Investigation of PCD in Family CHD1 
Due to the identification of a variant in DNAAF1 in family CHD1, the family was further 
contacted to investigate a diagnosis of PCD in the affected siblings. Initially, a specific 
clinical history was taken: neither child had suffered from typical symptoms of PCD 
such as persistent neonatal respiratory distress, rhinorrhea, respiratory infections or 
chronic cough. JT67 had suffered from recurrent episodes of otitis media. Exercise 
tolerance was reduced in both siblings, but this was thought to be due to cardiac 
disease.  
 
Clinical testing for PCD was performed by Dr. Amelia Shoemark, PCD senior clinical 
scientist, Royal Brompton and Harefield NHS Foundation Trust. Nasal cell brushings 
were taken concurrently from JT67 and a normal control individual. Video microscopy 
was initially performed on nasal epithelial cells to investigate ciliary beat and waveform. 
The sample from JT67 identified a sparsely ciliated epithelium. The cilia were 
effectively clearing surrounding debris and there was a mixed beat, with some slow, 
dyskinetic and static patches. The control sample taken concurrently showed a co-









similar to those seen in the patient, and likely resulting from sample storage and 
transport rather than an underlying pathology. The Ciliary Beat Frequency reported in 
affected individual JT67 was 8.7Hz (SD 2.2Hz; within the normal range), compared to 
9.1Hz; SD 2.1Hz) in the normal control sample taken concurrently. 
 
Transmission Electron Microscopy (TEM) was also undertaken and gave a normal 
result, demonstrating the presence of inner and outer dynein arms in the sample from 
patient JT67, although only 10 ciliary cross-sections could be assessed (data not 
shown). Nitric Oxide (NO) measurements in JT67 showed a level of 254 ppb (63 
nL/min) in the right nostril (normal level >187 ppb) and 121 ppb (30 nL/min) in left 
nostril (low, but this nostril was blocked by a upper respiratory tract infection at the time 
of testing). The ambient level was 17 ppb. Overall, there was no evidence to support a 
diagnosis of PCD in affected individual JT67 on clinical testing, although a sub-clinical 
PCD could not be excluded. 
5.2.8 Investigation of Mutations in DNAAF1 in Other Heterotaxy 
Patients 
Due to the finding of a putative pathogenic mutation in DNAAF1 in a family with 
heterotaxy, we screened other patients with a similar phenotype for mutations in the 
same gene. Lymphoblastoid cell lines were available to our group from a cohort of 
additional patients with heterotaxy and other limited phenotypic information. Those with 
the most complete clinical information, compatible with a diagnosis of heterotaxy, were 
selected for DNA extraction. Sanger sequencing was performed to sequence all 15 
exons of DNAAF1 in 19 patients and the identified variants were analyzed using in 
silico tools. Table 5-4 shows a summary of the 19 sequenced heterotaxy patients, 
showing the known clinical information and identified variants. No likely pathogenic 
variants were identified in these 19 patients. For primer sequences see appendix E.  
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Table 5-4: Heterotaxy samples screened for mutations in DNAAF1 by Sanger sequencing. 
Sample name Phenotypic information Sequencing 
IV5 Dextrocardia, situs inversus, VSD, PDA, 
isomerism 
Full gene covered. No 
mutation. 
IV9 AVSD, TGA, asplenia, trilobed lungs, RAI, 
symmetric liver, intestinal malrotation, 
pancreatic aplasia 
Full gene covered. No 
mutation. 
IV10 Right atrial isomerism, hepatic draining to 
IVC, aorta to right of spine, AVSD, DORV, 
asplenia 
Full gene covered. No 
mutation. 
IV15 Right atrial isomerism, AVSD, central liver. Sequencing failed, likely 
poor quality DNA 
IV19 Complete situs inversus Full gene covered. No 
mutation. 
CD5 Left isomerism sequence Full gene covered. No 
mutation. 
CD10 Right isomerism sequence Full gene covered. 
rs9972733 homozygous, 
MAF 0.097 in EXaC. 
CD20 Left isomerism sequence Full gene covered. No 
mutation. 
CD46 Left atrial isomerism, parents first cousins Full gene covered. No 
mutation. 
 
CD50 Right atrial isomerism, parents first cousins Full gene covered. 
rs372390124 
heterozygous, MAF 
0.0001 in ExAC. 
CD58 Tetralogy of Fallot.  Full gene covered. No 
mutation. 
CD60 Laterality defect, complex CHD, 
consanguineous family. 
Full gene covered. No 
mutation. 
CD61 Laterality defect, complex CHD Full gene covered. No 
mutation. 
CD133 Left atrial isomerism, sister died of complex 
CHD 
Full gene covered. No 
mutation. 
 
5.2.9 Identification of Further Families with Mutations in 
DNAAF1 Through Collaborating Centres 
Through collaboration, we were able to identify additional families with mutations in 
DNAAF1 who had been referred to the diagnostic PCD services based at University 
College London and the Yorkshire Molecular Genetics Laboratory. These families had 
been investigated by WES analysis and mutations in DNAAF1, but no other PCD gene, 
were identified. In contrast to the clinical features in family CHD1, all three families had 
typical features of PCD. 
 
Family 1b have three children affected with PCD (see Figure 5-6). All three children 
suffered with recurrent chest infections, bronchiectasis and multiple hospital 
admissions. A diagnosis of PCD was confirmed in each sibling following nitric oxide 
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testing (for example Individual II:1 had an NO level of 40 ppb (10nL/min)) and 
completely immotile cilia were identified when assessed by high speed video imaging. 
TEM analysis was abnormal in the three siblings, showing the absence of ciliary outer 
dynein arms in 84%, 92% and 100% of cilia cross-sections, with occasionally absent 
inner dynein arms (affecting 21%, 22% and 30% of cross-sections, respectively). Two 
of these three patients were affected with situs inversus, associated with asplenia and 
RAI. One of these siblings had concurrent AVSD, pulmonary stenosis and anomalous 
pulmonary venous drainage, and the other had dextrocardia (azygous vein to left-sided 
superior vena cava) and anomalous pulmonary venous drainage. This family had a 
further child affected with RAI, but who died of cardiac complications before a 
diagnosis of PCD was explored. In Family 1b, heterozygous frameshift mutations in 
DNAAF1; c.281delA and c.1484delC, were identified by the team at UCL. These 
mutations segregated with disease in the family and were confirmed by Sanger 
sequencing. 
 
Family 1c consists of a single affected male with confirmed PCD. He has typical 
features of the condition including longstanding otitis media, dextrocardia (but no other 
cardiac disease), and asthenospermia. This male has a homozygous mutation in 
DNAAF1, c.1484delC, resulting in a frameshift mutation, p.Pro495fs, identified by the 
Yorkshire Molecular Genetics Laboratory.  
 
Family 1d consists of two siblings affected with PCD. The first (II:1) had suffered from 
respiratory distress as a neonate and then episodes of persistent rhinorrhea. He had 
situs inversus (including dextrocardia), transposition of the great vessels, VSD and 
tricuspid regurgitation. A diagnosis of PCD was made following ciliary brushings, which 
showed static cilia, and a lack of IDA and ODA on TEM. However, ODA stubs were 
noted to be present. The second child (II:2) had a history of chronic cough, but no 
evidence of cardiac disease. Clinical investigations showed static cilia and a lack of 
both IDA and ODA. Both affected individuals in Family 1d share a 7kb out-of-frame 
homozygous deletion in DNAAF1 (GRCh37; Chr16:84,193,165-84,201,105) which 
affects exons 6 and 7 of the gene. This deletion was identified from whole exome 
sequencing data by Dr Chris Watson at the Yorkshire Molecular Genetics Laboratory. 
He was able to identify an absence of mapped reads at this position (Fig. 5-6). The 
breakpoints were confirmed by whole genome sequencing (WGS) and a breakpoint-




Figure 5-6: Pedigrees of families with DNAAF1 mutations. Mapping of an identified deletion in DNAAF1 using WGS and Sanger sequencing. 
Pedigrees of A) family CHD1, B) family 1b, C) family 1c & D) family 1d. A shaded upper left quadrant indicates a clinical diagnosis of PCD, a shaded upper 
right quadrant indicates a diagnosis of Congenital Heart Disease (CHD). E: IGV readout of sequencing reads in family 1d, showing an absence of aligned 
reads at position 16: 84,193,165-84,201,105. F: Sanger sequencing assay to show breakpoints of homozygous deletion in family 1d. 
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5.2.10 Creation of DNAAF1 Constructs  
 
Gateway cloning was used to create DNAAF1 N-terminal TAP (which includes a FLAG 
sequence) and pCS2+ constructs, for use in further experiments. The variant identified 
in family CHD1, c.571C>T, was introduced into the sequence by site-directed 
mutagenesis. Sanger sequencing was used to confirm the successful creation of the 
wildtype and mutant constructs. Figures 5-7 and 5-8 show maps of the N-terminal TAP 

















Figure 5-7: A representation of the N-terminal TAP DNAAF1 construct.  
The DNAAF1 gene is shown in purple. Restriction enzyme sites are shown by black lines. 





Figure 5-8: A map of the pCS2+ DNAAF1 construct.  
The DNAAF1 gene is shown in purple. Restriction enzyme sites are shown by black lines. 
Image adapted from SnapGene (http://www.snapgene.com). 
 
Prior to use in further experiments or transfer to collaborators, these constructs were 
Sanger sequenced to confirm orientation and absence of sequence errors from PCR. 
The pCS2+ constructs were linearized with the restriction enzyme EcoRI prior to their 
use as templates for in vitro transcription. Figure 5-9 shows agarose gel 
electrophoresis confirming a single band following linearization of the wildtype and 






Figure 5-9: Agarose gel electrophoresis to show digestion of wildtype (wt) and mutant 
L191F (mut) PCS2+ constructs with EcoR1 enzyme.  
UD= undigested. Bp= base pairs. Linearization of both plasmids is seen on digestion. 
5.2.11 Rescue of Heart Looping Defect in dnaaf1-/- Zebrafish 
The pathogenicity of c.571C>T (Leu191Phe) missense variant identified in family 
CHD1 was investigated by modeling the mutation in the lrrc50-/- (dnaaf1-/-) null mutant 
zebrafish line. These experiments were performed by Dr Glenn van de Hoek, PhD 
student, University Medical Center, Utrecht, The Netherlands. Dr Hartill created and 
sequenced the pCS2+ DNAAF1 mutant and wildtype constructs required for mRNA 
production and Dr van de Hoek completed all of the other laboratory work, 
interpretation and statistical analysis. 
 
The dnaaf1-/- zebrafish have a T>A mutation creating a premature stop codon. They 
have a typical ‘ciliopathy’ phenotype with ventral body curvature, pronephric cysts and 
duct dilatation, and randomised heart looping. These fish have static cilia, previously 
demonstrated both at the Kupffer’s vesicle and in the pronephros (Basten et al., 2013). 
mRNA of mutant (encoding p.Phe191) or wildtype (p.Leu191) DNAAF1 was 
microinjected into embryos derived from dnaaf1+/- heterozygote-heterozygote 
intercrosses at 72 hours post-fertilization and compared to mock-injected fish as a 
control. In mock-injected controls, around 16% of embryos showed reversed heart 
looping (Figure 5.10), less than the expected Mendelian ratio of 25% for a homozygous 
phenotype, because the laterality will be randomized (allowing 50% of affected fish to 
develop a left-sided heart and 50% a right-sided heart) in the mutant dnaaf1-/- embryos 
(van Rooijen et al., 2008). In support of the pathogenicity of the mutation, rescue of 





















not the mutant (p.L191F) mRNA (see Fig. 5-10). Pair-wise comparisons were 
performed with the mock-injected zebrafish and the data shown is from three combined 
biological replicates. The background incidence of situs defects in wild-type zebrafish, 
kept under identical conditions in the same facility, was <5%. 
 
Figure 5-10: Phenotypic rescue of dnaaf1+/- heterozygote-heterozygote intercrossed 
zebrafish embryos on injection of human wildtype, but not mutant L191F DNAAF1 
constructs. 
Showing dnaaf1+/- heterozygote-heterozygote intercrossed zebrafish embryos identified as 
control (mock-injected, n=405 embryos), or injected with mRNA expressed from human wildtype 
(wt, n=425 embryos) or p.Leu191Phe-mutant (mut, n=547 embryos) constructs. Left panels: 
Heart looping coded as normal (green), reversed (red) or ‘linear’ (orange), which is also an 
abnormal phenotype. Right panel: A graphical quantification of the three positions of heart 
looping following mock, DNAAF1 wildtype (wt) or DNAAF1 mutant (mut) injection. Phenotypic 
rescue is seen after injection of wildtype but not mutant mRNA. n.s.= not significant; *** p<0.001 
(one-way ANOVA, n=3 biological replicates).  
5.2.12 Tandem Affinity Purification to Identify Interacting 
Partners of DNAAF1 
The laboratory experiments described in this section were performed by Dr Kasia 
Szymanska, Post-Doctoral Research Fellow, University of Leeds, with data 
interrogation and statistical analysis performed by Dr Hartill.  
 
Following the observation of a specific mutation in DNAAF1 associated with a 
phenotype of pure cardiac defects, but not typical PCD, we wished to gain further 
biological insights into the function of DNAAF1. A Streptavidin-II/FLAG TAP experiment 
was performed to identify interacting partners of DNAAF1, using wildtype and mutant 
(p.L191F) N-TAP constructs to pull-down peptides, which were then interrogated by 
mass-spectrometry. Table 5-5 shows the proteins associated with the highest number 
of pulled-down unique peptides in three biological replicates of this experiment, with 
results ordered from the highest to the lowest number of pulled-down peptides. Only 
those proteins with greater than 5 pulled-down peptides and present in at least two of 
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the biological replicates are shown. Proteins have been excluded that were observed in 
only one replicate, as well as those that were an effect of contamination and were 
present in BSA washes. For the full mass-spectrometry results see appendix L. 
 
The peptide counts were highly reproducible between separate experiments, 
suggesting stable interactions. DNAAF1 pulled down itself, which validates the 
experimental technique, although the mutant protein was pulled down less efficiently, 
suggesting that the p.L191F mutation perturbed protein-protein interactions through the 
affected LRR repeat. As can be seen in Table 5-5, the mutant DNAAF1 appeared to 
have a number of novel interacting partners, not observed for the wildtype protein. 
Interacting partners of wildtype DNAAF1 were most commonly those involved in DNA 
damage/repair, mitochondrial membranes, ribosomes, vesicular trafficking, protein 
folding and viral infection. Of particular interest was the identification of the interaction 
of DNAAF1 with Heat Shock Proteins (HSPA1A, HSPA9, HSPA8 HSPA5, HSP90AA1 
and HSPA6) and RUVBL1 and RUVBL2 (Pontin and Reptin), members of AAA+ 
(ATPases Associated with various cellular Activities) protein family. The RUVBL1 
interaction, but not the interaction with RUVBL2, appeared to be perturbed by the 
L191F mutation, although this observation was not statistically significant (see Table 5-
5).   
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Table 5-5: Proteins associated with peptides pulled-down in a TAP experiment, identified 
by mass spectrometry, using DNAAF1 wildtype or mutant (L191F) constructs as bait.  
Only proteins with more than 5 pulled-down peptides in at least two of the biological replicates 
are shown. Results are ordered from highest to lowest number of pulled-down peptides. Log-
fold change of wildtype to mutant protein is shown, where a positive value indicates an 
increased association with the mutant protein and a negative value indicates an increased 
association with the wildtype. A number of proteins show a novel interaction with the mutant 
construct (+) and several proteins of the chaperonin containing TCP1 (CCT) complex, also 
associated with the mutant protein only, have been removed from the table for brevity. The final 
column shows statistically significant differences in peptide numbers for wild-type compared to 
mutant conditions (Chi-squared test; n.s. not significant, * p=<0.05, **** p=<0.0001; for n=3 






























Q8NEP3 80 378 -0.058 * 
HSPA9 heat-shock 
protein 
P38646 74 121 -0.004 n.s. 
HSPA8 heat-shock 
protein 
P11142 71 89 +0.181 **** 
HSPA1A heat-shock 
protein 
P08107 70 86 +0.186 **** 
HSPA5 heat-shock 
protein 
P11021 72 53 +0.075 n.s. 
ACACA acetyl co-A 
carboxylase 
Q13085 266 50 -0.344 n.s. 
RUVBL1 
 
Pontin Q9Y265 50 28 -0.049 n.s. 
TUBB4B tubulin P68371 50 24 +0.602 **** 
TUBA1B tubulin P68363 50 20 +0.531 **** 
RUVBL2 Reptin Q9Y230 51 19 +0.083 **** 




P62987 15 10 +0.146 n.s. 
PC pyruvate 
carboxylase 
P11498 130 8 +0.026 n.s. 
TUBB tubulin P07437 50 8 +0.495 **** 




















































P17066 71 0 + n/a 
HSP90AA1 heat-shock 
protein 
P07900 85 0 + n/a 
SUGT1 suppressor 
of G2 allele 
of SKP1 
Q9Y2Z0 41 0 + n/a 
 
Prior to the start of this research project, our collaborators in the Netherlands had  
investigated additional wildtype DNAAF1 interactions using a GAL4 yeast two-hybrid 
assay, using an oligo dT-primed human retinal cDNA library. This screen identified only 
one positive clone, and it encoded intraflagellar transport protein IFT88. This result was 
confirmed using a “one-to-one” yeast two-hybrid experiment and DNAAF1 was found to 
interact with full length and N-terminally truncated IFT88, but not C-terminally truncated 
IFT88 (Dr S. Basten, University Medical Center, Utrecht, The Netherlands; unpublished 
data).  
5.2.13 Co-Immunoprecipitation to Confirm Interactants of 
DNAAF1 
Dr Mitali Patel, Post-Doctoral Research Fellow, University College London, performed 
the majority of experiments shown in this section, with Dr Hartill performing coIPs using 
a rabbit polyclonal antibody against the endogenous DNAAF1 protein. In a number of 
these experiments an IFT88 with C-terminal tag eYFP construct was used. This 
construct was obtained from Dr Pamela Tran, Harvard Medical School, Boston, 
Massachusetts, USA, and was received in a pLenti CMV vector (Tran et al., 2008). It 
was subcloned into a p.TriEx-1 vector and was sequenced verified prior to the start of 
this project.  
 
Initially, co-immunoprecipitation (coIP) in HEK293 cells was used to confirm the 
interaction of DNAAF1 with RUVBL1 and RUVBL2, interactions identified in the TAP 
experiments. FLAG-DNAAF1 constructs with either the wildtype or Phe191 mutant 
sequence were overexpressed in this cell-line, then anti-FLAG antibodies were used 
for the immunoprecipitation pull-down and western blot of the membrane was 
performed with anti-RUVBL1 or anti-RUVBL2 antibodies, to assess interaction. Figure 
5-11 shows the confirmation of the interaction of DNAAF1 with RUVBL1 and RUVBL2, 
both of which were pulled-down in this experiment (Figure 5-11:A & B). Neither 
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interaction appeared to be affected by the presence of the p.Phe191 mutation. The 
reciprocal co-immunoprecipitation was also attempted, with overexpression of FLAG-
DNAAF1 then pull-down with anti-RUVBL1 or RUVBL2 antibody and western blot of 
the membrane with anti-FLAG antibody. Unfortunately, this experiment was not 
successful due to the anti-FLAG antibody giving a number of non-specific bands, which 
were not interpretable. 
 
A similar co-immunoprecipitation was also performed with the overexpression of FLAG-
DNAAF1, pull-down with endogenous DNAAF1 antibody and blot with anti-FLAG 
antibody and then, following stripping, with anti-RUVBL1 antibody (see Figure 5-11:C). 
Unfortunately no bands were seen in the IP lane, even on a number of repeats when 
the input protein concentration was increased. This was thought to be due to a problem 
with the specificity of the anti-DNAAF1 antibody. After three attempts this experiment 
was discontinued.  
 
Further coIPs were performed to confirm the interaction between DNAAF1 and IFT88. 
CoIP was performed with overexpression of IFT88-eYFP and FLAG-DNAAF1 
constructs (wildtype Leu191 and mutant Phe191), followed by immunoprecipitation 
pull-down with anti-FLAG antibody and western blot with the proprietary anti-native 
GFP “Living Colors” antibody. This confirmed the interaction of IFT88 with wildtype 
DNAAF1. Interestingly, the interaction of IFT88 with the mutant DNAAF1 appeared to 
be abrogated, with a loss of the largest band after immunoprecipitation (Figure 5-11). 





Figure 5-11: Co-immunoprecipitation assays to investigate interacting partners of DNAAF1.  
A) Overexpression of wildtype or mutant (Phe191) FLAG-DNAAF1, pull-down with anti-FLAG antibody and blot with anti-RUVBL1 antibody. Controls are 
empty vector and irrelevant IgG controls. Input lane is the whole cell extract (WCE). The results confirm the interaction between DNAAF1 (wt and mut) and 
RUVBL1/Pontin. B) Overexpression of wildtype or mutant (Phe191) FLAG-DNAAF1, pull-down with anti-FLAG antibody and blot with anti-RUVBL2 antibody 
An empty vector control is shown. The results confirm the interaction between DNAAF1 (wt and mut) and RUVBL2/Reptin C) Overexpression of wildtype or 
mutant (Phe191) FLAG-DNAAF1, pull-down with endogenous anti-DNAAF1 antibody and blot with anti-FLAG antibody. No bands are seen in the 
immunoprecipitation lanes. D) Overexpression of wildtype or mutant (Phe191) FLAG-DNAAF1 and IFT88-eYFP, pull-down with anti-FLAG antibody and blot 
with anti-GFP “living colours” antibody. Irrelevant IgG lanes and empty vector are shown as a control. The interaction of wildtype DNAAF1 with IFT88 is 

















































































































































5.2.14 Cellular Localization Studies to Assess Co-
localisation of DNAAF1 with Identified Interacting 
Partners 
We next assessed the co-localization of DNAAF1 and the identified interacting partners 
from previous experiments: RUVBL1, RUVBL2 and IFT88. Initially the localization of 
DNAAF1 was assessed in the primary-ciliated cell-lines, human hTERT-RPE1 and 
mouse IMCD3s. DNAAF1 was found to localize to the base of cilia in these cell lines 
using an endogenous DNAAF1 antibody and an antibody that recognized acetylated 
alpha tubulin as a ciliary marker. To further characterize this localization, 
immunofluorescence confocal microscopy using antibodies against RPGRIP1L 
(recognizing the ciliary transition zone), CEP290 (ciliary transition zone), Centrin-3 
(distal lumen of the centrioles) and γ-tubulin (ciliary basal body) was performed in 
hTERT-RPE1 cells. Endogenous DNAAF1 was identified close to RPGRIP1L, CEP290 
and Centrin-3, but overlapping with γ-tubulin, suggesting a specific basal body 

























Figure 5-12: Co-localization of endogenous DNAAF1 (green) and ciliary markers, 
RPGRIP1L, CEP290, Centrin-3 and γ-tubulin (red).  
DNAAF1 shows specific basal body localization. Scale bars = 10 µm. 
 
To gain further insights into the observed DNAAF1 missense mutation, experiments 
were performed with overexpression of wildtype and mutant (p.Leu191Phe) DNAAF1 
N-terminal FLAG constructs (FLAG-DNAAF1) and immunofluorescence with anti-FLAG 
antibody in hTERT-RPE1 cells. The FLAG-DNAAF1 protein accumulated mainly in the 
cell cytoplasm, however there was specific localization of FLAG-tagged protein at the 
basal body, which was particularly obvious in cells where there was a lower level of 
transfection. Figure 5-13 shows RPE1 cells with overexpression of the constructs, co-
stained with ARL13B as a ciliary membrane maker. The overexpressed wildtype and 
mutant constructs demonstrated similar levels of immunofluorescence intensity, as 
  
157 
demonstrated by assessing Corrected Total Cell Fluorescence (CTCF) analysis in 
ImageJ, suggesting no excessive degradation of the mutant protein (Fig. 5-13). 
 
Figure 5-13: Immunofluorescence of overexpressed wildtype or mutant F191 FLAG-
DNAAF1 in RPE1 cells.  
A) IF of RPE1 cells with overexpression of FLAG-DNAAF1 wildtype or mutant F191, co-stained 
with ARL13B. Expression of DNAAF1 is grossly cytoplasmic, but co-localization to the basal 
body is visualized. Scale bars = 10 µm. B) Comparison of Corrected Total Cell Fluorescence 
(CTCF) was assessed in RPE1 cells transfected with wildtype or mutant (F191) DNAAF1 
constructs using analysis by ImageJ. A total of 40 cells were assessed. The P value is the result 
of Mann-Whitney-U test. Error bars represent standard error of the mean. 
 
This experiment was repeated with overexpression of the FLAG-DNAAF1 constructs 
and immunofluorescence staining for endogenous IFT88, and a ciliary marker, γ-tubulin 
(Fig. 5-14). A clear co-localization was noted between DNAAF1, IFT88 and γ-tubulin. 
On quantitative assessment, the localization of IFT88 to DNAAF1 was not affected by 
the presence of the mutant construct, with a consistent finding of approximately 20% of 





5-14). This was further assessed by overexpression of eYFP-IFT88 alongside FLAG-
DNAAF1 and staining for the ciliary marker ARL13B. Again, co-localisation between 
DNAAF1 and IFT88 was observed. The co-localization of DNAAF1 to IFT88 was, 
similarly, not affected by the presence of expression of the mutant protein. Under these 
conditions, around 80% of cilia, per field of view, showed co-localisation of FLAG-
DNAAF1 to IFT88 (Fig. 5-14). In the presence of overexpressed IFT88, the cilia marker 
ARL13B appeared to be disrupted (Fig. 5-14), with more diffuse staining than 
previously seen, perhaps due to the effect of excessive IFT88 on the correct targeting 





Figure 5-14: Immunofluorescence of overexpressed wildtype or mutant F191 FLAG-
DNAAF1 in RPE1 cells and co-localisation with endogenous and overexpressed IFT88. 
 A) hTERT-RPE1 cells with overexpression of either wildtype or mutant FLAG-DNAAF1 (wt or 
mutant) and IF for anti-FLAG antibody (red), anti-IFT88 (green) and anti- γ-tubulin (cyan). B) 
hTERT-RPE1 cells with overexpression of either wildtype or mutant FLAG-DNAAF1 (wt or mut) 
and IFT88-eYFP (green) and IF for anti-FLAG antibody (magenta) and anti-ARL13B antibody 
(red). Scale bars = 10 µm C) Mean percentage IFT88 co-localization with wildtype or mutant 
(Phe191) DNAAF1 when assessing overexpressed or endogenous IFT88. P values indicate the 
results of Student’s T-test, comparing values for wildtype and mutant (F191) constructs under 
the conditions of staining for over-expressed IFT88 or endogenous IFT88. Error bars show the 





























Once RUVBL1 and RUVBL2 (Pontin and Reptin) were identified as interactors of 
DNAAF1, immunofluorescence was used to assess their localization. Both Pontin and 
Reptin had predominantly nuclear staining and there was overlap of Pontin/Reptin and 
DNAAF1 staining within the nucleus (Fig. 5-15).  
 
Figure 5-15: Immunofluorescence to show co-localisation of endogenous DNAAF1 and 
Pontin/Reptin in RPE1 cells.  
IF of hTERT-RPE1 cells stained for anti-Pontin (RUVBL1) or Reptin (RUVBL2) (magenta), γ-
tubulin (red) and DNAAF1 (green). Scale bars = 10 µm. Co-localization of DNAAF1 and 
RUVBL1/2 was not consistently seen at the basal body, but there was nuclear overlap of 
staining.  
5.2.15 siRNA Knockdown of Pontin (RUVBL1) and Reptin 
(RUVBL2) 
Due to the identified interaction between DNAAF1 and Pontin and Reptin, we 
hypothesized that this interaction was part of a novel function of a Pontin/Reptin 
complex involved in dynein arm assembly. We theorized that knockdown of Pontin or 
Reptin might affect the localization of DNAAF1 to the basal body or to IFT88. Pontin or 
Reptin knockdown using siRNAs was performed in hTERT-RPE1 cells with concurrent 
overexpression of wildtype or mutant (Phe191) FLAG-DNAAF1 constructs. Previous 
qPCR experiments performed by Dr Sander Basten, University Medical Center, 
Utrecht, had shown successful knockdown of Pontin and Reptin in T47D cells, using 
these same siRNAs, under identical conditions (Fig. 5-16:A). In our experiments, 
western blot was used to confirm the knockdown of these proteins in RPE1 cells. The 
results showed a successful Pontin knockdown, although Reptin knockdown was only 
to 80% of wildtype, so only Pontin knockdown was continued in further experiments 




Figure 5-16: qPCR and western blot to demonstrate knockdown of RUVBL1/2 using 
siRNA. 
A: qPCR to demonstrate siRNA knockdown of RUVBL1 (Pontin) and RUVBL2 (Reptin) in T47D 
cells. Scrambled siRNA (siScr) was used as a negative control. Experiment performed by Dr 
Sander Basten, University Medical Center, Utrecht. B: Western blot to demonstrate the effect of 
siRNA knockdown of Pontin or Reptin in RPE1 cells. β-actin was used as a loading control and 
relative reduction in expression (ratio) was compared to siScrambled knockdown. 
 
Immunofluorescence microscopy was used to assess the localization of overexpressed 
FLAG-DNAAF1, endogenous IFT88 and γ-tubulin in these Pontin knockdown cells. As 
previously noted, there was clear localization between IFT88, γ-tubulin and DNAAF1 
(both wildtype and mutant) in the scrambled siRNA transfected cells. This co-
localization was also present in the Pontin siRNA treated cells (Fig. 5-17:A). On 
quantification, there was marginal disruption of co-localization between DNAAF1 and 
IFT88 in the Pontin knockdown cells (p= 0.059, Student’s t-test, n=2 biological 




Figure 5-17: Results of siRNA knockdown of Pontin (RUVBL1) in RPE1 cells and affect on 
co-localisation of DNAAF1 to IFT88 and IFT88 to γ-tubulin. 
A: Immunofluorescence microscopy to demonstrate co-localization of FLAG-DNAAF1 wildtype 
or mutant (F191) to IFT88 and γ-tubulin in the presence of scrambled siRNA negative control 
(siScr) or siRUVBL1 (Pontin) knockdown. Scale bars = 10 µm. B: Quantification of the effect of 
siRUVBL1 knockdown on co-localization of DNAAF1 to IFT88 and IFT88 to γ-tubulin, in the 
presence of wildtype or F191 DNAAF1 overexpression. Statistical analysis is a one-way 





5.2.16 Mouse Embryo Whole Mount Immunofluorescence 
 
The work described in this section was performed in close collaboration with Ms Dina 
Abdelmottaleb, Visiting Researcher, Leeds Institute of Molecular Medicine, Leeds, UK. 
 
Due to the finding of pure heterotaxy in a family with a mutation in DNAAF1, we sought 
to further investigate the expression of DNAAF1 during murine cardiac development 
and at the mouse embryonic node. The localisation of DNAAF1 and RUVBL1 (Pontin) 
was assessed in wildtype BL6 mouse embryos using whole mount 
immunofluorescence on a Zeiss L1 light-sheet microscope. Both proteins were present 
in the E8.5 mouse heart. Pontin appeared to be present in a widespread distribution 
throughout the primitive ventricle and atrial chambers. DNAAF1 localisation was 
observed at the primary cilia in the developing cardiac cells, with one spot of DNAAF1 
visualised per cell, presumably associated with the basal body (see Figures 5-18 and 
5-19).  
 
E7.5-E7.75 mouse embryos were assessed to visualise expression of these proteins at 
the murine embryonic node. DNAAF1 was expressed at the node and in the 
surrounding tissues, likely associated with primary and nodal cilia. Pontin expression 
was seen at the node itself, but not in the surrounding tissues. Interestingly the Pontin 
expression was always to the left side of the node and this striking left-sided 





Figure 5-18: Light-sheet microscopy images showing immunofluorescence of RUVBL1 
and ARL13B in staged mouse embryos. 
A series of maximum intensity projections of light-sheet microscopy images to demonstrate 
RUVBL1/Pontin (red) and ARL13B (green) whole mount immunofluorescence in the E7.75 
murine embryonic node and E8.5 heart loop. RUVBL1 is asymmetrically distributed at the 
embryonic node, with a predominantly left-sided expression (upper two panels, see arrow-
heads). RUVBL1 is present in a widespread distribution throughout the atrial chambers and 
primitive ventricle (lower panels). EN= embryonic node, N= notochord, rAC and IAC = atrial 




Figure 5-19: Light-sheet microscopy images showing immunofluorescence of RUVBL1 
and DNAAF1 in staged mouse embryos. 
A series of maximum intensity projections of light-sheet microscopy images to show 
RUVBL1/Pontin (red), DNAAF1 (green) and γ-tubulin (grey) whole mount immunofluorescence 
in the E8.5 heart loop (upper panels) and E7.75 murine embryonic node (lower two panels). rAC 
and IAC = atrial chamber, PV= primitive ventricle and, ST= Septum Transversum. Scale bars = 
100 µm. 
5.2.17 Expression of DNAAF1 and Pontin at Kupffer’s 
Vesicle in Zebrafish Embryos 
The work in this section was performed by Mr Glenn van de Hoek, PhD student, 
University Medical Center, Utrecht, The Netherlands. Mr van de Hoek performed all of 




Due to the observation of a left-sided distribution of RUVBL1/Pontin in the mouse 
embryonic node, the dnaaf1-/- zebrafish were studied to assess Pontin distribution at 
the Kupffer’s Vesicle (KV). Again, the distribution was found to be mainly left-sided in 
the wildtype zebrafish. However in the mutant dnaaf1-/- zebrafish, this left-sided 
expression was abolished. This indicates that Pontin may play a role in the formation of 
asymmetry in the early embryo, and when nodal cilia are affected by dnaaf1 mutation, 









Figure 5-20: Pontin (ruvbl1) whole mount in situ hybridization in zebrafish embryos. 
A: Pontin (ruvbl1) whole mount in situ hybridization in zebrafish embryos. Wildtype or 
heterozygous embryos show a predominantly left-sided expression of Pontin, and mutant 
dnaaf1-/- embryos show a central expression. B: Quantification of ruvbl1 expression in wildtype 
and dnaaf1-/- zebrafish embryos. A significantly higher proportion of wild-type zebrafish have 
left-sided localization of ruvbl1 compared to mutant embryos (p=0.0023, statistics are results of 







5.3.1 Discussion of Candidate Variants in Family CHD1 
In family CHD1, the variant in DNAAF1, c.571C>T, p.L191F, was the only variant that 
passed all filters and was not present in a homozygous state in control databases. It 
appeared to be a good candidate for the phenotype, scoring highly on in silico 
bioinformatics tools and occurring at a highly conserved position of the protein. It also 
fell in a large (2,500,000 bp) homozygous region shared between the two affected 
siblings. DNAAF1 is a known cause of Primary Ciliary Dyskinesia (PCD; MIM 244400) 
(Loges et al., 2009, Duquesnoy et al., 2009) and as there is a known link between PCD 
and CHD, it was considered a likely candidate gene in this family, although the clinical 
phenotype was not consistent with typical PCD.  
5.3.2 Primary Ciliary Dyskinesia is a Disease of the Motile Cilia 
Cilia were previously introduced as microtubule-based organelles that play a role in 
sensing chemical, morphogenic and mechanical stimuli (see section 1.6.1). Primary 
cilia are present on the majority of vertebrate cell types (Satir and Christensen, 2007). 
Motile cilia are a specialized type of cilia that exist on certain cell types, including those 
of the respiratory tract, Fallopian tubes and middle ear, where they beat in a rhythmical 
pattern to fulfill various functions, for example movement of mucus in the respiratory 
tract or movement of the ovum within the Fallopian tube. A further type of cilia exist at 
the embryonic node, “nodal cilia”, which are motile, and are involved in the creation of 
a fluid flow, which is a key step in breaking symmetry in the early embryo (see Chapter 
1 section 1.5.2.3) (Norris, 2012). The nodal cilia also have differences from other motile 
cilia, since structurally they lack the inner microtubular doublets, giving them a 9+0 
arrangement, but their molecular differences are not well understood (Hirokawa et al., 
2009).  
 
Primary Ciliary Dyskinesia (PCD) is a disease of the motile cilia, causing impaired 
mucociliary clearance in the respiratory tract, leading to neonatal respiratory distress, 
chronic respiratory tract infections, bronchiectasis, sinusitis and otitis media (Horani et 
al., 2014). Other associated features include infertility in both males and females, due 
to motile ciliary dysfunction in spermatozoa and the Fallopian tube. PCD is a 
predominantly an autosomal recessive disease with an incidence of 1:15000 
(Katsuhara et al., 1972). 
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5.3.3 The Link between Primary Ciliary Dyskinesia and 
Congenital Heart Disease 
As introduced in Chapter 1, the link between PCD and CHD has long been recognized. 
Around 50% of PCD patients have situs inversus totalis, a total reversal of body 
anatomy, due to defects in the nodal cilia and therefore dysfunction in development of 
laterality in the early embryo. As well as situs inversus, both heterotaxy and complex 
CHD are also more common in PCD than in the general population. In one study, the 
incidence of heterotaxy was found to be around 6% in a cohort of more than 300 PCD 
patients, including 8 patients with complex CHD lesions (Kennedy et al., 2007). Mouse 
models of PCD show even higher rates of CHD, perhaps representing a proportion of 
unrecognised early pregnancy loss in human studies (Francis et al., 2012). A recent 
study which described a large murine forward genetic screen for CHD aetiology, 
revealed a high mutational burden in cilia and PCD-related genes (Li et al., 2015).  
 
As well as CHD and heterotaxy being prominent features of PCD, it appears that, 
conversely, ciliary dysfunction is common in heterotaxy patients. Nakhleh at al., 
assessed a cohort of over 40 patients with pure heterotaxy, and no previous diagnosis 
of PCD, and identified ciliary dysfunction in 42% of patients. An increased burden of 
variants in PCD genes was identified in this cohort. One had a single known DNAI1 
founder mutation, but none of the patients was found to have two pathogenic mutations 
in a PCD gene. This high burden of single PCD gene variants may indicate an 
increased mutational load to play a role in the aetiology of heterotaxy in these patients 
and the authors suggest that pre-screening heterotaxy patients for ciliary dysfunction 
may be a useful clinical tool prior to cardiac surgery (Nakhleh et al., 2012). 
5.3.4 The Known Functions of DNAAF1 and Its Role in PCD 
Motile cilia (except those present at the embryonic node) have a structure consisting of 
nine microtubule doublets surrounding a central pair (9+2). In motile cilia, the force 
required for motility is provided by molecular motors, which convert ATP into molecular 
energy. These motors are the inner and outer dynein arms (IDA and ODA), which 
connect to the microtubule doublets and drive their sliding past each other for motion 
(Nicastro et al., 2006) (see Fig. 5-21). It is considered that ODAs and IDAs provide 
slightly different functions in motility: ODAs are responsible for maintaining ciliary beat 
frequency and IDAs are required for the creation of a normal waveform. The dynein 
arms are incorporated into cilia as pre-assembled building blocks and this preassembly 
occurs in the cytoplasm, prior to transport to the ciliary axoneme. ODAs have a 
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complex structure and in human respiratory cilia ODAs consist of a globular head 
domain (heavy chain beta (DNAH11/DNAH9) and heavy chain gamma (DNAH5)), an 
intermediate domain (DNAI1, DNAI2) and a docking complex (CCDC114, CCDC151, 
ARMC4, TTC25), involved in anchoring the arms to the microtubule doublets (Nicastro 
et al., 2006). Multiple light chains are associated with this complex, required for motility 
and stability (Zariwala et al., 2007). The outer and central microtubules are connected 
by radial spokes (see Fig. 5-21), which provide support and were recently described to 
play an important role in the signal transduction pathway (Zariwala et al., 2007). PCD is 
known to be caused by mutations in 19 genes, all encoding proteins involved in parts 
of this complex machinery; radial spoke proteins, components of the inner and outer 
dynein arms and assembly factors (Horani et al., 2016).  
 
 
Figure 5-21: Transmission Electron Micrograph (TEM) of a human respiratory motile 
cilium.  
Figure showing the inner and outer dynein arms, radial spokes, central microtubules and outer 
microtubule doublets. Adapted from reference (Shoemark et al., 2013). 
 
DNAAF1 is orthologous to ODA7 in Chlamydomonas. ODA7 was initially identified as a 
dynein arm assembly factor with mutations in this gene causing a reduced ciliary beat 
frequency and block in ODA assembly in Chlamydomonas  (Freshour et al., 2007). 
Chlamydomonas ODA globular head domains have a different structure to their human 
counterparts, consisting of heavy chain-alpha, heavy chain-beta and heavy chain-
gamma subunits, plus an intermediate domain and docking complex. In 
Chlamdymonas with ODA7 mutations, there is a build up of outer arm subunits in the 
cytoplasmic pool (Mitchison et al., 2012), with a specific increase in the intermediate 
domain protein DNAI2. Furthermore, in these mutants there is a reduction in heavy 
chain-beta and heavy chain-gamma and almost a complete loss of heavy chain-alpha 







regulate heavy chain-alpha stability in these organisms (Fowkes and Mitchell, 1998), 
perhaps being involved in the folding of the globular dynein head domain (Mitchison et 
al., 2012), but may also play a role in providing a structural link between inner and 
outer row dyneins (Freshour et al., 2007, Fowkes and Mitchell, 1998). In human 
respiratory cell lines, mutations in DNAAF1 cause an absence of specific dynein heavy 
(DNAH5, DNAH9), intermediate (DNAI2) and light chains (DNALI1) from the ciliary 
axoneme (Loges et al., 2009). However, the mechanism by which DNAAF1 mediates 
ODA pre-assembly and targeting of dyneins to the axoneme is unknown.  
 
In human patients with mutations in DNAAF1, there are combined ODA and IDA 
defects, consistent with in vitro models (Loges et al., 2009). Furthermore, zebrafish 
dnaaf1-/- mutants have abnormalities of the dynein arms, lacking either ODA, or both 
IDA and ODA, and have misalignment of the outer microtubules, indicating instability in 
the microtubular architecture (van Rooijen et al., 2008, Basten et al., 2013).   
5.3.5 A Phenotypic Continuum Between CHD and PCD 
In this study we have identified a missense mutation in DNAAF1, p.L191F, associated 
with a phenotype of pure CHD, without a clinical diagnosis of PCD in family CHD1. In 
this family, NO levels and ciliary beat frequency were within normal limits and did not 
support a clinical diagnosis of PCD. Furthermore, TEM revealed no inner or outer 
dynein arm defects. This is a novel observation. The three other families described in 
this study, with truncating mutations or deletions in DNAAF1 (families 1b-d), had the 
typical clinical symptoms of PCD and diagnostic tests, such as exhaled Nitric Oxide 
levels. Defects in ciliary beat frequency confirmed this diagnosis. TEM gave variable 
results in these families: in family 1b ODA were mainly absent, and IDA were absent in 
20-30% of cilia. In family 1d, IDA were consistently absent and only ODA stubs were 
present. Similarly, in the previously published seven cases of patients with DNAAF1 
mutations in the literature, IDA and ODA were consistently absent and the phenotype 
was consistent with typical PCD (Loges et al., 2009, Duquesnoy et al., 2009).  
 
Our findings suggest that the truncating mutations in families 1b, c and d are 
associated with a full PCD phenotype, whereas the missense mutation in family CHD1, 
p.L191F, is hypomorphic and is associated with a predominant phenotype of cardiac 
disease. However, missense mutations in the same region of the gene, for example 
p.L175R, have been shown to cause the full PCD phenotype in other studies (Basten 
et al., 2013). There is in silico support for the pathogenicity of p.L191F, and this 
assumption is strongly supported by absence of genetic complementation in dnaaf1-/- 
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mutant zebrafish embryos. To explain this unexpected finding, we hypothesize that 
there are subtle defects in motile ciliary function present in family CHD1, which were 
not identified on clinical testing. These subtle defects may be sub-clinical in terms of 
their effect on respiratory function, but caused disruption of nodal ciliary function, 
therefore affecting correct cardiac looping, either due to the sensitive nature of the 
ciliary beat at the node during embryonic development, or due to the inherent 
differences between nodal and respiratory motile cilia, which are, as of yet, not well 
described. In this instance, the missense mutation may affect unrecognised DNAAF1 
functions, distinct from its known role in the assembly of dynein arms. Our findings 
suggest that CHD and PCD form a phenotypic continuum rather than comprising 
distinct clinical entities. Patients with complex CHD may therefore harbour mutations in 
PCD genes, even if respiratory ciliary function is apparently normal. Identification of 
these genetic aetiologies may help to refine the medical and surgical management of 
patients with these complex conditions, which carry a high burden of morbidity and 
mortality (Moller and Anderson, 2013).  
5.3.6 Novel Interactants of DNAAF1 and Insights into its 
Function 
To further understand the role of DNAAF1 in the assembly of motile ciliary dynein 
arms, we investigated if particular functions were being affected by the missense 
mutation identified in family CHD1. The results of our TAP and co-immunoprecipitation 
experiments have demonstrated DNAAF1 to interact with novel proteins, including 
RUVBL1 and RUVBL2 (Pontin and Reptin), intraflagellar transport protein IFT88 and 
members of the Heat Shock Protein (HSP) group. 
 
IFT88 is an intraflagellar transport protein that is a member of the IFT-B complex. 
IFT88 is important in the transport of large cargo molecules along the axonemal 
microtubules of primary and motile cilia, required for their assembly and maintenance 
(Pazour et al., 2002). Homozygous mutations in IFT88 cause a Meckel-Gruber 
syndrome-like ciliopathy (McIntyre et al., 2012), and mice with mutations in this gene 
have photoreceptor outer-segment abnormalities and retinal degeneration (Pazour et 
al., 2002). As well as providing data to support a biological interaction between 
DNAAF1 and IFT88, we observe co-localization of DNAAF1 and IFT88 at the basal 
body of primary cilia. The role of DNAAF1 in primary cilia is not known, but it has been 
identified to localize to the basal body in previous studies (Basten et al., 2013) and the 
immortalized primary ciliated cell lines used in this study are a useful model system 
which enables assessment of putative protein interactions. Our results suggest that 
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DNAAF1, as well as being involved in the assembly of dynein arm complexes, could 
mediate the delivery of these components directly to the intraflagellar transport 
machinery. This hypothesis would be supported by the experiments performed by 
Duquesnoy et al. in Trypanosoma brucei, which showed that on knockdown of the 
DNAAF1 orthologue, dynein arm components such as DNAI1 were synthesised, but 
not transported from the cytoplasm to the axoneme (Duquesnoy et al., 2009).  
 
Our TAP and coIP experiments also confirmed interactions of DNAAF1 with both 
RUVBL1 (Pontin) and RUVBL2 (Reptin). Immunofluorescence microscopy studies 
demonstrated co-localisation of DNAAF1 with both RUVBL1 and RUVBL2, although 
their location was mainly nuclear.  
 
RUVBL1 and RUVBL2 are DNA-dependent AAA+ ATPases involved in many cellular 
processes, such as energy metabolism, chromatin remodelling, transcription factor 
function, the DNA damage response and snoRNP assembly and maturation 
(Rosenbaum et al., 2013). Pontin has recently been identified as playing an important 
role in cell cycle progression (Breig et al., 2014). Pontin and Reptin form hetero-
hexamer and dodecameric-like structures. These structures form the core of a number 
of important assembly and chaperone complexes, for example the RT2P complex, 
which is involved in the assembly of certain complex molecules, such as snoRNPs, 
RNA polymerase II and DNA damage response kinases (ATM, ATR and DNA-PK) 
(Lakshminarasimhan et al., 2016). Alongside the Pontin/Reptin structure, this complex 
is associated with PIH1D1 (Protein interacting with Hsp90) and RPAP3 (a 
Tetratricopeptide Repeat (TPR)-containing protein), two interactors of HSP90 (Boulon 
et al., 2010, Zhao et al., 2008). The exact mechanism by which the RT2P complex 
functions is not known (von Morgen et al., 2015), but it has been suggested that 
HSP90 and RPAP3 stabilize PIH1D1, which directly binds these components (Paci et 
al., 2012). Interestingly, our TAP experiments showed that DNAAF1 interacts with a 
number of HSP-associated proteins, so named because of their upregulation in 
response to heat, including both HSP90 and SUGT1 (a TPR-repeat containing protein 
and a known co-chaperone of HSP90 (Prus and Filipek, 2011). In support of this 
finding, SUGT1 and HSP90 have been shown to interact with other LRR domain-
containing proteins in plant models (Taipale et al., 2010).  
 
We therefore hypothesise that dynein arm assembly involves a complex similar to the 
RT2P complex, involving a RUVBL1/RUVBL2 core, a TPR-containing protein (for 
example SUGT1) and a PIH1-domain containing protein. Appropriate PIH1-domain 
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containing proteins would include DNAAF2/KTU, mutated as a known cause of human 
PCD and recently shown to be involved in the preassembly of the dynein arms (Omran 
et al., 2008), PIH1D3, a recently described X-linked human PCD gene (Paff et al., 
2017) and MOT48, which has links to dynein arm preassembly and is reported to be 
required for the stability of heavy chains (Yamamoto et al., 2010). Yamamoto et al., 
2010, raised the suggestion that PIH-domain containing proteins are involved in dynein 
preassembly due to their increased presence in organisms with motile cilia and flagella 
(Yamamoto et al., 2010). Furthermore, PIH1D3 has been shown to interact with 
HSP90, DNAAF2/KTU, DNAAF4 and an intermediate chain of the ODA, although not 
DNAAF1 (Dong et al., 2014, Paff et al., 2017). Reptin has recently been shown to 
interact with LRRC6/Seahorse (Zhao et al., 2013), another dynein arm assembly factor 
and recognised PCD gene (Inaba et al., 2016), which would be consistent with our 
model. 
 
This work suggests a novel role of the RUVBL1/2 (Pontin/Reptin) complex in motile 
ciliary assembly, which confirms previous data that suggests a link between these 
proteins and motile ciliary function. In Chlamydomonas, Pontin and Reptin are 
upregulated following de-flagellation (Stolc et al., 2005). Zebrafish embryos with loss-
of-function ruvbl1 (Sun et al., 2004) or ruvbl2 (Zhao et al., 2013) mutations have ventral 
body curvature and kidney cysts, demonstrating a typical “ciliopathy” phenotype. These 
zebrafish ruvbl2 mutants have an absence of dynein arms in motile cilia, causing static 
cilia, further supporting the suggestion that RUVBL2 is involved in mediating dynein 
arm assembly or maintenance (Zhao et al., 2013). The same research group have 
demonstrated that Reptin genetically interacts with ift172, a subunit of the IFT-B 
complex necessary for ciliary assembly (Zhao et al., 2013).  
 
To link our findings, we hypothesise that DNAAF1 is further required to couple the 
dynein arm components, pre-assembled by the RT2P-like complex, to the IFT 
machinery (see Figure 5-22). This may help to explain the finding of low levels of 
DNAAF1 in ciliary axonemes (Duquesnoy et al., 2009). Furthermore, Pontin 
knockdown appeared to perturb the co-localisation of DNAAF1 to IFT88, as shown in 
our siRNA experiments. This may suggest that a failure of the formation of the 
Pontin/Reptin dynein arm assembly complex leads to a disruption of DNAAF1 coupling 
with the IFT machinery.  
 
The missense mutation identified in family CHD1 does not appear to affect the 
interaction of DNAAF1 with Pontin/Reptin, demonstrated here by coIP, or the 
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interaction of DNAAF1 with members of the RT2P-like complex, as shown by the TAP 
data, where a number of these proteins appeared to be more strongly associated with 
the mutant form of DNAAF1. The only exception was Pontin, which was slightly more 
highly associated with the wildtype form of DNAAF1, although the results were not 
statistically significant. The mutation did appear to affect the interaction of DNAAF1 
with IFT88, demonstrated by coIP, suggesting that the proposed subtle defect in motile 
ciliary function in family CHD1 may be related to delivery of the dynein arms to the 
transport machinery. 
 
Figure 5-22: Schematic diagram to show the hypothesized model of an RT2P-like 
complex involved in dynein arm assembly. 
The proposed complex involves a core RUVBL1/2 structure, HSP90, DNAAF2 and SUGT1. 
This complex is hypothesized to interact with dynein assembly components DNAAF1 and 
LRRC6. Transport to the ciliary axoneme is then coupled to the IFT machinery, for example 
IFT88.  
5.3.7 Asymmetry of Pontin at the Embryonic Node 
In murine whole mount immunofluorescence studies we observed the expression of 
DNAAF1 and RUVBL1 at the embryonic mouse heart and embryonic node in order to 
gain insights into the role of these proteins in early development. RUVBL1 (Pontin) was 
expressed across the primitive atria and ventricles during embryonic heart 
development, at gestational day E8.5. This finding is consistent with previous studies, 
which showed Pontin and Reptin to be associated with cardiac development, with heart 
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size in zebrafish antagonistically regulated by the action of Pontin and Reptin 
(Rottbauer et al., 2002). Furthermore, a number of Pontin/Reptin-containing complexes 
are known to be expressed in the developing heart (Ikura et al., 2000, Lough, 2002).  
 
During the course of our experiments we unexpectedly observed asymmetric 
distribution of Pontin (RUVBL1/ruvbl1) at the embryonic node in mice and Kupffer’s 
Vesicle (KV) in zebrafish. This expression was consistently left-sided in both animal 
models. This asymmetric distribution was dependent on the presence of DNAAF1, as it 
was abolished in the dnaaf1-/- zebrafish model. One explanation for this finding is that 
RUVBL1 is acting as a transcriptional regulator of asymmetrically expressed genes in 
early development. Gene transcription and chromatin modeling are previously known 
functions of both Pontin and Reptin (Jonsson et al., 2001, Gallant, 2007). They can act 
as ATP-dependent mediators of chromatin remodeling. They have been identified to 
play a role in a number of chromatin remodeling complexes, such as the Ino80 
complex in yeast, involved in the transcription of around 5% of genes (Jha and Dutta, 
2009, Jonsson et al., 2001). The asymmetric fluid flow from the ciliary beat at the 
embryonic node induces asymmetric gene expression on the left and right hand sides 
of the node. Cerl2 (Cerberus-like protein 2) is one of these asymmetrically expressed 
genes and is expressed in a right>left pattern. This asymmetry of Cerl2 mRNA is found 
to be controlled by Wnt signaling, with Wnt3 expression seen in a left>right pattern 
(Nakamura et al., 2012). In mouse models, knockout of the beta-catenin gene, a key 
downstream effector of the canonical Wnt pathway, results in randomization of Cerl2 
expression at the node. Furthermore, excessive levels of Wnt3A protein result in 
downregulation of Cerl2 mRNA. This model of asymmetry necessitates an increased 
expression of Wnt signaling on the left hand side of the node (Nakamura et al., 2012). 
Pontin and Reptin are known antagonistic regulators of Wnt signaling by binding to 
beta-catenin (Rottbauer et al., 2002), with Reptin inhibiting the Wnt pathway and Pontin 
activating it (Bauer et al., 2000). It may be hypothesized that an asymmetrical 
distribution of Pontin at the node is related to the regulation of Wnt signaling in left-right 
patterning. In this model, the absence of dnaaf1 in the knockout zebrafish leads to 
static cilia at the KV, abolishing asymmetrical gene expression, including asymmetrical 
Pontin expression (see Figure 5-23). 
 
A further possibility is that dynein arm assembly in nodal cilia is initially specified solely 
on the left side of the node in early embryonic development, so an asymmetric 
distribution of Pontin is present to initiate early nodal cilia formation. This earlier 
development of nodal cilia on the left could contribute to the establishment of leftward 
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nodal fluid flow. Earlier dynein arm assembly on the left of the node could also allow 
immotile cilia on the perinodal crown cells at the edge of the node to respond to nodal 
flow before those on the right side of the node. This hypothesis might be supported by 
studies that suggest that left-right patterning is established very early in development of 
the node by a weak flow of fluid from a subset of nodal cilia. This weak flow only 
requires a very small number of cilia to initiate symmetry breaking (Shinohara et al., 
2012). In the dnaaf1-/- embryo, the lack of active dnaaf1 could lead to a disruption of 
the dynein arm assembly complex, leading to a loss of asymmetrical Pontin. This 
intriguing observation of asymmetric distribution of RUVBL1/Pontin at the node 
requires further investigation to understand the unexpected role of Pontin (and likely 
also Reptin) in left-right axis determination.  
5.4 Conclusions 
We have shown that mutations in DNAAF1 can cause a phenotype of PCD, PCD with 
CHD or pure CHD, suggesting a phenotypic continuum between CHD and PCD. This 
has clinical implications, as CHD patients may have ciliary dysfunction, associated with 
poorer surgical outcome (Nakhleh et al., 2012), a situation that could be investigated 
by pre-screening prior to surgical intervention. We also suggest that CHD patients 
(even with apparently normal ciliary function) may harbor mutations in PCD-associated 
genes. This observation may allow for improved genetic diagnosis in CHD patients, 
which may allow for advances in medical and surgical management. 
 
We have demonstrated novel interacting partners of DNAAF1, including IFT88, Pontin, 
Reptin and a number of HSP proteins, giving key insights into the function of DNAAF1 
in dynein arm assembly. These investigations have allowed us to hypothesize 
regarding the function of DNAAF1 and to place it within a novel R2TP-like complex in 
dynein arm assembly, as well as suggesting a role for DNAAF1 in the transport of 
dynein arm components to the intraflagellar transport machinery. We have provided 
further evidence that Pontin and Reptin are important ciliary proteins, and have shown 
Pontin to be asymmetrically expressed at the developing embryonic node in mice and 
zebrafish. This suggests a role in the creation of laterality, possibly distinct from its 
suggested role in dynein arm assembly. This finding places DNAAF1 and Pontin as 
key players in the development of embryonic laterality, as well as generating many 
questions regarding the exact nature of this role. These questions deserve further 
investigation to ascertain the true nature of this exciting observation.  
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6 A Variant in KMT2D is Associated with a 
Syndrome of Athelia, Choanal atresia and 
Congenital Heart Disease 
6.1 Introduction 
In this chapter we present the results of investigations into a family with a specific 
phenotype of athelia (absence of the nipples), choanal atresia and congenital heart 
disease, associated with other developmental abnormalities. There was a single 
affected child in this family. Through exome sequencing we identified a de novo variant 
in KMT2D, a gene associated with Kabuki syndrome. Kabuki syndrome is 
characterized by developmental delay, distinctive facial features, skeletal 
abnormalities, short stature and haematological disorders (Dentici et al., 2015), a very 
different phenotype to that recognized here. Through collaboration we were able to 
identify a second family who had the same variant in KMT2D and were affected with a 
very similar phenotype. This variant was present in the father of the affected children 
and both affected individuals. We offer evidence to suggest that the father in this family 
is mosaic for the variant and is unaffected by features of the condition. We further 
investigate two other families affected by athelia and summarize the previous 
published cases of athelia and choanal atresia from the literature.  
6.2 Results 
6.2.1 Family CHD9 
6.2.1.1 Clinical Phenotype 
 
 







This is non-consanguineous family with a single child affected with multiple congenital 
anomalies. On antenatal 12 week scan, an increased nuchal thickness of 3.5mm was 
noted, and Chorionic Villous Sampling (CVS) was normal. At the 20 week antenatal 
scan an echogenic bowel was noted and the parents were investigated for mutations in 
CFTR, which were normal. At 37 weeks gestation, cerebral redistribution was 
recognized and so induction of labour was performed. Following a normal vaginal 
delivery there was fetal distress and intubation was performed at 8 minutes of age. 
This patient remained on the neonatal unit for 3 months receiving treatment for 
interstitial lung disease and multiple abnormalities were noted. These included bilateral 
choanal atresia, absent thymus, branchial cysts, absent gall bladder, hypothyroidism, a 
caudothalamic cyst, preauricular pits, tongue tie, moderate to severe hearing loss and 
neonatal teeth. Cardiac anomalies included ASD and pulmonary hypertension. This 
patient required nasal oxygen until the age of 18 months due to interstitial lung disease 
and at the age of 3 ½ years still requires oxygen supplementation for flights. He has 
suffered recurrent breath-holding attacks. He had Intrauterine Growth Retardation 
(IUGR) and was 2.35kg (<0.2nd centile) at birth, and has continued to fail to thrive with 
height and weight remaining below the 0.2nd centile until the age of 3 ½ years. His 
head circumference is on the 50th centile. He is being considered for gastrostomy 
placement due to poor oral intake. He has bile duct dilatation. He is growth hormone 
deficient and receives regular growth hormone injections. His gross motor development 
was delayed, he first sat at 12 months, crawled at 15 months and walked at 3 years. 
He also has delayed expressive language, which is thought to be related to his hearing 
loss. He has normal cognitive function at 3 ½ years. He has been found to have a low 
CD8 T-lymphocyte count. This is being monitored the haemotology team and he 
receives azathioprine coverage in the winter months. He had delayed tooth eruption. 
There are no ophthalmological concerns. Both parents are unaffected (Figure 6-1). 
6.2.1.2 Whole Exome Sequencing 
WES was performed using the Illumina XT method and sequencing was performed on 
the HiSeq2500 instrument with 6 samples pooled per lane. WES analysis was carried 
out for the affected individual and both parents. Data analysis was performed as 
previously described, in this case assuming a new dominant (de novo) mutation as the 
most likely cause, but also investigating for biallelic variants. Table 6-1 shows the 
number of variants remaining following each step in the filtering pathway for a de novo 
variant and table 6-3 shows the variants that remained after each filtering step. Table 
6-2 shows the number of variants remaining following each step filtering on a recessive 
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disease model and Table 6-3 shows the variants remaining following filtering assuming 
a de novo (dominant) disease model. 
Table 6-1: Number of variants remaining following each stage of filtering in family CHD9, 
assuming a new dominant disease model. 
Stage in Analysis Number of variants 
Called with GATK 487857 
Filter on dbSNP/EVS 
(<1% and b129) 
 
67307 
Filter on exac <1% 63894 
De novo 187 




Not in HLA gene 3 
 
Table 6-2: Number of variants remaining following each stage of filtering in family CHD9, 
assuming a recessive disease model 
Stage in Analysis Number of variants 
Called with GATK 487857 
Filter on dbSNP/EVS 69792 
Functional variants 2090 
Biallelic  49 
Pass hard filters 42 
CADD >15 13 
No mucin/ HLA genes 3 
<1% in exac 1 
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Data from patient JT538, the affected individual, was filtered to identify variants present 
in the CHD7 gene, which causes CHARGE syndrome and has possible phenotypic 
overlap with this syndrome, as well as TTF2, which causes Bamforth-Lazarus 
syndrome, a potentially overlapping phenotype. There was poor coverage of exon1 of 
CHD7, however, there were no mutations identified in these genes.  
6.2.1.3 CNV analysis 
CNV analysis of WES data for this family was done using the Exome Depth program in 
individual JT538. A full list of identified copy number variants is provided in appendix J. 
No likely causative CNV was identified that could be functionally linked to the 
phenotype in this patient. 
6.2.1.4 Confirmation of Variant in KMT2D by Sanger Sequencing 
The variant identified in KMT2D was thought to be a good candidate for the phenotype. 
It is a known cause of Kabuki syndrome, which has phenotypic overlap with the 
identified features. It was confirmed to be present in the heterozygous state in JT538 
and was not present in his parents (Fig. 6-2).  
 
 
Figure 6-2: Sanger sequencing electropherograms to demonstrate a mutation in KMT2D, 
c.10658 G>T, in family CHD9.  
The mutation is shown to be heterozygous in the affected child (A), and not present in the 












6.2.2  Identification of a Second Family affected with Athelia 
and Choanal Atresia: Family CHD9b 
Following the finding of a de novo variant in KMT2D in family CHD9, we conducted a 
search of a number of databases for this variant. It was found to be present in two 
individuals in a dataset containing a large number of control samples, but with some 
patient samples also present. On further investigation it was found that the family who 
carried this same variant in KMT2D (family CHD9b) had a very similar phenotype to 
that seen in family CHD9. This family had previously been described in the literature in 
2002 (Al-Gazali et al., 2002) and WES had been performed at Queen Mary’s Hospital 
in London.  
6.2.2.1 Clinical Phenotype 
This family is a first cousin union of Palestinian origin. Their first child had choanal 
atresia and died at birth. They had two further affected children. The male child had 
right choanal atresia, hypoplastic nipples, a PFO, a small thyroid gland and bilateral 
absent lacrimal duct with bilateral duct stenosis. He suffered with bilateral conductive 
hearing loss. His left testis was undescended. He had failure to thrive and chronic 
respiratory infections in the first year of life, which lead to chronic interstitial lung 
fibrosis. He had sparse hair and eyebrows, dystrophic nails, down-slanting palpebral 
fissures, low set ears and hypoplastic alai nasi. Cranial CT scan and renal ultrasound 
scan were normal. Thyroid function tests were normal. At the time of review he was 10 
years of age.  
 
The affected female child had widely spaced eyes, a depressed nasal bridge, a low 
right ear and a neck pit. She had hypoplastic nipples and bilateral choanal atresia. She 
had sparse hair and eyebrows. She had hypothyroidism and complete absence of the 
thyroid gland. An abdominal ultrasound scan and brain CT scan were normal. She died 
at the age of 4 months following a chest infection. Both children had growth parameters 
<5th centile. Both parents were unaffected and there were four unaffected children in 
the family (Al-Gazali et al., 2002).  
6.2.2.2 Data analysis 
.vcf files from Queen Mary’s Hospital, London were sent to our research team for 
analysis from the affected female child and both parents. The variant in KMT2D, 
c.10658C>A, was present in the affected female and her unaffected father. The 
number of reads for each call at this position were 30 wildtype to 33 mutant in the 
affected girl, and 33 wildtype to 17 mutant in her father, allowing for the possibility of 
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mosaicism in the father. The mother had 40 reads aligning to the wildtype sequence. 
The data was also filtered for other possible pathogenic mutations, or further overlap 
with family CHD9, but no likely candidates were identified.  
6.2.2.3 Sanger Sequencing 
Confirmation of the variants in KMT2D was performed by Dr Laura Southgate, 
Research Fellow of Queen Mary’s, University of London, by conventional Sanger 
sequencing methods. The variant was confirmed to be heterozygous in the father and 
heterozygous in the two affected siblings in this family. Mosaicism was supported by 
the finding of a reduced mutant peak on Sanger sequencing of the father, compared to 
the two affected children (Figure 6-3). 
 
 
Figure 6-3: Sanger sequencing electropherograms showing the presence of KMT2D 
c.10658G>T (p.G3553V) in family CHD9b.  
The position of the variant is indicated by a star. It is shown to be heterozygous in the father and 
both affected siblings and wildtype sequence is seen in the mother. The sequence peak height 
is reduced for the mutant allele in the father, suggesting mosaicism. This analysis was 
performed by Dr L. Southgate, University of London.  
6.2.3 Family CHD10 
Further to the findings in family CHD9 and CHD9b, we were sent data from a family 
affected with isolated athelia, to identify whether KMT2D was a consistent cause 
associated with athelia.  
6.2.3.1 Clinical Phenotype 
This is a family consisting of a mother and daughter affected with athelia, but with no 
other congenital anomalies. They were referred from Dr Meenakshi Bhat, Department 
of Fetal Medicine, Bangalore. 
Forward '''''''''''''''''''Reverse' Forward '''''''''''''''''''Reverse'
Forward '''''''''''''''''''Reverse' Forward '''''''''''''''''''Reverse'
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6.2.3.2 Whole Exome Sequencing Data Analysis 
WES data was received from the collaborating centre for the affected mother and child 
in the form of .fastq files. Data filtering was performed by following the standardized 
pipeline. The inheritance pattern in this family was assumed to be autosomal dominant 
inheritance, and so variants were filtered to identify rare heterozygous variants present 
in the mother and child. There were no unaffected samples to filter against, making the 
removal of variants extremely difficult. Variants were removed that were present in the 
EXaC, EVS and dbSNP control datasets. Even following this strict filtering criteria, 25 
variants with a CADD score >15, predicted to be damaging by in silico tools and 
passing hard filters remained (see Table 6-4). The remaining variants are listed in 
appendix N. The most likely candidate was a variant in PTCH1 (see Table 6-5). 
 
Table 6-4: Number of variants remaining following filtering assuming a dominant 
inheritance pattern in family CHD10. 
Stage in Analysis Number of variants 
Called with GATK 264327 
Filter on  
Exac 








Functional variants 461 
Hard filter 48 
‘Damaging’ 35 
CADD >15 23 
 
Table 6-5: Showing the variant in PTCH1 identified in family CHD10.  
















D (0) D 
(0.816) 
26.2 N/a Shh signalling 
 
The data was checked for candidate variants in the following genes; KMT2D, PTPRM, 
TXNL4A, PTPN13, PTPRO, FOXE1, CHD7, TBX5, TBX3, LEF1, NRG3, ERBB4 and 
the known interactants of PTPRM (NHS, CDKL5, PVRL3, PIP5K1C, CTNNB1, 
GNB2L1). No variant was identified that was present with a MAF <1% in control 
datasets.  
6.2.4 Family CHD11 
The team who cared for family CHD11 were contacted due to the overlap in phenotype 
between these patients and those of families CHD9 and CHD9b. The only available 
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material was in the form of FFPE embedded slides, which were sent to our laboratory 
with informed consent.  
6.2.4.1 Clinical Phenotype 
Paraffin embedded slides were sent from collaborators in Yale-New Haven Hospital 
(CT, USA) from a patient seen there in 1998. This was a member of a family described 
in the literature with a lethal syndrome involving renal tubular dysgenesis and absent 
nipples (Hisama et al., 1998).  
 
This is a non-consanguineous family: the mother was of German/Danish descent and 
the father was of Norwegian/Irish descent. In the first affected child, IUGR was 
recognized at 30 weeks gestation. The baby was born at 38 weeks gestation with 
dysmorphic features including hypertelorism, down-slanting palpebral fissures, 
micrognathia, a short beaked nose with hypoplastic alae nasi and a coloboma of the 
left nostril. His ears were low set and there was athelia, broad thumbs and an 
imperforate anus. The autopsy showed an abnormal right-sided lung lobe, ancillary 
spleen and hypoplastic kidneys with renal tubular dysgenesis on histology. The 
karyotype was normal except for the presence of a Y-heterochromatin marker 
chromosome. FISH for 22q11 deletion was normal. He died at 12 days of life.  
 
The second child was delivered at 37 weeks. A Chorionic Villus Sampling (CVS) had 
been performed and was normal. There were similar dysmorphic features, with a 
unilateral neck pit, absent nipples and undescended testes. He had cardiac defects 
including a large VSD, bicuspid aortic valve, distal aortic arch and large ductus 
arteriosus. His kidneys were hypoplastic. This patient died at 25 hours of life.  
 
Their 3rd child was affected with a similar syndrome. He was born at 36 weeks 
gestation. He had similar dysmorphic features, with a simple left ear and a pre-
auricular skin tag and pit. He had bilateral neck pits, choanal atresia, athelia and 5th 
finger clinodactyly. He had hypoplastic kidneys and a normal echocardiogram. He died 
at 35 hours of life. Parathyroid, thymus and gallbladder were absent. There was an 
accessory spleen, focal renal dysplasia in the left kidney and neuroblastoma in the left 
adrenal gland. There was a family history of neck cysts.  
6.2.4.2 DNA Extraction 
DNA was extracted from five kidney sections of paraffin embedded slides from patient 
JT619, the 3rd child in this family. The resulting DNA concentration was 7.68ng/µl, 
measured using the Qubit system.  
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6.2.4.3 Whole Exome Sequencing 
Due to the low concentration of DNA extracted from paraffin-embedded slides, sample 
JT619 was vacuum concentrated to give a total of 70ng in 2µl. WES library preparation 
was initially attempted using the Illumina QXT method, but initial Bioanalyser results 
following shearing gave a flat trace. When the sample was analysed using a high-
sensitivity Bioanalyser chip, the DNA was over-fragmented with the majority of DNA 
strands at 100-150bp and the DNA was at very low concentration (Fig. 6-4).  
 
Library preparation was re-attempted using the Illumina XT protocol, without shearing 
the DNA, as the DNA was already fragmented and degraded. End repair, addition of ‘A’ 
bases, ligation of adapters and amplification using two 6-cycle PCRs were performed. 
Figure 6-4 shows the high sensitivity Bioanalyser trace from this sample. Fragments 
were seen within the correct range at 200-400bp. The sample was vacuum 
concentrated to give 26ng/µl and hybridization was performed as recommended by the 
manufacturer’s protocol. Unfortunately the hybridization was unsuccessful and the 
second Bioanalyser trace, following hybridization, showed no usable remaining DNA 











Figure 6-4: High-sensitivity bioanalyser traces from sample JT619. 
A: following shearing using the QXT library preparation kit, B: following amplification using the 
XT library preparation kit, C: following hybridization using the XT library preparation kit. 
6.2.4.4 Sanger sequencing  
DNA was re-extracted from the remaining five FFPE slides from patient JT619 for 
Sanger sequencing. DNA concentration was measured on Nanodrop at 23.0ng/µl. 
Whole Genome Amplification (WGA) was performed on this sample. Initial PCR 
reactions failed to amplify the required product to sequence exon 38 of KMT2D, and so 








of DNA. This was successful and Sanger sequencing was performed. The variant in 
KMT2D, c.10658 C>A, was not present in sample JT619, as shown in Fig. 6-5.  
 
 
Figure 6-5: Demonstration of absence of c.10658G>T in patient JT619 from family CHD11.  
A and B show two biological replicates of Sanger sequencing using the same primer pair, but 
different aliquots of input DNA. 
6.3 Discussion  
6.3.1.1 Clinical Reports of Syndromes Consisting of Athelia and Choanal 
Atresia  
We have investigated four families affected with athelia (absent nipples), three of which 
have a rare developmental anomaly, associated with choanal atresia and other 
congenital anomalies. Table 6-6 shows a comparison of the phenotypic overlap of the 





Table 6-6: Summary of clinical features of patients with athelia syndromes from this study and the literature.  
























CHD9 De novo yes yes yes Hypo-
thyroidism 
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As can be seen from Table 6-6, there is significant phenotypic overlap between family 
CHD9 and family CHD9b, including athelia, choanal atresia, CHD, thyroid gland 
abnormalities, dysmorphic features, hearing loss and failure to thrive. There are many 
similarities with the phenotype of family CHD11, but who have the additional features 
of hypoplastic kidneys and focal renal dysplasia. The affected individuals from family 
CHD11 died in the neonatal period, whereas this was not a feature in families CHD9 
and CHD9b. 
 
There have been a number of reports in the literature of patients with a similar 
phenotype to these families. The individual described by Horvath et al. was thought to 
have the same syndrome as that seen in family CHD11. This child had periventricular 
leukomalacia, and a more wizened appearance than had been described in previous 
reports, but otherwise had consistent features (Horvath and Armstrong, 2007). An 
attempt was made by our team to source genetic material from this family, but the 
parents did not give consent for further investigation. The reports of Qazi et al., 1982, 
and Uchida et al., 2006, describe a similar phenotype, but do not report thyroid 
disease, cardiac defects or renal anomalies and no other organ absence is reported 
(see Table 6-6) (Qazi et al., 1982, Uchida et al., 2006). These reports may or may not 
represent the same syndrome. 
 
There is overlap of the phenotype seen in our families with methimazole embryopathy. 
Methimazole is the active metabolite of carbimazole, a drug that, in the past, was used 
to treat thyrotoxicosis during pregnancy. However, it has been linked to teratogenicity 
in a number of different reports. The major described features are choanal atresia, 
oesophageal atresia, dysmorphic facial features, athelia, CHD, learning difficulties, 
scalp defects and retinal coloboma (Clementi et al., 1999, Valdez et al., 2007, 
Greenberg, 1987, Wilson et al., 1998). Greenberg, 1987, published the initial report of 
a child with choanal atresia, athelia and learning difficulties following exposure to 
methimazole in pregnancy (Greenberg, 1987) and a number of consistent reports have 
been published since, although athelia is not always a consistent phenotype (Clementi 
et al., 1999). There is no history of this medication being used in the families we 
describe and the pathophysiology of the link between this drug and the described 
features is not known. 
 
The condition described in our families also overlaps with CHARGE syndrome, a 
syndrome characterized by Coloboma (80-90%), Heart defects (75-85%), Choanal 
atresia (50-60%), Mental Retardation, Genital hypoplasia (50-60%) and Ear anomalies 
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(90%). Other features include cranial nerve dysfunction (70-90%), growth delay (70-
80%), cleft palate (15-20%), distinctive facial features (70-80%) and trachea-
oesophageal fistulae (15-20%) (Aramaki et al., 2006). Renal anomalies are also 
occasionally associated with CHARGE syndrome. It is caused by mutations in CHD7, a 
transcriptional regulator (Vissers et al., 2004). Nipple abnormalities are only 
occasionally described as a feature of CHARGE syndrome; Glustein et al., 1996, 
describe a syndrome they classified as CHARGE syndrome, but with hypoplasic 
nipples (see Table 6-6) (Glustein et al., 1996). Molecular testing was not available at 
the time of this report.  
 
The other major differential diagnosis for our families is Bamforth-Lazarus syndrome. 
This is a condition with the features of congenital hypothyroidism due to thyroid 
dysplasia, cleft palate and spiky hair, with or without choanal atresia or bifid epiglottis 
(Bamforth et al., 1989). This condition therefore shares the overlapping features of 
thyroid dysplasia and choanal atresia with our families, but is not known to be 
associated with athelia.  It is due to homozygous loss of function mutations in FOXE1 
(TTF2). Foxe1 knockout mice had an ectopic or absent thyroid gland (Castanet and 
Polak, 2010). FOXE1 acts as a transcriptional activator of thyroglobulin and 
thyroperoxidase, is expressed in thyroid follicular cells, and plays a key role in thyroid 
development (Castanet and Polak, 2010). 
 
We suggest that our families display a distinct phenotype, with a specific set of features 
that consistently includes athelia, choanal atresia, cardiac defects, dysmorphic 
features, failure to thrive and thyroid gland abnormalities. It is often associated with 
gallbladder, thymus or parathyroid absence, and deafness. This phenotype appears to 
be caused by a specific mutation in exon 38 of KMT2D. 
6.3.1.2 KMT2D is a Known Cause of Kabuki Syndrome 
Kabuki syndrome (KS) is caused by mutations in KMT2D (also known as MLL2) and 
KDM6A, and is a disorder characterized by dysmorphic facial features, growth 
retardation, learning difficulties, skeletal and craniofacial abnormalities (Ng et al., 
2010). Dysmorphic features include long palpebral fissures, short columella with a thin 
upper lip, large cupped ears, sparse arched eyebrows and the presence of fetal 
fingertip pads. Associated anomalies include cleft palate, CHD, renal anomalies, 
feeding problems, gastrointestinal anomalies, seizures, congenital hypothyroidism and 
susceptibility to infections due to immune dysfunction (Matsumoto and Niikawa, 2003, 




KMT2D is reported to cause around 60% of Kabuki syndrome cases and is involved in 
chromatin regulation. It encodes a methyltransferase that di- and tri-methylates histone 
H3 lysine-4 (H3K4), associated with transcriptional activation (Lintas and Persico, 
2017). This protein contains a C-terminal SET domain, which is associated with its 
enzymatic activity (Ruthenburg et al., 2007). KMT2D appears to affect the expression 
of retinoic acid-responsive genes, so is likely to be important in anterior-posterior 
patterning in the brain (Guo et al., 2012). KMT2D is known to form a complex with 
MLL3 and other subunits such as WDR5, ASH2L, RbBP5 and DPY30 (also known as 
the WRAD complex) (Issaeva et al., 2007, Ernst and Vakoc, 2012). This complex is 
involved in the regulation of HOX gene expression (Ansari et al., 2011) and is a co-
activator of oestrogen receptor alpha (Mo et al., 2006). A recent study showed KMT2D 
loss to be associated with specific DNA methylation signatures and for this gene to 
regulate methylation of HOXA4, HOXA5 and SLITRK5 (Butcher et al., 2017). This is 
perhaps not surprising as HOX genes are important in axial patterning in the 
developing embryo and hoxa5 deficient mice have growth deficiencies, skeletal, and 
limb abnormalities, as well as defects in neural development (Lizen et al., 2017). 
Murine loss of Kmt2d slows growth and development, and causes early embryonic 
lethality, in part due to mis-regulation of homeobox gene expression (Ng et al., 2010). 
The MLL2/3 complex is somatically mutated in a number of different cancers, for 
example medulloblastoma and non-Hodgkin B-cell lymphomas (Morin et al., 2011). 
6.3.1.3 Mutations in KMT2D May Cause a Phenotype of Choanal Atresia, Athelia 
and Other Congenital Abnormalities, that is Distinct to Kabuki Syndrome 
We have described a potentially pathogenic missense variant in KMT2D in two families 
with a distinctive phenotype of choanal atresia, athelia and other associated congenital 
anomalies. This variant was predicted to be pathogenic by in silico tools and was not 
present in control datasets. It was confirmed to be de novo in the affected child in 
family CHD9, but present in both affected siblings and the unaffected father in family 
CHD9b. This suggests that, if pathogenic, this variant is either non-penetrant in the 
father in family CHD9b, or that he is mosaic for the variant. This possibility is supported 
by the reduced number of WES reads showing the mutant allele in the father, 
compared to the affected child, and the reduced mutant peak heights on Sanger 
sequencing electropherograms in the father. However, further investigation is required 
to confirm this, such as sampling buccal cells or fibroblasts from the father. 
Unfortunately, the father in this family has been approached by the family’s clinician 
and has declined to give further samples, so further evidence for mosaicism is not 
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available. If the father is mosaic, this is an example of gonadal mosaicism acting as a 
pheno-copy of recessive disease in a consanguineous union, as previous analysis in 
this family had always assumed a recessive inheritance pattern. 
 
Figure 6-6 shows the known domains of the KMT2D protein. There are 7 plant 
homeodomains (PHD) for protein binding, one high-mobility group domain (HMG), five 
LXXLL motifs (for nuclear receptor interaction), an FYRC and FRYN domain (for 
heterodimerisation) and a SET domain (for histone lysine methylation) (Banka et al., 
2012). Mutations known to cause KS are located throughout the protein, including exon 
38. The majority of KS mutations are protein truncating, but around 12-22% are 
missense (Hannibal et al., 2011) and these mutations are presumed to be loss-of-
function. G3553V falls within the LXLL domain (Banka et al., 2012) (see Fig. 6-6), but 
does not affect the LXLL motif. We cannot differentiate between this variant and 
mutations known to cause KS based on our knowledge of the protein structure of 
KMT2D. 
 
Figure 6-6: KMT2D protein showing domains and position of the G3553V variant.  
Figure adapted from (Banka et al., 2012). 
 
The mutation identified in family CHD9 and CHD9b, c.10658 C>A p.G3553V, is not 
present in control datasets, or in any of the previous publications of KS. It was 
identified in the COSMIC database (http://cancer.sanger.ac.uk/cosmic/mutation/; 
COSM940022 & COSM940021) as a somatic mutation identified in endometrial cancer 
and coded as pathogenic. This may give relevance to the finding of neuroblastoma in 
one of our described patients. 
 
As molecular testing has become more accessible, the spectrum of phenotypes of 
patients with KS has expanded. The overlap of KS with CHARGE syndrome has 
recently been delineated (Patel and Alkuraya, 2015). A number of reports have 
described coloboma in Kabuki syndrome, a feature more typically related to CHARGE 
syndrome (Ming et al., 2003, Genevieve et al., 2004, Schulz et al., 2014, Patel and 
Alkuraya, 2015, Verhagen et al., 2014).  A recent report described a family with 
autosomal dominant choanal atresia, hearing loss, dysmorphic features, learning 



































difficulties and dental anomalies. One family member had an ASD, but none of the 
other features of KS were present. This family had a heterozygous mutation in KMT2D, 
p.Gln3575His, which segregated with disease in the family. Interestingly this variant, 
which causes an atypical KS, also falls into exon 38 of the gene (Badalato et al., 2017), 
as seen in our families. CHARGE syndrome is caused by mutations in CHD7, an ATP-
dependent helicase that remodels chromatin, which appears to remodel methylated 
H3K4. There is a known molecular link between CHD7 and KMT2D function, as they 
are both known to interact with members of the WRAD complex (Zhang et al., 2012). 
This may explain the overlap in phenotypes in these two conditions (Van Laarhoven et 
al., 2015). 
 
The phenotype described in our families appears different from that of classical KS. On 
review of clinical photographs of the family members, a dysmorphologist who 
specializes in Kabuki syndrome did not classify these patients as having typical KS (Dr 
S. Banka; unpublished communication). We would therefore describe this phenotype 
as either a ‘novel KMT2D-related disorder’ or an ‘atypical Kabuki syndrome’ which 
expands the clinical spectrum of known KS. Further investigation is required to define a 
genotype-phenotype correlation within KMT2D-related disorders and to delineate 
classification for these families. We would recommend KMT2D sequencing in patients 
presenting with a similar phenotype.  
6.3.1.4 PTPRM as a Candidate Gene for Athelia 
In the analysis of family CHD9, a variant in PTPRM was also identified as de novo in 
the affected child. This was initially investigated as a possible candidate gene as the 
variant passed all filters, had a high CADD score and was not present in control 
datasets. PTPRM encodes a receptor protein-tyrosine phosphatase, important in cell-
cell adhesion (Gebbink et al., 1993) and has been shown to bind to and 
dephosphorylate p120 catenin (Zondag et al., 2000). PTPRM is reported to control 
organization of the actin cytoskeleton at sites of cell-cell interaction through p120 
phosphorylation (Koop et al., 2005).  
 
PTPRF, another receptor protein-tyrosine phosphatase, has previously been 
associated with athelia. In a recent paper, a homozygous truncating mutation in 
PTPRF was shown to cause athelia/hypothelia in a consanguineous Israeli-Arab 
family. The affected patients had hypoplasia or absence of the nipple and breast tissue 
and dysmorphic facial features, but no other abnormalities (Borck et al., 2014). In a 
further report, a balanced translocation, found to disrupt PTPRF, was associated with 
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bilateral amastia, ectodermal dysplasia, unilateral renal agenesis and dysmorphic 
features in a Thai woman (Ausavarat et al., 2011). Ptprf-/- mice have impaired 
mammary duct differentiation in the late stages of pregnancy (Schaapveld et al., 1997). 
Furthermore, PTPRF is expressed in human breast tissue (Du et al., 2013). 
 
This link between PTPRF and athelia led us to further investigate the potential 
pathogenicity of a variant in PTPRM. However, Ptprm-null mice have a diminished 
flow-induced dilation in mesenteric resistance arteries, but there is no effect on breast 
development or lactation (Koop et al., 2005). Expression of PTPRM was identified in 
the endothelial cells of the arteries, cardiac muscle and neuronal tissues (Koop et al., 
2005). Furthermore, no further mutations in PTPRM or other receptor protein-tyrosine 
phosphatases were identified in the other families investigated, including family CHD10 
who had a phenotype of isolated athelia. There was no further evidence of a role of 
PTPRM in breast or nipple development, and this variant was thought less likely to be 
the cause of the phenotype than KMT2D. However, it is possible that the variant in 
PTPRM is playing a modifier role in the phenotype seen in this patient.  
6.4 Conclusions 
We have demonstrated a specific variant in KMT2D, c.10658 C>A, to be associated 
with a phenotype of athelia, choanal atresia, CHD, thyroid dysgenesis and other 
congenital anomalies in two families. We suggest that the variant is present in a 
mosaic state in the father of the affected children in family CHD9b, explaining the 
apparent recessive inheritance pattern in this family as due to gonadal mosaicism. The 
reason for the association of this specific phenotype with the described variant is not 
currently known. It would be of interest to further investigate this finding, perhaps by 
studying methylation patterns of known KMT2D targets, such as HOXA5 (Butcher et 




7.1 Summary of Key Findings 
This thesis describes a study investigating the genetic causes of congenital heart 
disease (CHD) using whole exome sequencing. 16 families with CHD were recruited to 
the study. For the appropriate family members, a full clinical assessment was 
performed, and blood or saliva samples were taken for DNA extraction. The methods 
of WES used in this study are shown to provide a good and consistent depth of 
sequencing coverage across the exomic regions in the assessed samples, and have 
been successful in identifying known and candidate genes in CHD.  
 
In chapter 3, a family with a mutation identified in a known disease-causing gene, 
PIGV, was described. Children in this family presented with a range of structural 
abnormalities including congenital diaphragmatic hernia (CDH) and nail dysplasia. 
These were suggestive of a diagnosis of Fryns syndrome (MIM:229850). Whole exome 
analysis revealed variants in the PIGV gene (MIM:610274). Variants at this locus had 
previously been described in Hyperphosphatasia and Mental Retardation syndrome 
(HPMRS MIM:239300). Subsequent review confirmed the key finding of 
hyperphosphatasia in one affected child, consistent with the molecular findings. This 
represents an atypical presentation of HPMRS. In particular, the hallmark feature of 
CDH has not been previously described in HPMRS, nor has the absent bladder seen in 
one of the affected individuals. These features considerably extend the phenotype of 
HPMRS. 
 
Ten further families with CHD diagnoses and putative candidate variants identified by 
WES were investigated and discussed in chapter 3. A number of the candidate genes 
have functional links to CHD, for example variants in TMEM260 were identified in a 
family with Truncus Arteriosus. TMEM260 has recently been described to cause a 
syndrome associated with Truncus Arteriosus, renal anomalies and 
neurodevelopmental delay. Further studies will be required to delineate the true 
pathogenicity of these and the other candidate variants identified, possibly through 
collaboration with other groups. Eleven patients with laterality disorders from the DDD 
project were also analyzed, four with likely disease-causing mutations and a further 




In chapter 4, two children from a consanguineous family affected with sudden death in 
infancy, associated with cardiomyopathy, were identified to have homozygous 
mutations in PPA2. Through collaboration with other centers, this gene was identified 
to be the cause of disease in three further families, two with a very similar phenotype to 
the first, and one with a later onset of disease. Functional characterization of the 
identified mutations shows them to affect the pyrophosphatase activity of the PPA2 
enzyme. Defects in PPA2 enzyme activity are hypothesized to lead to insufficient 
inorganic phosphate for ATP synthesis, affecting cardiac muscle function, and leading 
to the phenotype of cardiomyopathy and arrhythmia.  
 
In chapter 5, two children from a consanguineous family affected with heterotaxy were 
shown to have homozygous mutations in DNAAF1. Mutations in this gene are a known 
cause of PCD, but there was an absence of clinical signs or symptoms of PCD in this 
family. Support for the pathogenicity of the identified missense mutation was presented 
using genetic complementation studies in a zebrafish mutant model. Three further 
families with mutations in DNAAF1 presenting with clinical PCD and CHD were 
discussed. Cellular studies showed DNAAF1 to interact with Pontin, Reptin and IFT88, 
suggesting DNAAF1 acts as part of a novel dynein arm assembly complex in motile 
ciliated cells. An assessment of Pontin expression at the embryonic node in mice and 
zebrafish showed an unexpected left-sided expression pattern, which was abolished in 
the dnaaf1-/- mutant fish embryos, placing DNAAF1 and Pontin in the pathways 
involved in the development of laterality in the early embryo.  
 
In two families with an unusual phenotype of athelia, choanal atresia, thyroid 
abnormalities and CHD, described in Chapter 6, a putative pathogenic variant in 
KMT2D was identified. This phenotype is distinct from Kabuki syndrome, usually 
caused by mutations in this gene. This is likely to represent a novel KMT2D-related 
disorder. 
 
WES has been shown to be a successful tool in gene identification in CHD and, 
coupled with functional studies to enable variant interpretation, this study has provided 




7.2 The Difficulties of Candidate Gene Identification in 
CHD 
A clear causative variant was not identified in all of the CHD families studied. In 5 of 16 
families (31%) a variant in a known disease-causing gene or a highly plausible 
candidate variant was identified. In the remaining 11 families, the most likely candidate 
was less clear-cut. These results are consistent with the published literature describing 
gene discovery rates in CHD using WES of around 30% (LaHaye et al., 2016).  
 
The difficulties in identifying candidates in this cohort may be due to a number of 
reasons. It may be that one of the identified candidate variants is the cause of disease 
in the family studied, but the link to cardiac disease is not yet clear. For example, there 
may be a paucity of previous literature or known animal models to give an important 
clue to gene function. In this situation, it is difficult to prioritize the likely disease-
causing variant from a short-list. One method to address this is to work collaboratively 
with other researchers in an attempt to identify multiple families with mutations in the 
same gene. To address this need, websites such as Matchmaker Exchange 
(http://www.matchmakerexchange.org) are playing an increasingly important role. 
However, it is important to verify that high quality and consistent phenotypic matching 
also occurs between families with candidate pathogenic variants in the same gene, in 
order to avoid false positive results.  
 
In this study, variants have been filtered to identify those that are likely to be 
‘functional’, and both synonymous and non-coding variants are filtered out in the 
analysis pipeline. It is possible that a true disease-causing variant could be missed due 
to the filtering stringency. For example, synonymous variants are known to affect 
splicing or codon usage (Scott et al., 2012). However, reducing the filtering stringency 
might leave the researcher with an unworkably long list of candidate variants (Cooper 
and Shendure, 2011). One of the other major difficulties of WES data analysis is in 
filtering potentially pathogenic mutations from general variation in the population. 
Publically-available databases, such as EXaC, dbSNP and EVS are useful tools for 
filtering variants, but none provide a comprehensive survey of normal variation and 
care needs to be taken in selecting a minor allele frequency on which to filter, to ensure 
the causative variant is not filtered out due to a comparatively high carrier frequency in 




The mutations causing the phenotype in these unsolved CHD families may be present 
in deep intronic regions or non-coding DNA, and these regions will not be captured by 
WES techniques. WGS may be a useful tool to further investigate the cause of disease 
in these families, but reliable filtering techniques will need to be developed. Large 
intragenic deletions could also have been missed in WES analysis. In some families, 
WGS at low read depth was utilized to assess for CNVs. However, due to cost 
restraints, this was not possible in all of the unsolved cases. Programs such as 
ExomeDepth, which assess for CNVs from WES data, can be useful in identifying 
CNVs (Plagnol et al., 2012), but intragenic deletions or duplications may be missed 
and we have found their use to be complicated by noise and false positive results.  
 
As previously discussed, the genetic causes of CHD are thought to be complex, so in 
this project we have focused on the assessment of families with an apparent 
Mendelian pattern of inheritance of CHD. However, we cannot discount the effect of 
environmental factors, modifier alleles and more complex genetics in these families. It 
may even be that levels of transcription of certain genes and their chaperones are the 
source of the observed phenotypes, or epigenetic factors, such as variants in DNA 
methylation patterns or histone modifications. Families with known disease-causing 
mutations in GATA4 and NKX2-5 are known to show incomplete penetrance and 
variable expressivity, even in family members who carry a known pathogenic mutation 
(Schott et al., 1998, Garg et al., 2003). This does suggest that some other effect, such 
as the epistatic effect of modifier alleles or environmental influences, may be playing a 
role in these conditions. This hypothesis is supported by the work of Granados-Riveron 
et al., 2012, who identified multiple variants in NKX2-5, MYH6 and GATA4 in single 
patients with CHD, perhaps indicating an additive effect of these variants in the 
pathogenesis of disease (Granados-Riveron et al., 2012). The cause of CHD in our 
unsolved families may therefore not be due to a single gene mutation, but perhaps the 
additive effect of many variants. With such a small number of analyzed families, 
genetic heterogeneity and epistatic effects would be difficult to interpret.  
7.3 WES Filtering Strategies 
An average dataset from a WES experiment will provide the researcher with more than 
20,000 variants for analysis, dependent upon the reagents and methods used (Stitziel 
et al., 2011). The methods described in this study for disease filtering have been 
shown to be robust and to have successfully identified candidate genes in Mendelian 
disease in numerous previous cases (Parry et al., 2013). However, as with all types of 
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WES analysis, it is important to understand these methods of filtering fully, as their use 
may require adjustment according to an individual case.  
 
Variants were filtered according to the observed inheritance pattern in the family. For a 
recessive disease, variants were retained that were biallelic in the affected individuals, 
but not biallelic in the parents or unaffected siblings. This methodology requires 
confidence in the clinical phenotyping, to ensure that ‘unaffected’ family members do 
not in fact harbor a sub-clinical disease, for example an undiagnosed VSD. To exclude 
this possibility, we have aimed to conduct or review echocardiogram investigations in 
unaffected family members in the families discussed in this project. This is particularly 
important in apparently unaffected parents who have had more than one child with 
CHD. 
 
In this project, variant filtering was performed on databases of known variation, for 
example dbSNP, where a minor allele frequency was selected and variants present 
above this frequency were removed. This assumes that the mutation causing a rare, 
recessive disease will not be present at high frequency in a database of known 
variation. This seemed an appropriate method in this study because, although CHD is 
relatively common in the population, Mendelian forms and specifically recessive forms 
of CHD are uncommon. However, difficulties can occur if patient samples are present 
in these databases, due to a late onset of disease, variable penetrance or variable 
expressivity as is the case for cardiac arrhythmias (Kaab and Schulze-Bahr, 2005). 
Databases, such as dbSNP have also been criticized for the quality of data submitted 
due to genotyping and base-calling errors. One review suggested that 15-17% of SNPs 
in the dbSNP database are false positives and that around half of the included SNPs 
are not validated (Mitchell et al., 2004). 
 
The in silico tools SIFT, Polyphen2 and CONDEL were further utilized in this project to 
score variants. Variants with low in silico pathogenicity predictions were not 
automatically filtered out, but always assessed by eye and pathogenicity scores were 
taken into account alongside functional data. These tools use information from a 
variety of sources, including sequence conservation, the observed range of variation at 
a nucleotide position and structural features of the new protein compared to wildtype 
(Thompson et al., 2013). These tools do have a limited specificity and sensitivity, but it 
is thought that the use of more than one tool concurrently increases accuracy (Chan et 
al., 2007). The combined annotation-dependent depletion (CADD) score was used in 
this project to prioritize variants. CADD is a framework that combines many diverse 
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functional annotations and combines them into one score. These functional 
annotations include conservation scores, DNAaseI hypersensitivity sites, transcription 
factor binding, distance to intron-exon boundaries, expression levels in commonly 
studied cell-lines, and pathogenicity scores such as SIFT and Polyphen (Kircher et al., 
2014). The CADD score is derived from a support vector machine that has been 
trained to differentiate ‘fixed’ SNPs, differences between the human genome and an 
inferred human-chimpanzee ancestral genome, which are tolerated, and simulated 
model polymorphisms. This machine was then used to calculate a score for every 
potential single nucleotide variant or short indel across the genome (Kircher et al., 
2014). These scores are then “PHRED-scaled” (ranking the variant relative to all 
possible substitutions in the genome in a logarithmic manner) so only the top 10% of 
variants will achieve a CADD score >10 and only the top 1% a score >20. The authors 
of the scoring system suggest using a CADD score of 15 as a cut-off for pathogenicity, 
but admit that this is arbitrary and should be adjusted according the project (Kircher et 
al., 2014). CADD scores were shown to be effective in assessing variants from a 
number of cohorts, for example in cohorts of children with autistic spectrum disorders 
(Kircher et al., 2014). However, the clinical utility of CADD score in non-coding regions 
of the genome has recently been questioned (Mather et al., 2016). 
 
Further selection of candidate variants relies on traditional methods such as review of 
the literature on encoded protein function and phenotypes of animal models. Ideally, 
these methods are combined in an automated pipeline, but attention is required by the 
research team to ensure that these tools are used appropriately, so that candidate 
variants are not missed.  
7.4 The Impact of Understanding the Genetic Cause of 
Disease 
The main aim of this project was the identification of genetic causes of CHD in families 
with an apparent Mendelian inheritance. The importance of identifying a genetic cause 
for disease is clear. For individual families, the existence of a definite molecular genetic 
diagnosis provides important information that can be used in lifestyle decisions and 
family planning. It allows families to understand the inheritance pattern of the disease, 
the risks to relatives and the likely recurrence risks to offspring, and permits an 
informed decision on genetic testing in the wider family. Genetic testing might affect 
life-style decisions, such as diet, smoking or undertaking risk-associated activities.  
Genetic testing can also improve the confidence in a clinical diagnosis. Those 
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individuals in a family requiring health surveillance can be identified, and those without 
the genetic mutation can be reassured (Arndt and MacRae, 2014). A genetic diagnosis 
may be utilized for interventions such as prenatal diagnosis or Pre-implantation 
Genetic Diagnosis (PGD).  
 
To illustrate this translational benefit, in one family recruited to this project, pathogenic 
homozygous mutations in PIGV were identified leading to a diagnosis of 
Hyperphosphatasia With Mental Retardation Syndrome Type 1. This finding gives the 
family precise information on recurrence risks, and could be used in prenatal testing. It 
also allows other family members to come forward for carrier testing. The parents of 
these children now have a name for the condition from which their children suffered, 
which may help in obtaining emotional support, for example through support groups 
such as Rare Disease UK (https://www.raredisease.org.uk). A recent publication from 
Rare Disease UK describes how patient organizations are often a main source of 
information for rare disease families and patients 
(https://www.raredisease.org.uk/media/1594/rduk-family-report.pdf). For future 
pregnancies, they can also now access more detailed prognostic information, including 
the likely level of developmental delay or learning difficulties in an affected child, which 
can be moderate to severe. Any future affected child could be provided with disease-
specific support, without the need for further investigation of raised Alkaline 
Phosphatase levels, and clinicians could monitor for known complications of this 
condition such as seizures and hypotonia. 
 
In other types of CHD, a genetic diagnosis may allow for counseling on disease 
prognosis, likely associated co-morbidities and appropriate management strategies. An 
example of this is in the case of syndromic CHD, which might be caused by a number 
of different conditions that include Down’s syndrome, Di George syndrome, Turner’s 
syndrome, Williams syndrome or Noonan syndrome. All have extra-cardiac anomalies 
and different potential managements, follow-up and screening. Noonan syndrome, for 
example, is associated with the risk of cardiomyopathy (LaHaye et al., 2016), which 
requires regular echocardiographic screening. In certain types of non-syndromic CHD, 
for example BAV, echocardiographic screening is recommended for first-degree 
relatives due to the risk of aortic dilatation (Nistri et al., 2005). Identification of a genetic 
mutation may therefore enable targeted screening in a family. This is further 
highlighted by the identification of PPA2 mutations in the families described in chapter 
4 of this thesis. The identification of the genetic cause in a family affected by this 
disease will allow the screening of family members for carrier status, 
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echocardiographic screening for cardiomyopathy, lifestyle modification (for example, 
the avoidance of alcohol) and ICD implantation in at-risk family members which is a 
potentially life-saving intervention. 
 
In the past, clinical diagnosis and management was purely based on clinical signs and 
symptoms. In the modern era, a genetic diagnosis can affect many aspects of clinical 
care, including recruitment to clinical trials, and access to therapeutic interventions, 
which may, in the near future, be stratified according to genetic aetiology. This so-
called ‘personalized medicine’ is already entering clinical practice. Warfarin is a 
commonly used anticoagulant in cardiovascular diseases. SNPs in the CYP2C9 gene 
can affect a patient’s metabolism of this drug, so undertaking genetic analysis can help 
to advise the clinician on dosage regimes (Voora et al., 2005).  
 
The genetic diagnosis of disease will allow researchers to follow-up a cohort of 
molecularly-defined patients to determine prognosis, therapeutic outcomes and co-
morbidities (as, for example, in the field of human cardiomyopathies) (Lakdawala, 
2013). Identification of the genetic causes of disease can lead to an increased scientific 
understanding of normal developmental pathways, the factors affected in disease 
processes, and ways in which these factors may be corrected. This leads towards 
potential therapeutics, the ultimate aim of disease research. An example of this is in 
the identification of mutations in CEP290 in patients with Leber’s Congenital Amaurosis 
(LCA), an inherited eye disease (den Hollander et al., 2006). This finding has provided 
novel insights into ciliary biology, and has lead the way towards antisense 
oligonucleotide therapy to redirect normal splicing in patient cell lines (Collin et al., 
2012), and lentivirus transfer of full-length CEP290 into patient-derived iPSC 
photoreceptor precursor cells (Burnight et al., 2014), revealing the potential for this 
type of therapy to treat CEP290-associated LCA.  
 
The advantages of genetic testing should be weighed against the potential negative 
impacts, including altered personal or social perceptions, such as stigmatization or 
discrimination, anxiety, the possibility of false-positive or false-negative results, 
incidental findings and uncertain outcomes (Katsanis and Katsanis, 2013). Genetic 
testing should therefore always be performed in the context of support from a qualified 




7.5 WES in the Clinical Setting 
NGS sequencing is now a routine genetic test in the healthcare setting (Katsanis and 
Katsanis, 2013). In the UK, NHS testing is currently mainly focused on gene panels, 
which are tailored to particular phenotypes or diseases. Compared to WES, targeted 
reagent panels have higher throughput and lower costs, and can provide a greater 
depth of coverage of the selected genes. Furthermore, certain centres can develop 
expertise in variant interpretation, reducing the identification of variants of unknown 
significance (Thomas et al., 2017).  
 
However, NGS panels may miss deep intronic, regulatory and splice variants, and 
developing a focused clinical panel of genes can be difficult owing to the variability of 
clinical presentations. This has led to the increased use of WES in the clinical setting, 
mainly in the form of clinical and research collaborations, for example the DDD project 
(Firth et al., 2011), which focused on WES in a trio-based approach alongside 
microarray analysis.  
 
For WES to be used appropriately in the clinical setting, robust filtering strategies and 
quality control should be in place, to reduce the number of incidental findings and 
variants of uncertain pathogenicity identified (Bertier et al., 2016). One of the main 
issues is in differentiating benign polymorphisms from disease-causing variants. 
Advances in analytical software tools and bioinformatics programs can go some way to 
support these decisions, but ultimately the development of high-throughput functional 
experiments to assess variants may be required if WES is to be in main-steam use (for 
example (Thouvenot et al., 2016)). Examples might include genome-wide phenotype 
screens, high-throughput massively-parallel reporter assays or in vitro splicing assays 
(Blaby-Haas and de Crecy-Lagard, 2011, Ipe et al., 2017). 
 
Guidelines have been created to standardize the assessment of variants, with the use 
of five reporting categories, but this assessment still contains many challenges 
(Richards et al., 2015). In order to address the potential ethical and moral issues 
associated with the reporting of incidental or secondary findings in the clinical setting a 
number of guidelines have been published. The most influential guidelines have been 
the American College of Genetics and Genomics Guidelines, published in 2013 (Green 
et al., 2013), which were extensively debated (Allyse and Michie, 2013) and then 
subsequently updated in 2014 (ACMG Board of Directors, 2015). The ACMG 
guidelines initially suggested a list of 56 genes should be searched for “actionable 
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variants” and reported back to patients, but this is a very contentious issue. The 
European Society of Human Genetics issued its own statement in 2015 (Hehir-Kwa et 
al., 2015), which highlights the key challenges in reaching a consensus on the 
reporting of incidental findings. It is generally thought that only “clinically actionable” 
incidental findings should be reported back to patients, or those that are likely to have 
serious consequences for future generations (Green et al., 2013). However, these 
guidelines remove individual patient choice (Holtzman, 2013), and have received 
considerable criticism due to the possibility of the identification of variants of unknown 
significance even in well-studied genes. For example, variants in BRCA1 and BRCA2, 
genes that are very well-studied and associated with a high risk of breast and ovarian 
cancers, can still be difficult to interpret (Rodriguez-Balada et al., 2016). 
 
Other issues for the use of WES in a clinical setting include the importance of 
developing secure systems for data storage, the development of robust reporting 
standards and guidelines on data ownership and privacy (Bertier et al., 2016). 
Furthermore, a key factor in the implementation of WES in the clinic is the standardized 
communication of results to patients (Bertier et al., 2016).   
 
In late 2012, the UK government launched the 100,000 Genomes Project. Run by 
Genomics England, this project aims to sequence the whole genomes of 100,000 NHS 
patients by 2018. The project will focus on two main groups of patients: those with 
cancer and those with rare diseases. The rare disease group will focus on WGS of 
trios. Syndromic CHD, familial CHD and young-onset cardiomyopathy are included in 
the list for rare disease recruitment. This project demonstrates a huge collaboration 
between clinicians, industry workers, researchers and patients and will, no doubt, 
change the face of clinical genetic testing in the UK. However, the project is likely to 
face many challenges, including many of those described for WES, such as delivering 
a consistent quality of clinical phenotype, sequencing, data annotation and filtering, 
and data storage and security. The vast amounts of data will need to be interpreted in 
a manner that is suitable for feedback of results to patients, including clear guidance on 
the appropriate reporting of incidental findings and variants of unknown significance 
(https://www.genomicsengland.co.uk).  
7.6 The Future of CHD Genetics 
The current known genetic causes of CHD only account for around 30% of cases, 
leaving a large proportion of CHD unsolved (Homsy et al., 2015). These unsolved 
cases may include those with variants in genes that are poorly annotated or not 
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covered by conventional sequencing techniques. These include variants in regulatory 
regions outside of exons, variants in unidentified enhancers or promoters, or 
synonymous variants that act as splice enhancers or silencers (Triedman and 
Newburger, 2016). Intragenic CNVs may also be currently under-identified in these 
families. WGS studies may help to delineate the causes in some of these cases. 
 
However, it may be that a large proportion of CHD is not monogenetic, but caused by 
the action of multiple genetic modifiers, and could therefore be characterized as a 
complex disease. Identification of these modifiers and the genetic backgrounds on 
which they work will require large cohorts of patients to create the required statistical 
power. For example, in the case of Cystic Fibrosis (CF), studies of more than 500 
patients are required for sufficient power to identify modifier genes, and there is often 
poor replication between studies of this size. One review suggests that modifiers with 
“probable effect” are those identified in at least three independent populations of >1000 
participants (Cutting, 2010). This size of CHD cohort is now being collated, for example 
the NHLBI Pediatric Cardiac Genomics Consortium (Pediatric Cardiac Genomics 
Consortium et al., 2013). GWAS studies have already been performed in some CHD 
cohorts, for example in left-sided lesions (Hanchard et al., 2016), but further studies will 
be required to delineate genetic causes in this manner.  
 
Transcriptome analysis of cardiac tissues, using techniques such as RNA-seq, may 
help to identify transcriptional changes that are associated with changes in 
haemodynamic load and that are implicated in post-transcriptional RNA processing 
during early cardiac development (Wang et al., 2016b). However, these techniques 
also depend on the development of robust data analysis pipelines.  
 
One of the main challenges in genetics in the modern era is not just the identification of 
genetic variants, but in their functional interpretation. Improved cellular models of 
cardiac disease, through the use of induced pluripotent stem cell lines and DNA 
manipulation technologies, such as CRISPR, offer exciting new resources to study the 
functional effects of mutations on cardiac development.  
 
Patient-derived induced pluripotent stem cells (iPSC) are an important new tool in the 
study of human disease. Using a combination of reprogramming factors, adult somatic 
cells, such as skin fibroblasts, can now be converted into pluripotent stem cells 
(Takahashi et al., 2007). These can then be directed into other cell types, such as 
cardiomyocytes (Lian et al., 2014, Zhang et al., 2009). iPSC-derived cardiomyocytes 
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demonstrate the immunohistochemistry, cardiac gene expression and action potential 
profiles of normal cardiomyocytes (Zhang et al., 2009). Granata et al., 2017, recently 
demonstrated the development of patient-derived hiPSC smooth muscle cell lines as a 
model of Marfan syndrome. These cells modeled the aortic pathology observed in 
patients with this condition. Through experiments on these cells lines, they were able to 
further delineate the role of TGF-beta in the development of the aortic pathology and 
identified a role for KLF4 in the Marfan’s syndrome disease process (Granata et al., 
2017). Patient-derived cell lines such as these can provide huge insights into disease 
physiology. However, patient-derived cardiomyocytes do display delayed maturation 
when compared to embryonic stem cells and it is unclear whether this is for technical 
or biological reasons (Blazeski et al., 2012). Other issues with iPSC-derived cells 
include the creation of mixed and variable populations of differentiated cell lineages, 
and interclonal variation even for cell lines derived from the same patient. These are 
presumably due to epigenetic effects (Gopalakrishnan et al., 2017).  
 
CRISPR-Cas9 is a system of immunity in bacteria and Archaea, used to respond to 
invading genetic material. CRISPRs are Clustered Regularly Interspaced Short 
Palindromic Repeats and Cas genes are CRISPR-associated nucleases. CRISPR 
repeats were initially identified in E. coli in the 1980s (Ishino et al., 1987), but it wasn’t 
until recently that their function was confirmed. In the CRISPR system, invading 
genetic material is identified, cut into small fragments and incorporated into the 
genome within the repeat sections of the CRISPR locus. When the sequence is 
transcribed, a CRISPR-RNA (cr-RNA) is generated (Jinek et al., 2012). This is used to 
guide effector endonucleases that target the invading DNA. The Cas9 endonuclease is 
a key player in this type of CRISPR system and participates in the destruction of 
invading DNA by the creation of double-stranded breaks and in processing the cr-
RNAs. For DNA cleavage, the Cas9 enzyme must be in the presence of crRNA and a 
separate trans-activating crRNA (trRNA) (Jinek et al., 2012). Also, a protospacer-
associated motif (PAM), which is a 2-5 nucleotide motif, should be present immediately 
3’ to the cr-RNA sequence (Swarts et al., 2012). This system has been adapted for use 
as a molecular tool, using a synthetic single guide RNA (sgRNA, a combination of cr-
RNA and tr-RNA sequence), along with Cas9, to create double-strand breaks at any 
specified location in the genome (Jinek et al., 2012). These double-strand breaks are 
either repaired by non-homologous end joining (NHEJ), resulting in insertions and 
deletions that disrupt gene function, or homology-directed repair (HDR), which can be 
exploited if a donor template is also provided, resulting in a specified substitution 




More recently, a mutant Cas9 enzyme was created, Cas9D10A (nickase), which only 
cleaves one DNA strand, reducing NHEJ and increasing HDR, resulting in a reduced 
number of indels (Cong et al., 2013). Using this technology, loci can be targeted by 
paired Cas-9 nickases to create targeted double-strand breaks with improved 
specificity and a decrease in off-target effects (Ran et al., 2013). Furthermore, a 
nuclease-deficient Cas9 enzyme (dCas9) without cleavage activity has been created, 
which can bind to specific sequences, but does not disrupt the gene sequence. This 
can then be used to manipulate gene expression, also called CRISPR interference 
(CRISPR-i) (Qi et al., 2013).  
 
The targeting efficiency of CRISPR is much higher than that of previous technologies 
such as Zinc Finger Nucleases (ZNFs) and transcription activator-like effectors 
(TALENs) (Mussolino et al., 2011). However, a major challenge exists in the creation of 
off-target effects, as the Cas9 enzyme can tolerate a number of mismatches in the 
target sequence (Fu et al., 2013). A recent paper highlighted the concerns regarding 
off-target effects in CRISPR-Cas9-edited mice. By using WGS, the authors showed a 
high number of off-target indels and SNVs in these mice, raising fears regarding the 
fidelity of the CRISPR-Cas9 system in an in vivo model (Schaefer et al., 2017). These 
off-target mutations can be difficult to detect and new developments, such as the use 
of paired nickases, are being used to reduce their effect. 
 
CRISPR-Cas9 technology is now being used in exciting new ways such as epigenetic 
modulation (Liu et al., 2016) and microscopic dynamic imaging (Chen et al., 2013). 
Perhaps one of the most exciting lines of work will be in the creation of animal models 
of disease. For example, the CRISPR-Cas9 system was recently used in zebrafish 
embryos to model MMP21 mutations, which caused cardiac looping defects, consistent 
with the observed phenotype in human patients (Perles et al., 2015). CRISPR-Cas9 
can also be used in genome-wide screening, similar to previous RNAi-based screens, 
but with the advantages of gene-level effects and the ability to assess non-transcribed 
elements (Koike-Yusa et al., 2014).  
 
Animal models, such as those studied in this project, including zebrafish and mice, can 
aid in the assessment of variants in vivo. Future work is likely to continue to rely on 
these animal models, possibly combined with CRIPSR technologies to study the 
pathogenicity of variants in their effect on normal development. Zebrafish are often 
used in CHD research due to the transparency of the embryo, and their ease of use in 
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genetic manipulation, which combined with CRISPR-Cas9 technologies provides an 
excellent research tool for cardiac development studies (Wilkinson et al., 2014). They 
also have a rapid embryonic development, high reproductive capacity, and a short 
generation time meaning a high-throughput of experimental results. There is good 
conservation between the human and zebrafish genomes, but teleost fish have 
undergone genome-wide duplication, so it is important to consider the physiological 
differences between species in the assessment of pathogenic variants. Since zebrafish 
are evolutionarily distinct from humans, disease phenotypes may not always be 
consistent (Guyon et al., 2007).  
7.7 Potential Therapeutics in Genetic Disease 
At the current time, patients affected by genetic disease have options to prevent 
passing a disease-causing mutation on to subsequent generations. Prenatal testing 
can be performed at an early stage of pregnancy to allow for parental choice regarding 
the continuation of the pregnancy. Testing for aneuploidies and single gene disorders 
can now be performed by Non Invasive Prenatal Testing (NIPT), analyzing cell-free 
DNA from a maternal blood sample, as early as 7 weeks gestation (Skrzypek and Hui, 
2017). However, to prevent passing a disease-causing gene on to offspring would 
involve the termination of an affected pregnancy. Pre-implantation Genetic Diagnosis 
(PGD) allows genetic testing of an embryo, created by in vitro fertilization (IVF), prior to 
implantation in the womb. A number of structural, muscular and arrhythmic cardiac 
disorders are included on the Human Fertilization and Embryology Authority’s list of 
conditions permissible for embryo selection, for example Cardiac Valvular Dysplasia 
and Dilated Cardiomyopathy and Left Ventricular Noncompaction Type 5. Perhaps 
unsurprisingly, conditions that do not affect life expectancy, such as VSD, are not 
included (http://guide.hfea.gov.uk/pgd/). However, these techniques do carry risks such 
as potential IVF failure, increased risk of multiple births and ovarian hyper-stimulation 
syndrome (Kumar et al., 2011). 
 
Theoretically, in the future, CRISPR-Cas9 technologies could be used to manipulate 
embryos prior to implantation. In fact, a Chinese group have already demonstrated that 
this could be a possibility. By injecting one-cell human embryos with Cas9 and sgRNA, 
they show correction of point mutations in the HBB and G6PD genes (Tang et al., 
2017). However the group met with many challenges: there was a poor mutation 
correction rate and many off-target effects were observed, higher even than those seen 
in other animals such as mice, creating many safety concerns (Schaefer et al., 2017). 
There are strong moral, ethical and legal concerns regarding the use of genetic 
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manipulation in human embryos, as any mutations created would be passed on to 
future generations. Off-target effects will have an unknown clinical outcome, which may 
not be apparent for many years. Furthermore, even if these techniques become 
feasible, for which diseases should they be used? Should parents be allowed to make 
such decisions for their unborn children? Do such technologies open the door to 
eugenic manipulation? (Lanphier et al., 2015) Current UK laws do not allow the culture 
of human embryos past 14 days gestation (Warnick, 1984) but the Human Fertilization 
and Embryology Authority has recently approved a license to allow CRIPSR gene 
editing in early human embryos (http://www.hfea.gov.uk/10187.html). It remains to be 
seen to what extent CRISPR technologies will be used in genetic editing of human 
embryos, and in the targeting of adult disease. In adult disease, much of the current 
work is focused on genetic manipulation of somatic cells, such as T-cells, in the 
treatment of viral infections such as HIV (Patel et al., 2016).  
 
Other current research focuses not only on the prevention of genetic disease in 
offspring but also on treatment in affected patients. Many genetic diseases, including 
some types of CHD, are caused by premature stop codons that terminate the amino 
acid sequence leading to premature protein truncation. These premature stop codons 
are not as efficient as normal stop codons and sometimes ‘readthrough’ can occur, 
meaning that the stop codon is ignored and the sequence is translated (Keeling et al., 
2014). This discovery has lead to the development of nonsense suppression therapy, 
which encourages ribosomal read-through of the premature stop codon to create a 
normal protein sequence. Therapeutic agents that can cause nonsense suppression 
include aminoglycoside antibiotics, such as gentamicin, non-aminoglycoside antibiotics 
such as negamycin (Arakawa et al., 2003) and other agents such as PTC124 
(Ataluren). Aminoglycosides are associated with toxic effects in long-term use, such as 
hearing loss and kidney damage, and clinical trials have produced variable results, 
restoring protein function in only a fraction of patients (Clancy et al., 2001). 
Researchers are now attempting to create aminoglycosides with reduced toxicity, for 
example using encapsulation in liposomes (Schiffelers et al., 2001). Ataluren is an 
oxadiazole compound that acts as a nonsense suppressor. It has been shown to be 
safe in human trials and to have minimal side effects (Hirawat et al., 2007). Numerous 
in vitro studies have confirmed its ability to suppress nonsense mutations, for example 
in the CFTR gene (Gonzalez-Hilarion et al., 2012). Recent double-blind, placebo-
controlled phase 3 clinical trials have been performed in Cystic Fibrosis (CF) and 
Duchenne Muscular Dystrophy (DMD). Some symptom relief was recognized in the CF 
group, although not to a significant level (Kerem et al., 2014) and a recent Cochrane 
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review of the use of Ataluren in CF shows insufficient evidence to support its use 
(Aslam et al., 2017). In DMD trials, Ataluren has shown some promising results, 
including an improvement in the 6-minute walk test (Bushby et al., 2014). However, 
further research will be needed to identify a role for these agents in the treatment of 
human disease. Other approaches to mediate premature stop codon readthrough 
include the use of suppressor tRNAs (Temple et al., 1982) and by using 
pseudouridylation modification of the first base of a stop codon (Karijolich and Yu, 
2011). 
 
The concept of ‘gene therapy’ or the introduction of normal genes to human cells has 
been around for over 20 years (Rosenberg et al., 1990). Vectors for gene delivery 
include viral vectors such lentivirus or adeno-associated virus (AAV), or non-viral 
vectors such as nanoparticles (Nance et al., 2017). Some of the earliest human trials of 
gene therapy were performed in X-linked Severe Combined Immunodeficiency 
Disorder (SCID), using a retroviral vector, but suffered a major set-back when a 
number of the treated patients developed leukaemia, raising safety concerns. However 
at the 10 year review, 8 of the 9 treated patients were still alive (Hacein-Bey-Abina et 
al., 2003). AAVs do not integrate into the host genome and so are not associated with 
the same safety risks. Recent successes using viral vectors in animal models has led 
the way for gene therapy trials in a number of human diseases, for example primary 
immunodeficiencies, leukodystrophies, thalassaemia, haemophilia and retinal 
dystrophies such as Leber’s Congenital Amaurosis (LCA) (Weleber et al., 2016). In 
these trials, genetic material is either transferred ex vivo (for example to T-
lymphocytes) and the cells are then returned to the body, or targeting is in vivo (for 
example in retinal disease) (Naldini, 2015). For in vivo work, eye diseases are often 
targeted due to the small, enclosed nature of the globe, with a tight blood-ocular barrier 
that can be easily accessed by injection and surgery (Samiy, 2014). The development 
of gene therapy in cardiac disease is less straightforward. For myocardial disease, 
therapy could conceivably be delivered directly to the heart using myocardial injection 
(Jones and Koch, 2005), but to prevent a structural disease, such as CHD, the 
developing heart would need to be targeted in utero at a very early developmental 
stage. Gene therapy still faces many challenges, for example in the development of 
efficient and safe vectors and in improving specificity (Samiy, 2014).  
 
iPSC cells are also being targeted as a therapeutic agent, for example patient-derived 
iPSC cells from a patient with cardiovascular disease could be used to generate 
functional cardiomyocytes to replace diseased heart tissue. Immune rejection would be 
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minimized as the cell lines originate from the patient’s own tissue. As proof of principle, 
iPSC cells from patients with Amyotrophic Lateral Sclerosis (ALS) have been 
differentiated into motor neurons, which could be used in autologous cell replacement 
therapies (Dimos et al., 2008).  
7.8 Plans for Future Research 
There are a number of ways in which the work from this project could be continued in 
further studies. There remain a number of unsolved cases of CHD that could initiate 
further investigation. WGS would be a good next step in investigation of families where 
no clear candidate is identified, since this would assess non-coding regions of the 
genome and enable further detailed structural analysis. All recruited unsolved families 
will be offered recruitment to the 100,000 Genomes Project, via the consenting 
clinician, to ensure that WGS is available to them if so desired.  
 
Some of the candidate variants identified in this project could be further assessed to 
gain insights into likely pathogenicity, perhaps in collaboration with other groups. 
Examples include the variants identified in PKHD1L1 for family CHD3 and in RBM48 
for family CHD16, which have been uploaded to Matchmaker Exchange 
(http://www.matchmakerexchange.org). It may be that identification of additional 
families with a similar phenotype and variants in these genes would provide the 
necessary support of pathogenicity to endorse further functional work.  
 
The functional assessment of mutations in DNAAF1, as detailed in chapter 5, has lead 
to a number of questions that could be further investigated. The exact role of DNAAF1 
within the Pontin/Reptin complex is not clear. Furthermore, the exciting finding of an 
asymmetric distribution of Pontin at the embryonic node requires further investigation. 
This could be taken forward using immunofluorescence labeling of other 
asymmetrically expressed genes, for example Nodal and Pitx2, at the Kupffer’s Vesicle 
in zebrafish to classify the hierarchy of Pontin expression in early development. It 
would also be very interesting to model the effect of loss of Pontin in the developing 
zebrafish, perhaps using a CRISPR model. This could be used to identify the effect on 
heart looping and expression of downstream laterality markers at the KV.  
 
The variant identified in KMT2D in chapter 6 in two families affected with athelia, 
choanal atresia and CHD deserves further investigation. This is a fascinating 
phenotype, but is very different to the usual phenotype caused by mutations in the 
gene (Kabuki Syndrome). Functional studies could be used to assess the pathogenicity 
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of this variant and to investigate the reason for the phenotype observed. KMT2D is a 
very large protein, making functional studies, such as over-expression experiments to 
model the mutation, very challenging. Therefore, having access to patient fibroblasts or 
creating a lymphoblastoid cell line from patient blood would be a key next step in the 
analysis of these families. A recent study assessed gene-specific histone methylation 
signatures of patients with KMT2D mutations, demonstrating KMT2D to be involved in 
the histone methylation of gene targets such as HOXA5 (Butcher et al., 2017). One 
suggestion would be to investigate the methylation of these gene targets in cell-lines 
from our patients and to identify whether a similar methylation signature is present. 
This would help to delineate the pathogenicity of this variant and may help to explain 
the effect of the variant on protein function. 
7.9 Overall Conclusions 
The hypothesis-free approach of WES has taken this project in a number of exciting 
and unexpected directions. New disease genes have been identified for early-onset 
cardiomyopathy and heterotaxy, and a number of candidate genes for structural CHD 
have been described. Further work is required to fully understand the complex genetic 
aetiology of CHD, but this study demonstrates that novel genes can be identified in a 
family-based approach. The field of genetics is now moving very rapidly and it is likely 
that CHD genetics will take huge steps forward with the introduction of new cellular and 
animal models, methods of genome modification, larger cohorts of patients and with 







Abu-Tair, T., Wiethoff, C. M., Kehr, J., Kuroczynski, W. & Kampmann, C. 2016. 
Transcatheter Closure of Atrial Septal Defects using the GORE((R)) Septal 
Occluder in Children Less Than 10 kg of Body Weight. Pediatr Cardiol, 37, 778-
83. 
Acmg Board of Directors 2015. ACMG policy statement: updated recommendations 
regarding analysis and reporting of secondary findings in clinical genome-scale 
sequencing. Genet Med, 17, 68-9. 
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., et al. 
2010. A method and server for predicting damaging missense mutations. Nat 
Methods, 7, 248-9. 
Agergaard, P., Olesen, C., Ostergaard, J. R., Christiansen, M. & Sorensen, K. M. 2012. 
The prevalence of chromosome 22q11.2 deletions in 2,478 children with 
cardiovascular malformations. A population-based study. Am J Med Genet A, 
158A, 498-508. 
Ahokas, K., Lohi, J., Lohi, H., Elomaa, O., Karjalainen-Lindsberg, M. L., et al. 2002. 
Matrix metalloproteinase-21, the human orthologue for XMMP, is expressed 
during fetal development and in cancer. Gene, 301, 31-41. 
Ahrens-Nicklas, R. C., Khan, S., Garbarini, J., Woyciechowski, S., D'alessandro, L., et 
al. 2016. Utility of genetic evaluation in infants with congenital heart defects 
admitted to the cardiac intensive care unit. Am J Med Genet A, 170, 3090-3097. 
Akawi, N., Mcrae, J., Ansari, M., Balasubramanian, M., Blyth, M., et al. 2015. Discovery 
of four recessive developmental disorders using probabilistic genotype and 
phenotype matching among 4,125 families. Nat Genet, 47, 1363-9. 
Al Turki, S., Manickaraj, A. K., Mercer, C. L., Gerety, S. S., Hitz, M. P., et al. 2014. 
Rare variants in NR2F2 cause congenital heart defects in humans. Am J Hum 
Genet, 94, 574-85. 
Al-Gazali, L. I., Hamid, Z., Hertecant, J., Bakir, M., Nath, D., et al. 2002. An autosomal 
recessive syndrome of choanal atresia, hypothelia/athelia and thyroid gland 
anomalies overlapping bamforth syndrome, ANOTHER syndrome and 
methimazole embryopathy. Clin Dysmorphol, 11, 79-85. 
Allyse, M. & Michie, M. 2013. Not-so-incidental findings: the ACMG recommendations 
on the reporting of incidental findings in clinical whole genome and whole 
exome sequencing. Trends Biotechnol, 31, 439-41. 
Amieux, P. S., Howe, D. G., Knickerbocker, H., Lee, D. C., Su, T., et al. 2002. 
Increased basal cAMP-dependent protein kinase activity inhibits the formation 
of mesoderm-derived structures in the developing mouse embryo. J Biol Chem, 
277, 27294-304. 
Andersen, T. A., Troelsen, K. D. & Larsen, L. A. 2013. Of mice and men: molecular 
genetics of congenital heart disease. Cell Mol Life Sci. 
Ang, S. Y., Uebersohn, A., Spencer, C. I., Huang, Y., Lee, J. E., et al. 2016. KMT2D 
regulates specific programs in heart development via histone H3 lysine 4 di-
methylation. Development, 143, 810-21. 
Angers, M., Uldry, M., Kong, D., Gimble, J. M. & Jetten, A. M. 2008. Mfsd2a encodes a 
novel major facilitator superfamily domain-containing protein highly induced in 
brown adipose tissue during fasting and adaptive thermogenesis. Biochem J, 
416, 347-55. 
Ansari, K. I., Hussain, I., Shrestha, B., Kasiri, S. & Mandal, S. S. 2011. HOXC6 Is 
transcriptionally regulated via coordination of MLL histone methylase and 
estrogen receptor in an estrogen environment. J Mol Biol, 411, 334-49. 
  
217 
Arakawa, M., Shiozuka, M., Nakayama, Y., Hara, T., Hamada, M., et al. 2003. 
Negamycin restores dystrophin expression in skeletal and cardiac muscles of 
mdx mice. J Biochem, 134, 751-8. 
Aramaki, M., Udaka, T., Kosaki, R., Makita, Y., Okamoto, N., et al. 2006. Phenotypic 
spectrum of CHARGE syndrome with CHD7 mutations. J Pediatr, 148, 410-4. 
Armstrong, L., Abd El Moneim, A., Aleck, K., Aughton, D. J., Baumann, C., et al. 2005. 
Further delineation of Kabuki syndrome in 48 well-defined new individuals. Am 
J Med Genet A, 132A, 265-72. 
Arndt, A. K. & Macrae, C. A. 2014. Genetic testing in cardiovascular diseases. Curr 
Opin Cardiol, 29, 235-40. 
Aslam, A. A., Higgins, C., Sinha, I. P. & Southern, K. W. 2017. Ataluren and similar 
compounds (specific therapies for premature termination codon class I 
mutations) for cystic fibrosis. Cochrane Database Syst Rev, 1, CD012040. 
Ausavarat, S., Tongkobpetch, S., Praphanphoj, V., Mahatumarat, C., Rojvachiranonda, 
N., et al. 2011. PTPRF is disrupted in a patient with syndromic amastia. BMC 
Med Genet, 12, 46. 
Baban, A., Postma, A. V., Marini, M., Trocchio, G., Santilli, A., et al. 2014. Identification 
of TBX5 mutations in a series of 94 patients with Tetralogy of Fallot. Am J Med 
Genet A, 164A, 3100-7. 
Badalato, L., Farhan, S. M., Dilliott, A. A., Care4rare Canada, C., Bulman, D. E., et al. 
2017. KMT2D p.Gln3575His segregating in a family with autosomal dominant 
choanal atresia strengthens the Kabuki/CHARGE connection. Am J Med Genet 
A, 173, 183-189. 
Bajpai, R., Chen, D. A., Rada-Iglesias, A., Zhang, J., Xiong, Y., et al. 2010. CHD7 
cooperates with PBAF to control multipotent neural crest formation. Nature, 
463, 958-62. 
Bamforth, J. S., Hughes, I. A., Lazarus, J. H., Weaver, C. M. & Harper, P. S. 1989. 
Congenital hypothyroidism, spiky hair, and cleft palate. J Med Genet, 26, 49-51. 
Banka, S., Veeramachaneni, R., Reardon, W., Howard, E., Bunstone, S., et al. 2012. 
How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116 
patients, review and analyses of mutation and phenotypic spectrum. Eur J Hum 
Genet, 20, 381-8. 
Basten, S. G., Davis, E. E., Gillis, A. J., Van Rooijen, E., Stoop, H., et al. 2013. 
Mutations in LRRC50 predispose zebrafish and humans to seminomas. PLoS 
Genet, 9, e1003384. 
Bauer, A., Chauvet, S., Huber, O., Usseglio, F., Rothbacher, U., et al. 2000. Pontin52 
and reptin52 function as antagonistic regulators of beta-catenin signalling 
activity. EMBO J, 19, 6121-30. 
Baumgartner, H., Bonhoeffer, P., De Groot, N. M., De Haan, F., Deanfield, J. E., et al. 
2010. ESC Guidelines for the management of grown-up congenital heart 
disease (new version 2010). Eur Heart J, 31, 2915-57. 
Becker, S. & Al Halees, Z. 1999. First-cousin matings and congenital heart disease in 
Saudi Arabia. Community Genet, 2, 69-73. 
Belkadi, A., Bolze, A., Itan, Y., Cobat, A., Vincent, Q. B., et al. 2015. Whole-genome 
sequencing is more powerful than whole-exome sequencing for detecting 
exome variants. Proc Natl Acad Sci U S A, 112, 5473-8. 
Benson, D. W., Silberbach, G. M., Kavanaugh-Mchugh, A., Cottrill, C., Zhang, Y., et al. 
1999. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac 
developmental pathways. J Clin Invest, 104, 1567-73. 
Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., et al. 
2008. Accurate whole human genome sequencing using reversible terminator 
chemistry. Nature, 456, 53-9. 
Bertier, G., Hetu, M. & Joly, Y. 2016. Unsolved challenges of clinical whole-exome 
sequencing: a systematic literature review of end-users' views. BMC Med 
Genomics, 9, 52. 
  
218 
Bettinelli, A. L., Mulder, T. J., Funke, B. H., Lafferty, K. A., Longo, S. A., et al. 2013. 
Familial ebstein anomaly, left ventricular hypertrabeculation, and ventricular 
septal defect associated with a MYH7 mutation. Am J Med Genet A. 
Bevilacqua, A., Willis, M. S. & Bultman, S. J. 2013. SWI/SNF chromatin-remodeling 
complexes in cardiovascular development and disease. Cardiovasc Pathol. 
Bichet, D., Peters, D., Patel, A. J., Delmas, P. & Honore, E. 2006. Cardiovascular 
polycystins: insights from autosomal dominant polycystic kidney disease and 
transgenic animal models. Trends Cardiovasc Med, 16, 292-8. 
Blaby-Haas, C. E. & De Crecy-Lagard, V. 2011. Mining high-throughput experimental 
data to link gene and function. Trends Biotechnol, 29, 174-82. 
Blainey, P., Krzywinski, M. & Altman, N. 2014. Points of significance: replication. Nat 
Methods, 11, 879-80. 
Blazeski, A., Zhu, R., Hunter, D. W., Weinberg, S. H., Zambidis, E. T., et al. 2012. 
Cardiomyocytes derived from human induced pluripotent stem cells as models 
for normal and diseased cardiac electrophysiology and contractility. Prog 
Biophys Mol Biol, 110, 166-77. 
Blue, G. M., Humphreys, D., Szot, J., Major, J., Chapman, G., et al. 2017. The 
promises and challenges of exome sequencing in familial, non-syndromic 
congenital heart disease. Int J Cardiol, 230, 155-163. 
Blue, G. M., Kirk, E. P., Giannoulatou, E., Dunwoodie, S. L., Ho, J. W., et al. 2014. 
Targeted next-generation sequencing identifies pathogenic variants in familial 
congenital heart disease. J Am Coll Cardiol, 64, 2498-506. 
Boogerd, C. J., Moorman, A. F. & Barnett, P. 2009. Protein interactions at the heart of 
cardiac chamber formation. Ann Anat, 191, 505-17. 
Borck, G., De Vries, L., Wu, H. J., Smirin-Yosef, P., Nurnberg, G., et al. 2014. 
Homozygous truncating PTPRF mutation causes athelia. Hum Genet, 133, 
1041-7. 
Boulon, S., Pradet-Balade, B., Verheggen, C., Molle, D., Boireau, S., et al. 2010. 
HSP90 and its R2TP/Prefoldin-like cochaperone are involved in the cytoplasmic 
assembly of RNA polymerase II. Mol Cell, 39, 912-24. 
Boycott, K. M., Vanstone, M. R., Bulman, D. E. & Mackenzie, A. E. 2013. Rare-disease 
genetics in the era of next-generation sequencing: discovery to translation. Nat 
Rev Genet, 14, 681-91. 
Brambilla, R., Gnesutta, N., Minichiello, L., White, G., Roylance, A. J., et al. 1997. A 
role for the Ras signalling pathway in synaptic transmission and long-term 
memory. Nature, 390, 281-6. 
Braun, D. A. & Hildebrandt, F. 2017. Ciliopathies. Cold Spring Harb Perspect Biol, 9. 
Braun, D. A., Schueler, M., Halbritter, J., Gee, H. Y., Porath, J. D., et al. 2016. Whole 
exome sequencing identifies causative mutations in the majority of 
consanguineous or familial cases with childhood-onset increased renal 
echogenicity. Kidney Int, 89, 468-75. 
Breckpot, J., Thienpont, B., Arens, Y., Tranchevent, L. C., Vermeesch, J. R., et al. 
2011. Challenges of interpreting copy number variation in syndromic and non-
syndromic congenital heart defects. Cytogenet Genome Res, 135, 251-9. 
Breig, O., Bras, S., Martinez Soria, N., Osman, D., Heidenreich, O., et al. 2014. Pontin 
is a critical regulator for AML1-ETO-induced leukemia. Leukemia, 28, 1271-9. 
Breuss, M., Heng, J. I., Poirier, K., Tian, G., Jaglin, X. H., et al. 2012. Mutations in the 
beta-tubulin gene TUBB5 cause microcephaly with structural brain 
abnormalities. Cell Rep, 2, 1554-62. 
Bruneau, B. G., Nemer, G., Schmitt, J. P., Charron, F., Robitaille, L., et al. 2001. A 
murine model of Holt-Oram syndrome defines roles of the T-box transcription 
factor Tbx5 in cardiogenesis and disease. Cell, 106, 709-21. 
Burgers, P. P., Ma, Y., Margarucci, L., Mackey, M., Van Der Heyden, M. A., et al. 2012. 
A small novel A-kinase anchoring protein (AKAP) that localizes specifically 
  
219 
protein kinase A-regulatory subunit I (PKA-RI) to the plasma membrane. J Biol 
Chem, 287, 43789-97. 
Burnight, E. R., Wiley, L. A., Drack, A. V., Braun, T. A., Anfinson, K. R., et al. 2014. 
CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype. 
Gene Ther, 21, 662-72. 
Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., et al. 2014. Ataluren 
treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve, 
50, 477-87. 
Butcher, D. T., Cytrynbaum, C., Turinsky, A. L., Siu, M. T., Inbar-Feigenberg, M., et al. 
2017. CHARGE and Kabuki Syndromes: Gene-Specific DNA Methylation 
Signatures Identify Epigenetic Mechanisms Linking These Clinically 
Overlapping Conditions. Am J Hum Genet, 100, 773-788. 
C. Yuen, R., Merico, D., Bookman, M., J, L. H., Thiruvahindrapuram, B., et al. 2017. 
Whole genome sequencing resource identifies 18 new candidate genes for 
autism spectrum disorder. Nat Neurosci, 20, 602-611. 
Cao, Y. & Aypar, U. 2016. A novel Xq22.1 deletion in a male with multiple congenital 
abnormalities and respiratory failure. Eur J Med Genet, 59, 274-7. 
Castanet, M. & Polak, M. 2010. Spectrum of Human Foxe1/TTF2 Mutations. Horm Res 
Paediatr, 73, 423-9. 
Cecchi, F., Tomberli, B. & Olivotto, I. 2012. Clinical and molecular classification of 
cardiomyopathies. Glob Cardiol Sci Pract, 2012, 4. 
Chaix, M. A., Andelfinger, G. & Khairy, P. 2016. Genetic testing in congenital heart 
disease: A clinical approach. World J Cardiol, 8, 180-91. 
Chalhoub, V., Abi-Rafeh, L., Hachem, K., Ayoub, E. & Yazbeck, P. 2013. Intracranial 
aneurysm and recessive polycystic kidney disease: the third reported case. 
JAMA Neurol, 70, 114-6. 
Chan, P. A., Duraisamy, S., Miller, P. J., Newell, J. A., Mcbride, C., et al. 2007. 
Interpreting missense variants: comparing computational methods in human 
disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum 
Mutat, 28, 683-93. 
Chang, C. P. & Bruneau, B. G. 2012. Epigenetics and cardiovascular development. 
Annu Rev Physiol, 74, 41-68. 
Chapman, A. B., Rubinstein, D., Hughes, R., Stears, J. C., Earnest, M. P., et al. 1992. 
Intracranial aneurysms in autosomal dominant polycystic kidney disease. N 
Engl J Med, 327, 916-20. 
Chen, B., Gilbert, L. A., Cimini, B. A., Schnitzbauer, J., Zhang, W., et al. 2013. 
Dynamic imaging of genomic loci in living human cells by an optimized 
CRISPR/Cas system. Cell, 155, 1479-91. 
Chen, J. & Wang, D. Z. 2012. microRNAs in cardiovascular development. J Mol Cell 
Cardiol, 52, 949-57. 
Chen, L., Liu, T., Tran, A., Lu, X., Tomilov, A. A., et al. 2012. OPA1 mutation and late-
onset cardiomyopathy: mitochondrial dysfunction and mtDNA instability. J Am 
Heart Assoc, 1, e003012. 
Chen, T., Shan, G., Ma, J. & Zhong, Y. 2015. Polymorphism in the RASGRF1 gene 
with high myopia: A meta-analysis. Mol Vis, 21, 1272-80. 
Ching, Y. H., Ghosh, T. K., Cross, S. J., Packham, E. A., Honeyman, L., et al. 2005. 
Mutation in myosin heavy chain 6 causes atrial septal defect. Nat Genet, 37, 
423-8. 
Chinnery, P. F. 1993. Mitochondrial Disorders Overview. In: PAGON, R. A., ADAM, M. 
P., ARDINGER, H. H., WALLACE, S. E., AMEMIYA, A., BEAN, L. J. H., BIRD, 
T. D., LEDBETTER, N., MEFFORD, H. C., SMITH, R. J. H. & STEPHENS, K. 
(eds.) GeneReviews(R). Seattle (WA). 
Chiyonobu, T., Inoue, N., Morimoto, M., Kinoshita, T. & Murakami, Y. 2014. 
Glycosylphosphatidylinositol (GPI) anchor deficiency caused by mutations in 
  
220 
PIGW is associated with West syndrome and hyperphosphatasia with mental 
retardation syndrome. J Med Genet, 51, 203-7. 
Chowdhury, S., Bandholz, A. M., Parkash, S., Dyack, S., Rideout, A. L., et al. 2014. 
Phenotypic and molecular characterization of 19q12q13.1 deletions: a report of 
five patients. Am J Med Genet A, 164A, 62-9. 
Chung, Y. W. & Kang, S. M. 2015. An experimental approach to study the function of 
mitochondria in cardiomyopathy. BMB Rep, 48, 541-8. 
Cizkova, A., Stranecky, V., Mayr, J. A., Tesarova, M., Havlickova, V., et al. 2008. 
TMEM70 mutations cause isolated ATP synthase deficiency and neonatal 
mitochondrial encephalocardiomyopathy. Nat Genet, 40, 1288-90. 
Clancy, J. P., Bebok, Z., Ruiz, F., King, C., Jones, J., et al. 2001. Evidence that 
systemic gentamicin suppresses premature stop mutations in patients with 
cystic fibrosis. Am J Respir Crit Care Med, 163, 1683-92. 
Clementi, M., Di Gianantonio, E., Pelo, E., Mammi, I., Basile, R. T., et al. 1999. 
Methimazole embryopathy: delineation of the phenotype. Am J Med Genet, 83, 
43-6. 
Coe, B. P., Ylstra, B., Carvalho, B., Meijer, G. A., Macaulay, C., et al. 2007. Resolving 
the resolution of array CGH. Genomics, 89, 647-53. 
Collin, R. W., Den Hollander, A. I., Van Der Velde-Visser, S. D., Bennicelli, J., Bennett, 
J., et al. 2012. Antisense Oligonucleotide (AON)-based Therapy for Leber 
Congenital Amaurosis Caused by a Frequent Mutation in CEP290. Mol Ther 
Nucleic Acids, 1, e14. 
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., et al. 2013. Multiplex genome 
engineering using CRISPR/Cas systems. Science, 339, 819-23. 
Conrad, D. F., Pinto, D., Redon, R., Feuk, L., Gokcumen, O., et al. 2010. Origins and 
functional impact of copy number variation in the human genome. Nature, 464, 
704-12. 
Cooper, G. M. & Hausman, R. E. 2016. The Cell : a molecular approach, Sunderland, 
Mass., Sinauer Associates. 
Cooper, G. M. & Shendure, J. 2011. Needles in stacks of needles: finding disease-
causal variants in a wealth of genomic data. Nat Rev Genet, 12, 628-40. 
Cordell, H. J., Bentham, J., Topf, A., Zelenika, D., Heath, S., et al. 2013. Genome-wide 
association study of multiple congenital heart disease phenotypes identifies a 
susceptibility locus for atrial septal defect at chromosome 4p16. Nat Genet, 45, 
822-4. 
Cripe, L., Andelfinger, G., Martin, L. J., Shooner, K. & Benson, D. W. 2004. Bicuspid 
aortic valve is heritable. J Am Coll Cardiol, 44, 138-43. 
Curbo, S., Lagier-Tourenne, C., Carrozzo, R., Palenzuela, L., Lucioli, S., et al. 2006. 
Human mitochondrial pyrophosphatase: cDNA cloning and analysis of the gene 
in patients with mtDNA depletion syndromes. Genomics, 87, 410-6. 
Cutting, G. R. 2010. Modifier genes in Mendelian disorders: the example of cystic 
fibrosis. Ann N Y Acad Sci, 1214, 57-69. 
Das, G., Yu, Q., Hui, R., Reuhl, K., Gale, N. W., et al. 2016. EphA5 and EphA6: 
regulation of neuronal and spine morphology. Cell Biosci, 6, 48. 
Den Hollander, A. I., Koenekoop, R. K., Yzer, S., Lopez, I., Arends, M. L., et al. 2006. 
Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber 
congenital amaurosis. Am J Hum Genet, 79, 556-61. 
Dentici, M. L., Di Pede, A., Lepri, F. R., Gnazzo, M., Lombardi, M. H., et al. 2015. 
Kabuki syndrome: clinical and molecular diagnosis in the first year of life. Arch 
Dis Child, 100, 158-64. 
Dhanoa, B. S., Cogliati, T., Satish, A. G., Bruford, E. A. & Friedman, J. S. 2013. Update 
on the Kelch-like (KLHL) gene family. Hum Genomics, 7, 13. 
Dimitrov, A., Paupe, V., Gueudry, C., Sibarita, J. B., Raposo, G., et al. 2009. The gene 
responsible for Dyggve-Melchior-Clausen syndrome encodes a novel peripheral 
  
221 
membrane protein dynamically associated with the Golgi apparatus. Hum Mol 
Genet, 18, 440-53. 
Dimos, J. T., Rodolfa, K. T., Niakan, K. K., Weisenthal, L. M., Mitsumoto, H., et al. 
2008. Induced pluripotent stem cells generated from patients with ALS can be 
differentiated into motor neurons. Science, 321, 1218-21. 
Doenst, T., Nguyen, T. D. & Abel, E. D. 2013. Cardiac metabolism in heart failure: 
implications beyond ATP production. Circ Res, 113, 709-24. 
Dong, F., Shinohara, K., Botilde, Y., Nabeshima, R., Asai, Y., et al. 2014. Pih1d3 is 
required for cytoplasmic preassembly of axonemal dynein in mouse sperm. J 
Cell Biol, 204, 203-13. 
Dong, Z., Zhang, J., Hu, P., Chen, H., Xu, J., et al. 2016. Low-pass whole-genome 
sequencing in clinical cytogenetics: a validated approach. Genet Med, 18, 940-
8. 
Du, W. W., Fang, L., Li, M., Yang, X., Liang, Y., et al. 2013. MicroRNA miR-24 
enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to 
promote EGF signaling. J Cell Sci, 126, 1440-53. 
Dumic, M., Cvitanovic, M., Saric, B., Spehar, A. & Batinica, S. 2002. Choanal stenosis, 
hypothelia, deafness, recurrent dacryocystitis, neck fistulas, short stature, and 
microcephaly: report of a case. Am J Med Genet, 113, 295-7. 
Duquesnoy, P., Escudier, E., Vincensini, L., Freshour, J., Bridoux, A. M., et al. 2009. 
Loss-of-function mutations in the human ortholog of Chlamydomonas reinhardtii 
ODA7 disrupt dynein arm assembly and cause primary ciliary dyskinesia. Am J 
Hum Genet, 85, 890-6. 
Durocher, D. & Nemer, M. 1998. Combinatorial interactions regulating cardiac 
transcription. Dev Genet, 22, 250-62. 
El Ghouzzi, V., Dagoneau, N., Kinning, E., Thauvin-Robinet, C., Chemaitilly, W., et al. 
2003. Mutations in a novel gene Dymeclin (FLJ20071) are responsible for 
Dyggve-Melchior-Clausen syndrome. Hum Mol Genet, 12, 357-64. 
Eldadah, Z. A., Hamosh, A., Biery, N. J., Montgomery, R. A., Duke, M., et al. 2001. 
Familial Tetralogy of Fallot caused by mutation in the jagged1 gene. Hum Mol 
Genet, 10, 163-9. 
Elliott, A. M., Simard, L. R., Coghlan, G., Chudley, A. E., Chodirker, B. N., et al. 2013. 
A novel mutation in KIAA0196: identification of a gene involved in Ritscher-
Schinzel/3C syndrome in a First Nations cohort. J Med Genet, 50, 819-22. 
Erdogan, F., Larsen, L. A., Zhang, L., Tumer, Z., Tommerup, N., et al. 2008. High 
frequency of submicroscopic genomic aberrations detected by tiling path array 
comparative genome hybridisation in patients with isolated congenital heart 
disease. J Med Genet, 45, 704-9. 
Ernst, P. & Vakoc, C. R. 2012. WRAD: enabler of the SET1-family of H3K4 
methyltransferases. Brief Funct Genomics, 11, 217-26. 
Fakhro, K. A., Choi, M., Ware, S. M., Belmont, J. W., Towbin, J. A., et al. 2011. Rare 
copy number variations in congenital heart disease patients identify unique 
genes in left-right patterning. Proc Natl Acad Sci U S A, 108, 2915-20. 
Fallet-Bianco, C., Laquerriere, A., Poirier, K., Razavi, F., Guimiot, F., et al. 2014. 
Mutations in tubulin genes are frequent causes of various foetal malformations 
of cortical development including microlissencephaly. Acta Neuropathol 
Commun, 2, 69. 
Feldheim, D. A., Nakamoto, M., Osterfield, M., Gale, N. W., Dechiara, T. M., et al. 
2004. Loss-of-function analysis of EphA receptors in retinotectal mapping. J 
Neurosci, 24, 2542-50. 
Fesslova, V., Brankovic, J., Lalatta, F., Villa, L., Meli, V., et al. 2011. Recurrence of 
congenital heart disease in cases with familial risk screened prenatally by 
echocardiography. J Pregnancy, 2011, 368067. 
Firth, H. V., Wright, C. F. & Study, D. D. D. 2011. The Deciphering Developmental 
Disorders (DDD) study. Dev Med Child Neurol, 53, 702-3. 
  
222 
Fleming, P. J., Blair, P. S. & Pease, A. 2015. Sudden unexpected death in infancy: 
aetiology, pathophysiology, epidemiology and prevention in 2015. Arch Dis 
Child, 100, 984-8. 
Font De Mora, J., Esteban, L. M., Burks, D. J., Nunez, A., Garces, C., et al. 2003. Ras-
GRF1 signaling is required for normal beta-cell development and glucose 
homeostasis. EMBO J, 22, 3039-49. 
Fowkes, M. E. & Mitchell, D. R. 1998. The role of preassembled cytoplasmic 
complexes in assembly of flagellar dynein subunits. Mol Biol Cell, 9, 2337-47. 
Francis, R. J., Christopher, A., Devine, W. A., Ostrowski, L. & Lo, C. 2012. Congenital 
heart disease and the specification of left-right asymmetry. Am J Physiol Heart 
Circ Physiol, 302, H2102-11. 
Frank, V., Habbig, S., Bartram, M. P., Eisenberger, T., Veenstra-Knol, H. E., et al. 
2013. Mutations in NEK8 link multiple organ dysplasia with altered Hippo 
signalling and increased c-MYC expression. Hum Mol Genet, 22, 2177-85. 
Freshour, J., Yokoyama, R. & Mitchell, D. R. 2007. Chlamydomonas flagellar outer row 
dynein assembly protein ODA7 interacts with both outer row and I1 inner row 
dyneins. J Biol Chem, 282, 5404-12. 
Freson, K., Thys, C., Wittewrongel, C., Vermylen, J., Hoylaerts, M. F., et al. 2003. 
Molecular cloning and characterization of the GATA1 cofactor human FOG1 
and assessment of its binding to GATA1 proteins carrying D218 substitutions. 
Hum Genet, 112, 42-9. 
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., et al. 2013. High-frequency 
off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat 
Biotechnol, 31, 822-6. 
Fujiwara, I., Murakami, Y., Niihori, T., Kanno, J., Hakoda, A., et al. 2015. Mutations in 
PIGL in a patient with Mabry syndrome. Am J Med Genet A, 167A, 777-85. 
Fulcoli, F. G., Franzese, M., Liu, X., Zhang, Z., Angelini, C., et al. 2016. Rebalancing 
gene haploinsufficiency in vivo by targeting chromatin. Nat Commun, 7, 11688. 
Gall, J. C., Jr., Stern, A. M., Cohen, M. M., Adams, M. S. & Davidson, R. T. 1966. Holt-
Oram syndrome: clinical and genetic study of a large family. Am J Hum Genet, 
18, 187-200. 
Gallant, P. 2007. Control of transcription by Pontin and Reptin. Trends Cell Biol, 17, 
187-92. 
Gana, S., Veggiotti, P., Sciacca, G., Fedeli, C., Bersano, A., et al. 2012. 19q13.11 
cryptic deletion: description of two new cases and indication for a role of WTIP 
haploinsufficiency in hypospadias. Eur J Hum Genet, 20, 852-6. 
Garg, V., Kathiriya, I. S., Barnes, R., Schluterman, M. K., King, I. N., et al. 2003. 
GATA4 mutations cause human congenital heart defects and reveal an 
interaction with TBX5. Nature, 424, 443-7. 
Gebbink, M. F., Zondag, G. C., Wubbolts, R. W., Beijersbergen, R. L., Van Etten, I., et 
al. 1993. Cell-cell adhesion mediated by a receptor-like protein tyrosine 
phosphatase. J Biol Chem, 268, 16101-4. 
Geiersbach, K. B., Gardiner, A. E., Wilson, A., Shetty, S., Bruyere, H., et al. 2014. 
Subjectivity in chromosome band-level estimation: a multicenter study. Genet 
Med, 16, 170-5. 
Genevieve, D., Amiel, J., Viot, G., Le Merrer, M., Sanlaville, D., et al. 2004. Atypical 
findings in Kabuki syndrome: report of 8 patients in a series of 20 and review of 
the literature. Am J Med Genet A, 129A, 64-8. 
Ghebranious, N., Giampietro, P. F., Wesbrook, F. P. & Rezkalla, S. H. 2007. A novel 
microdeletion at 16p11.2 harbors candidate genes for aortic valve development, 
seizure disorder, and mild mental retardation. Am J Med Genet A, 143A, 1462-
71. 
Gibson, W. T., Hood, R. L., Zhan, S. H., Bulman, D. E., Fejes, A. P., et al. 2012. 
Mutations in EZH2 cause Weaver syndrome. Am J Hum Genet, 90, 110-8. 
  
223 
Giese, K. P., Friedman, E., Telliez, J. B., Fedorov, N. B., Wines, M., et al. 2001. 
Hippocampus-dependent learning and memory is impaired in mice lacking the 
Ras-guanine-nucleotide releasing factor 1 (Ras-GRF1). Neuropharmacology, 
41, 791-800. 
Glanz, A. & Fraser, F. C. 1982. Spectrum of anomalies in Fanconi anaemia. J Med 
Genet, 19, 412-6. 
Glessner, J. T., Bick, A. G., Ito, K., Homsy, J. G., Rodriguez-Murillo, L., et al. 2014. 
Increased frequency of de novo copy number variants in congenital heart 
disease by integrative analysis of single nucleotide polymorphism array and 
exome sequence data. Circ Res, 115, 884-96. 
Glustein, J. Z., Weill, M. & Steinberg, A. 1996. Anomalies of the nipple: an additional 
finding in CHARGE syndrome. Am J Med Genet, 61, 201. 
Goldmuntz, E., Bamford, R., Karkera, J. D., Dela Cruz, J., Roessler, E., et al. 2002. 
CFC1 mutations in patients with transposition of the great arteries and double-
outlet right ventricle. Am J Hum Genet, 70, 776-80. 
Gong, C., Bongiorno, P., Martins, A., Stephanou, N. C., Zhu, H., et al. 2005. 
Mechanism of nonhomologous end-joining in mycobacteria: a low-fidelity repair 
system driven by Ku, ligase D and ligase C. Nat Struct Mol Biol, 12, 304-12. 
Gonzalez-Hilarion, S., Beghyn, T., Jia, J., Debreuck, N., Berte, G., et al. 2012. Rescue 
of nonsense mutations by amlexanox in human cells. Orphanet J Rare Dis, 7, 
58. 
Goodship, J. A., Hall, D., Topf, A., Mamasoula, C., Griffin, H., et al. 2012. A common 
variant in the PTPN11 gene contributes to the risk of tetralogy of Fallot. Circ 
Cardiovasc Genet, 5, 287-92. 
Gopalakrishnan, S., Hor, P. & Ichida, J. K. 2017. New approaches for direct conversion 
of patient fibroblasts into neural cells. Brain Res, 1656, 2-13. 
Grampa, V., Delous, M., Zaidan, M., Odye, G., Thomas, S., et al. 2016. Novel NEK8 
Mutations Cause Severe Syndromic Renal Cystic Dysplasia through YAP 
Dysregulation. PLoS Genet, 12, e1005894. 
Granados-Riveron, J. T., Ghosh, T. K., Pope, M., Bu'lock, F., Thornborough, C., et al. 
2010. Alpha-cardiac myosin heavy chain (MYH6) mutations affecting myofibril 
formation are associated with congenital heart defects. Hum Mol Genet, 19, 
4007-16. 
Granados-Riveron, J. T., Pope, M., Bu'lock, F. A., Thornborough, C., Eason, J., et al. 
2012. Combined mutation screening of NKX2-5, GATA4, and TBX5 in 
congenital heart disease: multiple heterozygosity and novel mutations. 
Congenit Heart Dis, 7, 151-9. 
Granata, A., Serrano, F., Bernard, W. G., Mcnamara, M., Low, L., et al. 2017. An iPSC-
derived vascular model of Marfan syndrome identifies key mediators of smooth 
muscle cell death. Nat Genet, 49, 97-109. 
Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., et al. 2013. ACMG 
recommendations for reporting of incidental findings in clinical exome and 
genome sequencing. Genet Med, 15, 565-74. 
Greenberg, F. 1987. Choanal atresia and athelia: methimazole teratogenicity or a new 
syndrome? Am J Med Genet, 28, 931-4. 
Greenway, S. C., Mcleod, R., Hume, S., Roslin, N. M., Alvarez, N., et al. 2014. Exome 
Sequencing Identifies a Novel Variant in ACTC1 Associated With Familial Atrial 
Septal Defect. Can J Cardiol, 30, 181-7. 
Griffiths, E. J. & Halestrap, A. P. 1993. Pyrophosphate metabolism in the perfused 
heart and isolated heart mitochondria and its role in regulation of mitochondrial 
function by calcium. Biochem J, 290 ( Pt 2), 489-95. 
Guest, S. S., Evans, C. D. & Winter, R. M. 1999. The Online London Dysmorphology 
Database. Genet Med, 1, 207-12. 
  
224 
Guimier, A., Gabriel, G. C., Bajolle, F., Tsang, M., Liu, H., et al. 2015. MMP21 is 
mutated in human heterotaxy and is required for normal left-right asymmetry in 
vertebrates. Nat Genet, 47, 1260-3. 
Guimier, A., Gordon, C. T., Godard, F., Ravenscroft, G., Oufadem, M., et al. 2016. 
Biallelic PPA2 Mutations Cause Sudden Unexpected Cardiac Arrest in Infancy. 
Am J Hum Genet, 99, 666-73. 
Guo, C., Chang, C. C., Wortham, M., Chen, L. H., Kernagis, D. N., et al. 2012. Global 
identification of MLL2-targeted loci reveals MLL2's role in diverse signaling 
pathways. Proc Natl Acad Sci U S A, 109, 17603-8. 
Guo, T., Chung, J. H., Wang, T., Mcdonald-Mcginn, D. M., Kates, W. R., et al. 2015. 
Histone Modifier Genes Alter Conotruncal Heart Phenotypes in 22q11.2 
Deletion Syndrome. Am J Hum Genet, 97, 869-77. 
Guyon, J. R., Steffen, L. S., Howell, M. H., Pusack, T. J., Lawrence, C., et al. 2007. 
Modeling human muscle disease in zebrafish. Biochim Biophys Acta, 1772, 
205-15. 
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., et al. 
2003. A serious adverse event after successful gene therapy for X-linked 
severe combined immunodeficiency. N Engl J Med, 348, 255-6. 
Hanchard, N. A., Swaminathan, S., Bucasas, K., Furthner, D., Fernbach, S., et al. 
2016. A genome-wide association study of congenital cardiovascular left-sided 
lesions shows association with a locus on chromosome 20. Hum Mol Genet, 
25, 2331-2341. 
Hang, C. T., Yang, J., Han, P., Cheng, H. L., Shang, C., et al. 2010. Chromatin 
regulation by Brg1 underlies heart muscle development and disease. Nature, 
466, 62-7. 
Hannibal, M. C., Buckingham, K. J., Ng, S. B., Ming, J. E., Beck, A. E., et al. 2011. 
Spectrum of MLL2 (ALR) mutations in 110 cases of Kabuki syndrome. Am J 
Med Genet A, 155A, 1511-6. 
Harris, P. C. & Rossetti, S. 2004. Molecular genetics of autosomal recessive polycystic 
kidney disease. Mol Genet Metab, 81, 75-85. 
Hehir-Kwa, J. Y., Claustres, M., Hastings, R. J., Van Ravenswaaij-Arts, C., 
Christenhusz, G., et al. 2015. Towards a European consensus for reporting 
incidental findings during clinical NGS testing. Eur J Hum Genet, 23, 1601-6. 
Heinonen, J. 2013. Biological Role of Inorganic Pyrophosphate, Springer Verlag. 
Helgason, C. D., Damen, J. E., Rosten, P., Grewal, R., Sorensen, P., et al. 1998. 
Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, 
and a shortened life span. Genes Dev, 12, 1610-20. 
Herman, M. A., Peroni, O. D., Villoria, J., Schon, M. R., Abumrad, N. A., et al. 2012. A 
novel ChREBP isoform in adipose tissue regulates systemic glucose 
metabolism. Nature, 484, 333-8. 
Hildebrandt, F., Benzing, T. & Katsanis, N. 2011. Ciliopathies. N Engl J Med, 364, 
1533-43. 
Hinton, R. B., Jr., Martin, L. J., Tabangin, M. E., Mazwi, M. L., Cripe, L. H., et al. 2007. 
Hypoplastic left heart syndrome is heritable. J Am Coll Cardiol, 50, 1590-5. 
Hirawat, S., Welch, E. M., Elfring, G. L., Northcutt, V. J., Paushkin, S., et al. 2007. 
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside 
nonsense mutation suppressor, following single- and multiple-dose 
administration to healthy male and female adult volunteers. J Clin Pharmacol, 
47, 430-44. 
Hiroi, Y., Kudoh, S., Monzen, K., Ikeda, Y., Yazaki, Y., et al. 2001. Tbx5 associates 
with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. Nat 
Genet, 28, 276-80. 
Hirokawa, N., Tanaka, Y. & Okada, Y. 2009. Left-right determination: involvement of 




Hisama, F. M., Reyes-Mugica, M., Wargowski, D. S., Thompson, K. J. & Mahoney, M. 
J. 1998. Renal tubular dysgenesis, absent nipples, and multiple malformations 
in three brothers: a new, lethal syndrome. Am J Med Genet, 80, 335-42. 
Hitz, M. P., Lemieux-Perreault, L. P., Marshall, C., Feroz-Zada, Y., Davies, R., et al. 
2012. Rare copy number variants contribute to congenital left-sided heart 
disease. PLoS Genet, 8, e1002903. 
Hoffman, J. I. & Kaplan, S. 2002. The incidence of congenital heart disease. J Am Coll 
Cardiol, 39, 1890-900. 
Hogan, M. C., Griffin, M. D., Rossetti, S., Torres, V. E., Ward, C. J., et al. 2003. 
PKHDL1, a homolog of the autosomal recessive polycystic kidney disease 
gene, encodes a receptor with inducible T lymphocyte expression. Hum Mol 
Genet, 12, 685-98. 
Holtzman, N. A. 2013. ACMG recommendations on incidental findings are flawed 
scientifically and ethically. Genet Med, 15, 750-1. 
Holzer, R. J., Sallehuddin, A. & Hijazi, Z. M. 2016. Surgical strategies and novel 
alternatives for the closure of ventricular septal defects. Expert Rev Cardiovasc 
Ther, 14, 831-41. 
Homsy, J., Zaidi, S., Shen, Y., Ware, J. S., Samocha, K. E., et al. 2015. De novo 
mutations in congenital heart disease with neurodevelopmental and other 
congenital anomalies. Science, 350, 1262-6. 
Horani, A., Brody, S. L. & Ferkol, T. W. 2014. Picking up speed: advances in the 
genetics of primary ciliary dyskinesia. Pediatr Res, 75, 158-64. 
Horani, A., Ferkol, T. W., Dutcher, S. K. & Brody, S. L. 2016. Genetics and biology of 
primary ciliary dyskinesia. Paediatr Respir Rev, 18, 18-24. 
Horn, D., Krawitz, P., Mannhardt, A., Korenke, G. C. & Meinecke, P. 2011. 
Hyperphosphatasia-mental retardation syndrome due to PIGV mutations: 
expanded clinical spectrum. Am J Med Genet A, 155A, 1917-22. 
Horn, D., Wieczorek, D., Metcalfe, K., Baric, I., Palezac, L., et al. 2014. Delineation of 
PIGV mutation spectrum and associated phenotypes in hyperphosphatasia with 
mental retardation syndrome. Eur J Hum Genet, 22, 762-7. 
Horvath, G. A. & Armstrong, L. 2007. Report of a fourth individual with a lethal 
syndrome of choanal atresia, athelia, evidence of renal tubulopathy, and family 
history of neck cysts. Am J Med Genet A, 143A, 1231-5. 
Howard, M. F., Murakami, Y., Pagnamenta, A. T., Daumer-Haas, C., Fischer, B., et al. 
2014. Mutations in PGAP3 impair GPI-anchor maturation, causing a subtype of 
hyperphosphatasia with mental retardation. Am J Hum Genet, 94, 278-87. 
Hu, Z., Shi, Y., Mo, X., Xu, J., Zhao, B., et al. 2013. A genome-wide association study 
identifies two risk loci for congenital heart malformations in Han Chinese 
populations. Nat Genet, 45, 818-21. 
Iascone, M., Ciccone, R., Galletti, L., Marchetti, D., Seddio, F., et al. 2012. 
Identification of de novo mutations and rare variants in hypoplastic left heart 
syndrome. Clin Genet, 81, 542-54. 
Ikura, T., Ogryzko, V. V., Grigoriev, M., Groisman, R., Wang, J., et al. 2000. 
Involvement of the TIP60 histone acetylase complex in DNA repair and 
apoptosis. Cell, 102, 463-73. 
Ilkovski, B., Pagnamenta, A. T., O'grady, G. L., Kinoshita, T., Howard, M. F., et al. 
2015. Mutations in PIGY: expanding the phenotype of inherited 
glycosylphosphatidylinositol deficiencies. Hum Mol Genet, 24, 6146-59. 
Inaba, Y., Shinohara, K., Botilde, Y., Nabeshima, R., Takaoka, K., et al. 2016. 
Transport of the outer dynein arm complex to cilia requires a cytoplasmic 
protein Lrrc6. Genes Cells, 21, 728-39. 
Ipe, J., Swart, M., Burgess, K. S. & Skaar, T. C. 2017. High-Throughput Assays to 
Assess the Functional Impact of Genetic Variants: A Road Towards Genomic-
Driven Medicine. Clin Transl Sci, 10, 67-77. 
  
226 
Ishino, Y., Shinagawa, H., Makino, K., Amemura, M. & Nakata, A. 1987. Nucleotide 
sequence of the iap gene, responsible for alkaline phosphatase isozyme 
conversion in Escherichia coli, and identification of the gene product. J 
Bacteriol, 169, 5429-33. 
Issaeva, I., Zonis, Y., Rozovskaia, T., Orlovsky, K., Croce, C. M., et al. 2007. 
Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in 
cell adhesion and growth. Mol Cell Biol, 27, 1889-903. 
Jenkins, K. J., Correa, A., Feinstein, J. A., Botto, L., Britt, A. E., et al. 2007. 
Noninherited risk factors and congenital cardiovascular defects: current 
knowledge: a scientific statement from the American Heart Association Council 
on Cardiovascular Disease in the Young: endorsed by the American Academy 
of Pediatrics. Circulation, 115, 2995-3014. 
Jerome, L. A. & Papaioannou, V. E. 2001. DiGeorge syndrome phenotype in mice 
mutant for the T-box gene, Tbx1. Nat Genet, 27, 286-91. 
Jha, S. & Dutta, A. 2009. RVB1/RVB2: running rings around molecular biology. Mol 
Cell, 34, 521-33. 
Jia, Y., Louw, J. J., Breckpot, J., Callewaert, B., Barrea, C., et al. 2015. The diagnostic 
value of next generation sequencing in familial nonsyndromic congenital heart 
defects. Am J Med Genet A, 167A, 1822-9. 
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., et al. 2012. A 
programmable dual-RNA-guided DNA endonuclease in adaptive bacterial 
immunity. Science, 337, 816-21. 
Jones, C. A., London, N. R., Chen, H., Park, K. W., Sauvaget, D., et al. 2008. Robo4 
stabilizes the vascular network by inhibiting pathologic angiogenesis and 
endothelial hyperpermeability. Nat Med, 14, 448-53. 
Jones, J. M. & Koch, W. J. 2005. Gene therapy approaches to cardiovascular disease. 
Methods Mol Med, 112, 15-35. 
Jonsson, Z. O., Dhar, S. K., Narlikar, G. J., Auty, R., Wagle, N., et al. 2001. Rvb1p and 
Rvb2p are essential components of a chromatin remodeling complex that 
regulates transcription of over 5% of yeast genes. J Biol Chem, 276, 16279-88. 
Jose, T., Gdynia, H. J., Mahrholdt, H., Vohringer, M., Klingel, K., et al. 2011. CMR 
gives clue to "ragged red fibers" in the heart in a patient with mitochondrial 
myopathy. Int J Cardiol, 149, e24-7. 
Kaab, S. & Schulze-Bahr, E. 2005. Susceptibility genes and modifiers for cardiac 
arrhythmias. Cardiovasc Res, 67, 397-413. 
Karijolich, J. & Yu, Y. T. 2011. Converting nonsense codons into sense codons by 
targeted pseudouridylation. Nature, 474, 395-8. 
Karp, N., Grosse-Wortmann, L. & Bowdin, S. 2012. Severe aortic stenosis, bicuspid 
aortic valve and atrial septal defect in a child with Joubert Syndrome and 
Related Disorders (JSRD) - a case report and review of congenital heart 
defects reported in the human ciliopathies. Eur J Med Genet, 55, 605-10. 
Katsanis, S. H. & Katsanis, N. 2013. Molecular genetic testing and the future of clinical 
genomics. Nat Rev Genet, 14, 415-26. 
Katsuhara, K., Kawamoto, S., Wakabayashi, T. & Belsky, J. L. 1972. Situs inversus 
totalis and Kartagener's syndrome in a Japanese population. Chest, 61, 56-61. 
Keeling, K. M., Xue, X., Gunn, G. & Bedwell, D. M. 2014. Therapeutics based on stop 
codon readthrough. Annu Rev Genomics Hum Genet, 15, 371-94. 
Keller, P. J., Schmidt, A. D., Santella, A., Khairy, K., Bao, Z., et al. 2010. Fast, high-
contrast imaging of animal development with scanned light sheet-based 
structured-illumination microscopy. Nat Meth, 7, 637-642. 
Kennedy, H., Haack, T. B., Hartill, V., Matakovic, L., Baumgartner, E. R., et al. 2016. 
Sudden Cardiac Death Due to Deficiency of the Mitochondrial Inorganic 
Pyrophosphatase PPA2. Am J Hum Genet, 99, 674-82. 
  
227 
Kennedy, M. P., Omran, H., Leigh, M. W., Dell, S., Morgan, L., et al. 2007. Congenital 
heart disease and other heterotaxic defects in a large cohort of patients with 
primary ciliary dyskinesia. Circulation, 115, 2814-21. 
Kerem, E., Konstan, M. W., De Boeck, K., Accurso, F. J., Sermet-Gaudelus, I., et al. 
2014. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a 
randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med, 
2, 539-47. 
Kerstjens-Frederikse, W. S., Van De Laar, I. M., Vos, Y. J., Verhagen, J. M., Berger, R. 
M., et al. 2016. Cardiovascular malformations caused by NOTCH1 mutations do 
not keep left: data on 428 probands with left-sided CHD and their families. 
Genet Med, 18, 914-23. 
Kim, T. G., Chen, J., Sadoshima, J. & Lee, Y. 2004. Jumonji represses atrial natriuretic 
factor gene expression by inhibiting transcriptional activities of cardiac 
transcription factors. Mol Cell Biol, 24, 10151-60. 
Kircher, M., Witten, D. M., Jain, P., O'roak, B. J., Cooper, G. M., et al. 2014. A general 
framework for estimating the relative pathogenicity of human genetic variants. 
Nat Genet, 46, 310-5. 
Kirshbom, P. M., Mahle, W. T., Joyner, R. W., Leong, T., Wilson, M., et al. 2008. The 
endothelin-1 G5665T polymorphism impacts transplant-free survival for single 
ventricle patients. J Thorac Cardiovasc Surg, 136, 117-22. 
Klattenhoff, C. A., Scheuermann, J. C., Surface, L. E., Bradley, R. K., Fields, P. A., et 
al. 2013. Braveheart, a long noncoding RNA required for cardiovascular lineage 
commitment. Cell, 152, 570-83. 
Klaver, E. C., Versluijs, G. M. & Wilders, R. 2011. Cardiac ion channel mutations in the 
sudden infant death syndrome. Int J Cardiol, 152, 162-70. 
Knoppers, B. M., Zawati, M. H. & Senecal, K. 2015. Return of genetic testing results in 
the era of whole-genome sequencing. Nat Rev Genet, 16, 553-9. 
Kodo, K., Nishizawa, T., Furutani, M., Arai, S., Yamamura, E., et al. 2009. GATA6 
mutations cause human cardiac outflow tract defects by disrupting semaphorin-
plexin signaling. Proc Natl Acad Sci U S A, 106, 13933-8. 
Koike-Yusa, H., Li, Y., Tan, E. P., Velasco-Herrera Mdel, C. & Yusa, K. 2014. Genome-
wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-
guide RNA library. Nat Biotechnol, 32, 267-73. 
Koop, E. A., Gebbink, M. F., Sweeney, T. E., Mathy, M. J., Heijnen, H. F., et al. 2005. 
Impaired flow-induced dilation in mesenteric resistance arteries from receptor 
protein tyrosine phosphatase-mu-deficient mice. Am J Physiol Heart Circ 
Physiol, 288, H1218-23. 
Krawitz, P. M., Murakami, Y., Hecht, J., Kruger, U., Holder, S. E., et al. 2012. Mutations 
in PIGO, a member of the GPI-anchor-synthesis pathway, cause 
hyperphosphatasia with mental retardation. Am J Hum Genet, 91, 146-51. 
Krawitz, P. M., Murakami, Y., Riess, A., Hietala, M., Kruger, U., et al. 2013. PGAP2 
mutations, affecting the GPI-anchor-synthesis pathway, cause 
hyperphosphatasia with mental retardation syndrome. Am J Hum Genet, 92, 
584-9. 
Krawitz, P. M., Schweiger, M. R., Rodelsperger, C., Marcelis, C., Kolsch, U., et al. 
2010. Identity-by-descent filtering of exome sequence data identifies PIGV 
mutations in hyperphosphatasia mental retardation syndrome. Nat Genet, 42, 
827-9. 
Kumar, P., Sait, S. F., Sharma, A. & Kumar, M. 2011. Ovarian hyperstimulation 
syndrome. J Hum Reprod Sci, 4, 70-5. 
Kurzrock, R., Kantarjian, H. M., Druker, B. J. & Talpaz, M. 2003. Philadelphia 
chromosome-positive leukemias: from basic mechanisms to molecular 
therapeutics. Ann Intern Med, 138, 819-30. 
  
228 
Lahaye, S., Corsmeier, D., Basu, M., Bowman, J. L., Fitzgerald-Butt, S., et al. 2016. 
Utilization of Whole Exome Sequencing to Identify Causative Mutations in 
Familial Congenital Heart Disease. Circ Cardiovasc Genet, 9, 320-9. 
Laity, J. H., Lee, B. M. & Wright, P. E. 2001. Zinc finger proteins: new insights into 
structural and functional diversity. Curr Opin Struct Biol, 11, 39-46. 
Lakdawala, N. K. 2013. Using genetic testing to guide therapeutic decisions in 
cardiomyopathy. Curr Treat Options Cardiovasc Med, 15, 387-96. 
Lakshminarasimhan, M., Boanca, G., Banks, C. A., Hattem, G. L., Gabriel, A. E., et al. 
2016. Proteomic and Genomic Analyses of the Rvb1 and Rvb2 Interaction 
Network upon Deletion of R2TP Complex Components. Mol Cell Proteomics, 
15, 960-74. 
Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., et al. 2001. Initial 
sequencing and analysis of the human genome. Nature, 409, 860-921. 
Landis, B. J. & Ware, S. M. 2016. The Current Landscape of Genetic Testing in 
Cardiovascular Malformations: Opportunities and Challenges. Front Cardiovasc 
Med, 3, 22. 
Lanphier, E., Urnov, F., Haecker, S. E., Werner, M. & Smolenski, J. 2015. Don't edit 
the human germ line. Nature, 519, 410-1. 
Lee, Y., Song, A. J., Baker, R., Micales, B., Conway, S. J., et al. 2000. Jumonji, a 
nuclear protein that is necessary for normal heart development. Circ Res, 86, 
932-8. 
Leonardi, M. L., Pai, G. S., Wilkes, B. & Lebel, R. R. 2001. Ritscher-Schinzel cranio-
cerebello-cardiac (3C) syndrome: report of four new cases and review. Am J 
Med Genet, 102, 237-42. 
Li, H. & Durbin, R. 2009. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics, 25, 1754-60. 
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., et al. 2009. The Sequence 
Alignment/Map format and SAMtools. Bioinformatics, 25, 2078-9. 
Li, J., Cao, Y., Ma, X. J., Wang, H. J., Zhang, J., et al. 2013. Roles of miR-1-1 and 
miR-181c in ventricular septal defects. Int J Cardiol, 168, 1441-6. 
Li, Y., Klena, N. T., Gabriel, G. C., Liu, X., Kim, A. J., et al. 2015. Global genetic 
analysis in mice unveils central role for cilia in congenital heart disease. Nature, 
521, 520-4. 
Lian, X., Xu, J., Li, J. & Chien, K. R. 2014. Next-generation models of human 
cardiogenesis via genome editing. Cold Spring Harb Perspect Med, 4, 
a013920. 
Lickert, H., Takeuchi, J. K., Von Both, I., Walls, J. R., Mcauliffe, F., et al. 2004. Baf60c 
is essential for function of BAF chromatin remodelling complexes in heart 
development. Nature, 432, 107-12. 
Lien, C. L., Wu, C., Mercer, B., Webb, R., Richardson, J. A., et al. 1999. Control of 
early cardiac-specific transcription of Nkx2-5 by a GATA-dependent enhancer. 
Development, 126, 75-84. 
Lin, C. J., Lin, C. Y., Chen, C. H., Zhou, B. & Chang, C. P. 2012. Partitioning the heart: 
mechanisms of cardiac septation and valve development. Development, 139, 
3277-99. 
Lintas, C. & Persico, A. M. 2017. Unraveling molecular pathways shared by Kabuki and 
Kabuki-like syndromes. Clin Genet. 
Liu, N., Bezprozvannaya, S., Williams, A. H., Qi, X., Richardson, J. A., et al. 2008. 
microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth 
muscle gene expression in the heart. Genes Dev, 22, 3242-54. 
Liu, Q., Shalaby, F., Jones, J., Bouchard, D. & Dumont, D. J. 1998. The SH2-
containing inositol polyphosphate 5-phosphatase, ship, is expressed during 
hematopoiesis and spermatogenesis. Blood, 91, 2753-9. 
  
229 
Liu, S., Lu, W., Obara, T., Kuida, S., Lehoczky, J., et al. 2002. A defect in a novel Nek-
family kinase causes cystic kidney disease in the mouse and in zebrafish. 
Development, 129, 5839-46. 
Liu, X. S., Wu, H., Ji, X., Stelzer, Y., Wu, X., et al. 2016. Editing DNA Methylation in the 
Mammalian Genome. Cell, 167, 233-247 e17. 
Lizen, B., Hutlet, B., Bissen, D., Sauvegarde, D., Hermant, M., et al. 2017. HOXA5 
localization in postnatal and adult mouse brain is suggestive of regulatory roles 
in postmitotic neurons. J Comp Neurol, 525, 1155-1175. 
Loges, N. T., Olbrich, H., Becker-Heck, A., Haffner, K., Heer, A., et al. 2009. Deletions 
and point mutations of LRRC50 cause primary ciliary dyskinesia due to dynein 
arm defects. Am J Hum Genet, 85, 883-9. 
Lough, J. W. 2002. Transient expression of TIP60 protein during early chick heart 
development. Dev Dyn, 223, 419-25. 
Lundin, M., Baltscheffsky, H. & Ronne, H. 1991. Yeast PPA2 gene encodes a 
mitochondrial inorganic pyrophosphatase that is essential for mitochondrial 
function. J Biol Chem, 266, 12168-72. 
Macarthur, D. G., Manolio, T. A., Dimmock, D. P., Rehm, H. L., Shendure, J., et al. 
2014. Guidelines for investigating causality of sequence variants in human 
disease. Nature, 508, 469-76. 
Mainwaring, R. D., Lamberti, J. J. & Uzark, K. 1994. The bidirectional Glenn procedure: 
palliation of the univentricular heart. Adv Card Surg, 5, 115-40. 
Malicki, J. J. & Johnson, C. A. 2017. The Cilium: Cellular Antenna and Central 
Processing Unit. Trends Cell Biol, 27, 126-140. 
Mather, C. A., Mooney, S. D., Salipante, S. J., Scroggins, S., Wu, D., et al. 2016. 
CADD score has limited clinical validity for the identification of pathogenic 
variants in noncoding regions in a hereditary cancer panel. Genet Med, 18, 
1269-1275. 
Matsson, H., Eason, J., Bookwalter, C. S., Klar, J., Gustavsson, P., et al. 2008. Alpha-
cardiac actin mutations produce atrial septal defects. Hum Mol Genet, 17, 256-
65. 
Matsumoto, N. & Niikawa, N. 2003. Kabuki make-up syndrome: a review. Am J Med 
Genet C Semin Med Genet, 117C, 57-65. 
Mauser, W. S. & Bonnemeier, H. 2012. Cardiomyopathy and sudden cardiac death in 
Williams-Beuren-syndrome. Int J Cardiol, 156, e53-4. 
Mayr, J. A., Havlickova, V., Zimmermann, F., Magler, I., Kaplanova, V., et al. 2010. 
Mitochondrial ATP synthase deficiency due to a mutation in the ATP5E gene for 
the F1 epsilon subunit. Hum Mol Genet, 19, 3430-9. 
Mcbride, K. L., Pignatelli, R., Lewin, M., Ho, T., Fernbach, S., et al. 2005. Inheritance 
analysis of congenital left ventricular outflow tract obstruction malformations: 
Segregation, multiplex relative risk, and heritability. Am J Med Genet A, 134A, 
180-6. 
Mcbride, K. L., Riley, M. F., Zender, G. A., Fitzgerald-Butt, S. M., Towbin, J. A., et al. 
2008. NOTCH1 mutations in individuals with left ventricular outflow tract 
malformations reduce ligand-induced signaling. Hum Mol Genet, 17, 2886-93. 
Mccarroll, S. A. & Altshuler, D. M. 2007. Copy-number variation and association 
studies of human disease. Nat Genet, 39, S37-42. 
Mcculley, D. J. & Black, B. L. 2012. Transcription factor pathways and congenital heart 
disease. Curr Top Dev Biol, 100, 253-77. 
Mcinerney-Leo, A. M., Harris, J. E., Gattas, M., Peach, E. E., Sinnott, S., et al. 2016. 
Fryns Syndrome Associated with Recessive Mutations in PIGN in two Separate 
Families. Hum Mutat, 37, 695-702. 
Mcintyre, J. C., Davis, E. E., Joiner, A., Williams, C. L., Tsai, I. C., et al. 2012. Gene 
therapy rescues cilia defects and restores olfactory function in a mammalian 
ciliopathy model. Nat Med, 18, 1423-8. 
  
230 
Mckellar, S. H., Tester, D. J., Yagubyan, M., Majumdar, R., Ackerman, M. J., et al. 
2007. Novel NOTCH1 mutations in patients with bicuspid aortic valve disease 
and thoracic aortic aneurysms. J Thorac Cardiovasc Surg, 134, 290-6. 
Mclaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P., et al. 2010. Deriving the 
consequences of genomic variants with the Ensembl API and SNP Effect 
Predictor. Bioinformatics, 26, 2069-70. 
Merla, G., Howald, C., Antonarakis, S. E. & Reymond, A. 2004. The subcellular 
localization of the ChoRE-binding protein, encoded by the Williams-Beuren 
syndrome critical region gene 14, is regulated by 14-3-3. Hum Mol Genet, 13, 
1505-14. 
Ming, J. E., Russell, K. L., Bason, L., Mcdonald-Mcginn, D. M. & Zackai, E. H. 2003. 
Coloboma and other ophthalmologic anomalies in Kabuki syndrome: distinction 
from charge association. Am J Med Genet A, 123A, 249-52. 
Ming, L., Wilk, R., Reed, B. H. & Lipshitz, H. D. 2013. Drosophila Hindsight and 
mammalian RREB-1 are evolutionarily conserved DNA-binding transcriptional 
attenuators. Differentiation, 86, 159-70. 
Mitchell, A. A., Zwick, M. E., Chakravarti, A. & Cutler, D. J. 2004. Discrepancies in 
dbSNP confirmation rates and allele frequency distributions from varying 
genotyping error rates and patterns. Bioinformatics, 20, 1022-32. 
Mitchell, M. E., Sander, T. L., Klinkner, D. B. & Tomita-Mitchell, A. 2007. The molecular 
basis of congenital heart disease. Semin Thorac Cardiovasc Surg, 19, 228-37. 
Mitchison, H. M., Schmidts, M., Loges, N. T., Freshour, J., Dritsoula, A., et al. 2012. 
Mutations in axonemal dynein assembly factor DNAAF3 cause primary ciliary 
dyskinesia. Nat Genet, 44, 381-9, S1-2. 
Miyague, N. I., Cardoso, S. M., Meyer, F., Ultramari, F. T., Araujo, F. H., et al. 2003. 
Epidemiological study of congenital heart defects in children and adolescents. 
Analysis of 4,538 cases. Arq Bras Cardiol, 80, 269-78. 
Mo, R., Rao, S. M. & Zhu, Y. J. 2006. Identification of the MLL2 complex as a 
coactivator for estrogen receptor alpha. J Biol Chem, 281, 15714-20. 
Moller, J. H. & Anderson, R. C. 2013. A 43- to 54-year follow-up of 1,000 patients with 
congenital heart disease. Am J Cardiol, 111, 1496-500. 
Mommersteeg, M. T., Andrews, W. D., Ypsilanti, A. R., Zelina, P., Yeh, M. L., et al. 
2013. Slit-roundabout signaling regulates the development of the cardiac 
systemic venous return and pericardium. Circ Res, 112, 465-75. 
Moniz, L., Dutt, P., Haider, N. & Stambolic, V. 2011. Nek family of kinases in cell cycle, 
checkpoint control and cancer. Cell Div, 6, 18. 
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., et al. 2011. 
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. 
Nature, 476, 298-303. 
Morton, S. U., Scherz, P. J., Cordes, K. R., Ivey, K. N., Stainier, D. Y., et al. 2008. 
microRNA-138 modulates cardiac patterning during embryonic development. 
Proc Natl Acad Sci U S A, 105, 17830-5. 
Moser, E., Kargl, J., Whistler, J. L., Waldhoer, M. & Tschische, P. 2010. G protein-
coupled receptor-associated sorting protein 1 regulates the postendocytic 
sorting of seven-transmembrane-spanning G protein-coupled receptors. 
Pharmacology, 86, 22-9. 
Moskowitz, I. P., Wang, J., Peterson, M. A., Pu, W. T., Mackinnon, A. C., et al. 2011. 
Transcription factor genes Smad4 and Gata4 cooperatively regulate cardiac 
valve development. [corrected]. Proc Natl Acad Sci U S A, 108, 4006-11. 
Moustafa, G. A., Kolokythas, A., Charitakis, K. & Avgerinos, D. V. 2016. Therapeutic 
Utilities of Pediatric Cardiac Catheterization. Curr Cardiol Rev, 12, 258-269. 
Murakami, Y., Kanzawa, N., Saito, K., Krawitz, P. M., Mundlos, S., et al. 2012. 
Mechanism for release of alkaline phosphatase caused by 
glycosylphosphatidylinositol deficiency in patients with hyperphosphatasia 
mental retardation syndrome. J Biol Chem, 287, 6318-25. 
  
231 
Mussolino, C., Morbitzer, R., Lutge, F., Dannemann, N., Lahaye, T., et al. 2011. A 
novel TALE nuclease scaffold enables high genome editing activity in 
combination with low toxicity. Nucleic Acids Res, 39, 9283-93. 
Nakamura, T., Saito, D., Kawasumi, A., Shinohara, K., Asai, Y., et al. 2012. Fluid flow 
and interlinked feedback loops establish left-right asymmetric decay of Cerl2 
mRNA. Nat Commun, 3, 1322. 
Nakhleh, N., Francis, R., Giese, R. A., Tian, X., Li, Y., et al. 2012. High prevalence of 
respiratory ciliary dysfunction in congenital heart disease patients with 
heterotaxy. Circulation, 125, 2232-42. 
Naldini, L. 2015. Gene therapy returns to centre stage. Nature, 526, 351-60. 
Nance, M. E., Hakim, C. H., Yang, N. N. & Duan, D. 2017. Nanotherapy for Duchenne 
muscular dystrophy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 
Ng, P. C. & Henikoff, S. 2003. SIFT: Predicting amino acid changes that affect protein 
function. Nucleic Acids Res, 31, 3812-4. 
Ng, S. B., Bigham, A. W., Buckingham, K. J., Hannibal, M. C., Mcmillin, M. J., et al. 
2010. Exome sequencing identifies MLL2 mutations as a cause of Kabuki 
syndrome. Nat Genet, 42, 790-3. 
Ni, W., Liu, T., Wang, H. Y., Liu, L. H. & Chen, G. X. 2016. [Expression of Slit3/Robo 
signal pathway in mouse aortic smooth muscle cell and its impact on 
proliferation and migration]. Zhonghua Xin Xue Guan Bing Za Zhi, 44, 542-7. 
Nicastro, D., Schwartz, C., Pierson, J., Gaudette, R., Porter, M. E., et al. 2006. The 
molecular architecture of axonemes revealed by cryoelectron tomography. 
Science, 313, 944-8. 
Niessen, K. & Karsan, A. 2008. Notch signaling in cardiac development. Circ Res, 102, 
1169-81. 
Nistri, S., Basso, C., Marzari, C., Mormino, P. & Thiene, G. 2005. Frequency of 
bicuspid aortic valve in young male conscripts by echocardiogram. Am J 
Cardiol, 96, 718-21. 
Nolasco, S., Bellido, J., Goncalves, J., Zabala, J. C. & Soares, H. 2005. Tubulin 
cofactor A gene silencing in mammalian cells induces changes in microtubule 
cytoskeleton, cell cycle arrest and cell death. FEBS Lett, 579, 3515-24. 
Nonaka, S., Shiratori, H., Saijoh, Y. & Hamada, H. 2002. Determination of left-right 
patterning of the mouse embryo by artificial nodal flow. Nature, 418, 96-9. 
Norris, D. P. 2012. Cilia, calcium and the basis of left-right asymmetry. BMC Biol, 10, 
102. 
O'brien, J. E., Jr., Kibiryeva, N., Zhou, X. G., Marshall, J. A., Lofland, G. K., et al. 2012. 
Noncoding RNA expression in myocardium from infants with tetralogy of Fallot. 
Circ Cardiovasc Genet, 5, 279-86. 
Omran, H., Kobayashi, D., Olbrich, H., Tsukahara, T., Loges, N. T., et al. 2008. 
Ktu/PF13 is required for cytoplasmic pre-assembly of axonemal dyneins. 
Nature, 456, 611-6. 
Ono, K., Kuwabara, Y. & Han, J. 2011. MicroRNAs and cardiovascular diseases. FEBS 
J, 278, 1619-33. 
Oshima, Y., Yamamoto, T., Ishikawa, T., Mishima, H., Matsusue, A., et al. 2017. 
Postmortem genetic analysis of sudden unexpected death in infancy: neonatal 
genetic screening may enable the prevention of sudden infant death. J Hum 
Genet. 
Otsuka, F., Sakakura, K., Yahagi, K., Joner, M. & Virmani, R. 2014. Has our 
understanding of calcification in human coronary atherosclerosis progressed? 
Arterioscler Thromb Vasc Biol, 34, 724-36. 
Ow, Y. P., Green, D. R., Hao, Z. & Mak, T. W. 2008. Cytochrome c: functions beyond 
respiration. Nat Rev Mol Cell Biol, 9, 532-42. 
Paci, A., Liu, X. H., Huang, H., Lim, A., Houry, W. A., et al. 2012. The stability of the 
small nucleolar ribonucleoprotein (snoRNP) assembly protein Pih1 in 
  
232 
Saccharomyces cerevisiae is modulated by its C terminus. J Biol Chem, 287, 
43205-14. 
Paff, T., Loges, N. T., Aprea, I., Wu, K., Bakey, Z., et al. 2017. Mutations in PIH1D3 
Cause X-Linked Primary Ciliary Dyskinesia with Outer and Inner Dynein Arm 
Defects. Am J Hum Genet, 100, 160-168. 
Paige, S. L., Thomas, S., Stoick-Cooper, C. L., Wang, H., Maves, L., et al. 2012. A 
temporal chromatin signature in human embryonic stem cells identifies 
regulators of cardiac development. Cell, 151, 221-32. 
Parry, D. A., Logan, C. V., Stegmann, A. P., Abdelhamed, Z. A., Calder, A., et al. 2013. 
SAMS, a syndrome of short stature, auditory-canal atresia, mandibular 
hypoplasia, and skeletal abnormalities is a unique neurocristopathy caused by 
mutations in Goosecoid. Am J Hum Genet, 93, 1135-42. 
Pashmforoush, M., Lu, J. T., Chen, H., Amand, T. S., Kondo, R., et al. 2004. Nkx2-5 
pathways and congenital heart disease; loss of ventricular myocyte lineage 
specification leads to progressive cardiomyopathy and complete heart block. 
Cell, 117, 373-86. 
Patel, N. & Alkuraya, F. S. 2015. Overlap between CHARGE and Kabuki syndromes: 
more than an interesting clinical observation? Am J Med Genet A, 167A, 259-
60. 
Patel, S., Jones, R. B., Nixon, D. F. & Bollard, C. M. 2016. T-cell therapies for HIV: 
Preclinical successes and current clinical strategies. Cytotherapy, 18, 931-42. 
Pazour, G. J., Baker, S. A., Deane, J. A., Cole, D. G., Dickert, B. L., et al. 2002. The 
intraflagellar transport protein, IFT88, is essential for vertebrate photoreceptor 
assembly and maintenance. J Cell Biol, 157, 103-13. 
Pediatric Cardiac Genomics Consortium, Gelb, B., Brueckner, M., Chung, W., 
Goldmuntz, E., et al. 2013. The Congenital Heart Disease Genetic Network 
Study: rationale, design, and early results. Circ Res, 112, 698-706. 
Pehlivan, T., Pober, B. R., Brueckner, M., Garrett, S., Slaugh, R., et al. 1999. GATA4 
haploinsufficiency in patients with interstitial deletion of chromosome region 
8p23.1 and congenital heart disease. Am J Med Genet, 83, 201-6. 
Peiffer, D. A., Le, J. M., Steemers, F. J., Chang, W., Jenniges, T., et al. 2006. High-
resolution genomic profiling of chromosomal aberrations using Infinium whole-
genome genotyping. Genome Res, 16, 1136-48. 
Perles, Z., Moon, S., Ta-Shma, A., Yaacov, B., Francescatto, L., et al. 2015. A human 
laterality disorder caused by a homozygous deleterious mutation in MMP21. J 
Med Genet, 52, 840-7. 
Peterson, K. M., Franchi, F., Loeffler, D. L., Psaltis, P. J., Harris, P. C., et al. 2013. 
Endothelial dysfunction occurs prior to clinical evidence of polycystic kidney 
disease. Am J Nephrol, 38, 233-40. 
Pfendner, E. & Uitto, J. 2005. Plectin gene mutations can cause epidermolysis bullosa 
with pyloric atresia. J Invest Dermatol, 124, 111-5. 
Pierpont, M. E., Basson, C. T., Benson, D. W., Jr., Gelb, B. D., Giglia, T. M., et al. 
2007. Genetic basis for congenital heart defects: current knowledge: a scientific 
statement from the American Heart Association Congenital Cardiac Defects 
Committee, Council on Cardiovascular Disease in the Young: endorsed by the 
American Academy of Pediatrics. Circulation, 115, 3015-38. 
Pikkarainen, S., Tokola, H., Kerkela, R. & Ruskoaho, H. 2004. GATA transcription 
factors in the developing and adult heart. Cardiovasc Res, 63, 196-207. 
Plagnol, V., Curtis, J., Epstein, M., Mok, K. Y., Stebbings, E., et al. 2012. A robust 
model for read count data in exome sequencing experiments and implications 
for copy number variant calling. Bioinformatics, 28, 2747-54. 
Postma, A. V., Bezzina, C. R. & Christoffels, V. M. 2016. Genetics of congenital heart 




Postma, A. V., Van Engelen, K., Van De Meerakker, J., Rahman, T., Probst, S., et al. 
2011. Mutations in the sarcomere gene MYH7 in Ebstein anomaly. Circ 
Cardiovasc Genet, 4, 43-50. 
Prus, W. & Filipek, A. 2011. S100A6 mediates nuclear translocation of Sgt1: a heat 
shock-regulated protein. Amino Acids, 41, 781-7. 
Pulkkinen, L., Smith, F. J., Shimizu, H., Murata, S., Yaoita, H., et al. 1996. 
Homozygous deletion mutations in the plectin gene (PLEC1) in patients with 
epidermolysis bullosa simplex associated with late-onset muscular dystrophy. 
Hum Mol Genet, 5, 1539-46. 
Pytela, R. & Wiche, G. 1980. High molecular weight polypeptides (270,000-340,000) 
from cultured cells are related to hog brain microtubule-associated proteins but 
copurify with intermediate filaments. Proc Natl Acad Sci U S A, 77, 4808-12. 
Qazi, Q. H., Kanchanapoomi, R., Beller, E. & Collins, R. 1982. Inheritance of posterior 
choanal atresia. Am J Med Genet, 13, 413-6. 
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., et al. 2013. 
Repurposing CRISPR as an RNA-guided platform for sequence-specific control 
of gene expression. Cell, 152, 1173-83. 
Rajagopalan, R., Grochowski, C. M., Gilbert, M. A., Falsey, A. M., Coleman, K., et al. 
2016. Compound heterozygous mutations in NEK8 in siblings with end-stage 
renal disease with hepatic and cardiac anomalies. Am J Med Genet A, 170, 
750-3. 
Ramsdell, A. F. 2005. Left-right asymmetry and congenital cardiac defects: getting to 
the heart of the matter in vertebrate left-right axis determination. Dev Biol, 288, 
1-20. 
Ran, F. A., Hsu, P. D., Lin, C. Y., Gootenberg, J. S., Konermann, S., et al. 2013. 
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing 
specificity. Cell, 154, 1380-9. 
Randall, V., Mccue, K., Roberts, C., Kyriakopoulou, V., Beddow, S., et al. 2009. Great 
vessel development requires biallelic expression of Chd7 and Tbx1 in 
pharyngeal ectoderm in mice. J Clin Invest, 119, 3301-10. 
Reamon-Buettner, S. M. & Borlak, J. 2004. TBX5 mutations in non-Holt-Oram 
syndrome (HOS) malformed hearts. Hum Mutat, 24, 104. 
Reller, M. D., Strickland, M. J., Riehle-Colarusso, T., Mahle, W. T. & Correa, A. 2008. 
Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J 
Pediatr, 153, 807-13. 
Requena, T., Cabrera, S., Martin-Sierra, C., Price, S. D., Lysakowski, A., et al. 2015. 
Identification of two novel mutations in FAM136A and DTNA genes in 
autosomal-dominant familial Meniere's disease. Hum Mol Genet, 24, 1119-26. 
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., et al. 2015. Standards and guidelines 
for the interpretation of sequence variants: a joint consensus recommendation 
of the American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology. Genet Med, 17, 405-24. 
Richter-Cook, N. J., Dever, T. E., Hensold, J. O. & Merrick, W. C. 1998. Purification 
and characterization of a new eukaryotic protein translation factor. Eukaryotic 
initiation factor 4H. J Biol Chem, 273, 7579-87. 
Rivera-Feliciano, J., Lee, K. H., Kong, S. W., Rajagopal, S., Ma, Q., et al. 2006. 
Development of heart valves requires Gata4 expression in endothelial-derived 
cells. Development, 133, 3607-18. 
Robinson, J. T., Thorvaldsdottir, H., Winckler, W., Guttman, M., Lander, E. S., et al. 
2011. Integrative genomics viewer. Nat Biotech, 29, 24-26. 
Rodriguez-Balada, M., Roig, B., Martorell, L., Mele, M., Salvat, M., et al. 2016. In silico, 
in vitro and case-control analyses as an effective combination for analyzing 
BRCA1 and BRCA2 unclassified variants in a population-based sample. Cancer 
Genet, 209, 487-492. 
  
234 
Rosenbaum, J., Baek, S. H., Dutta, A., Houry, W. A., Huber, O., et al. 2013. The 
emergence of the conserved AAA+ ATPases Pontin and Reptin on the 
signaling landscape. Sci Signal, 6, mr1. 
Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., et al. 1990. 
Gene transfer into humans--immunotherapy of patients with advanced 
melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene 
transduction. N Engl J Med, 323, 570-8. 
Rottbauer, W., Saurin, A. J., Lickert, H., Shen, X., Burns, C. G., et al. 2002. Reptin and 
pontin antagonistically regulate heart growth in zebrafish embryos. Cell, 111, 
661-72. 
Rual, J. F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., et al. 2005. 
Towards a proteome-scale map of the human protein-protein interaction 
network. Nature, 437, 1173-8. 
Ruthenburg, A. J., Allis, C. D. & Wysocka, J. 2007. Methylation of lysine 4 on histone 
H3: intricacy of writing and reading a single epigenetic mark. Mol Cell, 25, 15-
30. 
Sadiq, M., Stumper, O., Wright, J. G., De Giovanni, J. V., Billingham, C., et al. 1995. 
Influence of ethnic origin on the pattern of congenital heart defects in the first 
year of life. Br Heart J, 73, 173-6. 
Sajjadi, H. & Paparella, M. M. 2008. Meniere's disease. Lancet, 372, 406-14. 
Salmena, L., Poliseno, L., Tay, Y., Kats, L. & Pandolfi, P. P. 2011. A ceRNA 
hypothesis: the Rosetta Stone of a hidden RNA language? Cell, 146, 353-8. 
Samiy, N. 2014. Gene therapy for retinal diseases. J Ophthalmic Vis Res, 9, 506-9. 
Sansbury, B. E., Jones, S. P., Riggs, D. W., Darley-Usmar, V. M. & Hill, B. G. 2011. 
Bioenergetic function in cardiovascular cells: the importance of the reserve 
capacity and its biological regulation. Chem Biol Interact, 191, 288-95. 
Satir, P. & Christensen, S. T. 2007. Overview of structure and function of mammalian 
cilia. Annu Rev Physiol, 69, 377-400. 
Schaapveld, R. Q., Schepens, J. T., Robinson, G. W., Attema, J., Oerlemans, F. T., et 
al. 1997. Impaired mammary gland development and function in mice lacking 
LAR receptor-like tyrosine phosphatase activity. Dev Biol, 188, 134-46. 
Schaefer, E., Durand, M., Stoetzel, C., Doray, B., Viville, B., et al. 2011. Molecular 
diagnosis reveals genetic heterogeneity for the overlapping MKKS and BBS 
phenotypes. Eur J Med Genet, 54, 157-60. 
Schaefer, K. A., Wu, W. H., Colgan, D. F., Tsang, S. H., Bassuk, A. G., et al. 2017. 
Unexpected mutations after CRISPR-Cas9 editing in vivo. Nat Methods, 14, 
547-548. 
Scheuermann, J. C. & Boyer, L. A. 2013. Getting to the heart of the matter: long non-
coding RNAs in cardiac development and disease. EMBO J, 32, 1805-16. 
Schiffelers, R., Storm, G. & Bakker-Woudenberg, I. 2001. Liposome-encapsulated 
aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother, 
48, 333-44. 
Schott, J. J., Benson, D. W., Basson, C. T., Pease, W., Silberbach, G. M., et al. 1998. 
Congenital heart disease caused by mutations in the transcription factor NKX2-
5. Science, 281, 108-11. 
Schulz, Y., Freese, L., Manz, J., Zoll, B., Volter, C., et al. 2014. CHARGE and Kabuki 
syndromes: a phenotypic and molecular link. Hum Mol Genet, 23, 4396-405. 
Schweighoffer, F., Faure, M., Fath, I., Chevallier-Multon, M. C., Apiou, F., et al. 1993. 
Identification of a human guanine nucleotide-releasing factor (H-GRF55) 
specific for Ras proteins. Oncogene, 8, 1477-85. 
Scott, A., Petrykowska, H. M., Hefferon, T., Gotea, V. & Elnitski, L. 2012. Functional 
analysis of synonymous substitutions predicted to affect splicing of the CFTR 
gene. J Cyst Fibros, 11, 511-7. 
  
235 
Seidahmed, M. Z., Alkuraya, F. S., Shaheed, M., Al Zahrani, M., Al Manea, W., et al. 
2011. Ritscher-Schinzel (cranio-cerebello-cardiac, 3C) syndrome: report of four 
new cases with renal involvement. Am J Med Genet A, 155A, 1393-7. 
Serrano-Bueno, G., Hernandez, A., Lopez-Lluch, G., Perez-Castineira, J. R., Navas, 
P., et al. 2013. Inorganic pyrophosphatase defects lead to cell cycle arrest and 
autophagic cell death through NAD+ depletion in fermenting yeast. J Biol 
Chem, 288, 13082-92. 
Sheridan, E., Wright, J., Small, N., Corry, P. C., Oddie, S., et al. 2013. Risk factors for 
congenital anomaly in a multiethnic birth cohort: an analysis of the Born in 
Bradford study. Lancet, 382, 1350-9. 
Sherry, S. T., Ward, M. H., Kholodov, M., Baker, J., Phan, L., et al. 2001. dbSNP: the 
NCBI database of genetic variation. Nucleic Acids Res, 29, 308-11. 
Shigemizu, D., Momozawa, Y., Abe, T., Morizono, T., Boroevich, K. A., et al. 2015. 
Performance comparison of four commercial human whole-exome capture 
platforms. Sci Rep, 5, 12742. 
Shimojima, K., Komoike, Y., Tohyama, J., Takahashi, S., Paez, M. T., et al. 2009. 
TULIP1 (RALGAPA1) haploinsufficiency with brain development delay. 
Genomics, 94, 414-22. 
Shinohara, K., Kawasumi, A., Takamatsu, A., Yoshiba, S., Botilde, Y., et al. 2012. Two 
rotating cilia in the node cavity are sufficient to break left-right symmetry in the 
mouse embryo. Nat Commun, 3, 622. 
Shoemark, A., Dixon, M., Corrin, B. & Dewar, A. 2012. Twenty-year review of 
quantitative transmission electron microscopy for the diagnosis of primary ciliary 
dyskinesia. J Clin Pathol, 65, 267-71. 
Shoemark, A., Ives, A., Becker-Heck, A., Burgoyne, T., Dixon, M., et al. 2013. Inner 
Dynein Arm Defects in Primary Ciliary Dyskinesia. Journal of Genetic 
Syndromes & Gene Therapy, 4, 163. 
Sifrim, A., Hitz, M. P., Wilsdon, A., Breckpot, J., Turki, S. H., et al. 2016. Distinct 
genetic architectures for syndromic and nonsyndromic congenital heart defects 
identified by exome sequencing. Nat Genet, 48, 1060-5. 
Silversides, C. K., Lionel, A. C., Costain, G., Merico, D., Migita, O., et al. 2012. Rare 
copy number variations in adults with tetralogy of Fallot implicate novel risk 
gene pathways. PLoS Genet, 8, e1002843. 
Singh, V., Badheka, A. O., Patel, N. J., Chothani, A., Mehta, K., et al. 2015. Influence 
of hospital volume on outcomes of percutaneous atrial septal defect and patent 
foramen ovale closure: a 10-years US perspective. Catheter Cardiovasc Interv, 
85, 1073-81. 
Skrzypek, H. & Hui, L. 2017. Noninvasive prenatal testing for fetal aneuploidy and 
single gene disorders. Best Pract Res Clin Obstet Gynaecol. 
Slavotinek, A. M., Schauer, G., Machin, G., Dasouki, M., Rueda-Pedraza, M. E., et al. 
2005. Fryns syndrome: report of eight new cases. Genet Med, 7, 74-6. 
Slightom, J. L., Siemieniak, D. R., Sieu, L. C., Koop, B. F. & Hood, L. 1994. Nucleotide 
sequence analysis of 77.7 kb of the human V beta T-cell receptor gene locus: 
direct primer-walking using cosmid template DNAs. Genomics, 20, 149-68. 
Slough, J., Cooney, L. & Brueckner, M. 2008. Monocilia in the embryonic mouse heart 
suggest a direct role for cilia in cardiac morphogenesis. Dev Dyn, 237, 2304-14. 
Smemo, S., Campos, L. C., Moskowitz, I. P., Krieger, J. E., Pereira, A. C., et al. 2012. 
Regulatory variation in a TBX5 enhancer leads to isolated congenital heart 
disease. Hum Mol Genet, 21, 3255-63. 
Smith, F. J., Eady, R. A., Leigh, I. M., Mcmillan, J. R., Rugg, E. L., et al. 1996. Plectin 
deficiency results in muscular dystrophy with epidermolysis bullosa. Nat Genet, 
13, 450-7. 
Soemedi, R., Wilson, I. J., Bentham, J., Darlay, R., Topf, A., et al. 2012. Contribution of 
global rare copy-number variants to the risk of sporadic congenital heart 
disease. Am J Hum Genet, 91, 489-501. 
  
236 
Southgate, L., Sukalo, M., Karountzos, A. S., Taylor, E. J., Collinson, C. S., et al. 2015. 
Haploinsufficiency of the NOTCH1 Receptor as a Cause of Adams-Oliver 
Syndrome With Variable Cardiac Anomalies. Circ Cardiovasc Genet, 8, 572-81. 
Srivastava, D. 2006. Making or breaking the heart: from lineage determination to 
morphogenesis. Cell, 126, 1037-48. 
Stitziel, N. O., Kiezun, A. & Sunyaev, S. 2011. Computational and statistical 
approaches to analyzing variants identified by exome sequencing. Genome 
Biol, 12, 227. 
Stolc, V., Samanta, M. P., Tongprasit, W. & Marshall, W. F. 2005. Genome-wide 
transcriptional analysis of flagellar regeneration in Chlamydomonas reinhardtii 
identifies orthologs of ciliary disease genes. Proc Natl Acad Sci U S A, 102, 
3703-7. 
Stratakis, C. A., Kirschner, L. S. & Carney, J. A. 2001. Clinical and molecular features 
of the Carney complex: diagnostic criteria and recommendations for patient 
evaluation. J Clin Endocrinol Metab, 86, 4041-6. 
Sun, Z., Amsterdam, A., Pazour, G. J., Cole, D. G., Miller, M. S., et al. 2004. A genetic 
screen in zebrafish identifies cilia genes as a principal cause of cystic kidney. 
Development, 131, 4085-93. 
Sutherland, M. J. & Ware, S. M. 2009. Disorders of left-right asymmetry: heterotaxy 
and situs inversus. Am J Med Genet C Semin Med Genet, 151C, 307-17. 
Swarts, D. C., Mosterd, C., Van Passel, M. W. & Brouns, S. J. 2012. CRISPR 
interference directs strand specific spacer acquisition. PLoS One, 7, e35888. 
Sylva, M., Van Den Hoff, M. J. & Moorman, A. F. 2014. Development of the human 
heart. Am J Med Genet A, 164, 1347-71. 
Ta-Shma, A., Khan, T. N., Vivante, A., Willer, J. R., Matak, P., et al. 2017. Mutations in 
TMEM260 Cause a Pediatric Neurodevelopmental, Cardiac, and Renal 
Syndrome. Am J Hum Genet, 100, 666-675. 
Ta-Shma, A., Perles, Z., Yaacov, B., Werner, M., Frumkin, A., et al. 2015. A human 
laterality disorder associated with a homozygous WDR16 deletion. Eur J Hum 
Genet, 23, 1262-5. 
Taipale, M., Jarosz, D. F. & Lindquist, S. 2010. HSP90 at the hub of protein 
homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol, 11, 515-28. 
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., et al. 2007. Induction of 
pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 
861-72. 
Tang, L., Zeng, Y., Du, H., Gong, M., Peng, J., et al. 2017. CRISPR/Cas9-mediated 
gene editing in human zygotes using Cas9 protein. Mol Genet Genomics, 292, 
525-533. 
Tariq, M., Belmont, J. W., Lalani, S., Smolarek, T. & Ware, S. M. 2011. SHROOM3 is a 
novel candidate for heterotaxy identified by whole exome sequencing. Genome 
Biol, 12, R91. 
Temple, G. F., Dozy, A. M., Roy, K. L. & Kan, Y. W. 1982. Construction of a functional 
human suppressor tRNA gene: an approach to gene therapy for beta-
thalassaemia. Nature, 296, 537-40. 
Terada, H. 1990. Uncouplers of oxidative phosphorylation. Environ Health Perspect, 
87, 213-8. 
Thiagalingam, A., De Bustros, A., Borges, M., Jasti, R., Compton, D., et al. 1996. 
RREB-1, a novel zinc finger protein, is involved in the differentiation response to 
Ras in human medullary thyroid carcinomas. Mol Cell Biol, 16, 5335-45. 
Thomas, M. G., Maconachie, G., Sheth, V., Mclean, R. J. & Gottlob, I. 2017. 
Development and clinical utility of a novel diagnostic nystagmus gene panel 
using targeted next-generation sequencing. Eur J Hum Genet, 25, 725-734. 
Thompson, B. A., Greenblatt, M. S., Vallee, M. P., Herkert, J. C., Tessereau, C., et al. 
2013. Calibration of multiple in silico tools for predicting pathogenicity of 
mismatch repair gene missense substitutions. Hum Mutat, 34, 255-65. 
  
237 
Thouvenot, P., Ben Yamin, B., Fourriere, L., Lescure, A., Boudier, T., et al. 2016. 
Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical 
Decision-Making. PLoS Genet, 12, e1006096. 
Tian, Y., Yuan, L., Goss, A. M., Wang, T., Yang, J., et al. 2010. Characterization and in 
vivo pharmacological rescue of a Wnt2-Gata6 pathway required for cardiac 
inflow tract development. Dev Cell, 18, 275-87. 
Timmerman, L. A., Grego-Bessa, J., Raya, A., Bertran, E., Perez-Pomares, J. M., et al. 
2004. Notch promotes epithelial-mesenchymal transition during cardiac 
development and oncogenic transformation. Genes Dev, 18, 99-115. 
Tomita-Mitchell, A., Mahnke, D. K., Struble, C. A., Tuffnell, M. E., Stamm, K. D., et al. 
2012. Human gene copy number spectra analysis in congenital heart 
malformations. Physiol Genomics, 44, 518-41. 
Tomita-Mitchell, A., Maslen, C. L., Morris, C. D., Garg, V. & Goldmuntz, E. 2007. 
GATA4 sequence variants in patients with congenital heart disease. J Med 
Genet, 44, 779-83. 
Tran, P. V., Haycraft, C. J., Besschetnova, T. Y., Turbe-Doan, A., Stottmann, R. W., et 
al. 2008. THM1 negatively modulates mouse sonic hedgehog signal 
transduction and affects retrograde intraflagellar transport in cilia. Nat Genet, 
40, 403-10. 
Trapnell, C., Pachter, L. & Salzberg, S. L. 2009. TopHat: discovering splice junctions 
with RNA-Seq. Bioinformatics, 25, 1105-11. 
Triedman, J. K. & Newburger, J. W. 2016. Trends in Congenital Heart Disease: The 
Next Decade. Circulation, 133, 2716-33. 
Tsang, A. P., Visvader, J. E., Turner, C. A., Fujiwara, Y., Yu, C., et al. 1997. FOG, a 
multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 
in erythroid and megakaryocytic differentiation. Cell, 90, 109-19. 
Uchida, K., Konishi, N., Inoue, M., Otake, K. & Kusunoki, M. 2006. A case of congenital 
jejunal atresia associated with bilateral athelia and choanal atresia: new 
syndrome spectrum. Clin Dysmorphol, 15, 37-8. 
Valdez, R. M., Barbero, P. M., Liascovich, R. C., De Rosa, L. F., Aguirre, M. A., et al. 
2007. Methimazole embryopathy: a contribution to defining the phenotype. 
Reprod Toxicol, 23, 253-5. 
Valdmanis, P. N., Meijer, I. A., Reynolds, A., Lei, A., Macleod, P., et al. 2007. 
Mutations in the KIAA0196 gene at the SPG8 locus cause hereditary spastic 
paraplegia. Am J Hum Genet, 80, 152-61. 
Van Der Bom, T., Bouma, B. J., Meijboom, F. J., Zwinderman, A. H. & Mulder, B. J. 
2012. The prevalence of adult congenital heart disease, results from a 
systematic review and evidence based calculation. Am Heart J, 164, 568-75. 
Van Der Bom, T., Zomer, A. C., Zwinderman, A. H., Meijboom, F. J., Bouma, B. J., et 
al. 2011. The changing epidemiology of congenital heart disease. Nat Rev 
Cardiol, 8, 50-60. 
Van Laarhoven, P. M., Neitzel, L. R., Quintana, A. M., Geiger, E. A., Zackai, E. H., et 
al. 2015. Kabuki syndrome genes KMT2D and KDM6A: functional analyses 
demonstrate critical roles in craniofacial, heart and brain development. Hum 
Mol Genet, 24, 4443-53. 
Van Rooijen, E., Giles, R. H., Voest, E. E., Van Rooijen, C., Schulte-Merker, S., et al. 
2008. LRRC50, a conserved ciliary protein implicated in polycystic kidney 
disease. J Am Soc Nephrol, 19, 1128-38. 
Van Veldhoven, P. P. & Mannaerts, G. P. 1987. Inorganic and organic phosphate 
measurements in the nanomolar range. Anal Biochem, 161, 45-8. 
Vandenberg, L. N. & Levin, M. 2013. A unified model for left-right asymmetry? 
Comparison and synthesis of molecular models of embryonic laterality. Dev 
Biol, 379, 1-15. 
  
238 
Verhagen, J. M., Oostdijk, W., Terwisscha Van Scheltinga, C. E., Schalij-Delfos, N. E. 
& Van Bever, Y. 2014. An unusual presentation of Kabuki syndrome: clinical 
overlap with CHARGE syndrome. Eur J Med Genet, 57, 510-2. 
Villa-Bellosta, R., Hamczyk, M. R. & Andres, V. 2017. Novel phosphate-activated 
macrophages prevent ectopic calcification by increasing extracellular ATP and 
pyrophosphate. PLoS One, 12, e0174998. 
Villafane, J., Lantin-Hermoso, M. R., Bhatt, A. B., Tweddell, J. S., Geva, T., et al. 2014. 
D-transposition of the great arteries: the current era of the arterial switch 
operation. J Am Coll Cardiol, 64, 498-511. 
Vissers, L. E., Van Ravenswaaij, C. M., Admiraal, R., Hurst, J. A., De Vries, B. B., et al. 
2004. Mutations in a new member of the chromodomain gene family cause 
CHARGE syndrome. Nat Genet, 36, 955-7. 
Volk, S. E., Baykov, A. A., Kostenko, E. B. & Avaeva, S. M. 1983. Isolation, subunit 
structure and localization of inorganic pyrophosphatase of heart and liver 
mitochondria. Biochim Biophys Acta, 744, 127-34. 
Von Morgen, P., Horejsi, Z. & Macurek, L. 2015. Substrate recognition and function of 
the R2TP complex in response to cellular stress. Front Genet, 6, 69. 
Voora, D., Mcleod, H. L., Eby, C. & Gage, B. F. 2005. The pharmacogenetics of 
coumarin therapy. Pharmacogenomics, 6, 503-13. 
Walters, A. M., Porter, G. A., Jr. & Brookes, P. S. 2012. Mitochondria as a drug target 
in ischemic heart disease and cardiomyopathy. Circ Res, 111, 1222-36. 
Wang, C., Zhao, Y., Ming, Y., Zhao, S. & Guo, Z. 2016a. A polymorphism at the 
microRNA binding site in the 3'-untranslated region of C14orf101 is associated 
with the risk of gastric cancer development. Exp Ther Med, 12, 1867-1872. 
Wang, W., Niu, Z., Wang, Y., Li, Y., Zou, H., et al. 2016b. Comparative transcriptome 
analysis of atrial septal defect identifies dysregulated genes during heart 
septum morphogenesis. Gene, 575, 303-12. 
Wang, X., Wang, J., Zhao, P., Guo, Y., Wu, L., et al. 2013. Familial congenital heart 
disease. Cardiol Young, 23, 394-9. 
Warnes, C. A., Williams, R. G., Bashore, T. M., Child, J. S., Connolly, H. M., et al. 
2008. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital 
Heart Disease: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (writing committee to develop 
guidelines on the management of adults with congenital heart disease). 
Circulation, 118, e714-833. 
Warnick, M. 1984. Report of the Committee of Inquiry into Human Fertilisation and 
Embryology. Her Majesty's Stationary Office. 
Wei, D., Bao, H., Liu, X. Y., Zhou, N., Wang, Q., et al. 2013. GATA5 loss-of-function 
mutations underlie tetralogy of fallot. Int J Med Sci, 10, 34-42. 
Weleber, R. G., Pennesi, M. E., Wilson, D. J., Kaushal, S., Erker, L. R., et al. 2016. 
Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital 
Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. 
Ophthalmology, 123, 1606-20. 
Wilkinson, R. N., Jopling, C. & Van Eeden, F. J. 2014. Zebrafish as a model of cardiac 
disease. Prog Mol Biol Transl Sci, 124, 65-91. 
Wilson, L. C., Kerr, B. A., Wilkinson, R., Fossard, C. & Donnai, D. 1998. Choanal 
atresia and hypothelia following methimazole exposure in utero: a second 
report. Am J Med Genet, 75, 220-2. 
Wren, C., Birrell, G. & Hawthorne, G. 2003. Cardiovascular malformations in infants of 
diabetic mothers. Heart, 89, 1217-20. 
Yagi, H., Furutani, Y., Hamada, H., Sasaki, T., Asakawa, S., et al. 2003. Role of TBX1 
in human del22q11.2 syndrome. Lancet, 362, 1366-73. 
Yamada, T., Inoue, T., Nishida, T., Furuya, E. & Tagawa, K. 1988. Hepatic 




Yamamoto, R., Hirono, M. & Kamiya, R. 2010. Discrete PIH proteins function in the 
cytoplasmic preassembly of different subsets of axonemal dyneins. J Cell Biol, 
190, 65-71. 
Yamashita, H., Kaneyuki, T. & Tagawa, K. 2001. Production of acetate in the liver and 
its utilization in peripheral tissues. Biochim Biophys Acta, 1532, 79-87. 
Yang, B., Liu, C., Diao, L., Wang, C. & Guo, Z. 2014. A polymorphism at the microRNA 
binding site in the 3' untranslated region of C14orf101 is associated with non-
Hodgkin lymphoma overall survival. Cancer Genet, 207, 141-6. 
Yin, Z. & Kirschner, L. S. 2009. The Carney complex gene PRKAR1A plays an 
essential role in cardiac development and myxomagenesis. Trends Cardiovasc 
Med, 19, 44-9. 
Yunis, K., Mumtaz, G., Bitar, F., Chamseddine, F., Kassar, M., et al. 2006. 
Consanguineous marriage and congenital heart defects: a case-control study in 
the neonatal period. Am J Med Genet A, 140, 1524-30. 
Zaidi, S. & Brueckner, M. 2017. Genetics and Genomics of Congenital Heart Disease. 
Circ Res, 120, 923-940. 
Zaidi, S., Choi, M., Wakimoto, H., Ma, L., Jiang, J., et al. 2013. De novo mutations in 
histone-modifying genes in congenital heart disease. Nature, 498, 220-3. 
Zalli, D., Bayliss, R. & Fry, A. M. 2012. The Nek8 protein kinase, mutated in the human 
cystic kidney disease nephronophthisis, is both activated and degraded during 
ciliogenesis. Hum Mol Genet, 21, 1155-71. 
Zariwala, M. A., Knowles, M. R. & Omran, H. 2007. Genetic defects in ciliary structure 
and function. Annu Rev Physiol, 69, 423-50. 
Zhang, J., Wilson, G. F., Soerens, A. G., Koonce, C. H., Yu, J., et al. 2009. Functional 
cardiomyocytes derived from human induced pluripotent stem cells. Circ Res, 
104, e30-41. 
Zhang, P., Lee, H., Brunzelle, J. S. & Couture, J. F. 2012. The plasticity of WDR5 
peptide-binding cleft enables the binding of the SET1 family of histone 
methyltransferases. Nucleic Acids Res, 40, 4237-46. 
Zhang, Q. J. & Liu, Z. P. 2015. Histone methylations in heart development, congenital 
and adult heart diseases. Epigenomics, 7, 321-30. 
Zhao, L., Yuan, S., Cao, Y., Kallakuri, S., Li, Y., et al. 2013. Reptin/Ruvbl2 is a 
Lrrc6/Seahorse interactor essential for cilia motility. Proc Natl Acad Sci U S A, 
110, 12697-702. 
Zhao, R., Kakihara, Y., Gribun, A., Huen, J., Yang, G., et al. 2008. Molecular 
chaperone Hsp90 stabilizes Pih1/Nop17 to maintain R2TP complex activity that 
regulates snoRNA accumulation. J Cell Biol, 180, 563-78. 
Zhao, Y., Samal, E. & Srivastava, D. 2005. Serum response factor regulates a muscle-
specific microRNA that targets Hand2 during cardiogenesis. Nature, 436, 214-
20. 
Zheng, G. F., Wei, D., Zhao, H., Zhou, N., Yang, Y. Q., et al. 2012. A novel GATA6 
mutation associated with congenital ventricular septal defect. Int J Mol Med, 29, 
1065-71. 
Zhou, J., Goldberg, E. M., Leu, N. A., Zhou, L., Coulter, D. A., et al. 2014. Respiratory 
failure, cleft palate and epilepsy in the mouse model of human Xq22.1 deletion 
syndrome. Hum Mol Genet, 23, 3823-9. 
Zhu, H., Kartiko, S. & Finnell, R. H. 2009. Importance of gene-environment interactions 
in the etiology of selected birth defects. Clin Genet, 75, 409-23. 
Zhu, L., Vranckx, R., Khau Van Kien, P., Lalande, A., Boisset, N., et al. 2006. 
Mutations in myosin heavy chain 11 cause a syndrome associating thoracic 
aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet, 38, 
343-9. 
Zhu, Q., Wang, L., Xiao, Z., Xiao, F., Luo, J., et al. 2013. Decreased expression of 
Ras-GRF1 in the brain tissue of the intractable epilepsy patients and 
experimental rats. Brain Res, 1493, 99-109. 
  
240 
Zondag, G. C., Reynolds, A. B. & Moolenaar, W. H. 2000. Receptor protein-tyrosine 
phosphatase RPTPmu binds to and dephosphorylates the catenin p120(ctn). J 






This project aims to recruit families with a likely genetic cause of Congenital Heart 
Disease (CHD). 
CHD includes all structural, valvular and outflow tract lesions. The study will also 
include congenital and early-onset cardiomyopathy (<2 years of age).  
CHD may or may not be associated with other congenital anomalies (syndromic CHD) 
Included families: 
1) Consanguineous families with at least one child affected with CHD 
2) Sib pairs affected with CHD in non-consanguineous union 
3) Families with dominant or possible dominant (with reduced penetrance) pattern 
of CHD 
4) Parent and child affected with CHD 
AND 
CHD should be concordant within the family- e.g. AVSD in all family members or same 
‘type’ of CHD e.g. septal defects, outflow tract defects, laterality defects (i.e. potential 
underlying genetic basis). 
The presence of a normal karyotype/ 22q11 deletion testing/ Array CGH in an affected 
family member 
Patient able to give informed consent, or if <16 years parent/guardian able to give 
informed consent 
Patient under the care of Consultant Cardiologist or Clinical Geneticist. 
Exclusion Criteria 












PARTICIPANT’S INFORMATION SHEET for parents 
	  
INVITATION TO TAKE PART IN RESEARCH TO STUDY GENES THAT CAUSE RECESSIVE INHERITED 
CONDITIONS: 
“Molecular	  Genetic	  Investigations	  of	  Autosomal	  Recessive	  Conditions”	  
	  
Before	  you	  decide,	  it	  is	  important	  for	  you	  to	  understand	  why	  the	  research	  is	  being	  done	  and	  what	  it	  will	  involve.	  
Please	  take	  time	  to	  read	  the	  following	  information	  carefully.	  Talk	  to	  others	  about	  the	  study	  if	  you	  wish.	  
• Part	  1	  tells	  you	  the	  purpose	  of	  this	  study	  and	  what	  will	  happen	  to	  you	  if	  you	  take	  part.	  
• Part	  2	  gives	  you	  more	  detailed	  information	  about	  the	  conduct	  of	  the	  study.	  
Ask	  us	  if	  there	  is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  like	  more	  information.	  Take	  time	  to	  decide	  whether	  or	  
not	  you	  wish	  to	  take	  part.	  
	  
PART	  1:	  to	  give	  you	  first	  thoughts	  about	  the	  project	  	  
	  
WHAT	  DO	  WE	  WANT	  TO	  DO?	  
We	   are	   studying	   the	   inherited	   factors	   (genes)	   involved	   in	   recessive	   conditions.	   Recessive	   conditions	   are	   genetic	  
conditions	  that	  a	  couple	  can	  pass	  on	  to	  their	  children,	  but	  do	  not	  affect	  the	  couple	  themselves.	  Some	  children	  might	  
problems	  with	  their	  walking	  or	  learning,	  and	  might	  need	  operations	  because	  they	  have	  structural	  birth	  defects,	  such	  
as	  like	  heart	  defects,	  kidney	  defects,	  or	  abnormalities	  picked	  up	  on	  a	  brain	  scan.	  In	  some	  cases	  the	  gene	  causing	  the	  
condition	   isn’t	   known	  and	   the	  aim	  of	   this	   study	   is	   to	  do	   research	   to	   find	   these	   faulty	  genes.	  This	   could	   lead	   to	  a	  
better	  understanding	  of	  the	  condition.	  
	  
WHY	  ARE	  WE	  ASKING	  FOR	  YOUR	  HELP?	  
You	  have	  been	  asked	  to	  take	  part	  in	  this	  research	  study	  because	  your	  child	  has	  a	  recessive	  condition	  but	  the	  genetic	  
cause	  still	  isn’t	  known.	  As	  most	  recessive	  conditions	  are	  very	  rare,	  we	  are	  seeking	  your	  help	  so	  that	  we	  can	  look	  at	  
the	  genes	  of	  many	  families	  with	  exactly	  the	  same	  condition.	  	  
	  
DO	  I	  HAVE	  TO	  TAKE	  PART?	  
No.	  It	  is	  up	  to	  you	  to	  decide	  whether	  or	  not	  to	  take	  part.	  If	  you	  do,	  you	  will	  be	  given	  this	  information	  sheet	  to	  keep	  
and	  be	  asked	  to	  sign	  a	  consent	  form.	  If	  at	  a	  later	  date	  you	  decide	  you	  do	  not	  want	  to	  take	  part	  in	  the	  study	  you	  can	  
change	   your	  mind	   for	   any	   reason.	   If	   you	   do	   not	  wish	   to	   take	   part	   in	   the	   study	   this	  will	   not	   affect	   your	   or	   your	  
family’s	  medical	  care	  in	  any	  way.	  
	  
WHAT	  WILL	  WE	  BE	  ASKING	  YOU	  TO	  DO?	  
A	  researcher	  will	  discuss	  the	  study	  with	  you	  and	  answer	  any	  questions	  you	  may	  have.	  When	  you	  are	  satisfied	  you	  
have	  all	  the	  information	  you	  require	  and	  if	  you	  decide	  to	  take	  part,	  we	  will	  ask	  you	  to	  read	  and	  complete	  a	  consent	  
form.	  The	  researcher	  will	  ask	  you	  to	  sign	  this	  form	  to	  give	  your	  consent.	  The	  form	  will	  ask	  your	  permission	  for	  an	  
extra	  blood	  test	  on	  your	  child,	  yourself	  and	  your	  partner.	  We	  will	  try	  to	  only	  take	  blood	  from	  your	  child	  at	  a	  time	  
when	  blood	   is	  being	  taken	  as	  part	  of	  the	  usual	  clinical	  care.	   If	  we	  already	  have	  a	  sample	  of	  your	  child’s	  blood	  we	  
may	  ask	  you	  if	  we	  can	  use	  that	  instead	  of	  taking	  a	  new	  sample.	  We	  may	  also	  ask	  for	  a	  saliva	  sample	  in	  addition	  or	  
instead	  of	  a	  blood	  sample,	  and	  we	  may	  ask	  your	  permission	  to	  take	  samples	  from	  your	  other	  children	  if	  you	  have	  
them,	  including	  those	  that	  are	  healthy.	  We	  will	  ask	  some	  questions	  about	  your	  medical	  and	  family	  history,	  and	  we	  
may	  also	  ask	  your	  permission	  to	  look	  at	  your	  medical	  records.	  You	  will	  be	  given	  a	  copy	  of	  this	  information	  sheet	  and	  
your	  signed	  consent	  form	  to	  keep.	  
	  
WHAT	  INFORMATION	  WILL	  WE	  HOLD?	  
We	  will	   hold	   information	   that	   is	   routinely	   collected	   as	   part	   of	   your	   child’s	   usual	   clinical	   care.	  We	  will	   also	   hold	  
information	  that	  we	  gain	  from	  the	  blood	  samples	  that	  we	  have	  taken.	  In	  the	  future,	  we	  may	  need	  to	  contact	  you	  




ARE	  THERE	  ANY	  POSSIBLE	  DISADVANTAGES	  TO	  TAKING	  PART	  IN	  THE	  STUDY?	  
We	  do	  not	  think	  that	  taking	  part	  in	  this	  study	  will	  harm	  you	  in	  any	  way.	  We	  will	  be	  gathering	  information	  which	  is	  
already	   routinely	   collected	   by	   health	   professionals.	   If	   at	   any	   point	   you	  would	   like	   to	   discuss	   the	   study	   and	   your	  
involvement	   in	   it,	   you	   will	   be	   able	   to	   speak	   to	   a	   researcher.	   Contact	   details	   are	   provided	   at	   the	   end	   of	   this	  
information	  sheet.	  
	  
WILL	  THIS	  PROJECT	  BENEFIT	  MY	  FAMILY?	  
There	   are	   no	   immediate	   short	   term	   advantages	   to	   taking	   part	   in	   this	   study.	   We	   cannot	   guarantee	   to	   discover	  
anything	  that	  will	  directly	  benefit	  you	  or	  your	  family.	  However	  if	  we	  do	  find	  the	  faulty	  gene	  causing	  the	  condition	  in	  
your	  family	  then	  tests	  may	  be	  available	  for	  your	  relatives	  to	  find	  out	  if	  they	  are	  at	  risk	  of	  having	  children	  with	  the	  
condition.	  We	  also	  hope	  that	  studying	  the	  genetic	  causes	  of	  recessive	  conditions	  will	  help	  to	  discover	  the	  reasons	  
why	   these	   conditions	   occur.	   By	   increasing	   understanding	   in	   this	  way	  we	  may,	   in	   the	   long	   term,	   be	   able	   to	   offer	  
better	  help	  to	  children	  and	  their	  families	  
	  
WHAT	  IF	  THERE	  IS	  A	  PROBLEM?	  
We	  will	  address	  any	  complaint	  about	  the	  way	  you	  have	  been	  dealt	  with	  during	  the	  study	  or	  any	  possible	  harm	  that	  
you	  might	  suffer.	  The	  detailed	  information	  on	  this	  is	  given	  in	  Part	  2.	  
	  
	  
THIS	  COMPLETES	  PART	  1	  OF	  THE	  INFORMATION	  SHEET	  
If	  the	  information	  in	  Part	  1	  has	  interested	  you	  and	  you	  are	  considering	  participation,	  please	  continue	  to	  read	  the	  
additional	  information	  in	  Part	  2	  before	  making	  any	  decision.	  
	  
PART	  2:	  information	  you	  need	  to	  know	  if	  you	  still	  want	  to	  take	  part	  
	  
WHAT	  IF	  NEW	  INFORMATION	  BECOMES	  AVAILABLE?	  
We	  hope	  that	  this	  study	  will	  uncover	  the	  genetic	  cause	  for	  your	  child’s	  problems.	  If	  we	  do	  find	  the	  faulty	  gene,	  this	  
information	  will	  be	  fed	  back	  to	  you	  in	  the	  course	  of	  the	  clinics	  run	  by	  the	  doctors	  caring	  for	  your	  child.	  We	  will	  also	  
inform	  your	  local	  clinical	  genetics	  department	  so	  they	  can	  contact	  you.	  It	  may	  be	  possible	  to	  then	  offer	  tests	  to	  the	  
wider	  family,	  if	  they	  wish	  to	  see	  if	  they	  carry	  the	  same	  gene	  or	  not.	  It	  may	  also	  be	  possible	  to	  offer	  tests	  to	  either	  
you	  or	  your	  partner	  during	  a	  future	  pregnancy.	  
	  
HOW	  DO	  WE	  ENSURE	  CONFIDENTIALITY?	  
All	   information	   recorded	   on	   paper	   and	   any	   biological	   samples	   stored	   will	   be	   kept	   under	   conditions	   of	   strict	  
confidentiality	  as	  a	   legal	  requirement	  under	  the	  Data	  Protection	  and	  Human	  Tissue	  Acts.	  We	  will	  put	   information	  
about	  your	  family	  onto	  a	  secure	  computer	  database.	  However,	  we	  will	  remove	  all	  personal	  details,	  such	  as	  names	  
and	  addresses,	  so	  your	  family	  cannot	  be	  recognized	  from	  it.	  A	  study	  number,	  which	  can	  only	  be	  linked	  to	  you	  by	  the	  
research	   team,	   will	   be	   the	   identifier	   of	   the	   information.	   This	   is	   necessary	   so	   that	   we	   can	   put	   together	   your	  
information	  throughout	  the	  study.	  The	  results	  from	  any	  information	  or	  biological	  samples	  that	  we	  collect	  will	  only	  
be	  used	  for	  research	  purposes	  and	  will	  not	  be	  available	  to	  anyone	  else.	  
	  
WILL	  MY	  GENERAL	  PRACTITIONER/FAMILY	  DOCTOR	  KNOW	  THAT	  I	  AM	  PART	  OF	  THIS	  STUDY?	  
With	  your	  permission,	  we	  will	  contact	  your	  G.P.	  or	  other	  doctor	  involved	  in	  your	  family’s	  care	  to	  let	  them	  know	  that	  
your	  child	  is	  included	  in	  the	  study.	  
	  
WILL	  ANYONE	  ELSE	  KNOW	  ABOUT	  MY	  TAKING	  PART?	  
The	  information	  collected	  about	  you	  during	  the	  course	  of	  the	  research	  project	  will	  be	  kept	  strictly	  confidential	  and	  
you	  will	  not	  be	  identifiable	  from	  it.	  If	  any	  research	  results	  are	  published	  in	  medical	  articles	  as	  a	  result	  of	  this	  project,	  
all	  personal	  details	  will	  be	  removed	  so	  that	  your	  family	  cannot	  be	  recognized	  from	  it.	  
	  
WHAT	  WILL	  HAPPEN	  TO	  ANY	  SAMPLES	  THAT	  I	  GIVE?	  
We	  will	   request	  an	  extra	  sample	  bottle	  be	  filled	  at	  the	  time	  your	  child	   is	  having	  blood	  tests	  as	  part	  of	  their	  usual	  
clinical	  care.	  We	  will	  also	  request	  a	  sample	  of	  blood	  from	  you	  and	  your	  partner.	  We	  may	  also	  ask	  to	  take	  samples	  
from	  your	  other	  children	  if	  you	  have	  them,	  including	  those	  that	  are	  healthy.	  We	  could	  also	  ask	  you	  or	  your	  partner	  
to	  give	  a	  saliva	  sample	  instead	  or	  in	  addition	  to	  a	  blood	  sample.	  The	  samples	  will	  be	  sent	  to	  our	  lab	  and	  DNA	  will	  be	  
extracted.	  We	  will	  analyse	  the	  DNA	  to	  see	  if	  we	  can	  determine	  if	  there	  is	  a	  genetic	  cause	  for	  your	  child’s	  problems.	  
If	  you	  change	  your	  mind	  later	  and	  decide	  not	  to	  take	  part	  in	  the	  study	  then	  you	  should	  let	  us	  know	  what	  we	  should	  
do	  with	  any	  DNA	  samples.	  We	  need	  to	  ask	  you	  because	   it	  can	  often	  take	  some	  years	  to	  find	  the	  faulty	  gene	  that	  
causes	  the	  specific	  condition	  in	  your	  family.	  We	  can	  either	  keep	  the	  DNA	  for	  research	  in	  the	  future,	  or	  keep	  the	  DNA	  




WILL	  ANY	  GENETIC	  TESTS	  BE	  DONE?	  
Tests	  will	  be	  done	  to	  try	  to	  establish	  if	  your	  child’s	  problems	  are	  caused	  by	  a	  faulty	  gene.	  We	  will	  not	  use	  the	  sample	  
for	  any	  other	  genetic	  tests.	  We	  may	  use	  new	  technology	  (called	  “clonal”	  or	  next	  generation	  sequencing)	  to	  look	  at	  
many	  genes	  at	  once	  rather	  than	  one	  after	  another.	  We	  want	  to	  use	  this	  new	  technology	  because	  we	  might	  find	  the	  
faulty	  gene	  more	  quickly,	  but	  we	  will	  only	  use	  it	  for	  studies	  appropriate	  for	  your	  child’s	  condition.	  It	  is	  possible	  that	  
we	  may	   uncover	   other	   findings	   that	   are	   unconnected	   to	   your	   child’s	   condition	   but	  might	   be	   important	   for	   your	  
health.	  With	  your	  permission,	  we	  will	  inform	  your	  local	  clinical	  genetics	  department	  so	  they	  can	  contact	  you	  about	  
this	  information.	  
	  
WHO	  IS	  ORGANISING	  AND	  FUNDING	  THE	  RESEARCH?	  
The	  study	  is	  organized	  by	  the	  University	  of	  Leeds.	  The	  study	  is	  funded	  by	  a	  medical	  research	  charity	  called	  the	  Sir	  
Jules	  Thorn	  Charitable	  Trust.	  Neither	  you	  nor	  the	  researchers	  involved	  will	  benefit	  financially	  from	  this	  project.	  
	  
WHO	  HAS	  REVIEWED	  THE	  STUDY?	  
All	   research	   in	   the	  NHS	   is	   looked	   at	   by	   an	   independent	   group	   of	   people,	   called	   a	   Research	   Ethics	   Committee	   to	  
protect	  your	  safety,	  rights,	  wellbeing	  and	  dignity.	  This	  study	  has	  been	  reviewed	  and	  given	  a	  favourable	  opinion	  by	  
South	  Yorkshire	  Research	  Ethics	  Committee.	  The	  research	  has	  also	  been	  reviewed	  by	  the	  Sir	  Jules	  Thorn	  Charitable	  
Trust,	  to	  ensure	  that	  the	  proper	  science	  is	  being	  done	  for	  this	  study.	  
	  
WHAT	  IF	  I	  HAVE	  ANY	  CONCERNS?	  
If	  you	  have	  any	  concerns,	  other	  questions	  about	  this	  study	  or	  the	  way	  it	  has	  been	  carried	  out,	  you	  should	  contact	  
the	  investigators	  in	  charge	  of	  running	  the	  study:	  
	  
Prof.	  Colin	  Johnson:	  
	  
Section	  of	  Ophthalmology	  and	  Neurosciences	  
Wellcome	  Trust	  Brenner	  Building	  
Leeds	  Institute	  of	  Molecular	  Medicine	  
St	  James's	  University	  Hospital	  
Beckett	  Street	  
Leeds,	  LS9	  7TF,	  U.K.	  
	  
tel:	  (+44)	  0113	  343	  8443	  





Dr.	  Eamonn	  Sheridan:	  
	  
Section	  of	  Genetics	  
Wellcome	  Trust	  Brenner	  Building	  
Leeds	  Institute	  of	  Molecular	  Medicine	  
St	  James's	  University	  Hospital	  
Beckett	  Street	  
Leeds,	  LS9	  7TF,	  U.K.	  
	  




If	  you	  have	  a	  concern	  about	  any	  aspect	  of	  this	  study,	  you	  should	  ask	  to	  speak	  with	  the	  researchers	  who	  will	  do	  their	  
best	  to	  answer	  your	  questions.	  Please	  contact	  Prof.	  Johnson	  on	  0113	  343	  8443	  or	  Dr.	  Sheridan	  on	  0113	  206	  5927	  in	  
the	   first	   instance.	   If	   you	   remain	   unhappy	   and	   wish	   to	   complain	   formally,	   you	   can	   do	   this	   through	   the	   NHS	  
Complaints	  Procedure.	  Details	  can	  be	  obtained	  from	  the	  hospital.	  
	  
HARM	  
In	   the	   event	   that	   something	  does	   go	  wrong	   and	   you	   are	  harmed	  during	   the	   research	   study	   there	   are	   no	   special	  
compensation	   arrangements.	   If	   you	   are	   harmed	   and	   this	   is	   due	   to	   someone’s	   negligence	   then	   you	   may	   have	  
grounds	  for	  a	   legal	  action	  for	  compensation	  against	  Leeds	  Teaching	  Hospitals	  NHS	  Trust	  but	  you	  may	  have	  to	  pay	  















CONSENT	  FORM:	  for	  patients,	  or	  parents/guardians	  and	  children	  in	  the	  family	  	  
Participant	  to	  circle	  responses	  to	  all	  parts:	  
1.	   I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  for	  the	  study.	  I	  have	  had	  the	  
opportunity	   to	   consider	   the	   information,	   ask	   questions,	   and	   have	   had	   these	   answered	  
satisfactorily	  
2.	   I	   understand	   that	  my	  participation	   is	   voluntary	   and	   that	   I	   am	   free	   to	  withdraw	  at	   any	   time,	  
without	  giving	  any	  reason,	  and	  without	  my	  medical	  care	  or	  legal	  rights	  being	  affected	  
3.	   I	   understand	   that	   sections	   of	   any	   of	  my/my	   child’s	  medical	   notes	  may	   be	   reviewed	   by	   the	  
researchers	   and	   other	   responsible	   individuals	   from	   regulatory	   authorities	   or	   from	   the	   NHS	  
Trust,	  where	  it	  is	  relevant	  to	  my	  taking	  part	  in	  research.	  I	  give	  permission	  for	  these	  individuals	  
to	  have	  access	  to	  my/our	  records	  
4.	   i)	   I	  agree	  to	  allow	  medical	  information	  about	  me/my	  family	  to	  be	  entered	  on	  a	  confidential	  
computer	  database.	  I	  understand	  that	  personal	  details	  (including	  names	  and	  addresses)	  about	  
myself	  and	  my	  family	  will	  be	  accessed	  only	  by	  researcher	  team	  leaders	  (Johnson,	  Sheridan	  &	  
Bonthron).	   Information	   accessed	   by	   other	   researchers	   will	   have	   personal	   details	   removed,	  
thereby	  maintaining	  our	  privacy	  
ii)	   If	  further	  medical	  information	  is	  requested	  by	  researchers,	  I	  agree	  to	  be	  contacted	  again	  
for	  this	  purpose.	  
5.	   i)	   I	  agree	  that	  a	  blood	  sample/saliva	  sample/stored	  DNA	  sample	  from	  me	  may	  be	  used	  for	  
genetic	   research	   studies	   appropriate	   to	  my	   family’s	   condition.	   I	   understand	   that	   any	   results	  
arising	  from	  this	  research	  work	  will	  be	  kept	  strictly	  confidential.	  
ii)	  	   OR	   I	   agree	   that	  blood	   samples/saliva	   samples/stored	  DNA	   samples	   from	   the	   following	  
children	  in	  the	  family	  can	  be	  used	  for	  the	  project:	  
list	  of	  children	  agreed	  to	  be	  part	  of	  the	  research:	  
1.	   5.	  
2.	   6.	  
3.	   7.	  
4.	   8.	  
6.	   i)	   If	  a	  genetic	  test,	  or	  other	  genetic	  finding	  that	  might	  have	  health	   implications,	  becomes	  
available	  as	  a	  result	  of	  medical	   research	  on	  my	  own	  or	  my	  family’s	  sample(s)	   I	  would	   like	  to	  
have	   the	   opportunity	   to	   discuss	   the	   implications	   of	   these	   findings	  with	   appropriate	  medical	  
experts,	  including	  my	  local	  clinical	  genetics	  department	  
ii)	   I	   understand	   that	   genetic	   testing	  may	   sometimes	   reveal	   information	   that	  might	   have	  
health	  implications	  unconnected	  to	  my	  family’s	  condition.	  I	  would	  like	  to	  have	  the	  opportunity	  
to	  discuss	  the	  implications	  of	  any	  such	  findings	  with	  appropriate	  medical	  experts,	  including	  my	  
local	  clinical	  genetics	  department	  
iii)	   I	  agree	  that	  my	  G.P,	  or	  other	  healthcare	  professional	  in	  charge	  of	  my	  or	  my	  family’s	  care,	  















________________________	   ________________	   ____________________	  
Participant/Family	  Representative	  	   Date	   Signature	  
on	  behalf	  of	  children	  in	  the	  family	  
	  
_________________________	   ________________	   ____________________	  
Name	  of	  Person	  taking	  consent	   Date	   	   Signature	  
	  
	  
_________________________	   ________________	   ____________________	  
Researcher	   	   	   Date	   	   Signature	  
	  






























Primer sequences used in this thesis 








DNAAF1_central_plasmid_F CTGGATGCTCTTAACCTCAGC   
DNAAF1_centra_lplasmid_R TCTTCCAAGTCAGGTAGGTCA   
DNAAF1_ex1F GTACTCTCTGGCTGGGCTGG 296 59.5 
DNAAF1_ex1R GTATGTGGTGTGGGAAGGG 296 59.5 
DNAAF1_ex2F TAACCAAGCTGAAGTTGGGG 287 58.9 
DNAAF1_ex2R TTATCCGTACAAGGGGGTGA 287 58.9 
DNAAF1_ex3F GGCAGGAATGGATGTGGTAA 268 58.9 
DNAAF1_ex3R AAAGGTGATCCCTGCAAGTAA 268 58.9 
DNAAF1_ex4F AAAAACAAGGGTGACCGTGA 396 58.9 
DNAAF1_ex4R AAACACCACTTCTTGCCCAT 396 58.9 
DNAAF1_ex5F ATTCTCCCGCTTTAGCCTTC 382 58.9 
DNAAF1_ex5R GGCAGGAAGGAGAGAAAAGA 382 58.9 
DNAAF1_ex6F CCAGGACAGGATATTGGCAC 390 58.9 
DNAAF1_ex6R GCCATCAAGCCTATTTCCAA 390 58.9 
DNAAF1_ex7F CATGTCTGATGCTCACTTTGC 364 58.9 
DNAAF1_ex7R TCCCAAGATTAAAGACTGGGTT 364 58.9 
DNAAF1_ex8_part_1F AGCCCTTGATGTACCCACAA 485 51 
DNAAF1_ex8_part_1R TTCACAGGCGGTGACAGTAG 485 51 
DNAAF1_ex8_part_2F CCAGCTGAGACCCTGCTACT 356 59.5 
DNAAF1_ex8_part_2R CCACAGAGACGTGAGTCGAA 356 59.5 
DNAAF1_ex9F AGCCCATCTTCACCGTAGG 295 58.9 
DNAAF1_ex9R ACCACACTTGGGGTATCGAG 295 58.9 
DNAAF1_ex10F TGCCTTTATCGTGCCTATCA 243 58.9 
DNAAF1_ex10R TGCTTTATGCACAGGGAACA 243 58.9 
DNAAF1_ex11_part_1F AACTGGCATGGTGCATTGTA 475 51 
DNAAF1_ex11_part_1R GTCTCCACTGTGCTCTCGG 475 51 
DNAAF1_ex11_part_2F ACAAGACACCAAGTCCCCAA 241 58.9 
DNAAF1_ex11_part_2R TAAGGCTGAGTGACTGCCCT 241 58.9 
DNAAF1_ex12F GAATTTGGCCTGGACTGAAC 298 51 
DNAAF1_ex12R TCATACACTGACTCGCGTGG 298 51 
KMT2D_exon38_F AGGGTCGGAGAGGTCAGG 399 63 
KMT2D_exon38_R GGTTTGGGTCATATGGAGGA 399 63 
KMT2D_G3553V_F TCTTGCTCTGCTGCTCTGTA 171 58.9 













RREB1_F CCACCACAGACACCAACAAG 248 63 
RREB1_R GTGTGTGAGCATGTGCCTCT 248 63 
SDM_DNAAF1_1634G>T_F AAGGAGACATTCTGCATTGATG  59 
SDM_DNAAF1_1634G>T_R TGTCTCCAGTCTAATGGTTTC  59 
SDM_DNAAF1_571C>T_F CATTGAAAACTTCTCCTGCCTC  60 
SDM_DNAAF1_571C>T_R GTCTTGATGTAATTGTTGCTG  60 
SP6 ATTTAGGTGACACTATAG   
  
253 
T3 GCAATTAACCCTCACTAAAGG   
T7 TAATACGACTCACTATAGGG    
WGS breakpoint F TGTAAAACGACGGCCAGTTGTTCT
GGAGGGACGATGAG 
  
WGS breakpoint deletion R CAGGAAACAGCTATGACCTTGTTG
TGGCAGCTGTGAAA 
  
















Depth of coverage results for all samples studied in this thesis. 
Sample 
number 
Sample type  % dupli-
cation 
  Mean 
coverage 
(no. reads) 
 % bases 








Mapped reads % mapped  
JT67 blood 1.58 68.2 98.7 Hiseq 
2500 
XT v4 56054364 54787753 97.7404 
JT377 blood 5.27 110.3 99 Hiseq  XT v4 87809314 86101613 98.0552 
JT378 blood 4.5391 121.7 99 Hiseq 
2500 
XT v4 100248326 98278482 98.035 
JT379 blood 2.1309 121.2 99 Hiseq 
2500 
XT v4 93726067 91931756 98.0856 
JT380 blood 5.0487 83.9 99 Hiseq 
2500 
XT v4 65257890 63977628 98.0381 
JT384 blood 6.6175 74.7 99 Hiseq 
2500 
XT v4 62746406 61423573 97.8918 
JT385 blood 3.9764 108.1 98.9 Hiseq 
2500 
XT v4 85057668 83362581 98.0071 
JT386 blood 2.8289 94.4 98.9 Hiseq 
2500 
XT v4 74605022 73101219 97.9843 
JT439 blood 1.3179 69.5 98.6 Hiseq 
2500 
XT v5 57144102 55899749 97.8224 
JT440 blood 2.0791 86.2 98.6 Hiseq 
2500 
XT v5 68226938 66806953 97.9187 
JT441 blood 2.8506 60.7 96.5 Hiseq 
2500 
XT v4 51057910 50369003 98.6507 
JT442 blood 2.8107 57 95.3 Hiseq 
2500 
XT v4 51442802 50604420 98.3703 
JT443 blood 1.6717 86.5 98.8 Hiseq 
2500 
XT v5 76613248 74813903 97.6514 
JT445 blood 3.9172 78.2 98.9 Hiseq 
2500 
XT v5 71537052 69870697 97.6706 
JT446 blood 1.6387 61.1 98.6 Hiseq 
2500 
XT v5 56562376 55166817 97.5327 
JT447 blood 1.6253 77.4 98.8 Hiseq 
2500 
XT v5 75961880 74012166 97.4333 
JT448 blood 1.6282 67.8 98.7 Hiseq 
2500 
XT v5 66111470 64390173 97.3964 
JT474 saliva 4.4365 60.6 98.8 Hiseq 
2500 
XT v5 62965512 60245206 95.6797 
JT476 saliva 4.2329 63.1 98.6 Hiseq 
2500 
XT v5 63793938 61012400 95.6398 
JT538 blood 9.8618 50.3 96.6 Hiseq 
2500 
QXT v5 49437854 48671938 98.4507 
JT539 blood 10.9173 61.55 97.5 Hiseq 
2500 
QXT v5 59262186 58301306 98.3786 
JT540 blood 10.8186 55.27 97.2 Hiseq 
2500 
QXT v5 52317264 51461188 98.3637 
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JT541 blood 12.5238 63.87 96.6 Hiseq 
2500 
QXT v5 55944044 55072573 98.4422 
JT542 blood 14.0225 69.56 98 Hiseq 
2500 
QXT v5 67251694 66211635 98.4535 
JT543 blood 10.3385 54.56 97.3 Hiseq 
2500 
QXT v5 50636296 49669542 98.0908 
JT576 blood 17.6766 78.56 98.4 Hiseq 
2500 
QXT v5 73769160 72104134 97.7429 
JT577 blood 15.3413 64.22 98.2 Hiseq 
2500 
QXT v5 66440752 64892409 97.6696 
JT578 blood 15.3273 63.98 97.9 Hiseq 
2500 
QXT v5 59183468 57848931 97.7451 
JT579 blood 18.0831 73.97 98.4 Hiseq  QXT v5 74044360 72332089 97.6875 
JT584 blood 23.1056 96.63 98.7 Hiseq 
2500 
QXT v5 94390968 92277529 97.761 
JT586 blood 18.3522 69.63 98.4 Hiseq 
2500 
QXT v5 67918044 65897629 97.0252 
JT587 blood 18.6219 75.76 98.5 Hiseq 
2500 
QXT v5 74305842 72193713 97.1575 
JT588 blood 17.1385 65.42 98.3 Hiseq 
2500 
QXT v5 64183642 62485997 97.355 
JT609 fibroblasts 17.6582 75.35 98.4 Hiseq 
2500 
QXT v5 72844614 71182311 97.718 
JT622 saliva 33.6593 81.53 98.6 Hiseq 
3000 
QXT v6 72403416 71386985 98.5962 
JT623 saliva 29.7625 96.75 98.5 Hiseq 
3000 
QXT v6 77777666 77351173 99.4517 
JT624 saliva 21.5174 64.22 98 Hiseq 
3000 
QXT v6 46340272 46113939 99.5116 
JT625 saliva 29.8049 125.65 99.2 Hiseq 
3000 
QXT v6 98442630 98125155 99.6775 
JT666 blood 30.3101 134.87 99.3 Hiseq 
3000 
QXT v6 105566342 105213234 99.6655 
JT667 blood 31.1009 120.36 99.5 Hiseq 
3000 
QXT v6 95381764 94971101 99.5695 
JT668 blood 29.8402 107.53 99.5 Hiseq 
3000 
QXT v6 83903400 83668754 99.7203 
JT711 blood 27.5394 107.94 99.2 Hiseq 
3000 
QXT v6 85225814 84988938 99.7221 
JT712 blood 29.7685 133.97 99.4 Hiseq 
3000 
QXT v6 103585682 103371379 99.7931 
JT713 blood 29.8365 106.14 99.2 Hiseq 
3000 
QXT v6 85773756 84897237 98.9781 
JT714 saliva 24.0348 107.62 99.1 Hiseq 
3000 
QXT v6 77470374 77261295 99.7301 
JT720 blood 24.4923 105.47 99.4 Hiseq 
3000 
QXT v6 80002800 79647448 99.5558 
JT721 blood 25.8227 121.84 99.5 Hiseq 
3000 
QXT v6 92706434 92434532 99.7067 
JT722 blood 27.415 124.85 99.3 Hiseq 
3000 
QXT v6 95646452 95424422 99.7679 
JT724 blood 24.8708 104.23 99.4 Hiseq 
3000 
QXT v6 75821082 75641506 99.7632 
JT786 saliva 25.9555 119.85 99.4 Hiseq 
3000 
QXT v6 87447752 87188020 99.703 
JT787 saliva 26.8696 99.83 99.3 Hiseq 
3000 
QXT v6 76653748 76088223 99.2622 
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JT788 blood 30.8861 117.04 99.6 Hiseq 
3000 
QXT v6 94706276 94482940 99.7642 
Appendix G 
Known disease-causing genes assessed for variants in each recruited family. 
Family Associated disease Gene 
CHD1 Heterotaxy ZIC3, MMP21, CFC1, ACVR2B, PKD1L1, 
NODAL, CCDC11, Plus genes associated 
with PCD* 
CHD3 Familial aortic 
dilatation and 
dissection 
FBN1, FOXE3, TGFBR2, MYLK, LOX, 
TGFBR1, PRKG1, ACTA2, MFAP5, MYH11  
CHD4 Situs Inversus Totalis ZIC3, MMP21, CFC1, ACVR2B, PKD1L1, 




PRDM16, NEXN, LMNA, TNNT2, PSEN2, 
ACTN2, TTN, DES, RAF1, SCN5A, TNNC1, 
SDHA, SGCD, LAMA4, PLN, EYA4, 
GATAD1, FKTN, MYPN, VCL, LDB3, 
RBM20, BAG3, CSRP3, MYBPC3, CRYAB, 
ABCC9, MYH6, MYH7, PSEN1, ACTC1, 
TPM1, DSG2, TNNI3, DMD. 
CHD6 Tetralogy of Fallot NKX2-5, GATA4, ZFPM2, GATA6, GDF1, 
JAG1, TBX1.  
CHD7 Truncus Arteriosus NKX2-5, NKX2-6, GATA6, GDF1, TBX1.  
CHD8 VSD/HLHS NKX2-5, GATA4, CITED2, GJA1 
CHD9, 10, 11 Athelia, choanal 
atresia 
KMT2D, PTPRM, TXNL4A, PTPN13, 
PTPRO, FOXE1, CHD7, TBX5, TBX3, LEF1, 
NRG3, ERBB4. 
CHD12 ASD TLL1, NKX2-5, CITED2, TBX20, GATA4, 
MYH6, ACTC1, GATA6.  
CHD13 3C- syndrome like KIAA0196, CCDC22.  
CHD15 AVSD GJA1, GATA4, GATA6 
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CHD16 Tetralogy of fallot NKX2-5, GATA4, ZFPM2, GATA6, GDF1, 
JAG1, TBX1, MKKS. 
 
* Genes associated with PCD: DRC1, ZMYND10, CCDC39, DNAH5, CCNO, RSPH9, RSPH4A, RSPH3, HEATR2, DNAH11, NME8, SPAG1, 
LRRC6, DNAI1, ARMC4, DNAJB13, CCDC65, KTU, DNAL1, DNAAF4, HYDIN, DNAAF1, GAS8, TTC25, CCDC103, DNAI2, CCDC40, 
CCDC151, CCDC114, DNAAF3, C21ORF59, RSPH1, PIH1D3.  
Appendix H 
A list of heterozygous variant remaining following filtering in family CHD3 with a CADD score >15. PD= Probably Damaging, D= Deleterious, T= 
Tolerated, B= Benign, N= Neutral. 
Gene Variant Protein change Polyphen2 SIFT Condel CADD MAF 
(GnomAD) 
Protein function 
HIP1 7:75168711C>T ENSP00000336747.6, 
p.R998H 











SLIT2 4:20552506C>G ENSP00000422591.1, 
p.S849C 
PD D D 24.3 11/244776 GTPase inhibitor 
activity, slit2/ robo4 
stabilises vascular 
network 
PSMB7 9:127177647G>A ENSP00000259457.3, 
p.R20C 





PD T D 15.96 Not present  
RCE1 11:66610695C>G ENSP00000354227.4:p.P67
5R 
PD D D 15.62 Not present processing of CAAX-




Results from WGS analysis at low read depth to assess for CNVs in sample JT381 and JT443. 
Sample JT381, calls from CNVseq 
Location Del/dup Genes       
1-104134278-104313809 dup AMY2A AMY1A AMY1B AMY1C RNPC3   
1-149041231-149279969 del NBPF23            
1-149315068-149462199 del FCGR1C FAM72C          
3-129762478-129810356 del TRH ALG1L2      
4-69374731-69499460 del TMPRSS11E UGT2B17          
5-12515668-12744002 del CT49            
6-258367-390083 del DUSP22 IRF4      
8-7560068-7831482 dup DEFB107A SPAG11A      
8-12201691-12366392 dup FAM66A FAM86B2      
9-44711851-44864136 dup none       




dup TMTC3 cep290          
15-24439711-24548858 del none            
17-34508311-34570589 del CCL3L3 TBC1D3B CCL4L1 TBC1D3C
CCL4L2 
TBC1D3H CCL3L1  
17-34591351-34653629 del TBC1D3CCCL4
L2 
TBC1D3H CCL3L1     
19-20593054-20714875 del ZNF626P       
22-24308696-24399168 del GSTT2B DDTL DDT GSTT2 GSTTP1 GSTT1 CABIN1 
 
Sample JT381, calls from Read Depth 
Chr Start Stop Bins Calculated copy number (2 
is diploid) 
Agree with CNVseq 
chr1 148435101 149143500 4 0.43708931  
chr1 149143501 149194100 2 0.031369362 * 
  
259 
chr4 10195901 10246500 2 0.903815372  
chr4 34787501 34838100 2 1.058264312  
chr4 69482000 69499100 4 0.443405939 * 
chr5 695751 721351 4 3.213621459  
chr5 12523501 12751200 9 1.009961291 * 
chr7 38389800 38405400 4 1.31850222  
chr9 34559801 34661000 4 1.288506665  
chr9 135026101 135127300 4 1.307943299  
chr10 8070701 8146600 3 1.36983298  
chr10 126145801 126297600 6 1.368030125  
chr11 48297701 48341901 111 2.845929651  
chr11 48387700 48727801 111 2.845929651  
chr12 34787501 34814501 5 3.289116251  
chr12 88322301 88474100 6 1.066585781 * 
chr12 93888301 93989500 4 2.706446744  
chr12 130902201 130952800 2 1.321613199  
chr15 24439801 24541000 4 0.612040913 * 
chr17 41365501 41375601 4 2.823725797  
chr17 41414800 41466700 4 2.823725797  
chr17 47943501 48297700 14 1.356416275  
chr17 59505600 59581500 5 1.307399454  
chr18 77139701 77367400 9 1.317405976  
chr19 27954500 27956500 10 14.21754041  
chr21 22820601 22921800 4 1.349570179  
chr22 24313301 24313801 2 0.035275247 * 






JT381 CNVnator calls that agree with CNVseq 
CNV type Location Size Read depth normalised to 1 
duplication chr1:104134001-104304000 170000 1.58337 
deletion chr1:149036001-149267000 231000 0.299106 
duplication chr1:149267001-149321000 54000 1.57572 
deletion chr1:149329001-149647000 318000 0.60251 
deletion chr3:129764001-129807000 43000 0.313157 
deletion chr4:69381001-69492000 111000 0.133311 
deletion chr5:12513001-12746000 233000 0.551357 
deletion chr6:1-202000 202000 0.492946 
duplication chr8:12231001-12462000 231000 2.04784 
deletion chr9:44452001-44727000 275000 0.396005 
deletion chr12:88324001-88482000 158000 0.546109 
duplication chr12:88482001-88566000 84000 1.55536 
deletion chr15:24442001-24542000 100000 0.224522 
deletion chr17:34510001-34550000 40000 0.287563 
duplication chr17:34576001-34592000 16000 2.27308 
deletion chr17:34592001-34651000 59000 0.315863 
deletion chr19:20503001-20718000 215000 0.419569 
deletion chr22:24308001-24398000 90000 0.281255 
JT443 calls from CNVseq 
Location Del/dup Genes    
1-196713091-196827120 del CFHR1 CFHR2 CFHR3 CFHR4 
6-162678378-162856400 del PARK2    
7-8815943-8872405 del near 
NXPH1 
   
8-7232106-7469594 del SPAG11B DEFB4B   
8-7560068-7831482 del SPAG11A DEFB4A   
8-11955251-12106284 del DEFB130 USP17L7   
8-39225268-39396877 del ADAM3A    
  
261 
13-58313491-58406893 del none       
 
Sample JT443 calls from Read Depth 
Chr Start Stop Bins Calculated 
copy number 
(2 is diploid) 
Agree with 
CNVseq 
chr1 842800 850200 3 2.855216216  
chr1 5689801 5708501 2 3.42332912  
chr1 16807801 16816801 5 4.339413301  
chr1 72757501 72762801 2 0.669149279  
chr1 72814000 72822900 2 0.669149279  
chr1 117131401 117139001 2 3.120765598  
chr1 117189600 117196800 2 3.120765598  
chr2 89565301 89640601 8 12.70478451  
chr4 52699900 52712400 2 26.51799879  
chr5 21483901 21486501 2 2.946086929  
chr5 46303201 46303801 7 8.580727685  
chr5 49563500 49573200 7 8.580727685  
chr6 29909600 29920500 2 1.094521277  
chr6 32438401 32449301 6 1.132883885  
chr6 32540900 32540901 6 1.132883885  
chr6 57599500 57617400 8 4.247753359  
chr7 38291701 38293501 3 1.175928221  
chr7 57519301 57524801 9 3.38674649  
chr7 62053600 62064600 13 10.2553157  
chr7 65073001 65334600 4 2.670481704  
chr7 100519801 100580151 2 3.741975207  
chr8 6801601 6899700 2 3.007365049  
chr8 46922400 46924500 2 12.13750513  
  
262 
chr10 42832900 42837000 12 22.97511217  
chr10 127621700 127628100 2 5.310692512  
chr13 58336801 58402200 2 0.363442742 * 
chr13 63601501 63602001 2 3.22992351  
chr13 63660800 63666900 2 3.22992351  
chr15 22674750 22677450 17 5.388560788  
chr16 32209501 32217501 12 3.680240377  
chr16 35185201 35191801 4 14.75058227  
chr17 45191401 45197601 2 6.570941053  
chr18 14126401 14715000 6 2.68328445  
chr19 24459601 24519601 3 4.07669493  
chr19 44897101 44903601 2 4.256005455  
chr20 29854000 29855100 11 7.425560869  
JT443 CNVnator calls that agree with CNVseq 
CNV type Location Size Read depth normalised to 1 
deletion chr6:162680001-162858000 178000 0.524078 
deletion chr8:7018001-7985000 967000 0.67404 
deletion chr8:11897001-12342000 445000 0.57844 
deletion chr8:39232001-39387000 155000 0.0328512 




CNV calls from the Exome Depth program for all samples analysed. For brevity only CNVs absent from the Conrad database (Conrad et al., 
2010) and with a Bayes Factor >10 are included. All regions were assessed for genes related to the phenotype.  









JT67 135080 135115 duplication chr15:42052522-
42116259 








 71744 71749 deletion chr7:5939916-
5944900 
28.2 357 162 0.454 CCZ1_2,CCZ1_3,CCZ1_4,CCZ1_5,CCZ1_6,CCZ1_7 
 95380 95393 deletion chr10:18060293-
18152611 
22 103 3 0.0291 TMEM236_2,TMEM236_3,TMEM236_4,MRC1_1,MRC1_2,MRC1
_3,MRC1_4,MRC1_5,MRC1_6,MRC1_7,MRC1_8,MRC1_9,MRC1
_10,MRC1_11 
 127269 127278 duplication chr13:114535273
-114566893 
20.2 519 756 1.46 GAS6_10,GAS6_9,GAS6_8,GAS6_7,GAS6_6,GAS6_5,GAS6_4,
GAS6_3,GAS6_2,GAS6_1 
 71936 71942 deletion chr7:6826510-
6840706 
18 83 2 0.0241 RSPH10B2_16,RSPH10B2_17,RSPH10B2_18,RSPH10B2_19,RS
PH10B2_20,CCZ1B_15,CCZ1B_14 
 71926 71934 deletion chr7:6805338-
6821107 
14.7 240 122 0.508 RSPH10B2_6,RSPH10B2_7,RSPH10B2_8,RSPH10B2_9,RSPH1
0B2_10,RSPH10B2_11,RSPH10B2_12,RSPH10B2_13,RSPH10B
2_14 
 71029 71032 deletion chr6:167789455-
167794824 
12.8 161 77 0.478 TCP10_6,TCP10_5,TCP10_4,TCP10_3 
 60875 60877 duplication chr5:175386973-
175388437 
11.4 101 195 1.93 THOC3_6,THOC3_5,THOC3_4 
 110121 110126 deletion chr11:89768381-
89774718 
11.4 161 74 0.46 TRIM49C_3,TRIM49C_4,TRIM49C_5,TRIM49C_6,TRIM49C_7,T
RIM49C_8 
JT379 82439 82460 duplication chr8:42939854-
43054712 







 71772 71779 deletion chr7:5998625-
6018327 
49.4 685 287 0.419 RSPH10B_6,RSPH10B_5,RSPH10B_4,RSPH10B_3,RSPH10B_2
,PMS2_15,PMS2_14,PMS2_13 
 95350 95357 deletion chr10:17865074-
17898362 
39.4 708 303 0.428 MRC1L1_2,MRC1L1_3,MRC1L1_4,MRC1L1_5,MRC1L1_6,MRC1
L1_7,MRC1L1_8,MRC1L1_9 
 95384 95391 duplication chr10:18112045-
18145281 
34.9 150 476 3.17 MRC1_2,MRC1_3,MRC1_4,MRC1_5,MRC1_6,MRC1_7,MRC1_8,
MRC1_9 
 71941 71944 deletion chr7:6838856-
6844686 
28.1 136 1 0.00735 CCZ1B_15,CCZ1B_14,CCZ1B_13,CCZ1B_12 
 60875 60877 deletion chr5:175386973-
175388437 
22.2 181 51 0.282 THOC3_6,THOC3_5,THOC3_4 
 71029 71032 deletion chr6:167789455-
167794824 
16.6 287 157 0.547 TCP10_6,TCP10_5,TCP10_4,TCP10_3 
 96933 96937 duplication chr10:51970584-
51978390 
15 196 345 1.76 ASAH2_11,ASAH2_10,ASAH2_9,ASAH2_8,ASAH2_7 
 71932 71934 deletion chr7:6819242-
6821107 
12.3 201 97 0.483 RSPH10B2_12,RSPH10B2_13,RSPH10B2_14 
 151556 151561 deletion chr17:16664740-
16676947 
11 1336 955 0.715 CCDC144A_13,CCDC144A_13,CCDC144A_14,CCDC144A_14,C
CDC144A_15,CCDC144A_15,CCDC144A_16,CCDC144A_16,CC
DC144A_17,CCDC144A_18,CCDC144A_17 
 95948 95948 deletion chr10:29580773-
29580935 
10.7 85 18 0.212 LYZL1_2 
 39298 39299 deletion chr3:57620286-
57620496 
10.4 100 34 0.34 DENND6A_14,DENND6A_13 
 157450 157454 deletion chr17:61972383-
61973871 
10.3 201 107 0.532 CSH1_5,CSH1_4,CSH1_3,CSH1_2,CSH1_1 
JT384 119943 119977 deletion chr12:88374109-
88473006 







 182072 182091 deletion chr22:25115440-
25158466 




 119983 120020 duplication chr12:88480169-
88560359 









 71922 71944 deletion chr7:6797310-
6844686 






 6070 6087 duplication chr1:46083136-
46096278 




 95384 95394 deletion chr10:18112045-
18155690 
29.5 136 2 0.0147 MRC1_2,MRC1_3,MRC1_4,MRC1_5,MRC1_6,MRC1_7,MRC1_8,
MRC1_9,MRC1_10,MRC1_11,MRC1_12 
 71773 71780 duplication chr7:6000323-
6022622 
27.4 286 547 1.91 RSPH10B_5,RSPH10B_4,RSPH10B_3,RSPH10B_2,PMS2_15,P
MS2_14,PMS2_13,PMS2_12 
 110109 110109 deletion chr11:89531299-
89531797 
20.3 190 43 0.226 TRIM49_8 
 96932 96937 deletion chr10:51965743-
51978390 
18.4 160 58 0.362 ASAH2_12,ASAH2_11,ASAH2_10,ASAH2_9,ASAH2_8,ASAH2_7 
 60876 60880 duplication chr5:175388055-
175395211 
11.5 159 268 1.69 THOC3_5,THOC3_4,THOC3_3,THOC3_2,THOC3_1 
JT443 71940 71944 duplication chr7:6837995-
6844686 
35.4 120 409 3.41 RSPH10B2_20,CCZ1B_15,CCZ1B_14,CCZ1B_13,CCZ1B_12 
 95384 95389 deletion chr10:18112045-
18138693 
32.3 214 44 0.206 MRC1_2,MRC1_3,MRC1_4,MRC1_5,MRC1_6,MRC1_7 
 93184 93194 duplication chr9:135937382-
135947151 
25.7 1300 1789 1.38 CEL_1,CEL_2,CEL_3,CEL_4,CEL_5,CEL_6,CEL_7,CEL_8,CEL_
9,CEL_10,CEL_11 
 71932 71934 duplication chr7:6819242-
6821107 
21 125 321 2.57 RSPH10B2_12,RSPH10B2_13,RSPH10B2_14 
 96932 96937 deletion chr10:51965743-
51978390 
19.5 179 68 0.38 ASAH2_12,ASAH2_11,ASAH2_10,ASAH2_9,ASAH2_8,ASAH2_7 
 71027 71032 duplication chr6:167786658-
167794824 
19.1 474 690 1.46 TCP10_8,TCP10_7,TCP10_6,TCP10_5,TCP10_4,TCP10_3 
 151556 151560 duplication chr17:16664740-
16676023 
18.5 763 1104 1.45 CCDC144A_13,CCDC144A_13,CCDC144A_14,CCDC144A_14,C
CDC144A_15,CCDC144A_15,CCDC144A_16,CCDC144A_16,CC
DC144A_17 
 71754 71758 deletion chr7:5959481-
5966179 
15.1 627 392 0.625 CCZ1_12,CCZ1_13,CCZ1_14,CCZ1_15,RSPH10B_20 
 95350 95355 duplication chr10:17865074-
17891768 
13.5 347 527 1.52 MRC1L1_2,MRC1L1_3,MRC1L1_4,MRC1L1_5,MRC1L1_6,MRC1
L1_7 
 71777 71780 duplication chr7:6013031-
6022622 
12.5 83 183 2.2 PMS2_15,PMS2_14,PMS2_13,PMS2_12 
 110121 110126 deletion chr11:89768381-
89774718 
12.5 204 100 0.49 TRIM49C_3,TRIM49C_4,TRIM49C_5,TRIM49C_6,TRIM49C_7,T
RIM49C_8 
 61269 61271 deletion chr5:177166602-
177168333 
12.1 65 8 0.123 FAM153A_8,FAM153A_7,FAM153A_6 
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JT448 60875 60880 duplication chr5:175386973-
175395211 
26.2 158 360 2.28 THOC3_6,THOC3_5,THOC3_4,THOC3_3,THOC3_2,THOC3_1 
 95377 95386 deletion chr10:17951323-
18122792 
21.5 97 0 0 MRC1L1_29,MRC1L1_30,TMEM236_1,TMEM236_2,TMEM236_3
,TMEM236_4,MRC1_1,MRC1_2,MRC1_3,MRC1_4 
 142997 143006 duplication chr16:18532088-
18550286 
19.4 408 636 1.56 NOMO2_19,NOMO2_18,NOMO2_17,NOMO2_16,NOMO2_15,NO
MO2_14,NOMO2_13,NOMO2_12,NOMO2_11,NOMO2_10 
 74165 74168 deletion chr7:64838912-
64864788 
19.1 727 445 0.612 ZNF92_2,ZNF92_3,ZNF92_4 
 71932 71941 deletion chr7:6819242-
6838910 
16.6 227 114 0.502 RSPH10B2_12,RSPH10B2_13,RSPH10B2_14,RSPH10B2_15,RS
PH10B2_16,RSPH10B2_17,RSPH10B2_18,RSPH10B2_19,RSPH
10B2_20,CCZ1B_15 
 71773 71779 duplication chr7:6000323-
6018327 
15.7 168 306 1.82 RSPH10B_5,RSPH10B_4,RSPH10B_3,RSPH10B_2,PMS2_15,P
MS2_14,PMS2_13 
 88092 88099 duplication chr9:35562378-
35606282 
15.4 610 838 1.37 FAM166B_5,FAM166B_4,FAM166B_3,FAM166B_2,FAM166B_1,
TESK1_1,TESK1_2,TESK1_3 
 96932 96937 deletion chr10:51965743-
51978390 
15.2 142 55 0.387 ASAH2_12,ASAH2_11,ASAH2_10,ASAH2_9,ASAH2_8,ASAH2_7 
 25115 25116 deletion chr2:96652500-
96652954 
12.9 100 27 0.27 ANKRD36C_3,ANKRD36C_2 
 75855 75857 deletion chr7:98452864-
98457961 
12.9 273 152 0.557 TMEM130_5,TMEM130_4,TMEM130_3 
 34150 34151 deletion chr2:241631332-
241633966 
12.3 55 0 0 AQP12A_1,AQP12A_2,AQP12A_3 
 95350 95355 duplication chr10:17865074-
17891768 
12.2 328 485 1.48 MRC1L1_2,MRC1L1_3,MRC1L1_4,MRC1L1_5,MRC1L1_6,MRC1
L1_7 
 95389 95393 deletion chr10:18138509-
18152611 
12.2 58 2 0.0345 MRC1_7,MRC1_8,MRC1_9,MRC1_10,MRC1_11 
 71922 71925 deletion chr7:6797310-
6803732 
12.1 248 130 0.524 RSPH10B2_2,RSPH10B2_3,RSPH10B2_4,RSPH10B2_5 
 151556 151558 duplication chr17:16664740-
16667489 
10.9 592 808 1.36 CCDC144A_13,CCDC144A_13,CCDC144A_14,CCDC144A_14,C
CDC144A_15,CCDC144A_15 
JT538 21847 21905 deletion chr2:32701282-
33037682 










 151874 151885 deletion chr17:18291534-
18397681 





 94293 94303 deletion chr9:140387466-
140416168 
37.4 868 520 0.599 PNPLA7_20,PNPLA7_19,PNPLA7_18,PNPLA7_17,PNPLA7_16,P
NPLA7_15,PNPLA7_14,PNPLA7_13,PNPLA7_12,PNPLA7_11,PN
PLA7_10 
 71932 71944 deletion chr7:6819242-
6844686 
33.6 197 37 0.188 RSPH10B2_12,RSPH10B2_13,RSPH10B2_14,RSPH10B2_15,RS
PH10B2_16,RSPH10B2_17,RSPH10B2_18,RSPH10B2_19,RSPH
10B2_20,CCZ1B_15,CCZ1B_14,CCZ1B_13,CCZ1B_12 
 95384 95410 deletion chr10:18112045-
18196627 





 163282 163292 deletion chr19:863093-
881714 
23.8 552 347 0.629 CFD_5,MED16_16,MED16_15,MED16_14,MED16_13,MED16_12
,MED16_11,MED16_10,MED16_9,MED16_8,MED16_7 
 113222 113231 deletion chr12:1949906-
1984503 
18 693 478 0.69 CACNA2D4_26,CACNA2D4_25,CACNA2D4_24,CACNA2D4_23,
CACNA2D4_22,CACNA2D4_21,CACNA2D4_20,CACNA2D4_19,
CACNA2D4_18,CACNA2D4_17 
 96932 96937 deletion chr10:51965743-
51978390 
15.2 130 50 0.385 ASAH2_12,ASAH2_11,ASAH2_10,ASAH2_9,ASAH2_8,ASAH2_7 
 71922 71924 deletion chr7:6797310-
6799925 
15.1 100 18 0.18 RSPH10B2_2,RSPH10B2_3,RSPH10B2_4 
 159003 159008 deletion chr17:74921049-
74936930 
15.1 518 352 0.68 MGAT5B_8,MGAT5B_9,MGAT5B_10,MGAT5B_11,MGAT5B_12,
MGAT5B_13 
 21827 21839 deletion chr2:32660565-
32690232 
14.9 1321 993 0.752 BIRC6_14,BIRC6_15,BIRC6_16,BIRC6_17,BIRC6_18,BIRC6_19,
BIRC6_20,BIRC6_21,BIRC6_22,BIRC6_23,BIRC6_24,BIRC6_25,
BIRC6_26 
 71775 71779 duplication chr7:6005269-
6018327 
13.9 134 249 1.86 RSPH10B_3,RSPH10B_2,PMS2_15,PMS2_14,PMS2_13 
 184997 185004 duplication chr22:50943232-
50945095 
11.4 930 1154 1.24 LMF2_10,LMF2_9,LMF2_8,LMF2_7,LMF2_6,LMF2_5,LMF2_4,LM
F2_3 
 176320 176328 duplication chr20:33583140-
33587208 
11.2 923 1135 1.23 MYH7B_26,MYH7B_27,MYH7B_28,MYH7B_29,MYH7B_30,MYH
7B_31,MYH7B_32,MYH7B_33,MYH7B_34 
 71754 71759 duplication chr7:5959481-
5968025 
10.1 362 482 1.33 CCZ1_12,CCZ1_13,CCZ1_14,CCZ1_15,RSPH10B_20,RSPH10B
_19 
 154364 154369 duplication chr17:39525656-
39537464 
10 663 835 1.26 KRT33B_1,KRT34_7,KRT34_6,KRT34_5,KRT34_4,KRT34_3 
JT542 95384 95410 duplication chr10:18112045-
18196627 





 21849 21892 duplication chr2:32703704-
32875300 










 96505 96531 duplication chr10:47658500-
47758904 






 33392 33408 duplication chr2:233243514-
233273111 
18.8 2494 3138 1.26 ALPP_1,ALPP_2,ALPP_3,ALPP_4,ALPP_5,ALPP_6,ALPP_7,ALP
P_8,ALPP_9,ALPP_10,ALPP_11,ALPPL2_1,ALPPL2_2,ALPPL2_
3,ALPPL2_4,ALPPL2_5,ALPPL2_6 
 95360 95377 deletion chr10:17908572-
17951363 




 71922 71943 duplication chr7:6797310-
6841154 





 21827 21839 duplication chr2:32660565-
32690232 
12.5 1738 2200 1.27 BIRC6_14,BIRC6_15,BIRC6_16,BIRC6_17,BIRC6_18,BIRC6_19,
BIRC6_20,BIRC6_21,BIRC6_22,BIRC6_23,BIRC6_24,BIRC6_25,
BIRC6_26 
 71776 71776 deletion chr7:6006495-
6006747 
10.9 62 0 0 RSPH10B_2 
 94292 94299 duplication chr9:140379040-
140400212 
10.7 853 1163 1.36 PNPLA7_21,PNPLA7_20,PNPLA7_19,PNPLA7_18,PNPLA7_17,P
NPLA7_16,PNPLA7_15,PNPLA7_14 
 60875 60879 duplication chr5:175386973-
175394270 
10.3 266 407 1.53 THOC3_6,THOC3_5,THOC3_4,THOC3_3,THOC3_2 
 183132 183146 duplication chr22:36682765-
36697711 
10 1748 2136 1.22 MYH9_35,MYH9_34,MYH9_33,MYH9_32,MYH9_31,MYH9_30,M
YH9_29,MYH9_28,MYH9_27,MYH9_26,MYH9_25,MYH9_24,MY
H9_23,MYH9_22,MYH9_21 
JT587 127755 127824 duplication chr14:22554730-
22970647 

















 95380 95411 deletion chr10:18060293-
18198276 






 50372 50396 deletion chr4:104037735-
104081936 





 76853 76862 deletion chr7:102957278-
102968201 
13.9 732 421 0.575 DNAJC2_13,DNAJC2_12,DNAJC2_11,DNAJC2_10,DNAJC2_9,D
NAJC2_8,DNAJC2_7,DNAJC2_6,DNAJC2_5,DNAJC2_4 
 129092 129100 deletion chr14:39760224-
39777791 




JT624 80563 80580 duplication chr8:11968942-
12287960 




 171925 171936 duplication chr19:49055511-
49114104 
42.3 1424 2144 1.51 SULT2B1_1,SULT2B1_2,SULT2B1_3,SULT2B1_4,SULT2B1_5,S
ULT2B1_6,SULT2B1_7,FAM83E_5,FAM83E_4,SPACA4_1,FAM8
3E_3,FAM83E_2 
 133509 133528 duplication chr15:20739498-
21071610 




 51616 51626 deletion chr4:144258343-
144390342 
29.3 529 271 0.512 GAB1_1,GAB1_2,GAB1_3,GAB1_4,GAB1_5,GAB1_6,GAB1_7,G
AB1_8,GAB1_9,GAB1_10,GAB1_11 
 134035 134039 deletion chr15:30844282-
30848215 
25.1 149 22 0.148 GOLGA8Q_1,GOLGA8Q_2,GOLGA8Q_3,GOLGA8Q_4,GOLGA8
Q_5 
 102268 102270 duplication chr10:135139332
-135141519 
22.4 330 604 1.83 CALY_5,CALY_4,CALY_3 
 86336 86338 deletion chr8:145317757-
145318513 
22.3 107 2 0.0187 KM-PA-2_11,KM-PA-2_10,KM-PA-2_9 
 1868 1870 deletion chr1:13716802-
13743098 
20.8 97 1 0.0103 PRAMEF17_2,PRAMEF17_3,PRAMEF20_2 
 139030 139030 deletion chr15:79065426-
79065545 
19.9 118 11 0.0932 ADAMTS7_14 
 11168 11184 deletion chr1:146399556-
146420191 






 86358 86360 duplication chr8:145486843-
145487599 
14.5 180 336 1.87 BOP1_13,BOP1_12,BOP1_11 
 1853 1855 duplication chr1:13495968-
13522259 
14.2 79 191 2.42 PRAMEF16_2,PRAMEF16_3,PRAMEF21_2 
 11149 11164 duplication chr1:146232495-
146253110 
14.1 140 256 1.83 NBPF12_16,NBPF12_15,NBPF12_14,NBPF12_13,NBPF12_12,N
BPF12_11,NBPF12_10,NBPF12_9,NBPF12_8,NBPF12_7,NBPF1
2_6,NBPF12_5,NBPF12_4,NBPF12_3,NBPF12_2,NBPF12_1 
 46668 46672 deletion chr4:9175517-
9218723 
12.8 69 7 0.101 FAM90A26P_5,FAM90A26P_6,FAM90A26P_7,USP17L13_1,USP
17L10_1,USP17L11_1 
 96454 96455 duplication chr10:46312644-
46322838 
10.8 107 211 1.97 FAM25E_1,AGAP4_7 
 169777 169778 deletion chr19:39261667-
39262670 
10.7 49 0 0 LGALS7_4,LGALS7_3 
 154326 154327 deletion chr17:39215917-
39222097 
10.4 176 85 0.483 KRTAP2-3_1,KRTAP2-4_1 
JT668 46667 46675 deletion chr4:9174900-
9237700 
55.7 346 31 0.0896 FAM90A26P_4,FAM90A26P_5,FAM90A26P_6,FAM90A26P_7,US
P17L13_1,USP17L10_1,USP17L11_1,USP17L12_1,USP17L13_2
,USP17L15_1 
 86325 86346 deletion chr8:145314144-
145322083 





 96508 96534 duplication chr10:47667256-
47769665 






 95384 95393 deletion chr10:18112045-
18152611 
41 219 22 0.1 MRC1_2,MRC1_3,MRC1_4,MRC1_5,MRC1_6,MRC1_7,MRC1_8,
MRC1_9,MRC1_10,MRC1_11 
 71926 71951 duplication chr7:6805338-
6862991 






 96932 96937 deletion chr10:51965743-
51978390 
27.1 235 76 0.323 ASAH2_12,ASAH2_11,ASAH2_10,ASAH2_9,ASAH2_8,ASAH2_7 
 95350 95355 duplication chr10:17865074-
17891768 
24 272 521 1.92 MRC1L1_2,MRC1L1_3,MRC1L1_4,MRC1L1_5,MRC1L1_6,MRC1
L1_7 
 144262 144265 duplication chr16:29057332-
29062028 




 80621 80621 duplication chr8:13424502-
13425460 
19.3 347 883 2.54 C8orf48_1 
 96454 96458 duplication chr10:46312644-
46329564 
18.2 241 507 2.1 FAM25E_1,AGAP4_7,AGAP4_6,AGAP4_5,AGAP4_4 
 88584 88586 duplication chr9:43624656-
43629320 
16.5 1408 2201 1.56 SPATA31A6_4,SPATA31A6_3,SPATA31A6_2 
 86358 86360 duplication chr8:145486843-
145487599 
15 253 453 1.79 BOP1_13,BOP1_12,BOP1_11 
 74581 74583 deletion chr7:74191614-
74193768 
14.3 536 310 0.578 NCF1_2,NCF1_3,NCF1_4 
 134202 134205 deletion chr15:32889653-
32890378 
12.8 575 359 0.624 GOLGA8N_5,GOLGA8N_6,GOLGA8N_7,GOLGA8N_8 
 48971 48973 deletion chr4:75480840-
75484724 
12.1 72 11 0.153 AREGB_1,AREGB_2,AREGB_3 
 25134 25135 deletion chr2:96696155-
96696596 
12 86 20 0.233 GPAT2_7,GPAT2_6 
 147618 147620 deletion chr16:75239232-
75239890 
11.9 337 190 0.564 CTRB2_5,CTRB2_4,CTRB2_3 
 133985 133986 deletion chr15:30384912-
30385191 
11.4 195 91 0.467 GOLGA8J_16,GOLGA8J_17 
 1868 1870 deletion chr1:13716802-
13743098 
11.2 214 116 0.542 PRAMEF17_2,PRAMEF17_3,PRAMEF20_2 
 182121 182123 deletion chr22:25428577-
25445331 
11.2 54 2 0.037 KIAA1671_2,KIAA1671_3,KIAA1671_4 
 1853 1855 duplication chr1:13495968-
13522259 
10.6 118 217 1.84 PRAMEF16_2,PRAMEF16_3,PRAMEF21_2 
 11148 11157 deletion chr1:146231724-
146244717 
10.1 71 19 0.268 NBPF12_17,NBPF12_16,NBPF12_15,NBPF12_14,NBPF12_13,N
BPF12_12,NBPF12_11,NBPF12_10,NBPF12_9,NBPF12_8 
JT714 80564 80584 deletion chr8:11970084-
12338444 





 80366 80412 deletion chr8:7220458-
7809913 









 46667 46675 deletion chr4:9174900-
9237700 





 144038 144052 deletion chr16:28403074-
28478223 
45.9 463 161 0.348 EIF3CL_10,EIF3CL_9,EIF3CL_8,EIF3CL_7,EIF3CL_6,EIF3CL_5,
EIF3CL_4,EIF3CL_3,EIF3CL_2,NPIPL1_7,NPIPL1_6,NPIPL1_5,N
PIPL1_4,NPIPL1_3,NPIPL1_2 
 101374 101385 duplication chr10:121189888
-121275164 
44.2 1477 2130 1.44 GRK5_7,GRK5_8,GRK5_9,GRK5_10,GRK5_11,GRK5_12,GRK5_
13,GRK5_14,GRK5_15,GRK5_16,RGS10_5,RGS10_4 
 71941 71954 deletion chr7:6838856-
6864368 
41.7 593 287 0.484 CCZ1B_15,CCZ1B_14,CCZ1B_13,CCZ1B_12,CCZ1B_11,CCZ1B
_10,CCZ1B_9,CCZ1B_8,CCZ1B_7,CCZ1B_6,CCZ1B_5,CCZ1B_
4,CCZ1B_3,CCZ1B_2 
 79056 79061 deletion chr7:142045364-
142104553 
37 1001 568 0.567 TRBV4-2_1,TRBV4-2_2,TRBV7-8_2,TRBV7-8_1,TRBV6-
9_2,TRBV6-9_1 
 134035 134040 duplication chr15:30844282-
30848525 
26.4 265 503 1.9 GOLGA8Q_1,GOLGA8Q_2,GOLGA8Q_3,GOLGA8Q_4,GOLGA8
Q_5,GOLGA8Q_6 
 95386 95402 deletion chr10:18122629-
18169599 
25.3 154 29 0.188 MRC1_4,MRC1_5,MRC1_6,MRC1_7,MRC1_8,MRC1_9,MRC1_1
0,MRC1_11,MRC1_12,MRC1_13,MRC1_14,MRC1_15,MRC1_16,
MRC1_17,MRC1_18,MRC1_19,MRC1_20 
 61269 61273 deletion chr5:177166602-
177171968 
24.9 118 3 0.0254 FAM153A_8,FAM153A_7,FAM153A_6,FAM153A_5,FAM153A_4 
 61260 61267 deletion chr5:177156025-
177164113 
23.8 363 182 0.501 FAM153A_17,FAM153A_16,FAM153A_15,FAM153A_14,FAM153
A_13,FAM153A_12,FAM153A_11,FAM153A_10 
 96454 96458 deletion chr10:46312644-
46329564 
21.8 309 137 0.443 FAM25E_1,AGAP4_7,AGAP4_6,AGAP4_5,AGAP4_4 
 71743 71756 duplication chr7:5938432-
5963593 
19.8 767 1061 1.38 CCZ1_1,CCZ1_2,CCZ1_3,CCZ1_4,CCZ1_5,CCZ1_6,CCZ1_7,CC
Z1_8,CCZ1_9,CCZ1_10,CCZ1_11,CCZ1_12,CCZ1_13,CCZ1_14 
 127793 127800 deletion chr14:22907540-
22932202 
18.4 586 359 0.613 TRDD1_1,TRDD2_1,TRDD3_1,TRDJ1_1,TRDJ4_1,TRDJ2_1,TR
DJ3_1,TRDC_1 
 75449 75454 duplication chr7:92019286-
92028263 
17.5 639 923 1.44 ANKIB1_15,ANKIB1_16,ANKIB1_17,ANKIB1_18,ANKIB1_19,ANK
IB1_20 
 5149 5149 deletion chr1:39987049-
39987242 
16.4 240 99 0.412 BMP8A_4 
 134027 134030 deletion chr15:30701745-
30702470 
15.1 131 40 0.305 GOLGA8R_8,GOLGA8R_7,GOLGA8R_6,GOLGA8R_5 
 124177 124178 duplication chr13:24465429-
24468340 
14.6 890 1255 1.41 C1QTNF9B_3,C1QTNF9B_2 
 173903 173903 deletion chr19:56662315-
56662350 
14.3 139 45 0.324 AC024580.1_2 
 27341 27342 deletion chr2:132288153-
132289375 
13 609 395 0.649 CCDC74A_3,CCDC74A_4 
 144130 144131 deletion chr16:28763890-
28769404 
12.9 81 15 0.185 A-575C2.4_1,A-575C2.4_2 
 149208 149209 deletion chr17:3445817-
3446922 
12.8 232 117 0.504 TRPV3_6,TRPV3_5 
 96933 96937 duplication chr10:51970584-
51978390 
12.6 182 301 1.65 ASAH2_11,ASAH2_10,ASAH2_9,ASAH2_8,ASAH2_7 




 134158 134161 duplication chr15:32684984-
32685771 
11.8 243 374 1.54 GOLGA8K_19,GOLGA8K_18,GOLGA8K_17,GOLGA8K_16 
 103289 103291 deletion chr11:5270599-
5274635 
11.5 150 69 0.46 HBG1_2,HBG1_1,HBG2_8 
 27180 27181 duplication chr2:130898732-
130899954 
11.2 681 950 1.4 CCDC74B_4,CCDC74B_3 
 110120 110120 deletion chr11:89608779-
89609185 
11.1 178 82 0.461 TRIM64B_1 
 86336 86337 duplication chr8:145317757-
145318304 
10.7 141 245 1.74 KM-PA-2_11,KM-PA-2_10 
 11149 11164 deletion chr1:146232495-
146253110 
10.2 246 150 0.61 NBPF12_16,NBPF12_15,NBPF12_14,NBPF12_13,NBPF12_12,N
BPF12_11,NBPF12_10,NBPF12_9,NBPF12_8,NBPF12_7,NBPF1
2_6,NBPF12_5,NBPF12_4,NBPF12_3,NBPF12_2,NBPF12_1 
 70084 70084 duplication chr6:150343117-
150343379 
10.1 103 202 1.96 RAET1L_2 
 73250 73255 deletion chr7:38304951-
38339764 
10.1 477 313 0.656 TRGC1_1,TRGJ1_1,TRGJP_1,TRGJP1_1,TRGV11_1,TRGV10_1 
 88544 88558 deletion chr9:42368416-
42410483 





JT788 151876 151886 deletion chr17:18387190-
18430117 
111 855 71 0.083 LGALS9C_2,LGALS9C_3,LGALS9C_4,LGALS9C_5,LGALS9C_6,
LGALS9C_7,LGALS9C_8,LGALS9C_9,LGALS9C_10,LGALS9C_
11,FAM106A_1 
 71921 71944 deletion chr7:6744791-
6844686 






 46667 46675 deletion chr4:9174900-
9237700 
47.7 432 45 0.104 FAM90A26P_4,FAM90A26P_5,FAM90A26P_6,FAM90A26P_7,US
P17L13_1,USP17L10_1,USP17L11_1,USP17L12_1,USP17L13_2
,USP17L15_1 
 86325 86346 deletion chr8:145314144-
145322083 





 88658 88690 deletion chr9:69200360-
69424176 










 11127 11164 duplication chr1:146215076-
146253110 








 61028 61050 duplication chr5:176310772-
176385155 




 11169 11184 deletion chr1:146400092-
146420191 




 96932 96937 deletion chr10:51965743-
51978390 
26.9 282 105 0.372 ASAH2_12,ASAH2_11,ASAH2_10,ASAH2_9,ASAH2_8,ASAH2_7 
 144262 144265 deletion chr16:29057332-
29062028 
24.6 194 29 0.149 CTB-134H23.2_3,CTB-134H23.2_4,CTB-134H23.2_5,CTB-
134H23.2_6 
 95348 95352 deletion chr10:17837921-
17875838 
23.4 158 10 0.0633 TMEM236_4,MRC1L1_1,MRC1L1_2,MRC1L1_3,MRC1L1_4 
 142916 142928 deletion chr16:16345821-
16367932 
22 1114 645 0.579 NOMO3_8,NOMO3_9,NOMO3_10,NOMO3_11,NOMO3_12,NOM
O3_13,NOMO3_14,NOMO3_15,NOMO3_16,NOMO3_17,NOMO3
_18,NOMO3_19,NOMO3_20 
 139030 139030 deletion chr15:79065426-
79065545 
20.5 204 12 0.0588 ADAMTS7_14 
 71762 71779 duplication chr7:5977390-
6018327 




 25134 25135 deletion chr2:96696155-
96696596 
15.1 89 5 0.0562 GPAT2_7,GPAT2_6 
 147620 147628 deletion chr16:75239812-
75258086 
14.9 1269 808 0.637 CTRB2_3,CTRB2_2,CTRB2_1,CTRB1_1,CTRB1_2,CTRB1_3,CT
RB1_4,CTRB1_5,CTRB1_6 
 25393 25407 duplication chr2:97877284-
97911808 




 103288 103291 duplication chr11:5269590-
5274635 
14.5 189 448 2.37 HBG1_3,HBG1_2,HBG1_1,HBG2_8 
  
275 
 169777 169778 deletion chr19:39261667-
39262670 
14.1 74 0 0 LGALS7_4,LGALS7_3 
 71014 71015 deletion chr6:167594122-
167595404 
12.3 107 20 0.187 TCP10L2_7,TCP10L2_8 
 96454 96461 deletion chr10:46312644-
46342795 
12 245 99 0.404 FAM25E_1,AGAP4_7,AGAP4_6,AGAP4_5,AGAP4_4,AGAP4_3,A
GAP4_2,AGAP4_1 
 95382 95394 deletion chr10:18084908-
18155690 
11.4 269 314 1.17 TMEM236_4,MRC1_1,MRC1_2,MRC1_3,MRC1_4,MRC1_5,MRC
1_6,MRC1_7,MRC1_8,MRC1_9,MRC1_10,MRC1_11,MRC1_12 
 95382 95386 duplication chr10:18084908-
18122792 
11.1 127 297 2.34 TMEM236_4,MRC1_1,MRC1_2,MRC1_3,MRC1_4 
 166916 166917 deletion chr19:14508471-
14508747 
11 110 28 0.255 CD97_7,CD97_8 
 61010 61021 duplication chr5:176289626-
176305640 
10.8 2329 3029 1.3 UNC5A_2,UNC5A_3,UNC5A_4,UNC5A_5,UNC5A_6,UNC5A_7,U
NC5A_8,UNC5A_9,UNC5A_10,UNC5A_11,UNC5A_12,UNC5A_1
3 
 27177 27178 deletion chr2:130897465-
130897669 






A: Post-mortem section of the left ventricle from Patient P3, family 2b, showing 
circumferential scarring in the mid-myocardium. Arrows mark areas of fibrosis. B: Low-
power microscopy of posterior wall of the left ventricle showing loose mid-myocardial 
fibrosis in patient P3, staining is eosin and haematoxylin. C: High-power microscopy of 
posterior wall of the left ventricle showing loose mid-myocardial fibrosis in patient P3, 
staining is eosin and haematoxylin. D: Cardiac MRI showing mid-myocardial fibrosis 







A table to show the full mass-spectrometry results demonstrating the pulled down 
proteins and the number of peptides pulled down in each replicate (run 1, 2 & 3) for 
DNAAF1 Wildtype (WT) and mutant (MUT). Chi squared test wt to mut is given in the 
final column. 
run1 run2 run3 run1 run2 run3
Bio$View:Identified$Proteins$(647/696) Accession$NumberMolecular$Weight08_DNAAF1_WT0NTAP10_p27_NDAAF10WT26_p28_NDAAF10WT10_DNAAF1_Mut0NTAP2_p27_NDAAF10Mut28_p28_NDAAF10Mut Chi2$WT$vs$Mut
Dynein:assembly:factor:1,:axonemal:OS=Homo:sapiens:GN=DNAAF1:PE=1:SV=5 Q8NEP3 80:kDa 56 149 173 44 143 144 0.021555
40S:ribosomal:protein:S14:OS=Homo:sapiens:GN=RPS14:PE=1:SV=3 P62263 16:kDa 2 2 0
40S:ribosomal:protein:S15a:OS=Homo:sapiens:GN=RPS15A:PE=1:SV=2 P62244 15:kDa 2 3 2 0
40S:ribosomal:protein:S27:OS=Homo:sapiens:GN=RPS27:PE=1:SV=3 P42677 9:kDa 3 4 5 0
40S:ribosomal:protein:S3:OS=Homo:sapiens:GN=RPS3:PE=1:SV=2 P23396 27:kDa 3 2 3 0
40S:ribosomal:protein:S6:OS=Homo:sapiens:GN=RPS6:PE=1:SV=1 P62753 29:kDa 2 2 2 0
4F2:cell0surface:antigen:heavy:chain:OS=Homo:sapiens:GN=SLC3A2:PE=1:SV=3 P08195 68:kDa 3 2 0
60:kDa:heat:shock:protein,:mitochondrial:OS=Homo:sapiens:GN=HSPD1:PE=1:SV=2 P10809 61:kDa 3 2 0
60S:ribosomal:protein:L23:OS=Homo:sapiens:GN=RPL23:PE=1:SV=1 P62829 15:kDa 2 2 0
60S:ribosomal:protein:L38:OS=Homo:sapiens:GN=RPL38:PE=1:SV=2 P63173 8:kDa 2 2 2 2 0
78:kDa:glucose0regulated:protein:OS=Homo:sapiens:GN=HSPA5:PE=1:SV=2 P11021 72:kDa 14 21 18 15 25 23 0.329193
Acetyl0CoA:carboxylase:1:OS=Homo:sapiens:GN=ACACA:PE=1:SV=2 Q13085 266:kDa 50 55 7 6 0.778801
Actin,:cytoplasmic:1:OS=Homo:sapiens:GN=ACTB:PE=1:SV=1 P60709:(+1) 42:kDa 5 8 2 3 6 5 0.055023
ADP/ATP:translocase:2:OS=Homo:sapiens:GN=SLC25A5:PE=1:SV=7 P05141 33:kDa 2 3 9 14 10 6.59E020
ADP/ATP:translocase:3:OS=Homo:sapiens:GN=SLC25A6:PE=1:SV=4 P12236 33:kDa 2 2 0
Apoptosis0inducing:factor:1,:mitochondrial:OS=Homo:sapiens:GN=AIFM1:PE=1:SV=1 O95831 67:kDa 13 22 15 0
ATP:synthase:subunit:alpha,:mitochondrial:OS=Homo:sapiens:GN=ATP5A1:PE=1:SV=1 P25705 60:kDa 3 5 11 14 0.513417
ATP:synthase:subunit:beta,:mitochondrial:OS=Homo:sapiens:GN=ATP5B:PE=1:SV=3 P06576 57:kDa 2 5 3 0
CAD:protein:OS=Homo:sapiens:GN=CAD:PE=1:SV=3 P27708 243:kDa 2 7 3 0
Coatomer:subunit:beta:OS=Homo:sapiens:GN=COPB1:PE=1:SV=3 P53618 107:kDa 2 5 2 0
D030phosphoglycerate:dehydrogenase:OS=Homo:sapiens:GN=PHGDH:PE=1:SV=4 O43175 57:kDa 2 6 6 3 0.018316
DNA:damage0binding:protein:1:OS=Homo:sapiens:GN=DDB1:PE=1:SV=1 Q16531 127:kDa 3 2 0
DNA0dependent:protein:kinase:catalytic:subunit:OS=Homo:sapiens:GN=PRKDC:PE=1:SV=3P78527 469:kDa 10 11 3 0
DnaJ:homolog:subfamily:A:member:1:OS=Homo:sapiens:GN=DNAJA1:PE=1:SV=2 P31689 45:kDa 2 9 6 0
DnaJ:homolog:subfamily:A:member:2:OS=Homo:sapiens:GN=DNAJA2:PE=1:SV=1 O60884 46:kDa 4 3 0
Elongation:factor:10alpha:1:OS=Homo:sapiens:GN=EEF1A1:PE=1:SV=1 P68104:(+1) 50:kDa 4 6 5 7 0.606531
Filaggrin02:OS=Homo:sapiens:GN=FLG2:PE=1:SV=1 Q5D862 248:kDa 5 2 3 3 2 4 0.567414
Glyceraldehyde030phosphate:dehydrogenase:OS=Homo:sapiens:GN=GAPDH:PE=1:SV=3P04406 36:kDa 3 2 2 3 0.846482
HCLS10associated:protein:X01:OS=Homo:sapiens:GN=HAX1:PE=1:SV=2 O00165 32:kDa 2 4 2 0
Heat:shock:70:kDa:protein:1A/1B:OS=Homo:sapiens:GN=HSPA1A:PE=1:SV=5 P08107 70:kDa 46 40 71 61 4.52E006
Heat:shock:70:kDa:protein:4:OS=Homo:sapiens:GN=HSPA4:PE=1:SV=4 P34932 94:kDa 2 3 2 0.778801
Heat:shock:70:kDa:protein:6:OS=Homo:sapiens:GN=HSPA6:PE=1:SV=2 P17066 71:kDa 12 5 0
Heat:shock:cognate:71:kDa:protein:OS=Homo:sapiens:GN=HSPA8:PE=1:SV=1 P11142 71:kDa 47 42 71 64 6.86E006
Heat:shock:protein:HSP:900alpha:OS=Homo:sapiens:GN=HSP90AA1:PE=1:SV=5 P07900 85:kDa 4 13 10 0
Heat:shock:protein:HSP:900beta:OS=Homo:sapiens:GN=HSP90AB1:PE=1:SV=4 P08238 83:kDa 2 10 32 28 1.13E007
Peroxiredoxin01:OS=Homo:sapiens:GN=PRDX1:PE=1:SV=1 Q06830 22:kDa 3 4 2 2 2 0.606531
Peroxiredoxin04:OS=Homo:sapiens:GN=PRDX4:PE=1:SV=1 Q13162 31:kDa 3 2 2 0
Phosphate:carrier:protein,:mitochondrial:OS=Homo:sapiens:GN=SLC25A3:PE=1:SV=2 Q00325 40:kDa 4 3 0
Proliferating:cell:nuclear:antigen:OS=Homo:sapiens:GN=PCNA:PE=1:SV=1 P12004 29:kDa 2 4 3 0
Propionyl0CoA:carboxylase:alpha:chain,:mitochondrial:OS=Homo:sapiens:GN=PCCA:PE=1:SV=4P05165 80:kDa 4 4 4 0
Propionyl0CoA:carboxylase:beta:chain,:mitochondrial:OS=Homo:sapiens:GN=PCCB:PE=1:SV=3P05166 58:kDa 4 5 0
Protein:transport:protein:Sec61:subunit:alpha:isoform:1:OS=Homo:sapiens:GN=SEC61A1:PE=1:SV=2P61619 52:kDa 2 2 0
Pyruvate:carboxylase,:mitochondrial:OS=Homo:sapiens:GN=PC:PE=1:SV=2 P11498 130:kDa 8 14 3 0.105399
RuvB0like:1:OS=Homo:sapiens:GN=RUVBL1:PE=1:SV=1 Q9Y265 50:kDa 11 11 6 8 9 8 0.396832
RuvB0like:2:OS=Homo:sapiens:GN=RUVBL2:PE=1:SV=3 Q9Y230 51:kDa 7 10 2 9 6 8 4.17E005
Serpin:B12:OS=Homo:sapiens:GN=SERPINB12:PE=1:SV=1 Q96P63 46:kDa 3 2 3 0.846482
Sodium/potassium0transporting:ATPase:subunit:alpha01:OS=Homo:sapiens:GN=ATP1A1:PE=1:SV=1P05023 113:kDa 4 9 2 0
Stress070:protein,:mitochondrial:OS=Homo:sapiens:GN=HSPA9:PE=1:SV=2 P38646 74:kDa 22 50 49 21 51 48 0.957977
Suppressor:of:G2:allele:of:SKP1:homolog:OS=Homo:sapiens:GN=SUGT1:PE=1:SV=3 Q9Y2Z0 41:kDa 18 13 0
T0complex:protein:1:subunit:alpha:OS=Homo:sapiens:GN=TCP1:PE=1:SV=1 P17987 60:kDa 2 13 8 0
T0complex:protein:1:subunit:beta:OS=Homo:sapiens:GN=CCT2:PE=1:SV=4 P78371 57:kDa 2 24 3 0
T0complex:protein:1:subunit:delta:OS=Homo:sapiens:GN=CCT4:PE=1:SV=4 P50991 58:kDa 2 11 5 0
T0complex:protein:1:subunit:epsilon:OS=Homo:sapiens:GN=CCT5:PE=1:SV=1 P48643 60:kDa 2 3 15 7 0.778801
T0complex:protein:1:subunit:eta:OS=Homo:sapiens:GN=CCT7:PE=1:SV=2 Q99832 59:kDa 9 5 0
T0complex:protein:1:subunit:gamma:OS=Homo:sapiens:GN=CCT3:PE=1:SV=4 P49368 61:kDa 2 5 12 4 0.105399
T0complex:protein:1:subunit:theta:OS=Homo:sapiens:GN=CCT8:PE=1:SV=4 P50990 60:kDa 2 3 15 10 0.778801
T0complex:protein:1:subunit:zeta:OS=Homo:sapiens:GN=CCT6A:PE=1:SV=3 P40227 58:kDa 3 5 14 9 0.513417
Translocon0associated:protein:subunit:delta:OS=Homo:sapiens:GN=SSR4:PE=1:SV=1 P51571 19:kDa 3 3 2 0
Tubulin:alpha01B:chain:OS=Homo:sapiens:GN=TUBA1B:PE=1:SV=1 P68363 50:kDa 7 5 8 16 26 26 3.47E031
Tubulin:beta:chain:OS=Homo:sapiens:GN=TUBB:PE=1:SV=2 P07437 50:kDa 3 3 2 3 12 10 1.54E013
Tubulin:beta04A:chain:OS=Homo:sapiens:GN=TUBB4A:PE=1:SV=2 P04350 50:kDa 3 3 3 0
Tubulin:beta04B:chain:OS=Homo:sapiens:GN=TUBB4B:PE=1:SV=1 P68371 50:kDa 9 6 9 17 41 38 6.77E067
Ubiquitin060S:ribosomal:protein:L40:OS=Homo:sapiens:GN=UBA52:PE=1:SV=2 P62987 15:kDa 4 6 7 7 0.298695












The full list of variants remaining following filtering in family CHD10. PD= Probably Damaging, D= Deleterious, T= Tolerated. 
Gene Variant Protein 
change 
Polyphen2 SIFT Condel CADD MAF 
(GnomAD) 
Known protein function 
PYHIN 1: 158913587TA>T 337fs - - - - Not found Transcription regulation, cell 
cycle control. 
STAB1 3: 52549476TCTC>T FS1302F - - - - Not found Transmembrane receptor, 
angiogenesis. 
ANKRD20A3 9: 43121654TTAAG>T 259-260fs - - - - 862/8876 - 
CCDC73 11: 32624416T>TGTCA 1060-
1061fs 
- - - - 1/243930 - 
MTCH2 11: 47647293A>AAATC 227-228fs - - - - 4/30688 Mitochondrial inner membrane 
CARNS1 11:67191606TCTTCAACGTGGAG>T 
 
796-800fs - - - - Not found Carnasine synthase 
CARNS1 11: 67191631C>CG 804-805fs - - - - Not found Carnasine synthase 
ATXN3 14: 92537354C>CTG 305-306fs - - - - Not found ATPase binding, associated with 
Machado-Joseph disease, 
109150. 
C4ORF36 4: 87809325G>A Q57* - - - 27.4 Not found - 
PTCH1 9: 98240360 C>T, c.1324 C>T V442M PD 
(0.921) 
D (0) D 
(0.816) 
26.2 Not found Shh signalling 






25.1 Not found Polarity in the eye, associated 
with RP and LCA. 
ITSN1 21: 35206639G>C W1127S PD (0.94) D (0) D 
(0.830) 
24.3 Not found Endocytic membrane trafficing 
with the actin assembly 
machinery 






23.3 3/11598 Mitochondrial inner membrane 
ADCK1 14: 78365491T>C W211R PD (1) D (0) D 
(0.945) 
23.2 Not found ATP binding 
PTGIS 20:48156152G>T L210I PD T D 22.4 Not found Cytochrome P450 associated 
  
280 
(0.726) (0.06) (0.587) with essential Hypertension 






22.3 Not found Centromere-located regulator 
APLF 2: 68691455C>A W118C PD 
(0.999) 
D (0) D 
(0.935) 
22.2 Not found Response to DNA strand breaks 






19.74 Not found RNA polymerase II transcription 
corepressor 






19.43 15/27280 Actin binding 






18.91 Not found Regulation of acetyl-CoA 
biosynthetic process from 
pyruvate, associated with 
Lacticacidaemia (MIM 245349) 
CLUH 17: 2601422G>A R539C PD (0.67) D (0) D 
(0.682) 
18.84 3/202724 Intracellular distribution of 
mitochondria 






17.44 Not found Glycogen debrancher enzyme. 
Associated with Glycogen 
storage disease IIIa, 232400 and 
Glycogen storage disease IIIb, 
232400. 




16.34 1004/12016 Type I intermediate filament 
chain keratin 18 
